1	The	DT	O	the	det	4	SENT_1	[p1l385t81r431b102],
2	NEW	NNP	O	NEW	nn	4	SENT_1	[p1l449t83r534b102],
3	ENGLAND	NNP	O	ENGLAND	nn	4	SENT_1	[p1l553t83r741b102],
4	JOURNAL	NNP	O	JOURNAL	_	0	SENT_1	[p1l761t83r940b109],
5	of	IN	O	of	_	0	SENT_1	[p1l960t81r988b108],
6	MEDICINE	NNP	O	MEDICINE	prep_of	4	SENT_1	[p1l1000t83r1199b102],

1	l	NN	O	l	_	0	SENT_2	[p1l92t184r95b303],
2	CLINICAL	NNP	O	CLINICAL	nn	3	SENT_2	[p1l512t234r723b260],
3	THERAPEUTICS	NNS	O	therapeutics	dep	1	SENT_2	[p1l736t234r1072b260],
4	I	PRP	O	I	dep	1	SENT_2	[p1l1490t184r1493b303],

1	Treatment	NN	O	treatment	_	0	SENT_3	[p1l125t383r443b433],
2	of	IN	O	of	_	0	SENT_3	[p1l469t378r540b433],
3	N	NN	O	n	prep_of	1	SENT_3	[p1l554t384r606b434],
4	on	IN	O	on	prep	1	SENT_3	[p1l610t379r1040b433],
5	.	.	O	.	_	0	SENT_3	[p1l610t379r1040b433],

1	—	NN	O	—	_	0	SENT_4	[p1l610t379r1040b433],
2	.	.	O	.	_	0	SENT_4	[p1l610t379r1040b433],

1	Small-Cell	JJ	O	small-cell	amod	3	SENT_5	[p1l610t379r1040b433],
2	Lung	NN	O	lung	nn	3	SENT_5	[p1l1067t384r1223b449],
3	Cancer	NN	O	cancer	_	0	SENT_5	[p1l1249t383r1459b433],
4	with	IN	O	with	_	0	SENT_5	[p1l382t462r516b517],
5	Erlotinib	NN	O	erlotinib	prep_with	3	SENT_5	[p1l544t462r810b517],
6	or	CC	O	or	_	0	SENT_5	[p1l840t480r903b517],
7	Geﬁtinib	NN	O	geﬁtinib	prep_with	3	SENT_5	[p1l930t461r1199b517],

1	Vince	NNP	PERSON	Vince	nn	3	SENT_6	[p1l104t588r197b617],
2	D.	NNP	PERSON	D.	nn	3	SENT_6	[p1l213t588r246b616],
3	Cataldo	NNP	PERSON	Cataldo	_	0	SENT_6	[p1l260t585r398b622],
4	,	,	O	,	_	0	SENT_6	[p1l260t585r398b622],
5	M.D.	NNP	O	M.D.	appos	3	SENT_6	[p1l415t588r505b622],
6	,	,	O	,	_	0	SENT_6	[p1l415t588r505b622],
7	Don	NNP	PERSON	Don	nn	16	SENT_6	[p1l523t588r589b616],
8	L.	NNP	PERSON	L.	nn	16	SENT_6	[p1l607t588r631b616],
9	Gibbons	NNP	PERSON	Gibbons	nn	16	SENT_6	[p1l645t585r798b622],
10	,	,	O	,	_	0	SENT_6	[p1l645t585r798b622],
11	M.D.	NNP	O	M.D.	appos	16	SENT_6	[p1l815t588r905b622],
12	,	,	O	,	_	0	SENT_6	[p1l815t588r905b622],
13	Ph.D.	NNP	O	Ph.D.	appos	16	SENT_6	[p1l922t585r1021b622],
14	,	,	O	,	_	0	SENT_6	[p1l922t585r1021b622],
15	Roman	NNP	PERSON	Roman	appos	16	SENT_6	[p1l1038t588r1155b616],
16	Pérez	NNP	PERSON	Pérez	appos	5	SENT_6	[p1l1172t585r1370b622],
17	.	.	O	.	_	0	SENT_6	[p1l1172t585r1370b622],

1	—	NN	O	—	_	0	SENT_7	[p1l1172t585r1370b622],
2	.	.	O	.	_	0	SENT_7	[p1l1172t585r1370b622],

1	So	RB	O	so	advmod	3	SENT_8	[p1l1172t585r1370b622],
2	|	CD	NUMBER	|	num	3	SENT_8	[p1l1172t585r1370b622],
3	er	NN	O	er	_	0	SENT_8	[p1l1172t585r1370b622],
4	,	,	O	,	_	0	SENT_8	[p1l1172t585r1370b622],
5	M.D.	NNP	O	M.D.	dep	3	SENT_8	[p1l1388t588r1478b622],
6	,	,	O	,	_	0	SENT_8	[p1l1388t588r1478b622],

1	and	CC	O	and	cc	3	SENT_9	[p1l479t635r539b666],
2	Alfonso	NNP	PERSON	Alfonso	nn	3	SENT_9	[p1l552t634r682b666],
3	Quinta	NNP	PERSON	Quinta	_	0	SENT_9	[p1l696t635r1008b675],
4	’	CD	NUMBER	’	num	5	SENT_9	[p1l696t635r1008b675],
5	1s	NNS	O	1	dep	3	SENT_9	[p1l696t635r1008b675],
6	.	.	O	.	_	0	SENT_9	[p1l696t635r1008b675],

1	—	NN	O	—	_	0	SENT_10	[p1l696t635r1008b675],
2	.	.	O	.	_	0	SENT_10	[p1l696t635r1008b675],

1	Cardama	NNP	PERSON	Cardama	_	0	SENT_11	[p1l696t635r1008b675],
2	,	,	O	,	_	0	SENT_11	[p1l696t635r1008b675],
3	M.D.	NNP	O	M.D.	appos	1	SENT_11	[p1l1025t637r1105b666],

1	This	DT	O	this	det	3	SENT_12	[p1l104t737r161b764],
2	Journal	NNP	O	Journal	nn	3	SENT_12	[p1l166t737r278b769],
3	feature	NN	O	feature	nsubj	4	SENT_12	[p1l279t737r375b772],
4	begins	VBZ	O	begin	_	0	SENT_12	[p1l384t737r466b772],
5	with	IN	O	with	_	0	SENT_12	[p1l475t737r533b764],
6	a	DT	O	a	det	8	SENT_12	[p1l542t746r556b764],
7	case	NN	O	case	nn	8	SENT_12	[p1l567t746r617b764],
8	vignette	NN	O	vignette	prep_with	4	SENT_12	[p1l626t738r728b772],
9	that	WDT	O	that	nsubj	10	SENT_12	[p1l735t737r791b764],
10	includes	VBZ	O	include	rcmod	8	SENT_12	[p1l799t737r902b764],
11	a	DT	O	a	det	13	SENT_12	[p1l911t746r924b764],
12	therapeutic	JJ	O	therapeutic	amod	13	SENT_12	[p1l934t737r1079b772],
13	recommendation	NN	O	recommendation	dobj	10	SENT_12	[p1l1087t737r1312b764],
14	.	.	O	.	_	0	SENT_12	[p1l1087t737r1312b764],

1	A	DT	O	a	det	2	SENT_13	[p1l1321t739r1342b764],
2	discussion	NN	O	discussion	dep	15	SENT_13	[p1l1350t737r1480b764],
3	of	IN	O	of	_	0	SENT_13	[p1l100t778r131b813],
4	the	DT	O	the	det	6	SENT_13	[p1l132t778r171b805],
5	clinical	JJ	O	clinical	amod	6	SENT_13	[p1l179t778r272b805],
6	problem	NN	O	problem	prep_of	2	SENT_13	[p1l279t778r385b813],
7	and	CC	O	and	_	0	SENT_13	[p1l395t778r444b805],
8	the	DT	O	the	det	11	SENT_13	[p1l453t778r492b805],
9	mechanism	NN	O	mechanism	nn	11	SENT_13	[p1l501t778r647b805],
10	cf	NN	O	cf	nn	11	SENT_13	[p1l657t778r688b813],
11	beneﬁt	NN	O	beneﬁt	conj_and	6	SENT_13	[p1l690t778r776b813],
12	03	CD	NUMBER	03	num	13	SENT_13	[p1l784t778r815b813],
13	‘	NN	O	‘	dep	15	SENT_13	[p1l784t778r815b813],
14	this	DT	O	this	det	15	SENT_13	[p1l815t778r864b805],
15	form	NN	O	form	dep	18	SENT_13	[p1l864t778r932b813],
16	of	IN	O	of	_	0	SENT_13	[p1l942t778r974b813],
17	therapy	NN	O	therapy	prep_of	15	SENT_13	[p1l974t778r1073b813],
18	follows	VBZ	O	follow	_	0	SENT_13	[p1l1075t778r1184b813],
19	.	.	O	.	_	0	SENT_13	[p1l1075t778r1184b813],

1	Major	JJ	O	major	amod	3	SENT_14	[p1l1195t779r1278b813],
2	clinical	JJ	O	clinical	amod	3	SENT_14	[p1l1286t778r1378b805],
3	studies	NNS	O	study	nsubjpass	17	SENT_14	[p1l1387t778r1483b811],
4	,	,	O	,	_	0	SENT_14	[p1l1387t778r1483b811],
5	the	DT	O	the	det	7	SENT_14	[p1l137t819r177b847],
6	clinical	JJ	O	clinical	amod	7	SENT_14	[p1l185t819r277b847],
7	use	NN	O	use	appos	3	SENT_14	[p1l287t828r326b847],
8	of	IN	O	of	_	0	SENT_14	[p1l335t819r366b855],
9	this	DT	O	this	det	10	SENT_14	[p1l366t819r415b847],
10	therapy	NN	O	therapy	prep_of	7	SENT_14	[p1l423t819r531b855],
11	,	,	O	,	_	0	SENT_14	[p1l423t819r531b855],
12	and	CC	O	and	_	0	SENT_14	[p1l542t819r592b847],
13	potential	JJ	O	potential	amod	15	SENT_14	[p1l599t819r717b855],
14	adverse	JJ	O	adverse	amod	15	SENT_14	[p1l726t819r821b847],
15	eﬁects	NNS	O	eﬁects	conj_and	3	SENT_14	[p1l829t819r904b855],
16	are	VBP	O	be	auxpass	17	SENT_14	[p1l912t828r951b847],
17	reviewed	VBN	O	review	_	0	SENT_14	[p1l960t819r1078b847],
18	.	.	O	.	_	0	SENT_14	[p1l960t819r1078b847],

1	Relevant	JJ	O	relevant	_	0	SENT_15	[p1l1089t819r1204b848],
2	formal	JJ	O	formal	dep	3	SENT_15	[p1l1203t819r1298b855],
3	guidelines	NNS	O	guideline	dep	1	SENT_15	[p1l1303t819r1445b855],
4	,	,	O	,	_	0	SENT_15	[p1l1303t819r1445b855],

1	if	IN	O	if	mark	3	SENT_16	[p1l228t861r253b896],
2	they	PRP	O	they	nsubj	3	SENT_16	[p1l253t861r308b896],
3	exist	VBP	O	exist	csubjpass	6	SENT_16	[p1l318t862r383b894],
4	,	,	O	,	_	0	SENT_16	[p1l318t862r383b894],
5	are	VBP	O	be	auxpass	6	SENT_16	[p1l394t870r433b888],
6	presented	VBN	O	present	_	0	SENT_16	[p1l439t861r567b896],
7	.	.	O	.	_	0	SENT_16	[p1l439t861r567b896],

1	The	DT	O	the	det	2	SENT_17	[p1l578t861r626b888],
2	article	NN	O	article	nsubj	3	SENT_17	[p1l634t861r713b888],
3	ends	VBZ	O	end	_	0	SENT_17	[p1l722t861r778b888],
4	with	IN	O	with	mark	7	SENT_17	[p1l787t861r845b888],
5	the	DT	O	the	det	6	SENT_17	[p1l855t861r894b888],
6	authors	NNS	O	author	nsubj	7	SENT_17	[p1l902t861r1007b888],
7	’	VBP	O	’	advcl	3	SENT_17	[p1l902t861r1007b888],
8	clinical	JJ	O	clinical	amod	9	SENT_17	[p1l1017t861r1109b888],
9	recommendations	NNS	O	recommendation	dobj	7	SENT_17	[p1l1119t861r1356b888],
10	.	.	O	.	_	0	SENT_17	[p1l1119t861r1356b888],

1	A	DT	O	a	det	3	SENT_18	[p1l92t974r118b1002],
2	64-year-old	JJ	DURATION	64-year-old	amod	3	SENT_18	[p1l127t971r317b1011],
3	woman	NN	O	woman	nsubj	19	SENT_18	[p1l326t982r452b1003],
4	who	WP	O	who	nsubj	7	SENT_18	[p1l460t971r533b1003],
5	has	VBZ	O	have	aux	7	SENT_18	[p1l543t971r599b1002],
6	never	RB	O	never	neg	7	SENT_18	[p1l609t982r699b1003],
7	smoked	VBN	O	smoke	rcmod	3	SENT_18	[p1l708t971r838b1003],
8	receives	VBZ	O	receive	_	0	SENT_18	[p1l848t972r977b1003],
9	the	DT	O	the	det	10	SENT_18	[p1l987t971r1039b1003],
10	diagnosis	NN	O	diagnosis	dobj	8	SENT_18	[p1l1049t971r1209b1011],
11	of	IN	O	of	_	0	SENT_18	[p1l1219t971r1259b1003],
12	stage	NN	O	stage	nn	14	SENT_18	[p1l1261t978r1347b1011],
13	I	CD	NUMBER	i	num	14	SENT_18	[p1l1356t974r1368b1002],
14	adenocarcinoma	NN	O	adenocarcinoma	prep_of	10	SENT_18	[p1l1378t971r1491b1003, p1l93t1022r270b1053],
15	of	IN	O	of	_	0	SENT_18	[p1l277t1022r317b1053],
16	the	DT	O	the	det	17	SENT_18	[p1l318t1022r370b1053],
17	lung	NN	O	lung	prep_of	14	SENT_18	[p1l378t1022r454b1061],
18	and	CC	O	and	_	0	SENT_18	[p1l461t1022r523b1053],
19	undergoes	VBZ	O	undergo	conj_and	8	SENT_18	[p1l531t1022r706b1061],
20	right	JJ	O	right	amod	22	SENT_18	[p1l714t1022r797b1061],
21	upper	JJ	O	upper	amod	22	SENT_18	[p1l803t1032r900b1061],
22	lobectomy	NN	O	lobectomy	dobj	19	SENT_18	[p1l907t1022r1087b1061],
23	.	.	O	.	_	0	SENT_18	[p1l907t1022r1087b1061],

1	One	CD	DATE	one	num	2	SENT_19	[p1l1097t1024r1165b1053],
2	year	NN	DATE	year	npadvmod	3	SENT_19	[p1l1172t1032r1242b1061],
3	later	RB	DATE	later	advmod	9	SENT_19	[p1l1249t1022r1331b1060],
4	,	,	O	,	_	0	SENT_19	[p1l1249t1022r1331b1060],
5	bone	NN	O	bone	nn	8	SENT_19	[p1l1340t1022r1422b1053],
6	and	CC	O	and	_	0	SENT_19	[p1l1430t1022r1491b1053],
7	liver	NN	O	liver	conj_and	5	SENT_19	[p1l93t1072r165b1103],
8	metastases	NNS	O	metastase	nsubj	9	SENT_19	[p1l175t1078r357b1103],
9	develop	VBP	O	develop	_	0	SENT_19	[p1l368t1072r503b1111],
10	.	.	O	.	_	0	SENT_19	[p1l368t1072r503b1111],

1	She	PRP	O	she	nsubjpass	3	SENT_20	[p1l516t1072r574b1103],
2	is	VBZ	O	be	auxpass	3	SENT_20	[p1l585t1072r611b1102],
3	treated	VBN	O	treat	_	0	SENT_20	[p1l622t1072r737b1103],
4	with	IN	O	with	_	0	SENT_20	[p1l747t1072r825b1103],
5	carboplatin	NN	O	carboplatin	prep_with	3	SENT_20	[p1l835t1072r1036b1111],
6	,	,	O	,	_	0	SENT_20	[p1l835t1072r1036b1111],
7	paclitaxel	NN	O	paclitaxel	conj_and	5	SENT_20	[p1l1048t1072r1216b1111],
8	,	,	O	,	_	0	SENT_20	[p1l1048t1072r1216b1111],
9	and	CC	O	and	_	0	SENT_20	[p1l1228t1072r1290b1103],
10	bevacizumab	NN	O	bevacizumab	prep_with	3	SENT_20	[p1l1301t1072r1491b1103, p1l93t1121r141b1160],
11	,	,	O	,	_	0	SENT_20	[p1l1301t1072r1491b1103, p1l93t1121r141b1160],
12	but	CC	O	but	_	0	SENT_20	[p1l151t1121r206b1153],
13	progressive	JJ	O	progressive	amod	15	SENT_20	[p1l213t1122r404b1161],
14	bone	NN	O	bone	nn	15	SENT_20	[p1l413t1121r494b1153],
15	metastases	NNS	O	metastase	nsubjpass	17	SENT_20	[p1l502t1128r684b1153],
16	are	VBP	O	be	auxpass	17	SENT_20	[p1l693t1132r744b1153],
17	noted	VBN	O	note	conj_but	3	SENT_20	[p1l753t1121r846b1153],
18	after	IN	O	after	_	0	SENT_20	[p1l855t1121r933b1153],
19	6	CD	DURATION	6	num	20	SENT_20	[p1l941t1124r959b1152],
20	weeks	NNS	NUMBER	week	prep_after	17	SENT_20	[p1l967t1121r1070b1153],
21	of	IN	O	of	_	0	SENT_20	[p1l1079t1121r1119b1153],
22	therapy	NN	O	therapy	prep_of	20	SENT_20	[p1l1120t1121r1252b1161],
23	.	.	O	.	_	0	SENT_20	[p1l1120t1121r1252b1161],

1	An	DT	O	a	det	2	SENT_21	[p1l1260t1124r1309b1152],
2	oncologist	NN	O	oncologist	nsubj	3	SENT_21	[p1l1318t1121r1493b1161],
3	recommends	VBZ	O	recommend	_	0	SENT_21	[p1l93t1172r309b1203],
4	the	DT	O	the	det	5	SENT_21	[p1l319t1172r371b1203],
5	initiation	NN	O	initiation	dobj	3	SENT_21	[p1l380t1172r535b1203],
6	of	IN	O	of	_	0	SENT_21	[p1l543t1172r584b1203],
7	erlotinib	NN	O	erlotinib	nn	8	SENT_21	[p1l585t1172r728b1203],
8	therapy	NN	O	therapy	prep_of	5	SENT_21	[p1l737t1172r869b1212],
9	.	.	O	.	_	0	SENT_21	[p1l737t1172r869b1212],

1	THE	DT	O	the	det	3	SENT_22	[p1l523t1288r609b1310],
2	CLINICAL	NNP	O	CLINICAL	nn	3	SENT_22	[p1l629t1287r838b1311],
3	PROBLEM	NN	O	problem	_	0	SENT_22	[p1l859t1287r1059b1311],

1	Lung	NN	O	lung	_	0	SENT_23	[p1l93t1374r178b1411],
2	cancer	NN	O	cancer	nsubj	14	SENT_23	[p1l189t1382r305b1409],
3	,	,	O	,	_	0	SENT_23	[p1l189t1382r305b1409],
4	the	DT	O	the	det	6	SENT_23	[p1l320t1372r371b1402],
5	leading	VBG	O	lead	amod	6	SENT_23	[p1l383t1372r507b1411],
6	cause	NN	O	cause	appos	2	SENT_23	[p1l518t1382r608b1402],
7	of	IN	O	of	_	0	SENT_23	[p1l621t1371r659b1402],
8	cancer	NN	O	cancer	nn	11	SENT_23	[p1l665t1372r899b1402],
9	—	NN	O	—	nn	11	SENT_23	[p1l665t1372r899b1402],
10	related	JJ	O	related	amod	11	SENT_23	[p1l665t1372r899b1402],
11	death	NN	O	death	prep_of	6	SENT_23	[p1l911t1372r1003b1402],
12	worldwide	RB	O	worldwide	advmod	6	SENT_23	[p1l1014t1372r1197b1409],
13	,	,	O	,	_	0	SENT_23	[p1l1014t1372r1197b1409],
14	accounted	VBD	O	account	rcmod	1	SENT_23	[p1l1211t1372r1381b1403],
15	for	IN	O	for	_	0	SENT_23	[p1l1393t1371r1441b1402],
16	an	DT	O	a	det	19	SENT_23	[p1l1451t1382r1491b1402],
17	estimated	VBN	O	estimate	amod	19	SENT_23	[p1l94t1422r257b1453],
18	157,300	CD	NUMBER	157,300	num	19	SENT_23	[p1l270t1424r396b1459],
19	deaths	NNS	O	death	prep_for	14	SENT_23	[p1l408t1422r516b1453],
20	in	IN	O	in	_	0	SENT_23	[p1l529t1422r561b1452],
21	the	DT	O	the	det	23	SENT_23	[p1l573t1422r624b1452],
22	United	NNP	LOCATION	United	nn	23	SENT_23	[p1l636t1422r747b1453],
23	States	NNPS	LOCATION	States	prep_in	19	SENT_23	[p1l760t1424r856b1453],
24	in	IN	O	in	_	0	SENT_23	[p1l868t1422r901b1452],
25	2010.1	CD	NUMBER	2010.1	prep_in	19	SENT_23	[p1l912t1424r1014b1453],
26	Approximately	RB	O	approximately	quantmod	29	SENT_23	[p1l1024t1422r1271b1461],
27	85	CD	NUMBER	85	number	29	SENT_23	[p1l1281t1424r1318b1453],
28	to	TO	O	to	dep	29	SENT_23	[p1l1331t1428r1362b1453],
29	90	CD	NUMBER	90	num	30	SENT_23	[p1l1375t1424r1448b1453],
30	°	CD	NUMBER	°	dobj	14	SENT_23	[p1l1375t1424r1448b1453],
31	/	:	O	/	punct	1	SENT_23	[p1l1375t1424r1448b1453],
32	o	NN	O	o	nsubj	41	SENT_23	[p1l1375t1424r1448b1453],
33	of	IN	O	of	_	0	SENT_23	[p1l1460t1422r1499b1453],
34	all	DT	O	all	det	35	SENT_23	[p1l93t1472r134b1502],
35	cases	NNS	O	case	prep_of	32	SENT_23	[p1l150t1482r236b1502],
36	of	IN	O	of	_	0	SENT_23	[p1l254t1472r293b1503],
37	lung	NN	O	lung	nn	38	SENT_23	[p1l301t1472r376b1511],
38	cancer	NN	O	cancer	prep_of	35	SENT_23	[p1l392t1482r500b1502],
39	are	VBP	O	be	cop	41	SENT_23	[p1l515t1482r565b1502],
40	non	JJ	O	non	amod	41	SENT_23	[p1l581t1472r831b1503],
41	~	NN	O	~	dep	1	SENT_23	[p1l581t1472r831b1503],
42	small	JJ	O	small	amod	49	SENT_23	[p1l581t1472r831b1503],
43	—	NN	O	—	nn	49	SENT_23	[p1l581t1472r831b1503],
44	cell	NN	O	cell	nn	49	SENT_23	[p1l581t1472r831b1503],
45	lung	NN	O	lung	nn	49	SENT_23	[p1l846t1472r921b1511],
46	cancer	NN	O	cancer	nn	49	SENT_23	[p1l937t1482r1045b1502],
47	(	CD	NUMBER	(	num	49	SENT_23	[p1l1062t1474r1212b1507],
48	NSCLC	NN	O	nsclc	nn	49	SENT_23	[p1l1062t1474r1212b1507],
49	)	NN	O	)	dep	41	SENT_23	[p1l1062t1474r1212b1507],
50	.	.	O	.	_	0	SENT_23	[p1l1062t1474r1212b1507],

1	Advanced	NNP	O	Advanced	nn	4	SENT_24	[p1l1229t1472r1491b1511],
2	—	NNP	O	—	nn	4	SENT_24	[p1l1229t1472r1491b1511],
3	stage	NN	O	stage	nn	4	SENT_24	[p1l1229t1472r1491b1511],
4	NSCLC	NNP	ORGANIZATION	NSCLC	nsubjpass	7	SENT_24	[p1l93t1524r210b1553],
5	is	VBZ	O	be	auxpass	7	SENT_24	[p1l230t1522r255b1552],
6	currently	RB	DATE	currently	advmod	7	SENT_24	[p1l276t1522r427b1561],
7	considered	VBN	O	consider	_	0	SENT_24	[p1l444t1522r624b1553],
8	an	DT	O	a	det	10	SENT_24	[p1l643t1532r683b1552],
9	incurable	JJ	O	incurable	amod	10	SENT_24	[p1l701t1522r857b1553],
10	disease	NN	O	disease	dobj	7	SENT_24	[p1l876t1522r996b1553],
11	for	IN	O	for	_	0	SENT_24	[p1l1015t1522r1063b1553],
12	which	WDT	O	which	rel	15	SENT_24	[p1l1079t1522r1181b1553],
13	standard	JJ	O	standard	amod	14	SENT_24	[p1l1201t1522r1348b1553],
14	chemotherapy	NN	O	chemotherapy	nsubj	15	SENT_24	[p1l1367t1522r1491b1553, p1l94t1572r219b1611],
15	provides	VBZ	O	provide	rcmod	10	SENT_24	[p1l232t1572r372b1611],
16	marginal	JJ	O	marginal	amod	17	SENT_24	[p1l388t1572r542b1611],
17	improvement	NN	O	improvement	dobj	15	SENT_24	[p1l557t1572r780b1611],
18	in	IN	O	in	_	0	SENT_24	[p1l793t1572r826b1602],
19	overall	JJ	O	overall	amod	20	SENT_24	[p1l842t1572r952b1603],
20	survival	NN	O	survival	prep_in	17	SENT_24	[p1l968t1572r1097b1603],
21	at	IN	O	at	_	0	SENT_24	[p1l1112t1578r1143b1602],
22	the	DT	O	the	det	23	SENT_24	[p1l1157t1572r1208b1602],
23	expense	NN	O	expense	prep_at	15	SENT_24	[p1l1224t1582r1357b1611],
24	of	IN	O	of	_	0	SENT_24	[p1l1373t1572r1412b1603],
25	substantial	JJ	O	substantial	amod	26	SENT_24	[p1l1421t1572r1491b1603, p1l94t1622r219b1652],
26	morbidity	NN	O	morbidity	prep_of	23	SENT_24	[p1l240t1622r405b1661],
27	and	CC	O	and	_	0	SENT_24	[p1l424t1622r485b1653],
28	mortality	NN	O	mortality	prep_of	23	SENT_24	[p1l507t1622r668b1661],
29	.	.	O	.	_	0	SENT_24	[p1l507t1622r668b1661],

1	Furthermore	RB	O	furthermore	advmod	14	SENT_25	[p1l691t1622r913b1659],
2	,	,	O	,	_	0	SENT_25	[p1l691t1622r913b1659],
3	less	JJR	O	less	mwe	4	SENT_25	[p1l936t1622r996b1652],
4	than	IN	O	than	quantmod	6	SENT_25	[p1l1019t1622r1095b1652],
5	30	CD	NUMBER	30	number	6	SENT_25	[p1l1117t1624r1189b1653],
6	°	CD	NUMBER	°	nsubj	14	SENT_25	[p1l1117t1624r1189b1653],
7	/	:	O	/	punct	8	SENT_25	[p1l1117t1624r1189b1653],
8	o	NN	O	o	dep	6	SENT_25	[p1l1117t1624r1189b1653],
9	of	IN	O	of	_	0	SENT_25	[p1l1210t1622r1249b1653],
10	patients	NNS	O	patient	prep_of	8	SENT_25	[p1l1263t1622r1395b1661],
11	with	IN	O	with	_	0	SENT_25	[p1l1416t1622r1491b1653],
12	metastatic	JJ	O	metastatic	amod	13	SENT_25	[p1l93t1671r267b1701],
13	NSCLC	NN	ORGANIZATION	nsclc	prep_with	6	SENT_25	[p1l277t1673r394b1702],
14	have	VBP	O	have	_	0	SENT_25	[p1l407t1671r480b1702],
15	a	DT	O	a	det	16	SENT_25	[p1l492t1681r509b1701],
16	response	NN	O	response	dobj	14	SENT_25	[p1l520t1681r667b1710],
17	to	TO	O	to	_	0	SENT_25	[p1l679t1678r711b1702],
18	platinum	NN	O	platinum	nn	19	SENT_25	[p1l722t1671r984b1710],
19	—	NN	O	—	prep_to	16	SENT_25	[p1l722t1671r984b1710],
20	based	VBN	O	base	prep	14	SENT_25	[p1l722t1671r984b1710],
21	chemotherapy	NN	O	chemotherapy	dep	20	SENT_25	[p1l996t1671r1238b1710],
22	,	,	O	,	_	0	SENT_25	[p1l996t1671r1238b1710],
23	the	DT	O	the	det	28	SENT_25	[p1l1251t1671r1303b1701],
24	most	RBS	O	most	advmod	26	SENT_25	[p1l1314t1678r1398b1702],
25	commonly	RB	O	commonly	advmod	26	SENT_25	[p1l1408t1681r1491b1702, p1l93t1720r199b1759],
26	used	VBN	O	use	amod	28	SENT_25	[p1l210t1720r287b1751],
27	initial	JJ	O	initial	amod	28	SENT_25	[p1l300t1720r399b1750],
28	treatment	NN	O	treatment	appos	21	SENT_25	[p1l413t1726r577b1750],
29	in	IN	O	in	_	0	SENT_25	[p1l588t1720r621b1750],
30	this	DT	O	this	det	31	SENT_25	[p1l634t1720r696b1750],
31	stage	NN	O	stage	prep_in	28	SENT_25	[p1l711t1727r796b1759],
32	of	IN	O	of	_	0	SENT_25	[p1l810t1720r849b1751],
33	the	DT	O	the	det	34	SENT_25	[p1l855t1720r907b1750],
34	disease	NN	O	disease	prep_of	31	SENT_25	[p1l921t1720r1050b1751],
35	.	.	O	.	_	0	SENT_25	[p1l921t1720r1050b1751],

1	Even	RB	O	even	advmod	25	SENT_26	[p1l1065t1723r1142b1751],
2	with	IN	O	with	_	0	SENT_26	[p1l1154t1720r1229b1751],
3	the	DT	O	the	det	4	SENT_26	[p1l1243t1720r1294b1750],
4	addition	NN	O	addition	prep_with	1	SENT_26	[p1l1308t1720r1446b1751],
5	of	IN	O	of	_	0	SENT_26	[p1l1460t1720r1498b1751],
6	newer	JJR	O	newer	amod	7	SENT_26	[p1l93t1779r194b1800],
7	agents	NNS	O	agent	prep_of	4	SENT_26	[p1l208t1775r324b1808],
8	,	,	O	,	_	0	SENT_26	[p1l208t1775r324b1808],
9	such	JJ	O	such	_	0	SENT_26	[p1l342t1769r417b1800],
10	as	IN	O	as	_	0	SENT_26	[p1l431t1779r465b1799],
11	bevacizumab	NN	O	bevacizumab	prep_such_as	4	SENT_26	[p1l481t1769r707b1806],
12	,	,	O	,	_	0	SENT_26	[p1l481t1769r707b1806],
13	to	TO	O	to	_	0	SENT_26	[p1l724t1775r756b1800],
14	chemotherapy	NN	O	chemotherapy	prep_to	1	SENT_26	[p1l771t1769r1013b1808],
15	,	,	O	,	_	0	SENT_26	[p1l771t1769r1013b1808],
16	the	DT	O	the	det	19	SENT_26	[p1l1030t1769r1082b1799],
17	median	JJ	O	median	amod	19	SENT_26	[p1l1096t1769r1222b1800],
18	overall	JJ	O	overall	amod	19	SENT_26	[p1l1237t1769r1348b1800],
19	survival	NN	O	survival	nsubj	25	SENT_26	[p1l1363t1769r1492b1800],
20	of	IN	O	of	_	0	SENT_26	[p1l94t1818r132b1849],
21	patients	NNS	O	patient	prep_of	19	SENT_26	[p1l136t1818r266b1857],
22	with	IN	O	with	_	0	SENT_26	[p1l277t1818r352b1849],
23	metastatic	JJ	O	metastatic	amod	24	SENT_26	[p1l363t1818r533b1848],
24	NSCLC	NN	O	nsclc	prep_with	21	SENT_26	[p1l544t1820r659b1849],
25	remains	VBZ	O	remain	_	0	SENT_26	[p1l672t1818r805b1848],
26	approximately	RB	O	approximately	quantmod	27	SENT_26	[p1l817t1818r1051b1857],
27	1	CD	DURATION	1	nsubj	39	SENT_26	[p1l1062t1820r1080b1848],
28	year	NN	NUMBER	year	dep	27	SENT_26	[p1l1090t1820r1202b1857],
29	,23	CD	NUMBER	,23	num	28	SENT_26	[p1l1090t1820r1202b1857],
30	and	CC	O	and	_	0	SENT_26	[p1l1215t1818r1275b1849],
31	only	RB	O	only	quantmod	32	SENT_26	[p1l1287t1818r1357b1857],
32	3.5	CD	PERCENT	3.5	num	33	SENT_26	[p1l1368t1820r1448b1849],
33	%	NN	PERCENT	%	conj_and	27	SENT_26	[p1l1368t1820r1448b1849],
34	of	IN	O	of	_	0	SENT_26	[p1l1460t1818r1498b1849],
35	patients	NNS	O	patient	prep_of	33	SENT_26	[p1l93t1867r225b1906],
36	with	IN	O	with	_	0	SENT_26	[p1l238t1867r314b1898],
37	metastatic	JJ	O	metastatic	amod	38	SENT_26	[p1l327t1867r500b1897],
38	NSCLC	NN	O	nsclc	prep_with	35	SENT_26	[p1l512t1869r630b1898],
39	survive	VBP	O	survive	ccomp	25	SENT_26	[p1l645t1867r760b1898],
40	5	CD	DURATION	5	num	41	SENT_26	[p1l775t1870r791b1898],
41	years	NNS	NUMBER	year	tmod	39	SENT_26	[p1l804t1877r889b1906],
42	after	IN	O	after	_	0	SENT_26	[p1l903t1867r982b1897],
43	diagnosis	NN	O	diagnosis	prep_after	39	SENT_26	[p1l994t1867r1180b1906],
44	.	.	O	.	_	0	SENT_26	[p1l994t1867r1180b1906],

1	‘‘	NN	O	‘‘	_	0	SENT_27	[p1l994t1867r1180b1906],

1	PATHOPHYSIOLOGY	NN	O	pathophysiology	_	0	SENT_28	[p1l296t1983r715b2006],
2	AND	CC	O	and	cc	3	SENT_28	[p1l731t1983r824b2006],
3	EFFECT	NN	O	effect	dep	1	SENT_28	[p1l845t1983r1003b2006],
4	OF	IN	O	of	_	0	SENT_28	[p1l1021t1983r1072b2006],
5	THERAPY	NN	O	therapy	prep_of	3	SENT_28	[p1l1091t1983r1291b2006],

1	The	DT	O	the	det	3	SENT_29	[p1l92t2067r154b2097],
2	sobering	JJ	O	sobering	amod	3	SENT_29	[p1l169t2067r315b2106],
3	outcomes	NNS	O	outcome	nsubj	11	SENT_29	[p1l328t2073r488b2098],
4	from	IN	O	from	_	0	SENT_29	[p1l502t2067r584b2098],
5	studies	NNS	O	study	prep_from	3	SENT_29	[p1l598t2067r715b2098],
6	of	IN	O	of	_	0	SENT_29	[p1l730t2067r768b2098],
7	current	JJ	DATE	current	amod	9	SENT_29	[p1l776t2073r898b2098],
8	NSCLC	NN	O	nsclc	nn	9	SENT_29	[p1l909t2069r1026b2098],
9	therapy	NN	O	therapy	prep_of	5	SENT_29	[p1l1041t2067r1166b2106],
10	have	VBP	O	have	aux	11	SENT_29	[p1l1178t2067r1251b2098],
11	shifted	VBN	O	shift	_	0	SENT_29	[p1l1266t2067r1382b2098],
12	attention	NN	O	attention	dobj	11	SENT_29	[p1l1395t2073r1491b2097, p1l94t2116r159b2147],
13	to	TO	O	to	_	0	SENT_29	[p1l173t2122r204b2147],
14	new	JJ	O	new	amod	16	SENT_29	[p1l218t2126r287b2147],
15	treatment	NN	O	treatment	nn	16	SENT_29	[p1l298t2122r463b2146],
16	approaches	NNS	O	approach	prep_to	11	SENT_29	[p1l474t2116r670b2155],
17	.	.	O	.	_	0	SENT_29	[p1l474t2116r670b2155],

1	The	DT	O	the	det	3	SENT_30	[p1l684t2116r746b2146],
2	signaling	NN	O	signaling	nn	3	SENT_30	[p1l760t2116r917b2155],
3	pathway	NN	O	pathway	nsubjpass	21	SENT_30	[p1l928t2116r1068b2155],
4	of	IN	O	of	_	0	SENT_30	[p1l1079t2116r1118b2147],
5	the	DT	O	the	det	12	SENT_30	[p1l1124t2116r1176b2146],
6	epidermal	JJ	O	epidermal	amod	12	SENT_30	[p1l1189t2116r1357b2155],
7	growth	NN	O	growth	nn	12	SENT_30	[p1l1369t2116r1491b2155],
8	factor	NN	O	factor	nn	12	SENT_30	[p1l93t2165r191b2196],
9	receptor	NN	O	receptor	nn	12	SENT_30	[p1l207t2171r345b2204],
10	(	CD	NUMBER	(	num	12	SENT_30	[p1l364t2167r493b2202],
11	EGFR	NN	ORGANIZATION	egfr	nn	12	SENT_30	[p1l364t2167r493b2202],
12	)	NN	O	)	prep_of	3	SENT_30	[p1l364t2167r493b2202],
13	,	,	O	,	_	0	SENT_30	[p1l364t2167r493b2202],
14	a	DT	O	a	det	18	SENT_30	[p1l513t2175r530b2195],
15	cell	NN	O	cell	nn	18	SENT_30	[p1l548t2165r737b2196],
16	—	NN	O	—	nn	18	SENT_30	[p1l548t2165r737b2196],
17	surface	NN	O	surface	nn	18	SENT_30	[p1l548t2165r737b2196],
18	receptor	NN	O	receptor	appos	12	SENT_30	[p1l755t2171r901b2204],
19	,	,	O	,	_	0	SENT_30	[p1l755t2171r901b2204],
20	is	VBZ	O	be	auxpass	21	SENT_30	[p1l920t2165r946b2195],
21	activated	VBN	O	activate	ccomp	42	SENT_30	[p1l964t2165r1111b2196],
22	in	IN	O	in	_	0	SENT_30	[p1l1129t2165r1161b2195],
23	more	JJR	O	more	quantmod	25	SENT_30	[p1l1179t2175r1264b2196],
24	than	IN	O	than	quantmod	25	SENT_30	[p1l1282t2165r1359b2195],
25	half	NN	O	half	prep_in	21	SENT_30	[p1l1377t2165r1449b2195],
26	of	IN	O	of	_	0	SENT_30	[p1l1460t2165r1499b2196],
27	patients	NNS	O	patient	prep_of	25	SENT_30	[p1l93t2214r225b2253],
28	with	IN	O	with	_	0	SENT_30	[p1l241t2214r317b2245],
29	NSCLC	NN	ORGANIZATION	nsclc	prep_with	27	SENT_30	[p1l332t2216r459b2251],
30	,	,	O	,	_	0	SENT_30	[p1l332t2216r459b2251],
31	and	CC	O	and	_	0	SENT_30	[p1l477t2214r539b2245],
32	this	DT	O	this	det	33	SENT_30	[p1l555t2214r617b2244],
33	activation	NN	O	activation	nsubj	37	SENT_30	[p1l634t2214r795b2245],
34	can	MD	O	can	aux	37	SENT_30	[p1l812t2224r870b2244],
35	be	VB	O	be	cop	37	SENT_30	[p1l886t2214r924b2245],
36	the	DT	O	the	det	37	SENT_30	[p1l940t2214r992b2244],
37	result	NN	O	result	ccomp	42	SENT_30	[p1l1008t2214r1103b2245],
38	of	IN	O	of	_	0	SENT_30	[p1l1117t2214r1156b2245],
39	protein	NN	O	protein	nn	40	SENT_30	[p1l1164t2214r1285b2253],
40	overexpression	NN	O	overexpression	prep_of	37	SENT_30	[p1l1302t2224r1491b2253, p1l94t2263r171b2300],
41	,	,	O	,	_	0	SENT_30	[p1l1302t2224r1491b2253, p1l94t2263r171b2300],
42	increased	VBD	O	increase	_	0	SENT_30	[p1l185t2263r343b2294],
43	gene	NN	O	gene	nsubj	42	SENT_30	[p1l355t2273r432b2302],
44	copy	NN	O	copy	nn	45	SENT_30	[p1l444t2273r520b2302],
45	number	NN	O	number	dep	43	SENT_30	[p1l530t2263r668b2300],
46	,	,	O	,	_	0	SENT_30	[p1l530t2263r668b2300],
47	or	CC	O	or	_	0	SENT_30	[p1l682t2273r717b2294],
48	genetic	JJ	O	genetic	amod	49	SENT_30	[p1l727t2263r847b2302],
49	mutations	NNS	O	mutation	conj_or	43	SENT_30	[p1l858t2263r1074b2294],
50	.	.	O	.	_	0	SENT_30	[p1l858t2263r1074b2294],

1	“	NN	O	“	nsubj	6	SENT_31	[p1l858t2263r1074b2294],
2	The	DT	O	the	det	5	SENT_31	[p1l1085t2263r1147b2293],
3	ERBB	NN	O	erbb	nn	5	SENT_31	[p1l1159t2266r1253b2295],
4	receptor	NN	O	receptor	nn	5	SENT_31	[p1l1265t2269r1403b2302],
5	family	NN	O	family	dep	1	SENT_31	[p1l1414t2263r1491b2293, p1l93t2312r133b2351],
6	consists	VBZ	O	consist	_	0	SENT_31	[p1l147t2313r279b2343],
7	of	IN	O	of	_	0	SENT_31	[p1l296t2312r335b2343],
8	four	CD	NUMBER	four	num	11	SENT_31	[p1l343t2312r413b2343],
9	receptor	NN	O	receptor	nn	11	SENT_31	[p1l427t2319r565b2351],
10	tyrosine	NN	O	tyrosine	nn	11	SENT_31	[p1l579t2312r713b2351],
11	kinases	NNS	O	kinase	prep_of	6	SENT_31	[p1l728t2312r863b2343],
12	:	:	O	:	_	0	SENT_31	[p1l728t2312r863b2343],
13	EGFR	NN	O	egfr	nn	14	SENT_31	[p1l879t2314r978b2344],
14	(	NN	O	(	nsubj	16	SENT_31	[p1l991t2312r1067b2347],
15	also	RB	O	also	advmod	16	SENT_31	[p1l991t2312r1067b2347],
16	called	VBD	O	call	conj_and	6	SENT_31	[p1l1083t2312r1181b2343],
17	ERBB1	NN	O	erbb1	nn	20	SENT_31	[p1l1196t2314r1309b2344],
18	or	CC	O	or	_	0	SENT_31	[p1l1325t2322r1359b2343],
19	HER1	NN	O	her1	conj_or	17	SENT_31	[p1l1373t2314r1489b2349],
20	)	NN	O	)	dobj	16	SENT_31	[p1l1373t2314r1489b2349],
21	,	,	O	,	_	0	SENT_31	[p1l1373t2314r1489b2349],
22	ERBB2	NN	O	erbb2	nn	23	SENT_31	[p1l93t2363r207b2393],
23	(	NN	O	(	nsubj	25	SENT_31	[p1l223t2361r299b2396],
24	also	RB	O	also	advmod	25	SENT_31	[p1l223t2361r299b2396],
25	called	VBD	O	call	ccomp	6	SENT_31	[p1l314t2361r412b2392],
26	HER2/neu	NN	O	her2/neu	nn	27	SENT_31	[p1l425t2363r615b2398],
27	)	NN	O	)	dobj	25	SENT_31	[p1l425t2363r615b2398],
28	,	,	O	,	_	0	SENT_31	[p1l425t2363r615b2398],
29	ERBB3	NN	O	erbb3	nn	30	SENT_31	[p1l630t2363r744b2393],
30	(	NN	O	(	nsubj	32	SENT_31	[p1l761t2361r837b2396],
31	also	RB	O	also	advmod	32	SENT_31	[p1l761t2361r837b2396],
32	called	VBD	O	call	ccomp	6	SENT_31	[p1l851t2361r949b2392],
33	HER3	NN	O	her3	nn	34	SENT_31	[p1l963t2363r1080b2398],
34	)	NN	O	)	dobj	32	SENT_31	[p1l963t2363r1080b2398],
35	,	,	O	,	_	0	SENT_31	[p1l963t2363r1080b2398],
36	and	CC	O	and	_	0	SENT_31	[p1l1096t2361r1158b2392],
37	ERBB4	NN	O	erbb4	nn	38	SENT_31	[p1l1171t2363r1287b2393],
38	(	NN	O	(	nsubj	40	SENT_31	[p1l1302t2361r1378b2396],
39	also	RB	O	also	advmod	40	SENT_31	[p1l1302t2361r1378b2396],
40	called	VBD	O	call	conj_and	6	SENT_31	[p1l1393t2361r1491b2392],
41	HER4	NN	O	her4	nn	42	SENT_31	[p1l93t2412r209b2445],
42	)	NN	O	)	dobj	40	SENT_31	[p1l93t2412r209b2445],
43	.	.	O	.	_	0	SENT_31	[p1l93t2412r209b2445],

1	All	DT	O	all	nsubj	6	SENT_32	[p1l223t2410r272b2440],
2	of	IN	O	of	_	0	SENT_32	[p1l285t2410r324b2441],
3	these	DT	O	these	prep_of	1	SENT_32	[p1l331t2410r417b2440],
4	except	IN	O	except	_	0	SENT_32	[p1l431t2416r537b2449],
5	HER3	NN	O	her3	prep_except	3	SENT_32	[p1l548t2412r645b2442],
6	have	VBP	O	have	_	0	SENT_32	[p1l659t2410r733b2441],
7	tyrosine	NN	O	tyrosine	nn	9	SENT_32	[p1l747t2410r881b2449],
8	kinase	NN	O	kinase	nn	9	SENT_32	[p1l894t2410r1003b2441],
9	activity	NN	O	activity	dobj	6	SENT_32	[p1l1016t2410r1141b2449],
10	.	.	O	.	_	0	SENT_32	[p1l1016t2410r1141b2449],

1	Binding	NN	O	binding	nsubj	32	SENT_33	[p1l143t2459r276b2498],
2	of	IN	O	of	_	0	SENT_33	[p1l290t2459r329b2490],
3	secreted	VBN	O	secrete	prepc_of	1	SENT_33	[p1l337t2459r472b2490],
4	growth	NN	O	growth	nn	5	SENT_33	[p1l486t2459r608b2498],
5	factors	NNS	O	factor	dobj	3	SENT_33	[p1l623t2459r745b2496],
6	,	,	O	,	_	0	SENT_33	[p1l623t2459r745b2496],
7	such	JJ	O	such	_	0	SENT_33	[p1l762t2459r837b2490],
8	as	IN	O	as	_	0	SENT_33	[p1l851t2469r885b2489],
9	the	DT	O	the	det	15	SENT_33	[p1l900t2459r952b2489],
10	epidermal	JJ	O	epidermal	amod	15	SENT_33	[p1l966t2459r1134b2498],
11	growth	NN	O	growth	nn	15	SENT_33	[p1l1148t2459r1270b2498],
12	factor	NN	O	factor	nn	15	SENT_33	[p1l1284t2459r1382b2490],
13	(	CD	NUMBER	(	num	15	SENT_33	[p1l1397t2461r1489b2494],
14	EGF	NN	O	egf	nn	15	SENT_33	[p1l1397t2461r1489b2494],
15	)	NN	O	)	prep_such_as	5	SENT_33	[p1l1397t2461r1489b2494],
16	and	CC	O	and	_	0	SENT_33	[p1l93t2508r155b2539],
17	other	JJ	O	other	amod	18	SENT_33	[p1l172t2508r261b2539],
18	EGF	NN	O	egf	prep_such_as	5	SENT_33	[p1l277t2508r420b2539],
19	—	CD	NUMBER	—	num	18	SENT_33	[p1l277t2508r420b2539],
20	like	IN	O	like	_	0	SENT_33	[p1l277t2508r420b2539],
21	growth	NN	O	growth	nn	22	SENT_33	[p1l438t2508r560b2547],
22	factors	NNS	O	factor	prep_like	3	SENT_33	[p1l578t2508r700b2545],
23	,	,	O	,	_	0	SENT_33	[p1l578t2508r700b2545],
24	including	VBG	O	include	_	0	SENT_33	[p1l719t2508r879b2547],
25	transforming	VBG	O	transform	prepc_including	22	SENT_33	[p1l895t2508r1120b2547],
26	growth	NN	O	growth	nn	27	SENT_33	[p1l1136t2508r1258b2547],
27	factor	NN	O	factor	dobj	25	SENT_33	[p1l1276t2508r1373b2539],
28	or	CC	O	or	_	0	SENT_33	[p1l1389t2520r1412b2538],
29	and	CC	O	and	conj_or	22	SENT_33	[p1l1430t2508r1492b2539],
30	epiregulin	NN	O	epiregulin	conj_or	22	SENT_33	[p1l94t2557r279b2596],
31	,	,	O	,	_	0	SENT_33	[p1l94t2557r279b2596],
32	induces	VBZ	O	induce	_	0	SENT_33	[p1l300t2557r429b2588],
33	receptor	NN	O	receptor	nn	34	SENT_33	[p1l450t2563r591b2596],
34	dimerization	NN	O	dimerization	dobj	32	SENT_33	[p1l610t2557r840b2594],
35	,	,	O	,	_	0	SENT_33	[p1l610t2557r840b2594],
36	resulting	VBG	O	result	partmod	32	SENT_33	[p1l862t2557r1015b2596],
37	in	IN	O	in	_	0	SENT_33	[p1l1033t2557r1066b2587],
38	the	DT	O	the	det	39	SENT_33	[p1l1086t2557r1139b2587],
39	phosphorylation	NN	O	phosphorylation	prep_in	36	SENT_33	[p1l1158t2557r1439b2596],
40	of	IN	O	of	_	0	SENT_33	[p1l1459t2557r1498b2588],
41	tyrosine	NN	O	tyrosine	nn	42	SENT_33	[p1l94t2606r229b2645],
42	residues	NNS	O	residue	prep_of	39	SENT_33	[p1l242t2606r377b2637],
43	in	IN	O	in	_	0	SENT_33	[p1l390t2606r423b2636],
44	the	DT	O	the	det	48	SENT_33	[p1l436t2606r488b2636],
45	kinase	NN	O	kinase	nn	48	SENT_33	[p1l501t2606r609b2637],
46	domain	NN	O	domain	nn	48	SENT_33	[p1l623t2606r812b2637],
47	.7	CD	NUMBER	.7	num	48	SENT_33	[p1l623t2606r812b2637],
48	‘	NN	O	‘	prep_in	42	SENT_33	[p1l623t2606r812b2637],
49	1	CD	NUMBER	1	number	50	SENT_33	[p1l623t2606r812b2637],
50	°	CD	NUMBER	°	dobj	36	SENT_33	[p1l623t2606r812b2637],
51	These	DT	O	these	det	52	SENT_33	[p1l824t2606r922b2636],
52	phosphotyrosines	NNS	O	phosphotyrosine	nsubj	53	SENT_33	[p1l934t2606r1232b2645],
53	recruit	VBP	O	recruit	rcmod	50	SENT_33	[p1l1246t2607r1357b2637],
54	partner	NN	O	partner	nn	55	SENT_33	[p1l1368t2613r1492b2645],
55	proteins	NNS	O	protein	dobj	53	SENT_33	[p1l93t2655r230b2694],
56	that	WDT	O	that	nsubj	57	SENT_33	[p1l244t2655r311b2685],
57	trigger	VBP	O	trigger	rcmod	55	SENT_33	[p1l322t2655r436b2694],
58	intracellular	JJ	O	intracellular	amod	60	SENT_33	[p1l447t2655r653b2686],
59	signaling	NN	O	signaling	nn	60	SENT_33	[p1l665t2655r821b2694],
60	cascades	NNS	O	cascade	dobj	57	SENT_33	[p1l833t2655r987b2692],
61	,	,	O	,	_	0	SENT_33	[p1l833t2655r987b2692],
62	chieﬂy	NN	O	chieﬂy	appos	60	SENT_33	[p1l1002t2655r1116b2694],
63	through	IN	O	through	_	0	SENT_33	[p1l1127t2655r1262b2694],
64	the	DT	O	the	det	66	SENT_33	[p1l1275t2655r1327b2685],
65	mitogen	NN	O	mitogen	nn	66	SENT_33	[p1l1340t2655r1491b2694],
66	—	NN	O	—	prep_through	57	SENT_33	[p1l1340t2655r1491b2694],
67	activated	VBN	O	activate	partmod	66	SENT_33	[p1l93t2704r243b2735],
68	protein	NN	O	protein	nn	69	SENT_33	[p1l259t2704r382b2743],
69	kinase	NN	O	kinase	dobj	67	SENT_33	[p1l398t2704r508b2735],
70	(	CD	NUMBER	(	num	72	SENT_33	[p1l526t2707r656b2739],
71	MAPK	NN	O	mapk	nn	72	SENT_33	[p1l526t2707r656b2739],
72	)	NN	O	)	dep	69	SENT_33	[p1l526t2707r656b2739],
73	and	CC	O	and	_	0	SENT_33	[p1l674t2704r736b2735],
74	phosphatidylinositol	NN	O	phosphatidylinositol	nn	77	SENT_33	[p1l752t2704r1104b2743],
75	3	CD	NUMBER	3	num	77	SENT_33	[p1l1120t2704r1264b2735],
76	—	NN	O	—	nn	77	SENT_33	[p1l1120t2704r1264b2735],
77	kinase	NN	O	kinase	conj_and	69	SENT_33	[p1l1120t2704r1264b2735],
78	(	CD	NUMBER	(	num	79	SENT_33	[p1l1281t2706r1384b2739],
79	PI3I	NN	O	pi3us	dep	77	SENT_33	[p1l1281t2706r1384b2739],
80	(	CD	NUMBER	(	number	81	SENT_33	[p1l1281t2706r1384b2739],
81	)	CD	NUMBER	)	num	82	SENT_33	[p1l1281t2706r1384b2739],
82	pathN	NN	O	pathn	dep	79	SENT_33	[p1l1402t2704r1491b2743, p1l464t2828r478b2843],

1	ENGLJ	NNP	O	ENGLJ	nn	2	SENT_34	[p1l493t2828r571b2850],
2	MED	NNP	O	MED	_	0	SENT_34	[p1l585t2828r637b2843],
3	364,10	CD	NUMBER	364,10	dep	2	SENT_34	[p1l647t2822r729b2850],
4	NEJM.ORG	NNP	O	NEJM.ORG	nn	5	SENT_34	[p1l764t2828r888b2850],
5	MARCH	NNP	DATE	MARCH	dep	2	SENT_34	[p1l925t2828r1010b2843],
6	10	CD	DATE	10	num	5	SENT_34	[p1l1023t2828r1057b2848],
7	,	,	DATE	,	_	0	SENT_34	[p1l1023t2828r1057b2848],
8	2011	CD	DATE	2011	num	5	SENT_34	[p1l1068t2828r1120b2844],

1	The	DT	O	the	det	4	SENT_35	[p1l752t2885r803b2909],
2	New	NNP	O	New	nn	4	SENT_35	[p1l812t2886r874b2909],
3	England	NNP	O	England	nn	4	SENT_35	[p1l883t2885r994b2916],
4	Journal	NNP	O	Journal	_	0	SENT_35	[p1l1002t2885r1100b2909],
5	of	IN	O	of	_	0	SENT_35	[p1l1109t2885r1138b2909],
6	Medicine	NNP	O	Medicine	prep_of	4	SENT_35	[p1l1145t2885r1270b2909],

1	From	IN	O	from	dep	16	SENT_36	[p1l1533t979r1597b1001],
2	Louisiana	NNP	ORGANIZATION	Louisiana	nn	7	SENT_36	[p1l1615t979r1737b1001],
3	State	NNP	ORGANIZATION	State	nn	7	SENT_36	[p1l1753t979r1818b1001],
4	University	NNP	ORGANIZATION	University	nn	7	SENT_36	[p1l1834t979r1965b1008],
5	Health	NNP	ORGANIZATION	Health	nn	7	SENT_36	[p1l1981t977r2065b1001],
6	Sciences	NNPS	ORGANIZATION	Sciences	nn	7	SENT_36	[p1l1531t1017r1643b1039],
7	Center	NNP	ORGANIZATION	Center	pobj	1	SENT_36	[p1l1681t1017r1767b1039],
8	and	CC	O	and	_	0	SENT_36	[p1l1804t1015r1849b1039],
9	HematologyOncology	NNP	ORGANIZATION	HematologyOncology	nn	10	SENT_36	[p1l1890t1015r2067b1046, p1l1531t1053r1657b1084],
10	Clinic	NNP	ORGANIZATION	Clinic	pobj	1	SENT_36	[p1l1672t1053r1751b1080],
11	,	,	O	,	_	0	SENT_36	[p1l1672t1053r1751b1080],
12	Baton	NNP	LOCATION	Baton	nn	13	SENT_36	[p1l1769t1055r1842b1076],
13	Rouge	NNP	LOCATION	Rouge	appos	7	SENT_36	[p1l1861t1055r1940b1084],
14	(	CD	NUMBER	(	num	16	SENT_36	[p1l1958t1054r2065b1084],
15	V.D.C.	NNP	O	V.D.C.	nn	16	SENT_36	[p1l1958t1054r2065b1084],
16	)	NN	O	)	_	0	SENT_36	[p1l1958t1054r2065b1084],
17	;	:	O	;	_	0	SENT_36	[p1l1958t1054r2065b1084],
18	the	DT	O	the	det	19	SENT_36	[p1l1530t1090r1571b1114],
19	University	NNP	ORGANIZATION	University	dep	16	SENT_36	[p1l1588t1092r1719b1121],
20	of	IN	ORGANIZATION	of	_	0	SENT_36	[p1l1734t1090r1762b1114],
21	Texas	NNP	ORGANIZATION	Texas	nn	29	SENT_36	[p1l1772t1092r1843b1114],
22	M.D.	NNP	ORGANIZATION	M.D.	nn	29	SENT_36	[p1l1862t1092r1923b1114],
23	Anderson	NNP	ORGANIZATION	Anderson	nn	29	SENT_36	[p1l1939t1090r2065b1114],
24	Cancer	NNP	ORGANIZATION	Cancer	nn	29	SENT_36	[p1l1531t1129r1620b1151],
25	Center	NNP	ORGANIZATION	Center	nn	29	SENT_36	[p1l1628t1129r1716b1155],
26	,	,	O	,	_	0	SENT_36	[p1l1628t1129r1716b1155],
27	Houston	NNP	LOCATION	Houston	appos	29	SENT_36	[p1l1728t1129r1838b1151],
28	(	CD	NUMBER	(	num	29	SENT_36	[p1l1850t1129r1946b1158],
29	D.L.G.	NNP	O	D.L.G.	prep_of	19	SENT_36	[p1l1850t1129r1946b1158],
30	,	,	O	,	_	0	SENT_36	[p1l1850t1129r1946b1158],
31	A.Q.-C	NNP	O	A.Q.-C	nn	33	SENT_36	[p1l1955t1129r2065b1158],
32	.	.	O	.	_	0	SENT_36	[p1l1955t1129r2065b1158],
33	)	NN	O	)	appos	29	SENT_36	[p1l1955t1129r2065b1158],

1	;	:	O	;	_	0	SENT_37	[p1l1955t1129r2065b1158],
2	and	CC	O	and	advmod	5	SENT_37	[p1l1531t1165r1577b1189],
3	Montefiore	NNP	ORGANIZATION	Montefiore	nn	5	SENT_37	[p1l1597t1165r1741b1189],
4	Medical	NNP	ORGANIZATION	Medical	nn	5	SENT_37	[p1l1760t1165r1860b1189],
5	Center	NNP	ORGANIZATION	Center	_	0	SENT_37	[p1l1878t1167r1969b1193],
6	,	,	O	,	_	0	SENT_37	[p1l1878t1167r1969b1193],
7	Albert	NNP	PERSON	Albert	nn	9	SENT_37	[p1l1986t1165r2066b1189],
8	Einstein	NNP	PERSON	Einstein	nn	9	SENT_37	[p1l1533t1205r1633b1227],
9	College	NNP	ORGANIZATION	College	appos	5	SENT_37	[p1l1647t1203r1743b1234],
10	of	IN	ORGANIZATION	of	_	0	SENT_37	[p1l1755t1203r1783b1227],
11	Medicine	NNP	ORGANIZATION	Medicine	nn	17	SENT_37	[p1l1793t1203r1918b1231],
12	,	,	O	,	_	0	SENT_37	[p1l1793t1203r1918b1231],
13	Bronx	NNP	LOCATION	Bronx	appos	17	SENT_37	[p1l1933t1205r2013b1231],
14	,	,	O	,	_	0	SENT_37	[p1l1933t1205r2013b1231],
15	NY	NNP	O	NY	appos	17	SENT_37	[p1l2029t1205r2067b1227],
16	(	NNP	O	(	nn	17	SENT_37	[p1l1533t1242r1641b1271],
17	R.P.	NNP	PERSON	R.P.	prep_of	5	SENT_37	[p1l1533t1242r1641b1271],
18	.	.	O	.	_	0	SENT_37	[p1l1533t1242r1641b1271],

1	—	NN	O	—	_	0	SENT_38	[p1l1533t1242r1641b1271],
2	.	.	O	.	_	0	SENT_38	[p1l1533t1242r1641b1271],

1	S.	NNP	O	S.	nn	2	SENT_39	[p1l1533t1242r1641b1271],
2	)	NNP	O	)	_	0	SENT_39	[p1l1533t1242r1641b1271],
3	.	.	O	.	_	0	SENT_39	[p1l1533t1242r1641b1271],

1	Address	NN	O	address	nsubj	2	SENT_40	[p1l1652t1240r1758b1264],
2	reprint	VB	O	reprint	_	0	SENT_40	[p1l1771t1242r1858b1271],
3	requests	NNS	O	request	dobj	2	SENT_40	[p1l1870t1245r1980b1271],
4	to	TO	O	to	_	0	SENT_40	[p1l1991t1245r2016b1264],
5	Dr.	NNP	O	Dr.	nn	6	SENT_40	[p1l2030t1242r2065b1264],
6	Cataldo	NNP	PERSON	Cataldo	prep_to	2	SENT_40	[p1l1531t1277r1630b1301],
7	at	IN	O	at	_	0	SENT_40	[p1l1644t1282r1667b1301],
8	the	DT	O	the	det	9	SENT_40	[p1l1679t1277r1720b1301],
9	Department	NNP	ORGANIZATION	Department	prep_at	6	SENT_40	[p1l1735t1279r1893b1308],
10	of	IN	ORGANIZATION	of	_	0	SENT_40	[p1l1906t1277r1934b1301],
11	Hematology	NNP	ORGANIZATION	Hematology	prep_of	9	SENT_40	[p1l1945t1277r2066b1301, p1l1531t1323r1576b1346],
12	and	CC	O	and	_	0	SENT_40	[p1l1589t1315r1635b1339],
13	Oncology	NNP	O	Oncology	prep_of	9	SENT_40	[p1l1650t1315r1781b1346],
14	,	,	O	,	_	0	SENT_40	[p1l1650t1315r1781b1346],
15	Louisiana	NNP	ORGANIZATION	Louisiana	nn	20	SENT_40	[p1l1798t1317r1920b1339],
16	State	NNP	ORGANIZATION	State	nn	20	SENT_40	[p1l1934t1317r1999b1339],
17	University	NNP	ORGANIZATION	University	nn	20	SENT_40	[p1l2013t1317r2066b1339, p1l1530t1354r1615b1383],
18	Health	NNP	ORGANIZATION	Health	nn	20	SENT_40	[p1l1628t1352r1712b1376],
19	Sciences	NNPS	ORGANIZATION	Sciences	nn	20	SENT_40	[p1l1724t1354r1836b1376],
20	Center	NNP	ORGANIZATION	Center	prep_of	9	SENT_40	[p1l1848t1354r1938b1380],
21	,	,	O	,	_	0	SENT_40	[p1l1848t1354r1938b1380],
22	5825	CD	NUMBER	5825	num	24	SENT_40	[p1l1951t1354r2010b1376],
23	Airline	NN	O	airline	nn	24	SENT_40	[p1l2022t1354r2066b1375, p1l1532t1390r1576b1413],
24	Hwy.	NN	O	hwy.	prep_of	9	SENT_40	[p1l1590t1392r1659b1421],
25	,	,	O	,	_	0	SENT_40	[p1l1590t1392r1659b1421],
26	Baton	NNP	LOCATION	Baton	nn	27	SENT_40	[p1l1674t1392r1747b1414],
27	Rouge	NNP	LOCATION	Rouge	prep_of	9	SENT_40	[p1l1762t1392r1849b1421],
28	,	,	O	,	_	0	SENT_40	[p1l1762t1392r1849b1421],
29	LA	NNP	LOCATION	LA	prep_of	9	SENT_40	[p1l1864t1391r1896b1413],
30	70805	CD	NUMBER	70805	num	29	SENT_40	[p1l1909t1391r1993b1418],
31	,	,	O	,	_	0	SENT_40	[p1l1909t1391r1993b1418],
32	or	CC	O	or	_	0	SENT_40	[p1l2006t1398r2032b1413],
33	at	IN	O	at	advmod	11	SENT_40	[p1l2044t1394r2066b1413],
34	vincelsu@aol.com	NNP	O	vincelsu@aol.com	conj_or	11	SENT_40	[p1l1530t1427r1780b1456],
35	.	.	O	.	_	0	SENT_40	[p1l1530t1427r1780b1456],

1	N	NN	MISC	n	nn	3	SENT_41	[p1l1533t1505r1550b1526],
2	Englj	NNP	MISC	Englj	nn	3	SENT_41	[p1l1564t1503r1632b1534],
3	Med	NNP	O	Med	_	0	SENT_41	[p1l1645t1503r1700b1526],
4	2011	CD	DATE	2011	num	3	SENT_41	[p1l1711t1504r1926b1530],
5	;	:	O	;	_	0	SENT_41	[p1l1711t1504r1926b1530],
6	364:947	CD	NUMBER	364:947	number	7	SENT_41	[p1l1711t1504r1926b1530],
7	-55	CD	NUMBER	-55	dep	3	SENT_41	[p1l1711t1504r1926b1530],
8	.	.	O	.	_	0	SENT_41	[p1l1711t1504r1926b1530],

1	Copyright	NN	O	copyright	_	0	SENT_42	[p1l1531t1547r1624b1572],
2	©	CD	NUMBER	©	num	6	SENT_42	[p1l1634t1549r1655b1569],
3	2011	CD	DATE	2011	num	6	SENT_42	[p1l1665t1548r1712b1566],
4	Massachusetts	NNP	ORGANIZATION	Massachusetts	nn	6	SENT_42	[p1l1722t1547r1863b1566],
5	Medical	NNP	ORGANIZATION	Medical	nn	6	SENT_42	[p1l1872t1547r1949b1566],
6	Society	NNP	ORGANIZATION	Society	dep	1	SENT_42	[p1l1957t1547r2029b1571],
7	.	.	O	.	_	0	SENT_42	[p1l1957t1547r2029b1571],

1	Downloaded	VBN	O	download	_	0	SENT_43	[p1l194t2926r364b2949],
2	from	IN	O	from	_	0	SENT_43	[p1l373t2926r437b2949],
3	nejm.org	NN	O	nejm.org	prep_from	1	SENT_43	[p1l446t2926r564b2956],
4	at	IN	O	at	_	0	SENT_43	[p1l574t2930r597b2949],
5	UW-Madison	NN	O	uw-madison	prep_at	1	SENT_43	[p1l606t2926r788b2949],
6	on	IN	O	on	_	0	SENT_43	[p1l798t2933r830b2949],
7	January	NNP	DATE	January	prep_on	1	SENT_43	[p1l839t2926r942b2956],
8	5	CD	DATE	5	num	7	SENT_43	[p1l952t2926r974b2954],
9	,	,	DATE	,	_	0	SENT_43	[p1l952t2926r974b2954],
10	2014	CD	DATE	2014	num	7	SENT_43	[p1l985t2926r1057b2949],
11	.	.	O	.	_	0	SENT_43	[p1l985t2926r1057b2949],

1	For	IN	O	for	_	0	SENT_44	[p1l1068t2926r1114b2949],
2	personal	JJ	O	personal	amod	3	SENT_44	[p1l1122t2926r1235b2956],
3	use	NN	O	use	pobj	1	SENT_44	[p1l1244t2933r1287b2949],
4	only	RB	O	only	advmod	3	SENT_44	[p1l1297t2926r1362b2956],
5	.	.	O	.	_	0	SENT_44	[p1l1297t2926r1362b2956],

1	No	DT	O	no	det	3	SENT_45	[p1l1372t2926r1412b2949],
2	other	JJ	O	other	amod	3	SENT_45	[p1l1422t2926r1490b2949],
3	uses	NNS	O	use	_	0	SENT_45	[p1l1498t2933r1554b2949],
4	without	IN	O	without	_	0	SENT_45	[p1l1565t2926r1666b2949],
5	permission	NN	O	permission	prep_without	3	SENT_45	[p1l1674t2926r1826b2956],
6	.	.	O	.	_	0	SENT_45	[p1l1674t2926r1826b2956],

1	Copyright	NN	O	copyright	_	0	SENT_46	[p1l544t2967r679b2998],
2	©	CD	NUMBER	©	num	6	SENT_46	[p1l688t2967r711b2991],
3	2011	CD	DATE	2011	num	6	SENT_46	[p1l721t2967r784b2991],
4	Massachusetts	NNP	ORGANIZATION	Massachusetts	nn	6	SENT_46	[p1l796t2967r987b2991],
5	Medical	NNP	ORGANIZATION	Medical	nn	6	SENT_46	[p1l997t2967r1105b2991],
6	Society	NNP	ORGANIZATION	Society	dep	1	SENT_46	[p1l1115t2967r1220b2998],
7	.	.	O	.	_	0	SENT_46	[p1l1115t2967r1220b2998],

1	All	DT	O	all	det	2	SENT_47	[p1l1231t2967r1273b2991],
2	rights	NNS	O	rights	nsubj	3	SENT_47	[p1l1282t2967r1356b2998],
3	reserved	VBN	O	reserve	_	0	SENT_47	[p1l1366t2967r1485b2991],
4	.	.	O	.	_	0	SENT_47	[p1l1366t2967r1485b2991],

1	The	DT	O	the	det	4	SENT_48	[p1l673t3073r718b3094],
2	NEW	NNP	O	NEW	nn	4	SENT_48	[p1l737t3075r822b3094],
3	ENGLAND	NNP	O	ENGLAND	nn	4	SENT_48	[p1l841t3075r1029b3094],
4	JOURNAL	NNP	O	JOURNAL	_	0	SENT_48	[p1l1048t3075r1227b3101],
5	of	IN	O	of	_	0	SENT_48	[p1l1247t3073r1275b3100],
6	MEDICINE	NNP	O	MEDICINE	prep_of	4	SENT_48	[p1l1287t3075r1486b3094],

1	EGFR-specific	JJ	O	egfr-specific	amod	2	SENT_49	[p2l222t161r539b216],
2	ligands	NNS	O	ligand	_	0	SENT_49	[p2l558t161r719b217],
3	HER1	NN	O	her1	nn	6	SENT_49	[p2l1082t140r1207b179],
4	__	CD	NUMBER	__	num	6	SENT_49	[p2l1407t208r1413b218],
5	HER1	NN	O	her1	nn	6	SENT_49	[p2l1620t140r1745b179],
6	lEGFRl	NN	O	legfrl	dep	2	SENT_49	[p2l1769t140r1946b193],
7	’	CD	NUMBER	’	num	9	SENT_49	[p2l1769t140r1946b193],
8	HER2	NN	O	her2	nn	9	SENT_49	[p2l1970t140r2109b187],
9	’	NN	O	’	dep	2	SENT_49	[p2l1970t140r2109b187],

1	(	NN	O	(	_	0	SENT_50	[p2l84t225r437b281],
2	e.g.	FW	O	e.g.	dep	1	SENT_50	[p2l84t225r437b281],
3	,	,	O	,	_	0	SENT_50	[p2l84t225r437b281],
4	epiregu	FW	O	epiregu	nn	5	SENT_50	[p2l84t225r437b281],
5	|	FW	O	|	appos	1	SENT_50	[p2l84t225r437b281],
6	in	IN	O	in	dep	5	SENT_50	[p2l84t225r437b281],
7	and	CC	O	and	_	0	SENT_50	[p2l458t225r539b268],
8	transforming	VBG	O	transform	dep	5	SENT_50	[p2l558t225r861b281],
9	(	JJ	O	(	amod	11	SENT_50	[p2l1064t204r1224b257],
10	EGFR	NN	ORGANIZATION	egfr	nn	11	SENT_50	[p2l1064t204r1224b257],
11	)	NN	O	)	dobj	8	SENT_50	[p2l1064t204r1224b257],
12	f	FW	O	f	nn	13	SENT_50	[p2l1348t228r1358b266],
13	צ	FW	O	צ	amod	11	SENT_50	[p2l1418t235r1443b257],
14	*	SYM	O	*	dep	11	SENT_50	[p2l1418t235r1443b257],
15	-	:	O	-	_	0	SENT_50	[p2l1492t247r1513b258],
16	A	NN	O	a	nn	17	SENT_50	[p2l1492t247r1513b258],
17	V	NN	O	v	dep	5	SENT_50	[p2l1556t239r1566b249],
18	‘	CD	NUMBER	‘	dep	17	SENT_50	[p2l1556t239r1566b249],
19	i	FW	O	i	dep	17	SENT_50	[p2l1639t258r1640b263],
20	HER3	NN	O	her3	dep	19	SENT_50	[p2l1689t205r2041b251],
21	'	''	O	'	_	0	SENT_50	[p2l1689t205r2041b251],
22	°	CD	NUMBER	°	num	23	SENT_50	[p2l1689t205r2041b251],
23	rl_lER4	NN	O	rl_ler4	dep	19	SENT_50	[p2l1689t205r2041b251],

1	tl	NN	O	tl	_	0	SENT_51	[p2l395t289r478b332],
2	"	''	O	"	punct	1	SENT_51	[p2l395t289r478b332],
3	If	IN	O	if	mark	5	SENT_51	[p2l395t289r478b332],
4	t	NN	O	t	nsubj	5	SENT_51	[p2l524t297r540b332],
5	grow	VBP	O	grow	dep	1	SENT_51	[p2l282t304r394b345],
6	ac	NN	O	ac	dobj	5	SENT_51	[p2l475t304r523b332],
7	or	CC	O	or	_	0	SENT_51	[p2l543t304r590b332],
8	a	DT	O	a	det	10	SENT_51	[p2l605t293r652b345],
9	)	CD	NUMBER	)	num	10	SENT_51	[p2l605t293r652b345],
10	g	NN	O	g	conj_or	6	SENT_51	[p2l1707t378r1710b379],
11	_	CD	NUMBER	_	num	13	SENT_51	[p2l1735t386r1737b388],
12	Cell	NN	O	cell	nn	13	SENT_51	[p2l1761t328r1841b371],
13	membrane	NN	O	membrane	dep	10	SENT_51	[p2l1864t328r2112b371],

1	k	NN	O	k	_	0	SENT_52	[p2l589t1489r720b1557],
2	*	CD	NUMBER	*	dobj	1	SENT_52	[p2l589t1489r720b1557],
3	_	NN	O	_	dep	2	SENT_52	[p2l873t1547r881b1554],
4	e	SYM	O	e	dep	2	SENT_52	[p2l954t1514r978b1542],
5	proieration	NN	O	proieration	dep	1	SENT_52	[p2l1022t1496r1342b1555],
6	,	,	O	,	_	0	SENT_52	[p2l1022t1496r1342b1555],
7	“	CD	NUMBER	“	number	8	SENT_52	[p2l1022t1496r1342b1555],
8	֦	CD	NUMBER	֦	appos	5	SENT_52	[p2l1390t1505r1432b1558],
9	*	NN	O	*	dep	8	SENT_52	[p2l1390t1505r1432b1558],
10	‘	CD	NUMBER	‘	num	9	SENT_52	[p2l477t1574r600b1623],
11	Nu	NN	O	nu	nn	13	SENT_52	[p2l477t1574r600b1623],
12	'	''	O	'	_	0	SENT_52	[p2l477t1574r600b1623],
13	c	NN	O	c	dep	8	SENT_52	[p2l477t1574r600b1623],
14	|	CD	NUMBER	|	num	15	SENT_52	[p2l477t1574r600b1623],
15	M	NN	O	m	dep	13	SENT_52	[p2l477t1574r600b1623],
16	,	,	O	,	_	0	SENT_52	[p2l477t1574r600b1623],
17	.	.	O	.	_	0	SENT_52	[p2l477t1574r600b1623],

1	i	LS	O	i	advmod	2	SENT_53	[p2l706t1564r708b1566],
2	fell	VBD	O	fall	_	0	SENT_53	[p2l821t1564r905b1619],
3	survival	NN	O	survival	nsubj	2	SENT_53	[p2l926t1564r1112b1614],
4	,	,	O	,	_	0	SENT_53	[p2l926t1564r1112b1614],
5	metastasis	NN	O	metastasis	appos	3	SENT_53	[p2l1135t1568r1392b1614],
6	,	,	O	,	_	0	SENT_53	[p2l1135t1568r1392b1614],
7	i	FW	O	i	conj_and	5	SENT_53	[p2l1425t1568r1428b1570],
8	and	CC	O	and	_	0	SENT_53	[p2l919t1628r1000b1670],
9	angiogenesis	NN	O	angiogenesis	conj_and	5	SENT_53	[p2l1021t1632r1321b1684],

1	Figure	NNP	O	Figure	_	0	SENT_54	[p2l65t1756r228b1818],
2	1	CD	NUMBER	1	dep	1	SENT_54	[p2l251t1759r293b1803],
3	.	.	O	.	_	0	SENT_54	[p2l251t1759r293b1803],

1	Epidermal	JJ	O	epidermal	amod	4	SENT_55	[p2l319t1755r584b1817],
2	Growth	NN	O	growth	nn	4	SENT_55	[p2l607t1755r805b1803],
3	Factor	NN	O	factor	nn	4	SENT_55	[p2l831t1759r996b1803],
4	Receptor	NN	O	receptor	_	0	SENT_55	[p2l1018t1759r1254b1817],
5	(	CD	NUMBER	(	num	6	SENT_55	[p2l1276t1758r1457b1819],
6	EGFR	NN	ORGANIZATION	egfr	dep	4	SENT_55	[p2l1276t1758r1457b1819],
7	)	CD	NUMBER	)	num	9	SENT_55	[p2l1276t1758r1457b1819],
8	Signaling	NN	O	signaling	nn	9	SENT_55	[p2l1480t1755r1728b1818],
9	Pathways	NNS	O	pathway	dep	6	SENT_55	[p2l1751t1755r2013b1818],
10	.	.	O	.	_	0	SENT_55	[p2l1751t1755r2013b1818],

1	Shown	VBN	O	show	csubj	11	SENT_56	[p2l63t1851r238b1900],
2	in	IN	O	in	_	0	SENT_56	[p2l265t1856r307b1899],
3	the	DT	O	the	det	7	SENT_56	[p2l329t1851r413b1900],
4	left	JJ	O	left	amod	7	SENT_56	[p2l437t1850r520b1900],
5	portion	NN	O	portion	nn	7	SENT_56	[p2l544t1856r736b1914],
6	ofthe	NN	O	ofthe	nn	7	SENT_56	[p2l761t1850r913b1900],
7	figure	NN	O	figure	prep_in	1	SENT_56	[p2l933t1850r1089b1915],
8	are	VBP	O	be	cop	11	SENT_56	[p2l1112t1868r1189b1900],
9	the	DT	O	the	det	11	SENT_56	[p2l1210t1851r1293b1900],
10	four	CD	NUMBER	four	num	11	SENT_56	[p2l1314t1850r1423b1900],
11	members	NNS	O	member	_	0	SENT_56	[p2l1446t1851r1696b1900],
12	ofthe	VBP	O	ofthe	rcmod	11	SENT_56	[p2l1719t1850r1871b1900],
13	ERBB	NN	O	erbb	dobj	12	SENT_56	[p2l1897t1856r2035b1899],
14	(	CD	NUMBER	(	num	13	SENT_56	[p2l67t1935r138b1995],
15	or	CC	O	or	_	0	SENT_56	[p2l67t1935r138b1995],
16	HER	NN	O	her	nn	18	SENT_56	[p2l162t1935r291b1995],
17	)	NN	O	)	nn	18	SENT_56	[p2l162t1935r291b1995],
18	family	NN	O	family	conj_or	13	SENT_56	[p2l318t1931r479b1995],
19	of	IN	O	of	_	0	SENT_56	[p2l500t1931r557b1980],
20	receptors	NNS	O	receptor	prep_of	18	SENT_56	[p2l573t1940r836b1994],
21	.	.	O	.	_	0	SENT_56	[p2l573t1940r836b1994],

1	All	DT	O	all	det	5	SENT_57	[p2l858t1931r923b1979],
2	four	CD	NUMBER	four	num	3	SENT_57	[p2l946t1931r1056b1980],
3	members	NNS	O	member	npadvmod	4	SENT_57	[p2l1078t1931r1328b1980],
4	ofthis	JJ	O	ofthis	amod	5	SENT_57	[p2l1352t1931r1516b1980],
5	family	NN	O	family	nsubj	6	SENT_57	[p2l1538t1931r1700b1995],
6	have	VBP	O	have	_	0	SENT_57	[p2l1722t1931r1840b1980],
7	tyrosine	NN	O	tyrosine	nn	9	SENT_57	[p2l1860t1936r2073b1995],
8	kinase	NN	O	kinase	nn	9	SENT_57	[p2l64t2012r229b2060],
9	domains	NNS	O	domain	dobj	6	SENT_57	[p2l251t2012r480b2060],
10	in	IN	O	in	_	0	SENT_57	[p2l506t2016r547b2059],
11	the	DT	O	the	det	15	SENT_57	[p2l570t2012r654b2060],
12	cytoplasmic	JJ	O	cytoplasmic	amod	15	SENT_57	[p2l676t2012r997b2075],
13	portion	NN	O	portion	nn	15	SENT_57	[p2l1021t2016r1213b2075],
14	ofthe	NN	O	ofthe	nn	15	SENT_57	[p2l1238t2011r1390b2060],
15	receptor	NN	O	receptor	prep_in	9	SENT_57	[p2l1415t2021r1645b2075],
16	.	.	O	.	_	0	SENT_57	[p2l1415t2021r1645b2075],

1	However	RB	O	however	advmod	11	SENT_58	[p2l1673t2016r1917b2068],
2	,	,	O	,	_	0	SENT_58	[p2l1673t2016r1917b2068],
3	the	DT	O	the	det	6	SENT_58	[p2l1940t2012r2023b2060],
4	tyrosine	NN	O	tyrosine	nn	6	SENT_58	[p2l60t2096r273b2156],
5	kinase	NN	O	kinase	nn	6	SENT_58	[p2l298t2092r462b2140],
6	domain	NN	O	domain	nsubj	11	SENT_58	[p2l484t2092r683b2140],
7	of	IN	O	of	_	0	SENT_58	[p2l708t2091r766b2140],
8	HER3	NN	O	her3	prep_of	6	SENT_58	[p2l782t2096r925b2140],
9	does	VBZ	O	do	aux	11	SENT_58	[p2l950t2092r1075b2140],
10	not	RB	O	not	neg	11	SENT_58	[p2l1101t2101r1185b2140],
11	have	VB	O	have	_	0	SENT_58	[p2l1208t2092r1326b2140],
12	catalytic	JJ	O	catalytic	amod	13	SENT_58	[p2l1348t2092r1568b2155],
13	activity	NN	O	activity	dobj	11	SENT_58	[p2l1589t2096r1789b2156],
14	.	.	O	.	_	0	SENT_58	[p2l1589t2096r1789b2156],

1	The	DT	O	the	det	5	SENT_59	[p2l1811t2092r1910b2140],
2	right	JJ	O	right	amod	5	SENT_59	[p2l1935t2092r2056b2156],
3	portion	NN	O	portion	nn	5	SENT_59	[p2l65t2176r257b2235],
4	ofthe	NN	O	ofthe	nn	5	SENT_59	[p2l281t2172r433b2220],
5	figure	NN	O	figure	nsubj	6	SENT_59	[p2l454t2172r609b2236],
6	shows	VBZ	O	show	_	0	SENT_59	[p2l632t2172r797b2220],
7	that	IN	O	that	complm	16	SENT_59	[p2l818t2172r923b2220],
8	binding	VBG	O	bind	amod	9	SENT_59	[p2l947t2172r1146b2236],
9	ofligands	NNS	O	ofligand	nsubj	16	SENT_59	[p2l1166t2172r1426b2236],
10	to	TO	O	to	_	0	SENT_59	[p2l1448t2181r1499b2220],
11	the	DT	O	the	det	13	SENT_59	[p2l1519t2172r1603b2220],
12	HER	NN	O	her	nn	13	SENT_59	[p2l1629t2176r1741b2220],
13	family	NN	O	family	prep_to	9	SENT_59	[p2l1762t2172r1923b2236],
14	of	IN	O	of	_	0	SENT_59	[p2l1944t2172r2002b2220],
15	receptors	NNS	O	receptor	prep_of	13	SENT_59	[p2l65t2261r311b2315],
16	induces	VBZ	O	induce	ccomp	6	SENT_59	[p2l337t2252r539b2301],
17	either	CC	O	either	prep	16	SENT_59	[p2l563t2252r716b2300],
18	homodimerization	NN	O	homodimerization	nn	22	SENT_59	[p2l739t2252r1233b2300],
19	or	CC	O	or	_	0	SENT_59	[p2l1258t2269r1312b2300],
20	heterodimerization	NN	O	heterodimerization	conj_or	18	SENT_59	[p2l1334t2252r1843b2300],
21	ofthe	NN	O	ofthe	nn	22	SENT_59	[p2l1869t2252r2020b2300],
22	receptors	NNS	O	receptor	dep	17	SENT_59	[p2l65t2342r327b2396],
23	.	.	O	.	_	0	SENT_59	[p2l65t2342r327b2396],

1	Dimerization	NN	O	dimerization	nsubj	2	SENT_60	[p2l355t2337r699b2381],
2	results	VBZ	O	result	_	0	SENT_60	[p2l726t2333r901b2381],
3	in	IN	O	in	mark	8	SENT_60	[p2l926t2337r968b2380],
4	phosphorylation	NN	O	phosphorylation	nn	7	SENT_60	[p2l995t2332r1430b2396],
5	ofthe	NN	O	ofthe	nn	7	SENT_60	[p2l1455t2332r1607b2381],
6	tyrosine	NN	O	tyrosine	nn	7	SENT_60	[p2l1627t2337r1840b2396],
7	residues	NNS	O	residue	nsubj	8	SENT_60	[p2l1865t2333r2085b2381],
8	ofthe	VBP	O	ofthe	advcl	2	SENT_60	[p2l62t2412r214b2461],
9	EGFR	NN	ORGANIZATION	egfr	nn	11	SENT_60	[p2l240t2416r381b2461],
10	kinase	NN	O	kinase	nn	11	SENT_60	[p2l405t2413r570b2461],
11	domain	NN	O	domain	dobj	8	SENT_60	[p2l592t2413r809b2461],
12	.	.	O	.	_	0	SENT_60	[p2l592t2413r809b2461],

1	The	DT	O	the	det	3	SENT_61	[p2l830t2413r929b2461],
2	activated	VBN	O	activate	amod	3	SENT_61	[p2l952t2413r1189b2461],
3	receptor	NN	O	receptor	nsubj	6	SENT_61	[p2l1217t2422r1438b2476],
4	may	MD	O	may	aux	6	SENT_61	[p2l1460t2430r1566b2477],
5	then	RB	O	then	advmod	6	SENT_61	[p2l1584t2413r1701b2461],
6	phosphorylate	VB	O	phosphorylate	_	0	SENT_61	[p2l1729t2413r2110b2477],
7	a	DT	O	a	det	9	SENT_61	[p2l63t2510r87b2541],
8	wide	JJ	O	wide	amod	9	SENT_61	[p2l106t2493r228b2541],
9	array	NN	O	array	dobj	6	SENT_61	[p2l250t2510r376b2556],
10	ofintracellular	JJ	O	ofintracellular	amod	12	SENT_61	[p2l395t2492r773b2542],
11	signaling	NN	O	signaling	nn	12	SENT_61	[p2l793t2493r1026b2557],
12	cascades	NNS	O	cascade	dep	9	SENT_61	[p2l1046t2493r1297b2550],
13	,	,	O	,	_	0	SENT_61	[p2l1046t2493r1297b2550],
14	such	JJ	O	such	_	0	SENT_61	[p2l1321t2493r1439b2542],
15	as	IN	O	as	_	0	SENT_61	[p2l1463t2510r1516b2541],
16	the	DT	O	the	det	17	SENT_61	[p2l1536t2493r1618b2541],
17	RAS	NN	O	ra	prep_such_as	9	SENT_61	[p2l1643t2496r2091b2541],
18	.	.	O	.	_	0	SENT_61	[p2l1643t2496r2091b2541],

1	—	NN	O	—	_	0	SENT_62	[p2l1643t2496r2091b2541],
2	.	.	O	.	_	0	SENT_62	[p2l1643t2496r2091b2541],

1	RAF	NN	O	raf	_	0	SENT_63	[p2l1643t2496r2091b2541],
2	.	.	O	.	_	0	SENT_63	[p2l1643t2496r2091b2541],

1	—	NN	O	—	_	0	SENT_64	[p2l1643t2496r2091b2541],
2	.	.	O	.	_	0	SENT_64	[p2l1643t2496r2091b2541],

1	MEK	NN	O	mek	nn	2	SENT_65	[p2l1643t2496r2091b2541],
2	ERK	NN	O	erk	nsubj	5	SENT_65	[p2l66t2578r167b2621],
3	and	CC	O	and	_	0	SENT_65	[p2l188t2573r282b2622],
4	P	NN	O	p	nsubj	5	SENT_65	[p2l310t2576r575b2622],
5	|	VBP	O	|	_	0	SENT_65	[p2l310t2576r575b2622],
6	3K	NN	O	3k	dobj	5	SENT_65	[p2l310t2576r575b2622],
7	.	.	O	.	_	0	SENT_65	[p2l310t2576r575b2622],

1	—	NN	O	—	_	0	SENT_66	[p2l310t2576r575b2622],
2	.	.	O	.	_	0	SENT_66	[p2l310t2576r575b2622],

1	AKT	NN	O	akt	nn	2	SENT_67	[p2l310t2576r575b2622],
2	pathways	NNS	O	pathway	_	0	SENT_67	[p2l598t2573r857b2637],
3	,	,	O	,	_	0	SENT_67	[p2l598t2573r857b2637],
4	that	IN	O	that	dep	5	SENT_67	[p2l879t2573r984b2622],
5	induce	VBP	O	induce	dep	2	SENT_67	[p2l1007t2573r1182b2622],
6	cellular	JJ	O	cellular	amod	7	SENT_67	[p2l1204t2573r1396b2622],
7	proliferation	NN	O	proliferation	dobj	5	SENT_67	[p2l1419t2573r1760b2636],
8	,	,	O	,	_	0	SENT_67	[p2l1419t2573r1760b2636],
9	angiogenesis	NN	O	angiogenesis	dobj	5	SENT_67	[p2l1785t2578r2080b2637, p2l63t2658r145b2711],
10	,	,	O	,	_	0	SENT_67	[p2l1785t2578r2080b2637, p2l63t2658r145b2711],
11	and	CC	O	and	_	0	SENT_67	[p2l170t2654r263b2702],
12	metastases	NNS	O	metastase	dobj	5	SENT_67	[p2l291t2663r607b2702],
13	.	.	O	.	_	0	SENT_67	[p2l291t2663r607b2702],

1	EGFR	NN	ORGANIZATION	egfr	nn	2	SENT_68	[p2l636t2657r777b2702],
2	amplification	NN	O	amplification	nsubj	4	SENT_68	[p2l799t2653r1150b2716],
3	can	MD	O	can	aux	4	SENT_68	[p2l1174t2671r1263b2702],
4	obviate	VB	O	obviate	_	0	SENT_68	[p2l1288t2653r1479b2702],
5	the	DT	O	the	det	6	SENT_68	[p2l1499t2654r1583b2702],
6	requirement	NN	O	requirement	dobj	4	SENT_68	[p2l1607t2658r1934b2716],
7	for	IN	O	for	_	0	SENT_68	[p2l1954t2653r2029b2702],
8	ligand-induced	JJ	O	ligand-induced	amod	9	SENT_68	[p2l64t2734r458b2797],
9	dimerization	NN	O	dimerization	prep_for	6	SENT_68	[p2l483t2734r836b2782],
10	.	.	O	.	_	0	SENT_68	[p2l483t2734r836b2782],

1	MTOR	NN	ORGANIZATION	mtor	nsubj	2	SENT_69	[p2l864t2737r1034b2782],
2	denotes	VBZ	O	denote	_	0	SENT_69	[p2l1056t2734r1267b2782],
3	mammalian	JJ	O	mammalian	amod	4	SENT_69	[p2l1293t2734r1606b2782],
4	target	NN	O	target	dobj	2	SENT_69	[p2l1629t2743r1786b2797],
5	of	IN	O	of	_	0	SENT_69	[p2l1807t2733r1864b2782],
6	rapamycin	NN	O	rapamycin	prep_of	4	SENT_69	[p2l1880t2751r2011b2797, p2l65t2819r233b2878],
7	,	,	O	,	_	0	SENT_69	[p2l1880t2751r2011b2797, p2l65t2819r233b2878],
8	P	NN	O	p	nn	9	SENT_69	[p2l261t2819r289b2862],
9	phosphorylation	NN	O	phosphorylation	prep_of	4	SENT_69	[p2l313t2814r765b2878],
10	,	,	O	,	_	0	SENT_69	[p2l313t2814r765b2878],
11	and	CC	O	and	_	0	SENT_69	[p2l790t2814r884b2863],
12	SOS	NNP	O	SOS	nn	13	SENT_69	[p2l909t2818r1020b2863],
13	son	NN	O	son	prep_of	4	SENT_69	[p2l1045t2831r1135b2863],
14	of	IN	O	of	_	0	SENT_69	[p2l1160t2813r1218b2863],
15	sevenless	JJ	O	sevenless	prep_of	13	SENT_69	[p2l1232t2814r1500b2863],
16	.	.	O	.	_	0	SENT_69	[p2l1232t2814r1500b2863],

1	ways	NNS	O	way	_	0	SENT_70	[p2l561t3081r733b3136],
2	,	,	O	,	_	0	SENT_70	[p2l561t3081r733b3136],
3	which	WDT	O	which	nsubjpass	5	SENT_70	[p2l762t3062r958b3121],
4	are	VBP	O	be	auxpass	5	SENT_70	[p2l985t3081r1082b3120],
5	involved	VBN	O	involve	rcmod	1	SENT_70	[p2l1110t3062r1372b3121],
6	in	IN	O	in	_	0	SENT_70	[p2l1400t3063r1462b3120],
7	the	DT	O	the	det	8	SENT_70	[p2l1490t3062r1590b3120],
8	induction	NN	O	induction	prep_in	5	SENT_70	[p2l1617t3062r1925b3121],
9	of	IN	O	of	_	0	SENT_70	[p2l1953t3061r2028b3121],
10	cell	NN	O	cell	nn	11	SENT_70	[p2l2043t3062r2149b3120],
11	proliferation	NN	O	proliferation	prep_of	8	SENT_70	[p2l563t3156r976b3231],
12	,	,	O	,	_	0	SENT_70	[p2l563t3156r976b3231],
13	protection	NN	O	protection	prep_in	5	SENT_70	[p2l1022t3158r1347b3231],
14	from	IN	O	from	_	0	SENT_70	[p2l1389t3156r1544b3216],
15	apoptosis	NN	O	apoptosis	prep_from	13	SENT_70	[p2l1585t3158r1903b3231],
16	,	,	O	,	_	0	SENT_70	[p2l1585t3158r1903b3231],
17	activation	NN	O	activation	prep_in	5	SENT_70	[p2l1949t3158r2148b3216, p2l565t3253r689b3311],
18	of	IN	O	of	_	0	SENT_70	[p2l715t3251r790b3311],
19	angiogenesis	NN	O	angiogenesis	prep_of	17	SENT_70	[p2l802t3253r1237b3327],
20	,	,	O	,	_	0	SENT_70	[p2l802t3253r1237b3327],
21	and	CC	O	and	_	0	SENT_70	[p2l1267t3252r1385b3311],
22	development	NN	O	development	conj_and	8	SENT_70	[p2l1412t3252r1823b3326],
23	of	IN	O	of	_	0	SENT_70	[p2l1845t3251r1920b3311],
24	metastasis	NN	O	metastasis	prep_of	22	SENT_70	[p2l1933t3264r2148b3310, p3l565t17r708b74],

1	(	NN	O	(	_	0	SENT_71	[p3l743t17r879b91],
2	Fig	NN	O	fig	dep	1	SENT_71	[p3l743t17r879b91],
3	.	.	O	.	_	0	SENT_71	[p3l743t17r879b91],

1	1	CD	NUMBER	1	_	0	SENT_72	[p3l917t20r1130b84],
2	)	CD	NUMBER	)	number	3	SENT_72	[p3l917t20r1130b84],
3	.7	CD	NUMBER	.7	dep	1	SENT_72	[p3l917t20r1130b84],
4	v8	NN	O	v8	dep	3	SENT_72	[p3l917t20r1130b84],
5	’11	CD	NUMBER	’11	num	4	SENT_72	[p3l917t20r1130b84],

1	Erlotinib	NN	O	erlotinib	nsubjpass	5	SENT_73	[p3l660t111r943b170],
2	and	CC	O	and	_	0	SENT_73	[p3l976t111r1094b170],
3	gefitinib	NN	O	gefitinib	nsubjpass	5	SENT_73	[p3l1125t110r1403b186],
4	were	VBD	O	be	auxpass	5	SENT_73	[p3l1432t130r1583b170],
5	developed	VBN	O	develop	_	0	SENT_73	[p3l1616t111r1935b185],
6	as	IN	O	as	_	0	SENT_73	[p3l1967t130r2030b169],
7	reversible	JJ	O	reversible	amod	14	SENT_73	[p3l2064t130r2148b169, p3l561t206r804b265],
8	and	CC	O	and	_	0	SENT_73	[p3l830t206r948b265],
9	highly	RB	O	highly	advmod	10	SENT_73	[p3l976t206r1179b281],
10	speciﬁc	JJ	O	speciﬁc	conj_and	7	SENT_73	[p3l1204t205r1450b280],
11	small-molecule	JJ	O	small-molecule	amod	14	SENT_73	[p3l1479t206r1968b265],
12	tyrosine	NN	O	tyrosine	nn	14	SENT_73	[p3l1996t218r2148b280, p3l566t302r689b359],
13	kinase	NN	O	kinase	nn	14	SENT_73	[p3l713t301r917b360],
14	inhibitors	NNS	O	inhibitor	prep_as	5	SENT_73	[p3l940t301r1247b360],
15	that	WDT	O	that	nsubj	17	SENT_73	[p3l1273t301r1399b359],
16	competitively	RB	O	competitively	advmod	17	SENT_73	[p3l1419t301r1839b375],
17	block	VBP	O	block	rcmod	14	SENT_73	[p3l1859t301r2032b360],
18	the	DT	O	the	det	19	SENT_73	[p3l2052t301r2149b359],
19	binding	NN	O	binding	dobj	17	SENT_73	[p3l565t396r816b471],
20	of	IN	O	of	_	0	SENT_73	[p3l841t395r915b455],
21	adenosine	NN	O	adenosine	nn	22	SENT_73	[p3l928t396r1250b455],
22	triphosphate	NN	O	triphosphate	prep_of	19	SENT_73	[p3l1276t396r1684b470],
23	to	TO	O	to	_	0	SENT_73	[p3l1711t408r1772b455],
24	its	PRP$	O	its	poss	26	SENT_73	[p3l1798t397r1872b454],
25	binding	NN	O	binding	nn	26	SENT_73	[p3l1900t396r2152b471],
26	site	NN	O	site	prep_to	17	SENT_73	[p3l566t492r672b549],
27	in	IN	O	in	_	0	SENT_73	[p3l720t492r782b549],
28	the	DT	O	the	det	31	SENT_73	[p3l830t491r929b549],
29	tyrosine	NN	O	tyrosine	nn	31	SENT_73	[p3l978t492r1236b565],
30	kinase	NN	O	kinase	nn	31	SENT_73	[p3l1284t491r1492b550],
31	domain	NN	O	domain	prep_in	17	SENT_73	[p3l1541t491r1787b550],
32	of	IN	O	of	_	0	SENT_73	[p3l1836t490r1910b550],
33	EGFR	NN	ORGANIZATION	egfr	prep_of	31	SENT_73	[p3l1944t496r2145b562],
34	,	,	O	,	_	0	SENT_73	[p3l1944t496r2145b562],
35	thereby	RB	O	thereby	advmod	36	SENT_73	[p3l565t586r796b660],
36	inhibiting	VBG	O	inhibit	dep	17	SENT_73	[p3l816t586r1130b661],
37	autophosphorylation	NN	O	autophosphorylation	dobj	36	SENT_73	[p3l1150t586r1800b660],
38	and	CC	O	and	_	0	SENT_73	[p3l1822t586r1938b645],
39	blocking	VBG	O	block	dep	17	SENT_73	[p3l1962t586r2148b645, p3l564t682r668b756],
40	downstream	JJ	O	downstream	amod	41	SENT_73	[p3l711t681r1114b740],
41	signaling	NN	O	signaling	dobj	39	SENT_73	[p3l1159t681r1460b756],
42	(	CD	NUMBER	(	num	43	SENT_73	[p3l1506t682r1640b756],
43	Fig	NN	O	fig	dobj	36	SENT_73	[p3l1506t682r1640b756],
44	.	.	O	.	_	0	SENT_73	[p3l1506t682r1640b756],

1	2	CD	NUMBER	2	number	2	SENT_74	[p3l1688t685r1822b749],
2	)	CD	NUMBER	)	nsubj	7	SENT_74	[p3l1688t685r1822b749],
3	.12	CD	NUMBER	.12	num	4	SENT_74	[p3l1688t685r1822b749],
4	Erlotinib	NN	O	erlotinib	dep	2	SENT_74	[p3l1865t681r2148b740],
5	and	CC	O	and	_	0	SENT_74	[p3l564t776r682b835],
6	gefitinib	NN	O	gefitinib	conj_and	2	SENT_74	[p3l710t775r988b851],
7	appear	VBP	O	appear	_	0	SENT_74	[p3l1016t795r1235b850],
8	to	TO	O	to	aux	11	SENT_74	[p3l1261t788r1322b835],
9	be	VB	O	be	cop	11	SENT_74	[p3l1352t776r1424b835],
10	especially	RB	O	especially	advmod	11	SENT_74	[p3l1453t776r1766b850],
11	effective	JJ	O	effective	xcomp	7	SENT_74	[p3l1792t775r2059b835],
12	in	IN	O	in	_	0	SENT_74	[p3l2087t777r2149b833],
13	tumors	NNS	O	tumor	prep_in	11	SENT_74	[p3l565t883r794b930],
14	with	IN	O	with	_	0	SENT_74	[p3l821t871r966b930],
15	gene	NN	O	gene	nn	16	SENT_74	[p3l994t890r1142b946],
16	mutations	NNS	O	mutation	prep_with	13	SENT_74	[p3l1170t872r1494b930],
17	that	WDT	O	that	nsubj	18	SENT_74	[p3l1524t871r1653b929],
18	activate	VBP	O	activate	rcmod	13	SENT_74	[p3l1676t872r1916b930],
19	EGFR	NN	ORGANIZATION	egfr	dobj	18	SENT_74	[p3l1943t876r2145b933],
20	.	.	O	.	_	0	SENT_74	[p3l1943t876r2145b933],

1	Such	JJ	O	such	amod	2	SENT_75	[p3l566t966r717b1025],
2	tumors	NNS	O	tumor	nsubj	5	SENT_75	[p3l748t978r978b1025],
3	may	MD	O	may	aux	5	SENT_75	[p3l1011t985r1145b1040],
4	become	VB	O	become	cop	5	SENT_75	[p3l1174t966r1420b1025],
5	dependent	JJ	O	dependent	_	0	SENT_75	[p3l1453t966r1789b1040],
6	on	IN	O	on	_	0	SENT_75	[p3l1818t985r1896b1025],
7	the	DT	O	the	det	8	SENT_75	[p3l1928t966r2028b1024],
8	activity	NN	O	activity	prep_on	5	SENT_75	[p3l2059t985r2148b1024, p3l565t1062r726b1135],
9	of	IN	O	of	_	0	SENT_75	[p3l753t1060r827b1120],
10	the	DT	O	the	det	12	SENT_75	[p3l844t1061r943b1119],
11	EGFR	NN	ORGANIZATION	egfr	nn	12	SENT_75	[p3l971t1066r1162b1123],
12	pathway	NN	O	pathway	prep_of	8	SENT_75	[p3l1183t1061r1453b1135],
13	for	IN	O	for	_	0	SENT_75	[p3l1479t1060r1570b1120],
14	their	PRP$	O	they	poss	15	SENT_75	[p3l1598t1061r1750b1119],
15	survival	NN	O	survival	prep_for	12	SENT_75	[p3l1779t1061r2100b1120],
16	.13	CD	NUMBER	.13	tmod	5	SENT_75	[p3l1779t1061r2100b1120],

1	CLINICAL	JJ	O	clinical	amod	2	SENT_76	[p3l924t1286r1328b1329],
2	EVIDENCE	NN	O	evidence	_	0	SENT_76	[p3l1367t1286r1789b1329],

1	Erlotinib	NN	O	erlotinib	nsubjpass	6	SENT_77	[p3l564t1450r853b1509],
2	and	CC	O	and	_	0	SENT_77	[p3l891t1450r1010b1509],
3	gefitinib	NN	O	gefitinib	conj_and	1	SENT_77	[p3l1047t1449r1331b1525],
4	have	VBP	O	have	aux	6	SENT_77	[p3l1369t1450r1513b1509],
5	been	VBN	O	be	auxpass	6	SENT_77	[p3l1551t1450r1704b1509],
6	studied	VBN	O	study	_	0	SENT_77	[p3l1742t1450r1981b1509],
7	in	IN	O	in	_	0	SENT_77	[p3l2017t1451r2080b1507],
8	a	DT	O	a	det	9	SENT_77	[p3l2117t1469r2150b1508],
9	variety	NN	O	variety	prep_in	6	SENT_77	[p3l561t1555r780b1628],
10	of	IN	O	of	_	0	SENT_77	[p3l807t1553r882b1613],
11	settings	NNS	O	setting	prep_of	9	SENT_77	[p3l900t1555r1151b1629],
12	in	IN	O	in	_	0	SENT_77	[p3l1183t1555r1245b1611],
13	clinical	JJ	O	clinical	amod	14	SENT_77	[p3l1276t1554r1510b1612],
14	trials	NNS	O	trial	prep_in	6	SENT_77	[p3l1540t1554r1722b1625],
15	,	,	O	,	_	0	SENT_77	[p3l1540t1554r1722b1625],
16	all	DT	O	all	dep	17	SENT_77	[p3l1756t1554r1834b1612],
17	of	IN	O	of	nsubj	20	SENT_77	[p3l1865t1553r1939b1613],
18	which	WDT	O	which	pobj	17	SENT_77	[p3l1953t1554r2149b1613],
19	have	VBP	O	have	aux	20	SENT_77	[p3l11t1824r202b1903],
20	sought	VBN	O	seek	rcmod	14	SENT_77	[p3l237t1824r534b1925],
21	to	TO	O	to	aux	22	SENT_77	[p3l562t1841r645b1903],
22	determine	VB	O	determine	xcomp	20	SENT_77	[p3l680t1824r1121b1903],
23	how	WRB	O	how	advmod	26	SENT_77	[p3l1154t1824r1340b1903],
24	best	JJS	O	best	nsubj	26	SENT_77	[p3l1370t1824r1548b1903],
25	to	TO	O	to	aux	26	SENT_77	[p3l1578t1841r1659b1903],
26	exploit	VB	O	exploit	ccomp	22	SENT_77	[p3l1695t1824r1988b1924],
27	the	DT	O	the	det	30	SENT_77	[p3l2016t1824r2150b1902],
28	potential	JJ	O	potential	amod	30	SENT_77	[p3l10t1952r400b2053],
29	beneficial	JJ	O	beneficial	amod	30	SENT_77	[p3l445t1951r871b2032],
30	effects	NNS	O	effect	dobj	26	SENT_77	[p3l916t1951r1200b2031],
31	of	IN	O	of	_	0	SENT_77	[p3l1247t1951r1348b2032],
32	these	DT	O	these	det	33	SENT_77	[p3l1374t1952r1599b2031],
33	agents	NNS	O	agent	prep_of	30	SENT_77	[p3l1644t1969r1946b2054],
34	.	.	O	.	_	0	SENT_77	[p3l1644t1969r1946b2054],

1	(	NN	O	(	nsubj	4	SENT_78	[p3l2002t1959r2150b2044],
2	An	DT	O	a	det	4	SENT_78	[p3l2002t1959r2150b2044],
3	extensive	JJ	O	extensive	amod	4	SENT_78	[p3l12t2081r403b2160],
4	discussion	NN	O	discussion	_	0	SENT_78	[p3l435t2080r890b2160],
5	of	IN	O	of	_	0	SENT_78	[p3l922t2079r1023b2159],
6	the	DT	O	the	det	9	SENT_78	[p3l1036t2080r1169b2158],
7	major	JJ	O	major	amod	9	SENT_78	[p3l1201t2081r1452b2180],
8	clinical	JJ	O	clinical	amod	9	SENT_78	[p3l1482t2080r1797b2158],
9	trials	NNS	O	trial	prep_of	4	SENT_78	[p3l1829t2080r2049b2158],
10	is	VBZ	O	be	auxpass	11	SENT_78	[p3l2082t2081r2148b2158],
11	provided	VBN	O	provide	rcmod	4	SENT_78	[p3l10t2209r387b2309],
12	in	IN	O	in	_	0	SENT_78	[p3l431t2210r515b2287],
13	the	DT	O	the	det	15	SENT_78	[p3l560t2209r694b2287],
14	Supplementary	NNP	O	Supplementary	nn	15	SENT_78	[p3l742t2209r1394b2309],
15	Appendix	NNP	O	Appendix	prep_in	11	SENT_78	[p3l1430t2209r1872b2309],
16	,	,	O	,	_	0	SENT_78	[p3l1430t2209r1872b2309],
17	available	JJ	O	available	amod	24	SENT_78	[p3l1921t2209r2149b2288, p3l10t2338r183b2418],
18	with	IN	O	with	_	0	SENT_78	[p3l207t2338r404b2418],
19	the	DT	O	the	det	21	SENT_78	[p3l435t2338r568b2417],
20	full	JJ	O	full	amod	21	SENT_78	[p3l598t2337r747b2418],
21	text	NN	O	text	prep_with	17	SENT_78	[p3l777t2355r940b2417],
22	of	IN	O	of	_	0	SENT_78	[p3l964t2337r1065b2418],
23	this	DT	O	this	prep_of	21	SENT_78	[p3l1076t2338r1237b2417],
24	article	NN	O	article	dobj	4	SENT_78	[p3l1268t2338r1538b2417],
25	at	IN	O	at	prep	24	SENT_78	[p3l1567t2355r1647b2417],
26	N	NN	O	n	nn	27	SENT_78	[p3l1669t2346r1745b2418],
27	EJM.org	NN	O	ejm.org	dep	25	SENT_78	[p3l1748t2345r2145b2440],
28	.	.	O	.	_	0	SENT_78	[p3l1748t2345r2145b2440],
29	)	SYM	O	)	dep	24	SENT_78	[p3l1748t2345r2145b2440],

1	In	IN	O	in	_	0	SENT_79	[p3l140t2475r229b2545],
2	two	CD	NUMBER	two	num	4	SENT_79	[p3l268t2484r427b2546],
3	parallel	JJ	O	parallel	amod	4	SENT_79	[p3l466t2467r793b2567],
4	phase	NN	O	phase	prep_in	12	SENT_79	[p3l830t2467r1080b2567],
5	3	CD	NUMBER	3	num	6	SENT_79	[p3l1121t2473r1165b2546],
6	studies	NNS	O	study	dep	4	SENT_79	[p3l1209t2467r1536b2563],
7	,	,	O	,	_	0	SENT_79	[p3l1209t2467r1536b2563],
8	erlotinib	NN	O	erlotinib	nsubjpass	12	SENT_79	[p3l1582t2467r1951b2546],
9	and	CC	O	and	_	0	SENT_79	[p3l1991t2467r2150b2546],
10	gefitinib	NN	O	gefitinib	conj_and	8	SENT_79	[p3l11t2595r377b2698],
11	were	VBD	O	be	auxpass	12	SENT_79	[p3l410t2622r611b2676],
12	compared	VBN	O	compare	_	0	SENT_79	[p3l648t2596r1070b2697],
13	with	IN	O	with	_	0	SENT_79	[p3l1102t2596r1296b2676],
14	placebo	NN	O	placebo	prep_with	12	SENT_79	[p3l1331t2596r1656b2697],
15	in	IN	O	in	_	0	SENT_79	[p3l1693t2597r1776b2674],
16	patients	NNS	O	patient	prep_in	12	SENT_79	[p3l1812t2597r2148b2697],
17	with	IN	O	with	_	0	SENT_79	[p3l6t2726r200b2805],
18	advanced	JJ	O	advanced	amod	19	SENT_79	[p3l236t2726r627b2805],
19	NSCLC	NNP	ORGANIZATION	NSCLC	prep_with	16	SENT_79	[p3l661t2732r962b2805],
20	in	IN	O	in	_	0	SENT_79	[p3l999t2727r1083b2803],
21	whom	WP	O	whom	rel	25	SENT_79	[p3l1115t2726r1384b2805],
22	standard	JJ	O	standard	amod	23	SENT_79	[p3l1422t2726r1797b2805],
23	chemotherapy	NN	O	chemotherapy	nsubj	25	SENT_79	[p3l1833t2726r2148b2805, p3l11t2853r335b2953],
24	had	VBD	O	have	aux	25	SENT_79	[p3l363t2853r521b2932],
25	failed	VBN	O	fail	rcmod	16	SENT_79	[p3l552t2852r817b2932],
26	.	.	O	.	_	0	SENT_79	[p3l552t2852r817b2932],

1	In	IN	O	in	_	0	SENT_80	[p3l854t2861r942b2931],
2	a	DT	O	a	det	5	SENT_80	[p3l974t2879r1019b2931],
3	National	NNP	ORGANIZATION	National	nn	5	SENT_80	[p3l1047t2853r1423b2932],
4	Cancer	NNP	ORGANIZATION	Cancer	nn	5	SENT_80	[p3l1454t2860r1755b2932],
5	Institute	NNP	ORGANIZATION	Institute	pobj	1	SENT_80	[p3l1783t2854r2150b2932],
6	of	IN	ORGANIZATION	of	_	0	SENT_80	[p3l11t2980r111b3060],
7	Canada	NNP	ORGANIZATION	Canada	nn	9	SENT_80	[p3l127t2981r446b3060],
8	Clinical	JJ	ORGANIZATION	clinical	amod	9	SENT_80	[p3l479t2981r806b3060],
9	Trials	NNPS	ORGANIZATION	Trials	prep_of	5	SENT_80	[p3l837t2981r1078b3059],
10	Group	NNP	ORGANIZATION	Group	dep	17	SENT_80	[p3l1115t2988r1381b3081],
11	(	CD	NUMBER	(	num	10	SENT_80	[p3l1422t2988r1678b3072],
12	NCIC	NNP	ORGANIZATION	NCIC	nn	13	SENT_80	[p3l1422t2988r1678b3072],
13	CTG	NNP	ORGANIZATION	CTG	dep	10	SENT_80	[p3l1716t2987r1935b3072],
14	)	CD	NUMBER	)	num	15	SENT_80	[p3l1716t2987r1935b3072],
15	trial	NN	O	trial	dep	17	SENT_80	[p3l1976t2981r2150b3059],
16	(	CD	NUMBER	(	num	17	SENT_80	[p3l16t3116r314b3201],
17	BR	NN	O	br	dep	9	SENT_80	[p3l16t3116r314b3201],
18	.21	CD	NUMBER	.21	number	19	SENT_80	[p3l16t3116r314b3201],
19	)	CD	NUMBER	)	dep	17	SENT_80	[p3l16t3116r314b3201],
20	(	CD	NUMBER	(	num	21	SENT_80	[p3l346t3110r1101b3211],
21	ClinicalTrials	NNS	O	clinicaltrial	dep	19	SENT_80	[p3l346t3110r1101b3211],
22	.	.	O	.	_	0	SENT_80	[p3l346t3110r1101b3211],

1	gov	NN	O	gov	nn	2	SENT_81	[p3l346t3110r1101b3211],
2	number	NN	O	number	nsubjpass	17	SENT_81	[p3l1119t3110r1465b3206],
3	,	,	O	,	_	0	SENT_81	[p3l1119t3110r1465b3206],
4	NCTOOO36647	NN	O	nctooo36647	nn	5	SENT_81	[p3l1491t3116r2144b3206],
5	)	NN	O	)	appos	2	SENT_81	[p3l1491t3116r2144b3206],
6	,	,	O	,	_	0	SENT_81	[p3l1491t3116r2144b3206],
7	731	CD	NUMBER	731	num	8	SENT_81	[p3l12t3244r160b3317],
8	patients	NNS	O	patient	conj_or	5	SENT_81	[p3l207t3239r551b3338],
9	with	IN	O	with	_	0	SENT_81	[p3l597t3238r793b3317],
10	stage	NN	O	stage	nn	11	SENT_81	[p3l843t3255r1064b3339],
11	IIIB	NN	O	iiib	prep_with	8	SENT_81	[p3l1111t3244r1273b3316],
12	or	CC	O	or	_	0	SENT_81	[p3l1324t3264r1413b3317],
13	IV	CD	NUMBER	iv	num	14	SENT_81	[p3l1457t3246r1554b3316],
14	NSCLC	NN	O	nsclc	conj_or	5	SENT_81	[p3l1596t3244r1901b3317],
15	were	VBD	O	be	auxpass	17	SENT_81	[p3l1946t3264r2149b3317],
16	randomly	RB	O	randomly	advmod	17	SENT_81	[p3l11t3366r429b3466],
17	assigned	VBN	O	assign	_	0	SENT_81	[p3l458t3366r835b3467],
18	to	TO	O	to	aux	19	SENT_81	[p3l870t3383r952b3445],
19	receive	VB	O	receive	xcomp	17	SENT_81	[p3l988t3367r1273b3445],
20	either	CC	O	either	prep	19	SENT_81	[p3l1306t3366r1549b3444],
21	erlotinib	JJ	O	erlotinib	amod	22	SENT_81	[p3l1579t3366r1940b3445],
22	(	NN	O	(	dep	20	SENT_81	[p3l1979t3373r2080b3457],
23	at	IN	O	at	_	0	SENT_81	[p3l1979t3373r2080b3457],
24	a	DT	O	a	det	26	SENT_81	[p3l2107t3392r2152b3444],
25	daily	JJ	SET	daily	amod	26	SENT_81	[p3l12t3494r217b3595],
26	dose	NN	O	dose	prep_at	19	SENT_81	[p3l255t3494r447b3574],
27	of	IN	O	of	_	0	SENT_81	[p3l491t3493r590b3574],
28	150	CD	NUMBER	150	num	30	SENT_81	[p3l618t3500r765b3574],
29	mg	NN	O	mg	nn	30	SENT_81	[p3l808t3501r972b3596],
30	)	NN	O	)	prep_of	26	SENT_81	[p3l808t3501r972b3596],
31	or	CC	O	or	_	0	SENT_81	[p3l1024t3520r1113b3574],
32	placebo	NN	O	placebo	conj_or	30	SENT_81	[p3l1153t3494r1507b3595],
33	.	.	O	.	_	0	SENT_81	[p3l1153t3494r1507b3595],

1	In	IN	O	in	_	0	SENT_82	[p3l1556t3502r1646b3572],
2	all	PDT	O	all	predet	4	SENT_82	[p3l1690t3494r1795b3573],
3	the	DT	O	the	det	4	SENT_82	[p3l1839t3494r1973b3573],
4	patients	NNS	O	patient	pobj	1	SENT_82	[p3l2016t3520r2149b3595, p3l11t3624r281b3719],
5	,	,	O	,	_	0	SENT_82	[p3l2016t3520r2149b3595, p3l11t3624r281b3719],
6	who	WP	O	who	nsubj	7	SENT_82	[p3l326t3623r513b3702],
7	had	VBD	O	have	rcmod	4	SENT_82	[p3l559t3623r719b3702],
8	an	DT	O	a	det	11	SENT_82	[p3l763t3649r867b3701],
9	Eastern	NNP	O	Eastern	nn	11	SENT_82	[p3l911t3631r1242b3701],
10	Cooperative	NNP	O	Cooperative	nn	11	SENT_82	[p3l1287t3624r1812b3723],
11	Oncology	NNP	O	Oncology	dobj	7	SENT_82	[p3l1856t3623r2149b3702, p4l12t48r170b124],

1	Group	NNP	O	Group	nn	3	SENT_83	[p4l214t29r486b123],
2	(	CD	NUMBER	(	num	3	SENT_83	[p4l540t29r864b114],
3	ECOG	NNP	O	ECOG	nsubj	6	SENT_83	[p4l540t29r864b114],
4	)	CD	NUMBER	)	num	6	SENT_83	[p4l540t29r864b114],
5	performance	NN	O	performance	nn	6	SENT_83	[p4l917t21r1472b123],
6	status	NN	O	status	_	0	SENT_83	[p4l1521t39r1768b102],
7	ranging	VBG	O	range	partmod	6	SENT_83	[p4l1817t23r2154b124],
8	from	IN	O	from	_	0	SENT_83	[p4l11t151r219b232],
9	o	NN	O	o	prep_from	7	SENT_83	[p4l274t159r321b232],
10	to	TO	O	to	_	0	SENT_83	[p4l378t169r458b232],
11	3	CD	NUMBER	3	number	12	SENT_83	[p4l515t159r559b232],
12	(	CD	NUMBER	(	prep_to	7	SENT_83	[p4l622t152r876b244],
13	Table	NNP	O	Table	dobj	6	SENT_83	[p4l622t152r876b244],
14	1	CD	NUMBER	1	number	15	SENT_83	[p4l934t159r1027b249],
15	)	CD	NUMBER	)	dep	13	SENT_83	[p4l934t159r1027b249],
16	,	,	O	,	_	0	SENT_83	[p4l934t159r1027b249],
17	f1rst	CD	NUMBER	f1rst	number	18	SENT_83	[p4l1086t151r1454b231],
18	—	CD	NUMBER	—	num	19	SENT_83	[p4l1086t151r1454b231],
19	line	NN	O	line	dobj	6	SENT_83	[p4l1086t151r1454b231],
20	or	CC	O	or	_	0	SENT_83	[p4l1511t178r1601b232],
21	second	JJ	ORDINAL	second	amod	24	SENT_83	[p4l1656t152r2150b232],
22	—	NN	O	—	nn	24	SENT_83	[p4l1656t152r2150b232],
23	line	NN	O	line	nn	24	SENT_83	[p4l1656t152r2150b232],
24	chemotherapy	NN	O	chemotherapy	nsubj	26	SENT_83	[p4l12t280r628b380],
25	had	VBD	O	have	aux	26	SENT_83	[p4l673t280r831b359],
26	failed	VBN	O	fail	conj_or	6	SENT_83	[p4l881t279r1224b359],
27	.	.	O	.	_	0	SENT_83	[p4l881t279r1224b359],

1	“	NN	O	“	nsubj	12	SENT_84	[p4l881t279r1224b359],
2	Erlotinib	NNP	O	Erlotinib	nsubj	4	SENT_84	[p4l1273t280r1655b359],
3	Was	VBD	O	be	cop	4	SENT_84	[p4l1703t306r1867b360],
4	superior	JJ	O	superior	rcmod	1	SENT_84	[p4l1920t306r2149b380, p4l11t409r169b487],
5	to	TO	O	to	_	0	SENT_84	[p4l198t425r280b487],
6	placebo	NN	O	placebo	prep_to	4	SENT_84	[p4l313t408r644b508],
7	in	IN	O	in	_	0	SENT_84	[p4l677t409r761b486],
8	analyses	NNS	O	analysis	prep_in	4	SENT_84	[p4l793t408r1154b508],
9	of	IN	O	of	_	0	SENT_84	[p4l1190t407r1291b487],
10	overall	JJ	O	overall	amod	11	SENT_84	[p4l1305t408r1593b487],
11	survival	NN	O	survival	prep_of	8	SENT_84	[p4l1626t408r1960b488],
12	(	VBP	O	(	_	0	SENT_84	[p4l1998t415r2149b499],
13	6.7	CD	NUMBER	6.7	dobj	12	SENT_84	[p4l1998t415r2149b499],
14	vs.	CC	O	vs.	prep	13	SENT_84	[p4l6t564r117b617],
15	4.7	CD	DURATION	4.7	num	16	SENT_84	[p4l167t544r294b617],
16	months	NNS	NUMBER	month	dep	14	SENT_84	[p4l342t537r697b634],
17	,	,	O	,	_	0	SENT_84	[p4l342t537r697b634],
18	P	NN	O	p	dobj	12	SENT_84	[p4l748t544r1171b634],
19	=	JJ	O	=	amod	21	SENT_84	[p4l748t544r1171b634],
20	0.001	CD	NUMBER	0.001	tmod	19	SENT_84	[p4l748t544r1171b634],
21	)	NN	O	)	dep	18	SENT_84	[p4l748t544r1171b634],
22	,	,	O	,	_	0	SENT_84	[p4l748t544r1171b634],
23	progression	NN	O	progression	dobj	12	SENT_84	[p4l1222t536r1936b639],
24	—	CD	NUMBER	—	num	23	SENT_84	[p4l1222t536r1936b639],
25	free	JJ	O	free	amod	27	SENT_84	[p4l1222t536r1936b639],
26	survival	NN	O	survival	dep	27	SENT_84	[p4l1985t563r2148b617, p4l6t666r203b745],
27	(	NN	O	(	dep	23	SENT_84	[p4l255t672r412b757],
28	2.2	CD	NUMBER	2.2	num	27	SENT_84	[p4l255t672r412b757],
29	vs.	CC	O	vs.	prep	27	SENT_84	[p4l456t692r565b745],
30	1.8	CD	DURATION	1.8	num	31	SENT_84	[p4l622t672r746b745],
31	months	NNS	NUMBER	month	dep	29	SENT_84	[p4l797t666r1151b762],
32	,	,	O	,	_	0	SENT_84	[p4l797t666r1151b762],
33	P	NN	O	p	dep	34	SENT_84	[p4l1203t672r1595b762],
34	<	JJR	O	<	conj_and	13	SENT_84	[p4l1203t672r1595b762],
35	0.001	CD	NUMBER	0.001	num	36	SENT_84	[p4l1203t672r1595b762],
36	)	NN	O	)	dep	34	SENT_84	[p4l1203t672r1595b762],
37	,	,	O	,	_	0	SENT_84	[p4l1203t672r1595b762],
38	and	CC	O	and	_	0	SENT_84	[p4l1647t666r1806b745],
39	quality	NN	O	quality	conj_and	13	SENT_84	[p4l1854t666r2154b766],
40	of	IN	O	of	_	0	SENT_84	[p4l12t795r112b876],
41	life	NN	O	life	prep_of	39	SENT_84	[p4l132t795r293b876],
42	.	.	O	.	_	0	SENT_84	[p4l132t795r293b876],

1	Similarly	RB	O	similarly	advmod	18	SENT_85	[p4l144t925r555b1025],
2	,	,	O	,	_	0	SENT_85	[p4l144t925r555b1025],
3	the	DT	O	the	det	6	SENT_85	[p4l621t925r756b1003],
4	Iressa	NNP	O	Iressa	nn	6	SENT_85	[p4l815t933r1075b1003],
5	Survival	NNP	O	Survival	nn	6	SENT_85	[p4l1135t925r1485b1004],
6	Evaluation	NN	O	evaluation	dep	11	SENT_85	[p4l1543t925r2006b1004],
7	in	IN	O	in	_	0	SENT_85	[p4l2065t926r2150b1003],
8	Lung	NN	O	lung	prep_in	6	SENT_85	[p4l10t1062r228b1155],
9	Cancer	NN	O	cancer	dep	11	SENT_85	[p4l266t1060r562b1133],
10	(	CD	NUMBER	(	num	9	SENT_85	[p4l605t1060r846b1145],
11	ISEL	NN	O	isel	dep	18	SENT_85	[p4l605t1060r846b1145],
12	)	CD	NUMBER	)	num	13	SENT_85	[p4l605t1060r846b1145],
13	trial	NN	O	trial	dep	11	SENT_85	[p4l894t1054r1068b1132],
14	(	CD	NUMBER	(	num	16	SENT_85	[p4l1114t1060r1772b1145],
15	NCTOO242801	NN	O	nctoo242801	nn	16	SENT_85	[p4l1114t1060r1772b1145],
16	)	NN	O	)	nsubjpass	18	SENT_85	[p4l1114t1060r1772b1145],
17	was	VBD	O	be	auxpass	18	SENT_85	[p4l1814t1080r1976b1133],
18	designed	VBN	O	design	_	0	SENT_85	[p4l2020t1054r2148b1133, p4l12t1182r294b1284],
19	to	TO	O	to	aux	20	SENT_85	[p4l344t1199r426b1262],
20	evaluate	VB	O	evaluate	xcomp	18	SENT_85	[p4l478t1182r826b1262],
21	the	DT	O	the	det	22	SENT_85	[p4l877t1182r1010b1261],
22	effects	NNS	O	effect	dobj	20	SENT_85	[p4l1061t1181r1344b1261],
23	of	IN	O	of	_	0	SENT_85	[p4l1397t1181r1497b1262],
24	gefitinib	NN	O	gefitinib	nn	25	SENT_85	[p4l1528t1181r1903b1284],
25	(	NN	O	(	prep_of	22	SENT_85	[p4l1959t1189r2063b1274],
26	at	IN	O	at	_	0	SENT_85	[p4l1959t1189r2063b1274],
27	a	DT	O	a	det	29	SENT_85	[p4l2107t1209r2152b1261],
28	daily	JJ	SET	daily	amod	29	SENT_85	[p4l12t1311r217b1412],
29	dose	NN	O	dose	prep_at	20	SENT_85	[p4l246t1311r439b1391],
30	of	IN	O	of	_	0	SENT_85	[p4l473t1310r573b1391],
31	250	CD	NUMBER	250	num	33	SENT_85	[p4l588t1318r738b1391],
32	mg	NN	O	mg	nn	33	SENT_85	[p4l773t1318r962b1413],
33	)	NN	O	)	prep_of	29	SENT_85	[p4l773t1318r962b1413],
34	,	,	O	,	_	0	SENT_85	[p4l773t1318r962b1413],
35	as	IN	O	as	_	0	SENT_85	[p4l999t1338r1084b1390],
36	compared	VBN	O	compare	prepc_as	20	SENT_85	[p4l1121t1311r1543b1412],
37	With	IN	O	with	pcomp	36	SENT_85	[p4l1572t1311r1765b1391],
38	placebo	NN	O	placebo	pobj	37	SENT_85	[p4l1798t1311r2144b1412],
39	,	,	O	,	_	0	SENT_85	[p4l1798t1311r2144b1412],
40	on	IN	O	on	_	0	SENT_85	[p4l12t1466r117b1519],
41	overall	JJ	O	overall	amod	42	SENT_85	[p4l153t1440r434b1519],
42	survival	NN	O	survival	prep_on	20	SENT_85	[p4l469t1440r796b1519],
43	in	IN	O	in	_	0	SENT_85	[p4l829t1441r912b1518],
44	patients	NNS	O	patient	prep_in	42	SENT_85	[p4l945t1441r1282b1540],
45	who	WP	O	who	nsubjpass	49	SENT_85	[p4l1314t1440r1496b1519],
46	had	VBD	O	have	aux	49	SENT_85	[p4l1532t1440r1687b1519],
47	previously	RB	DATE	previously	advmod	49	SENT_85	[p4l1721t1440r2154b1540],
48	been	VBN	O	be	auxpass	49	SENT_85	[p4l11t1569r214b1648],
49	treated	VBN	O	treat	rcmod	44	SENT_85	[p4l254t1569r555b1648],
50	with	IN	O	with	_	0	SENT_85	[p4l590t1569r786b1648],
51	standard	JJ	O	standard	amod	52	SENT_85	[p4l827t1569r1209b1648],
52	chemotherapy	NN	O	chemotherapy	prep_with	49	SENT_85	[p4l1249t1569r1954b1669],
53	.	.	O	.	_	0	SENT_85	[p4l1249t1569r1954b1669],

1	“	NN	O	“	nn	2	SENT_86	[p4l1249t1569r1954b1669],
2	Gefitinib	NN	O	gefitinib	nsubj	4	SENT_86	[p4l1997t1575r2149b1648, p4l11t1696r283b1776],
3	was	VBD	O	be	cop	4	SENT_86	[p4l328t1723r492b1777],
4	superior	JJ	O	superior	_	0	SENT_86	[p4l544t1698r901b1797],
5	to	TO	O	to	_	0	SENT_86	[p4l947t1714r1029b1776],
6	placebo	NN	O	placebo	prep_to	4	SENT_86	[p4l1077t1697r1409b1797],
7	in	IN	O	in	_	0	SENT_86	[p4l1457t1698r1541b1775],
8	terms	NNS	O	term	prep_in	6	SENT_86	[p4l1590t1714r1835b1775],
9	of	IN	O	of	_	0	SENT_86	[p4l1886t1696r1986b1776],
10	the	DT	O	the	det	11	SENT_86	[p4l2017t1697r2150b1775],
11	time	NN	O	time	prep_of	8	SENT_86	[p4l11t1828r209b1906],
12	to	TO	O	to	_	0	SENT_86	[p4l262t1844r344b1907],
13	treatment	NN	O	treatment	nn	15	SENT_86	[p4l399t1844r834b1906],
14	failure	NN	O	failure	nn	15	SENT_86	[p4l881t1826r1167b1907],
15	(	NN	O	(	prep_to	11	SENT_86	[p4l1224t1834r1383b1919],
16	3.0	CD	NUMBER	3.0	dep	4	SENT_86	[p4l1224t1834r1383b1919],
17	vs.	CC	O	vs.	dep	16	SENT_86	[p4l1431t1854r1543b1907],
18	2.6	CD	DURATION	2.6	num	19	SENT_86	[p4l1601t1834r1731b1907],
19	months	NNS	NUMBER	month	dep	17	SENT_86	[p4l1784t1827r2145b1924],
20	,	,	O	,	_	0	SENT_86	[p4l1784t1827r2145b1924],
21	P	NN	O	p	npadvmod	22	SENT_86	[p4l10t1963r387b2048],
22	<	JJR	O	<	dep	4	SENT_86	[p4l10t1963r387b2048],
23	0.001	CD	NUMBER	0.001	num	24	SENT_86	[p4l10t1963r387b2048],
24	)	NN	O	)	dep	4	SENT_86	[p4l10t1963r387b2048],
25	.	.	O	.	_	0	SENT_86	[p4l10t1963r387b2048],

1	However	RB	O	however	advmod	7	SENT_87	[p4l423t1964r808b2053],
2	,	,	O	,	_	0	SENT_87	[p4l423t1964r808b2053],
3	no	DT	O	no	det	5	SENT_87	[p4l845t1982r949b2036],
4	significant	JJ	O	significant	amod	5	SENT_87	[p4l984t1955r1436b2058],
5	differences	NNS	O	difference	nsubjpass	7	SENT_87	[p4l1463t1955r1923b2036],
6	were	VBD	O	be	auxpass	7	SENT_87	[p4l1952t1982r2150b2036],
7	observed	VBN	O	observe	_	0	SENT_87	[p4l12t2086r395b2165],
8	in	IN	O	in	_	0	SENT_87	[p4l435t2087r519b2164],
9	overall	JJ	O	overall	amod	10	SENT_87	[p4l559t2086r846b2165],
10	survival	NN	O	survival	prep_in	7	SENT_87	[p4l887t2086r1244b2165],
11	.	.	O	.	_	0	SENT_87	[p4l887t2086r1244b2165],

1	In	IN	O	in	_	0	SENT_88	[p4l140t2222r229b2292],
2	a	DT	O	a	det	5	SENT_88	[p4l269t2241r313b2293],
3	subsequent	JJ	O	subsequent	amod	5	SENT_88	[p4l354t2214r844b2315],
4	noninferiority	JJ	O	noninferiority	amod	5	SENT_88	[p4l878t2213r1490b2315],
5	trial	NN	O	trial	prep_in	9	SENT_88	[p4l1526t2214r1728b2311],
6	,	,	O	,	_	0	SENT_88	[p4l1526t2214r1728b2311],
7	gefitinib	NN	O	gefitinib	nsubjpass	9	SENT_88	[p4l1774t2213r2149b2316],
8	was	VBD	O	be	auxpass	9	SENT_88	[p4l6t2369r173b2422],
9	compared	VBN	O	compare	_	0	SENT_88	[p4l241t2343r678b2443],
10	with	IN	O	with	_	0	SENT_88	[p4l740t2343r940b2422],
11	docetaxel	NN	O	docetaxel	prep_with	9	SENT_88	[p4l1007t2343r1424b2422],
12	as	IN	O	as	_	0	SENT_88	[p4l1489t2369r1576b2421],
13	second	JJ	ORDINAL	second	amod	16	SENT_88	[p4l1646t2343r2150b2422],
14	—	NN	O	—	nn	16	SENT_88	[p4l1646t2343r2150b2422],
15	line	NN	O	line	nn	16	SENT_88	[p4l1646t2343r2150b2422],
16	therapy	NN	O	therapy	prep_as	9	SENT_88	[p4l11t2472r342b2572],
17	in	IN	O	in	_	0	SENT_88	[p4l388t2473r473b2550],
18	patients	NNS	O	patient	prep_in	16	SENT_88	[p4l522t2473r874b2572],
19	With	IN	O	with	_	0	SENT_88	[p4l923t2472r1123b2551],
20	NSCLC	NN	O	nsclc	prep_with	18	SENT_88	[p4l1172t2478r1508b2551],
21	.	.	O	.	_	0	SENT_88	[p4l1172t2478r1508b2551],

1	In	IN	O	in	_	0	SENT_89	[p4l1564t2480r1654b2550],
2	the	DT	O	the	det	5	SENT_89	[p4l1705t2472r1841b2550],
3	Iressa	NNP	O	Iressa	nn	5	SENT_89	[p4l1891t2480r2152b2550],
4	NSCLC	NNP	O	NSCLC	nn	5	SENT_89	[p4l8t2607r318b2680],
5	Trial	NNP	O	Trial	nsubj	6	SENT_89	[p4l362t2601r572b2679],
6	Evaluating	VBG	O	evaluate	prepc_in	34	SENT_89	[p4l615t2601r1084b2702],
7	Response	NN	O	response	dobj	6	SENT_89	[p4l1125t2607r1546b2701],
8	and	CC	O	and	_	0	SENT_89	[p4l1592t2601r1753b2680],
9	Survival	NN	O	survival	conj_and	7	SENT_89	[p4l1801t2601r2150b2680],
10	versus	CC	O	versus	prep	7	SENT_89	[p4l6t2755r269b2808],
11	Taxotere	NN	MISC	taxotere	nn	13	SENT_89	[p4l297t2735r662b2808],
12	(	CD	NUMBER	(	num	13	SENT_89	[p4l696t2735r1215b2820],
13	INTEREST	NN	O	interest	dep	10	SENT_89	[p4l696t2735r1215b2820],
14	)	CD	NUMBER	)	num	13	SENT_89	[p4l696t2735r1215b2820],
15	trial	NN	O	trial	nn	18	SENT_89	[p4l1250t2729r1425b2807],
16	(	CD	NUMBER	(	num	18	SENT_89	[p4l1458t2735r2144b2825],
17	NCT00076388	NN	O	nct00076388	nn	18	SENT_89	[p4l1458t2735r2144b2825],
18	)	NN	O	)	nsubjpass	34	SENT_89	[p4l1458t2735r2144b2825],
19	,	,	O	,	_	0	SENT_89	[p4l1458t2735r2144b2825],
20	1433	CD	DATE	1433	num	21	SENT_89	[p4l15t2864r207b2937],
21	patients	NNS	O	patient	appos	18	SENT_89	[p4l275t2859r626b2958],
22	who	WP	O	who	nsubj	24	SENT_89	[p4l690t2858r876b2937],
23	had	VBD	O	have	aux	24	SENT_89	[p4l943t2858r1104b2937],
24	received	VBN	O	receive	rcmod	21	SENT_89	[p4l1169t2858r1525b2937],
25	at	IN	O	at	quantmod	27	SENT_89	[p4l1589t2875r1670b2936],
26	least	JJS	O	least	mwe	25	SENT_89	[p4l1730t2858r1934b2936],
27	one	CD	NUMBER	one	num	29	SENT_89	[p4l1996t2884r2150b2937],
28	platinum	NN	O	platinum	nn	29	SENT_89	[p4l10t2987r676b3087],
29	—	NN	O	—	dobj	24	SENT_89	[p4l10t2987r676b3087],
30	based	VBN	O	base	partmod	29	SENT_89	[p4l10t2987r676b3087],
31	regimen	NNS	O	regimen	dobj	30	SENT_89	[p4l714t2988r1066b3088],
32	were	VBD	O	be	auxpass	34	SENT_89	[p4l1100t3013r1300b3066],
33	randomly	RB	O	randomly	advmod	34	SENT_89	[p4l1338t2987r1749b3087],
34	assigned	VBN	O	assign	_	0	SENT_89	[p4l1781t2987r2150b3088],
35	to	TO	O	to	aux	36	SENT_89	[p4l11t3132r93b3195],
36	receive	VB	O	receive	xcomp	34	SENT_89	[p4l131t3116r422b3195],
37	either	CC	O	either	prep	36	SENT_89	[p4l460t3115r709b3194],
38	gefitinib	NN	O	gefitinib	dep	37	SENT_89	[p4l742t3114r1117b3217],
39	or	CC	O	or	_	0	SENT_89	[p4l1155t3141r1245b3195],
40	docetaxel	NN	O	docetaxel	dep	37	SENT_89	[p4l1279t3115r1711b3195],
41	.	.	O	.	_	0	SENT_89	[p4l1279t3115r1711b3195],

1	Gefitinib	JJ	O	gefitinib	amod	2	SENT_90	[p4l1753t3114r2149b3195],
2	therapy	NN	O	therapy	nsubj	3	SENT_90	[p4l11t3243r335b3343],
3	resulted	VBD	O	result	_	0	SENT_90	[p4l379t3243r725b3322],
4	in	IN	O	in	_	0	SENT_90	[p4l772t3244r856b3321],
5	noninferior	JJ	O	noninferior	amod	7	SENT_90	[p4l904t3242r1404b3322],
6	overall	JJ	O	overall	amod	7	SENT_90	[p4l1450t3243r1738b3323],
7	survival	NN	O	survival	prep_in	3	SENT_90	[p4l1787t3243r2144b3339],
8	,	,	O	,	_	0	SENT_90	[p4l1787t3243r2144b3339],
9	as	IN	O	as	_	0	SENT_90	[p4l10t3398r95b3450],
10	compared	VBN	O	compare	prepc_as	3	SENT_90	[p4l135t3372r557b3472],
11	with	IN	O	with	pcomp	10	SENT_90	[p4l588t3372r782b3451],
12	docetaxel	NN	O	docetaxel	nn	14	SENT_90	[p4l820t3372r1219b3451],
13	monotherapy	NN	O	monotherapy	nn	14	SENT_90	[p4l1255t3372r1824b3472],
14	(	NN	O	(	pobj	11	SENT_90	[p4l1860t3378r2004b3463],
15	7.6	CD	NUMBER	7.6	dep	14	SENT_90	[p4l1860t3378r2004b3463],
16	vs.	CC	O	vs.	prep	15	SENT_90	[p4l2037t3398r2145b3451],
17	8.0	CD	DURATION	8.0	num	18	SENT_90	[p4l11t3509r136b3582],
18	months	NNS	NUMBER	month	dep	16	SENT_90	[p4l171t3502r543b3599],
19	)	RB	O	)	advmod	11	SENT_90	[p4l171t3502r543b3599],
20	,	,	O	,	_	0	SENT_90	[p4l171t3502r543b3599],
21	with	IN	O	with	_	0	SENT_90	[p4l578t3502r772b3582],
22	a	DT	O	a	det	24	SENT_90	[p4l805t3529r850b3581],
23	hazard	NN	O	hazard	nn	24	SENT_90	[p4l882t3502r1175b3582],
24	ratio	NN	O	ratio	prep_with	3	SENT_90	[p4l1209t3503r1403b3582],
25	for	IN	O	for	_	0	SENT_90	[p4l1439t3501r1560b3582],
26	death	NN	O	death	prep_for	24	SENT_90	[p4l1592t3502r1826b3582],
27	of	IN	O	of	_	0	SENT_90	[p4l1861t3501r1960b3582],
28	1.02	CD	PERCENT	1.02	num	32	SENT_90	[p4l1979t3508r2149b3582],
29	(	CD	PERCENT	(	number	30	SENT_90	[p4l16t3637r230b3724],
30	96	CD	PERCENT	96	dep	31	SENT_90	[p4l16t3637r230b3724],
31	%	NN	PERCENT	%	dep	32	SENT_90	[p4l16t3637r230b3724],
32	confidence	NN	O	confidence	prep_of	26	SENT_90	[p4l270t3631r745b3712],
33	interval	NN	O	interval	nn	36	SENT_90	[p4l784t3632r1113b3712],
34	[	CD	NUMBER	[	num	36	SENT_90	[p4l1161t3639r1338b3729],
35	CI	NN	O	ci	nn	36	SENT_90	[p4l1161t3639r1338b3729],
36	]	NN	O	]	tmod	32	SENT_90	[p4l1161t3639r1338b3729],
37	,	,	O	,	_	0	SENT_90	[p4l1161t3639r1338b3729],
38	0.91	CD	NUMBER	0.91	appos	36	SENT_90	[p4l1384t3638r1560b3712],
39	to	TO	O	to	_	0	SENT_90	[p4l1601t3649r1682b3712],
40	1.15	CD	NUMBER	1.15	number	41	SENT_90	[p4l1727t3636r2035b3724],
41	)	CD	NUMBER	)	prep_to	3	SENT_90	[p4l1727t3636r2035b3724],
42	.	.	O	.	_	0	SENT_90	[p4l1727t3636r2035b3724],

1	“	NN	O	“	_	0	SENT_91	[p4l1727t3636r2035b3724],

1	Subgroup	NN	O	subgroup	nn	2	SENT_92	[p5l144t23r557b125],
2	analyses	NNS	O	analysis	nsubj	8	SENT_92	[p5l620t23r982b124],
3	from	IN	O	from	_	0	SENT_92	[p5l1046t22r1257b103],
4	the	DT	O	the	det	7	SENT_92	[p5l1320t23r1453b102],
5	initial	JJ	O	initial	amod	7	SENT_92	[p5l1514t23r1773b102],
6	clinical	JJ	O	clinical	amod	7	SENT_92	[p5l1835t23r2150b102],
7	trials	NNS	O	trial	prep_from	2	SENT_92	[p5l11t152r232b230],
8	showed	VBD	O	show	ccomp	41	SENT_92	[p5l280t152r606b231],
9	that	IN	O	that	complm	17	SENT_92	[p5l649t152r823b230],
10	patients	NNS	O	patient	nsubj	17	SENT_92	[p5l860t153r1205b252],
11	with	IN	O	with	_	0	SENT_92	[p5l1246t152r1443b231],
12	certain	JJ	O	certain	amod	13	SENT_92	[p5l1487t153r1790b230],
13	clinical	JJ	O	clinical	prep_with	10	SENT_92	[p5l1835t152r2150b230],
14	and	CC	O	and	_	0	SENT_92	[p5l10t281r170b361],
15	histologic	JJ	O	histologic	amod	16	SENT_92	[p5l204t281r633b383],
16	characteristics	NNS	O	characteristic	conj_and	13	SENT_92	[p5l668t281r1293b360],
17	(	VBP	O	(	ccomp	8	SENT_92	[p5l1335t280r1866b382],
18	specifically	RB	O	specifically	advmod	17	SENT_92	[p5l1335t280r1866b382],
19	,	,	O	,	_	0	SENT_92	[p5l1335t280r1866b382],
20	Women	NNS	O	woman	nsubj	41	SENT_92	[p5l1902t307r2148b361, p5l12t435r134b505],
21	,	,	O	,	_	0	SENT_92	[p5l1902t307r2148b361, p5l12t435r134b505],
22	patients	NNS	O	patient	nsubj	41	SENT_92	[p5l172t410r516b509],
23	of	IN	O	of	_	0	SENT_92	[p5l554t408r655b488],
24	East	JJ	MISC	east	amod	26	SENT_92	[p5l669t417r852b487],
25	Asian	JJ	MISC	asian	amod	26	SENT_92	[p5l878t410r1124b487],
26	descent	NN	O	descent	prep_of	22	SENT_92	[p5l1159t409r1508b505],
27	,	,	O	,	_	0	SENT_92	[p5l1159t409r1508b505],
28	those	DT	O	those	nsubj	41	SENT_92	[p5l1548t409r1781b488],
29	with	IN	O	with	_	0	SENT_92	[p5l1811t409r2008b488],
30	no	DT	O	no	det	31	SENT_92	[p5l2042t435r2149b488],
31	history	NN	O	history	prep_with	28	SENT_92	[p5l11t538r317b639],
32	of	IN	O	of	_	0	SENT_92	[p5l358t537r459b618],
33	smoking	NN	O	smoking	prep_of	31	SENT_92	[p5l486t538r884b640],
34	,	,	O	,	_	0	SENT_92	[p5l486t538r884b640],
35	and	CC	O	and	_	0	SENT_92	[p5l933t538r1092b618],
36	those	DT	O	those	conj_and	22	SENT_92	[p5l1137t538r1370b618],
37	with	IN	O	with	_	0	SENT_92	[p5l1410t538r1607b618],
38	adenocarci	JJ	O	adenocarci	amod	40	SENT_92	[p5l1650t538r2149b618],
39	—	NN	O	—	nn	40	SENT_92	[p5l1650t538r2149b618],
40	nomas	NNS	O	noma	prep_with	36	SENT_92	[p5l11t674r324b759],
41	)	VBP	O	)	_	0	SENT_92	[p5l11t674r324b759],
42	who	WP	O	who	nsubj	43	SENT_92	[p5l375t667r559b747],
43	received	VBD	O	receive	ccomp	41	SENT_92	[p5l610t667r959b747],
44	erlotinib	NN	O	erlotinib	nsubj	47	SENT_92	[p5l1010t667r1379b747],
45	or	CC	O	or	_	0	SENT_92	[p5l1431t693r1520b747],
46	gefitinib	NN	O	gefitinib	conj_or	44	SENT_92	[p5l1567t666r1942b769],
47	had	VBD	O	have	ccomp	43	SENT_92	[p5l1993t667r2150b747],
48	higher	JJR	O	higher	amod	49	SENT_92	[p5l11t796r287b898],
49	rates	NNS	O	rate	dobj	47	SENT_92	[p5l313t813r511b875],
50	of	IN	O	of	_	0	SENT_92	[p5l542t795r642b876],
51	response	NN	O	response	prep_of	49	SENT_92	[p5l651t822r1026b897],
52	and	CC	O	and	_	0	SENT_92	[p5l1054t796r1210b876],
53	overall	JJ	O	overall	amod	54	SENT_92	[p5l1238t796r1518b876],
54	survival	NN	O	survival	dobj	47	SENT_92	[p5l1547t796r2150b876],
55	.14	CD	NUMBER	.14	num	56	SENT_92	[p5l1547t796r2150b876],
56	>	JJR	O	>	dep	54	SENT_92	[p5l1547t796r2150b876],
57	15	CD	NUMBER	15	number	58	SENT_92	[p5l1547t796r2150b876],
58	’17	CD	NUMBER	’17	dep	56	SENT_92	[p5l1547t796r2150b876],

1	948	CD	NUMBER	948	num	4	SENT_93	[p5l149t973r206b996],
2	N	NN	O	n	nn	4	SENT_93	[p5l951t983r964b998],
3	ENGLJ	NN	O	englj	nn	4	SENT_93	[p5l979t983r1057b1005],
4	MED	NN	O	med	_	0	SENT_93	[p5l1072t983r1124b998],
5	364	CD	NUMBER	364	num	7	SENT_93	[p5l1134t977r1216b1005],
6	;	:	O	;	_	0	SENT_93	[p5l1134t977r1216b1005],
7	1o	CD	NUMBER	1o	dep	4	SENT_93	[p5l1134t977r1216b1005],
8	NEjM	NNP	O	NEjM	nn	11	SENT_93	[p5l1251t983r1375b1005],
9	,	,	O	,	_	0	SENT_93	[p5l1251t983r1375b1005],
10	ORG	NNP	O	ORG	appos	11	SENT_93	[p5l1251t983r1375b1005],
11	MARCH	NNP	DATE	MARCH	dep	7	SENT_93	[p5l1412t983r1497b999],
12	10	CD	DATE	10	num	11	SENT_93	[p5l1510t983r1537b999],
13	2011	CD	DATE	2011	dep	4	SENT_93	[p5l1555t983r1606b999],

1	The	DT	O	the	det	4	SENT_94	[p5l936t1016r987b1040],
2	New	NNP	O	New	nn	4	SENT_94	[p5l996t1017r1058b1040],
3	England	NNP	O	England	nn	4	SENT_94	[p5l1067t1016r1178b1047],
4	Journal	NNP	O	Journal	_	0	SENT_94	[p5l1187t1016r1284b1040],
5	of	IN	O	of	_	0	SENT_94	[p5l1294t1016r1323b1040],
6	Medicine	NNP	O	Medicine	prep_of	4	SENT_94	[p5l1330t1016r1455b1040],

1	Downloaded	VBN	O	download	_	0	SENT_95	[p5l378t1057r548b1080],
2	from	IN	O	from	_	0	SENT_95	[p5l557t1057r622b1080],
3	nejm.org	NN	O	nejm.org	prep_from	1	SENT_95	[p5l630t1057r748b1087],
4	at	IN	O	at	_	0	SENT_95	[p5l759t1060r782b1080],
5	UW-Madison	NN	O	uw-madison	prep_at	1	SENT_95	[p5l790t1057r973b1080],
6	on	IN	O	on	_	0	SENT_95	[p5l982t1064r1015b1080],
7	January	NNP	DATE	January	prep_on	1	SENT_95	[p5l1023t1057r1126b1087],
8	5	CD	DATE	5	num	7	SENT_95	[p5l1136t1057r1159b1084],
9	,	,	DATE	,	_	0	SENT_95	[p5l1136t1057r1159b1084],
10	2014	CD	DATE	2014	num	7	SENT_95	[p5l1169t1057r1242b1080],
11	.	.	O	.	_	0	SENT_95	[p5l1169t1057r1242b1080],

1	For	IN	O	for	_	0	SENT_96	[p5l1252t1057r1299b1080],
2	personal	JJ	O	personal	amod	3	SENT_96	[p5l1307t1057r1419b1087],
3	use	NN	O	use	pobj	1	SENT_96	[p5l1428t1064r1472b1080],
4	only	RB	O	only	advmod	3	SENT_96	[p5l1481t1057r1546b1087],
5	.	.	O	.	_	0	SENT_96	[p5l1481t1057r1546b1087],

1	No	DT	O	no	det	3	SENT_97	[p5l1557t1057r1596b1080],
2	other	JJ	O	other	amod	3	SENT_97	[p5l1606t1057r1674b1080],
3	uses	NNS	O	use	_	0	SENT_97	[p5l1683t1064r1739b1080],
4	without	IN	O	without	_	0	SENT_97	[p5l1749t1057r1850b1080],
5	permission	NN	O	permission	prep_without	3	SENT_97	[p5l1858t1057r2011b1087],
6	.	.	O	.	_	0	SENT_97	[p5l1858t1057r2011b1087],

1	Copyright	NN	O	copyright	_	0	SENT_98	[p5l729t1098r863b1129],
2	©	CD	NUMBER	©	num	6	SENT_98	[p5l872t1098r896b1122],
3	2011	CD	DATE	2011	num	6	SENT_98	[p5l906t1098r968b1122],
4	Massachusetts	NNP	ORGANIZATION	Massachusetts	nn	6	SENT_98	[p5l980t1098r1171b1122],
5	Medical	NNP	ORGANIZATION	Medical	nn	6	SENT_98	[p5l1181t1098r1289b1122],
6	Society	NNP	ORGANIZATION	Society	dep	1	SENT_98	[p5l1300t1098r1405b1129],
7	.	.	O	.	_	0	SENT_98	[p5l1300t1098r1405b1129],

1	All	DT	O	all	det	2	SENT_99	[p5l1416t1098r1457b1122],
2	rights	NNS	O	rights	nsubj	3	SENT_99	[p5l1466t1098r1541b1129],
3	reserved	VBN	O	reserve	_	0	SENT_99	[p5l1551t1098r1669b1122],
4	.	.	O	.	_	0	SENT_99	[p5l1551t1098r1669b1122],

1	CLINICAL	JJ	O	clinical	amod	2	SENT_100	[p5l868t1204r1027b1223],
2	THERAPEUTICS	NNS	O	therapeutics	_	0	SENT_100	[p5l1039t1204r1292b1223],

1	Figure	NN	O	figure	_	0	SENT_101	[p6l84t175r301b256],
2	2	CD	NUMBER	2	dep	1	SENT_101	[p6l328t179r390b237],
3	.	.	O	.	_	0	SENT_101	[p6l328t179r390b237],

1	Mechanisms	NNS	O	mechanism	nsubj	15	SENT_102	[p6l426t172r877b237],
2	of	IN	O	of	_	0	SENT_102	[p6l905t171r986b237],
3	Action	NNP	O	Action	prep_of	1	SENT_102	[p6l996t174r1225b237],
4	of	IN	O	of	_	0	SENT_102	[p6l1255t171r1337b237],
5	Epidermal	NNP	O	Epidermal	nn	8	SENT_102	[p6l1355t172r1710b256],
6	Growth	NNP	O	Growth	nn	8	SENT_102	[p6l1740t172r2004b237],
7	Factor	NN	O	factor	nn	8	SENT_102	[p6l83t286r298b344],
8	Receptor	NN	O	receptor	prep_of	3	SENT_102	[p6l325t286r633b364],
9	(	CD	NUMBER	(	num	10	SENT_102	[p6l659t285r896b365],
10	EGFR	NN	ORGANIZATION	egfr	dep	8	SENT_102	[p6l659t285r896b365],
11	)	CD	NUMBER	)	num	14	SENT_102	[p6l659t285r896b365],
12	Tyrosine	NN	O	tyrosine	nn	14	SENT_102	[p6l924t282r1215b365],
13	Kinase	NN	O	kinase	nn	14	SENT_102	[p6l1244t282r1469b344],
14	Inhibitors	NNS	O	inhibitor	dep	10	SENT_102	[p6l1498t280r1825b344],
15	(	VBP	O	(	_	0	SENT_102	[p6l1856t286r2075b365],
16	TKls	NNS	O	tkl	dobj	15	SENT_102	[p6l1856t286r2075b365],
17	)	CD	NUMBER	)	tmod	15	SENT_102	[p6l1856t286r2075b365],
18	.	.	O	.	_	0	SENT_102	[p6l1856t286r2075b365],

1	Panel	NN	O	panel	nn	2	SENT_103	[p6l85t409r269b473],
2	A	NN	O	a	nsubj	3	SENT_103	[p6l300t413r350b472],
3	shows	VBZ	O	show	dep	7	SENT_103	[p6l380t409r599b473],
4	the	DT	O	the	det	6	SENT_103	[p6l628t409r740b473],
5	chemical	NN	O	chemical	nn	6	SENT_103	[p6l769t408r1084b473],
6	structures	NNS	O	structure	dobj	3	SENT_103	[p6l1120t421r1480b473],
7	oftwo	VBP	O	oftwo	_	0	SENT_103	[p6l1512t408r1734b473],
8	EG	NN	O	eg	nn	9	SENT_103	[p6l1770t414r1859b473],
9	FR	NN	O	fr	dobj	7	SENT_103	[p6l1876t415r1959b472],
10	tyrosine	NN	O	tyrosine	nn	12	SENT_103	[p6l1985t421r2072b494, p6l83t523r296b581],
11	kinase	NN	O	kinase	nn	12	SENT_103	[p6l329t517r549b581],
12	inhibitors	NNS	O	inhibitor	nsubj	7	SENT_103	[p6l582t517r938b592],
13	,	,	O	,	_	0	SENT_103	[p6l582t517r938b592],
14	erlotinib	NN	O	erlotinib	appos	12	SENT_103	[p6l972t517r1267b581],
15	and	CC	O	and	_	0	SENT_103	[p6l1299t517r1423b581],
16	gefitinib	NN	O	gefitinib	appos	12	SENT_103	[p6l1458t515r1768b602],
17	.	.	O	.	_	0	SENT_103	[p6l1458t515r1768b602],

1	Panel	NN	O	panel	nn	2	SENT_104	[p6l1807t517r1991b581],
2	B	NN	O	b	nsubj	3	SENT_104	[p6l2030t522r2067b580],
3	shows	VBZ	O	show	_	0	SENT_104	[p6l81t624r301b689],
4	the	DT	O	the	det	6	SENT_104	[p6l331t624r442b689],
5	intracellular	JJ	O	intracellular	amod	6	SENT_104	[p6l475t624r896b689],
6	binding	NN	O	binding	dobj	3	SENT_104	[p6l926t624r1193b709],
7	of	IN	O	of	_	0	SENT_104	[p6l1221t624r1298b689],
8	erlotinib	JJ	O	erlotinib	amod	9	SENT_104	[p6l1315t624r1610b689],
9	(	NN	O	(	prep_of	6	SENT_104	[p6l1649t624r1912b709],
10	similar	JJ	O	similar	amod	9	SENT_104	[p6l1649t624r1912b709],
11	to	TO	O	to	_	0	SENT_104	[p6l1936t637r2005b689],
12	that	DT	O	that	prep_to	10	SENT_104	[p6l77t731r217b796],
13	of	IN	O	of	_	0	SENT_104	[p6l245t731r322b796],
14	gefitinib	NN	O	gefitinib	nn	15	SENT_104	[p6l341t731r656b816],
15	)	NN	O	)	prep_of	12	SENT_104	[p6l341t731r656b816],
16	to	TO	O	to	_	0	SENT_104	[p6l690t744r758b796],
17	the	DT	O	the	det	23	SENT_104	[p6l786t731r897b796],
18	ATP-binding	JJ	O	atp-binding	amod	23	SENT_104	[p6l925t731r1366b816],
19	site	NN	O	site	nn	23	SENT_104	[p6l1396t737r1516b796],
20	ofthe	NN	O	ofthe	nn	23	SENT_104	[p6l1546t731r1748b796],
21	tyrosine	NN	O	tyrosine	nn	23	SENT_104	[p6l1776t737r2062b816],
22	kinase	NN	O	kinase	nn	23	SENT_104	[p6l83t839r299b904],
23	domain	NN	O	domain	prep_to	10	SENT_104	[p6l327t839r589b904],
24	of	IN	O	of	_	0	SENT_104	[p6l621t838r697b904],
25	EGFR	NN	ORGANIZATION	egfr	prep_of	23	SENT_104	[p6l718t844r923b915],
26	,	,	O	,	_	0	SENT_104	[p6l718t844r923b915],
27	which	WDT	O	which	nsubj	28	SENT_104	[p6l952t839r1154b904],
28	blocks	VBZ	O	block	rcmod	9	SENT_104	[p6l1190t839r1407b904],
29	the	DT	O	the	det	33	SENT_104	[p6l1435t839r1545b904],
30	catalytic	JJ	O	catalytic	amod	33	SENT_104	[p6l1573t839r1860b923],
31	activity	NN	O	activity	nn	33	SENT_104	[p6l1887t845r2071b904, p6l82t953r162b1032],
32	ofthe	NN	O	ofthe	nn	33	SENT_104	[p6l190t946r393b1011],
33	kinase	NN	O	kinase	dobj	28	SENT_104	[p6l426t946r665b1023],
34	,	,	O	,	_	0	SENT_104	[p6l426t946r665b1023],
35	thereby	RB	O	thereby	advmod	36	SENT_104	[p6l697t946r963b1032],
36	inhibiting	VBG	O	inhibit	xcomp	28	SENT_104	[p6l994t946r1331b1032],
37	downstream	JJ	O	downstream	amod	40	SENT_104	[p6l1359t946r1800b1011],
38	signaling	NN	O	signaling	nn	40	SENT_104	[p6l1836t946r2066b1032, p6l82t1060r185b1139],
39	ofthe	NN	O	ofthe	nn	40	SENT_104	[p6l212t1053r411b1118],
40	pathways	NNS	O	pathway	nsubj	41	SENT_104	[p6l443t1054r762b1139],
41	responsible	JJ	O	responsible	xcomp	36	SENT_104	[p6l795t1054r1196b1138],
42	for	IN	O	for	_	0	SENT_104	[p6l1223t1053r1320b1118],
43	cellular	JJ	O	cellular	amod	44	SENT_104	[p6l1346t1054r1596b1118],
44	proliferation	NN	O	proliferation	prep_for	41	SENT_104	[p6l1625t1053r2071b1138],
45	.	.	O	.	_	0	SENT_104	[p6l1625t1053r2071b1138],

1	The	DT	O	the	det	3	SENT_105	[p6l76t1162r208b1226],
2	T79OM	NN	O	t79om	nn	3	SENT_105	[p6l235t1166r484b1227],
3	mutation	NN	O	mutation	nsubjpass	16	SENT_105	[p6l524t1167r866b1237],
4	,	,	O	,	_	0	SENT_105	[p6l524t1167r866b1237],
5	one	CD	NUMBER	one	num	6	SENT_105	[p6l899t1184r1028b1226],
6	mechanism	NN	O	mechanism	appos	3	SENT_105	[p6l1062t1162r1470b1226],
7	of	IN	O	of	_	0	SENT_105	[p6l1504t1160r1581b1226],
8	resistance	NN	O	resistance	prep_of	6	SENT_105	[p6l1601t1168r1958b1226],
9	to	TO	O	to	_	0	SENT_105	[p6l1985t1174r2054b1226],
10	EGFR	NN	ORGANIZATION	egfr	nn	13	SENT_105	[p6l85t1274r274b1334],
11	tyrosine	NN	O	tyrosine	nn	13	SENT_105	[p6l301t1275r586b1354],
12	kinase	NN	O	kinase	nn	13	SENT_105	[p6l619t1269r839b1334],
13	inhibition	NN	O	inhibition	prep_to	8	SENT_105	[p6l872t1269r1229b1345],
14	,	,	O	,	_	0	SENT_105	[p6l872t1269r1229b1345],
15	is	VBZ	O	be	auxpass	16	SENT_105	[p6l1265t1275r1314b1334],
16	detected	VBN	O	detect	_	0	SENT_105	[p6l1345t1269r1652b1334],
17	in	IN	O	in	_	0	SENT_105	[p6l1687t1275r1743b1332],
18	approximately	RB	O	approximately	quantmod	19	SENT_105	[p6l1778t1275r2064b1353, p6l83t1376r312b1461],
19	50	CD	PERCENT	50	num	20	SENT_105	[p6l338t1380r492b1443],
20	%	NN	PERCENT	%	prep_in	16	SENT_105	[p6l338t1380r492b1443],
21	of	IN	O	of	_	0	SENT_105	[p6l520t1376r596b1441],
22	patients	NNS	O	patient	prep_of	20	SENT_105	[p6l615t1382r892b1460],
23	who	WP	O	who	nsubj	24	SENT_105	[p6l919t1376r1065b1441],
24	have	VBP	O	have	rcmod	22	SENT_105	[p6l1097t1376r1251b1441],
25	a	DT	O	a	det	26	SENT_105	[p6l1280t1399r1313b1441],
26	relapse	NN	O	relapse	dobj	24	SENT_105	[p6l1346t1376r1591b1460],
27	while	IN	O	while	_	0	SENT_105	[p6l1616t1376r1798b1441],
28	receiving	VBG	O	receive	prepc_while	26	SENT_105	[p6l1829t1382r2052b1441, p6l83t1490r188b1569],
29	an	DT	O	a	det	33	SENT_105	[p6l216t1507r294b1549],
30	EGFR	NN	ORGANIZATION	egfr	nn	33	SENT_105	[p6l333t1489r522b1549],
31	tyrosine	NN	O	tyrosine	nn	33	SENT_105	[p6l549t1490r834b1569],
32	kinase	NN	O	kinase	nn	33	SENT_105	[p6l867t1484r1087b1549],
33	inhibitor	NN	O	inhibitor	dobj	28	SENT_105	[p6l1120t1484r1432b1549],
34	.	.	O	.	_	0	SENT_105	[p6l1120t1484r1432b1549],

1	T79OM	NN	O	t79om	nsubj	2	SENT_106	[p6l1462t1488r1711b1549],
2	causes	VBZ	O	cause	_	0	SENT_106	[p6l1747t1507r1985b1549],
3	steric	JJ	O	steric	amod	5	SENT_106	[p6l81t1598r275b1656],
4	hindrance	NN	O	hindrance	nn	5	SENT_106	[p6l306t1591r659b1656],
5	ofthe	NN	O	ofthe	dobj	2	SENT_106	[p6l689t1591r893b1656],
6	binding	NN	O	binding	prep	2	SENT_106	[p6l926t1591r1194b1677],
7	ofthe	NN	O	ofthe	nn	10	SENT_106	[p6l1222t1591r1426b1656],
8	tyrosine	NN	O	tyrosine	nn	10	SENT_106	[p6l1454t1598r1741b1677],
9	kinase	NN	O	kinase	nn	10	SENT_106	[p6l1774t1591r1995b1656],
10	inhibitor	NN	O	inhibitor	dep	6	SENT_106	[p6l82t1699r384b1763],
11	and	CC	O	and	_	0	SENT_106	[p6l413t1699r537b1763],
12	promotes	VBZ	O	promote	conj_and	2	SENT_106	[p6l575t1711r915b1783],
13	constitutive	JJ	O	constitutive	amod	16	SENT_106	[p6l947t1705r1367b1763],
14	activation	NN	O	activation	nn	16	SENT_106	[p6l1397t1705r1743b1763],
15	ofthe	NN	O	ofthe	nn	16	SENT_106	[p6l1778t1698r1982b1763],
16	EGFR	NN	ORGANIZATION	egfr	dobj	12	SENT_106	[p6l85t1812r274b1871],
17	mutated	VBN	O	mutate	partmod	16	SENT_106	[p6l308t1807r602b1871],
18	kinase	NN	O	kinase	dobj	17	SENT_106	[p6l639t1807r879b1871],
19	.	.	O	.	_	0	SENT_106	[p6l639t1807r879b1871],

1	Thus	RB	O	thus	advmod	5	SENT_107	[p6l910t1807r1106b1882],
2	,	,	O	,	_	0	SENT_107	[p6l910t1807r1106b1882],
3	downstream	JJ	O	downstream	amod	4	SENT_107	[p6l1139t1807r1582b1871],
4	signaling	NN	O	signaling	nsubj	5	SENT_107	[p6l1618t1807r1939b1892],
5	occurs	VBZ	O	occur	_	0	SENT_107	[p6l79t1937r312b1979],
6	despite	IN	O	despite	_	0	SENT_107	[p6l345t1914r603b1998],
7	the	DT	O	the	det	12	SENT_107	[p6l631t1914r742b1979],
8	use	NN	O	use	nn	12	SENT_107	[p6l777t1937r893b1979],
9	ofa	NN	O	ofa	nn	12	SENT_107	[p6l924t1914r1051b1979],
10	tyrosine	NN	O	tyrosine	nn	12	SENT_107	[p6l1080t1920r1367b1999],
11	kinase	NN	O	kinase	nn	12	SENT_107	[p6l1400t1914r1621b1979],
12	inhibitor	NN	O	inhibitor	prep_despite	5	SENT_107	[p6l1654t1914r1969b1979],
13	.	.	O	.	_	0	SENT_107	[p6l1654t1914r1969b1979],

1	Panel	NN	O	panel	nn	2	SENT_108	[p6l85t2021r270b2086],
2	C	NN	O	c	nsubj	3	SENT_108	[p6l305t2026r350b2086],
3	shows	VBZ	O	show	_	0	SENT_108	[p6l382t2021r602b2086],
4	another	DT	O	another	det	5	SENT_108	[p6l635t2021r913b2086],
5	mechanism	NN	O	mechanism	dobj	3	SENT_108	[p6l943t2021r1354b2086],
6	of	IN	O	of	_	0	SENT_108	[p6l1388t2021r1465b2086],
7	resistance	NN	O	resistance	prep_of	5	SENT_108	[p6l1486t2027r1844b2086],
8	to	TO	O	to	prep	3	SENT_108	[p6l1872t2034r1940b2086],

1	EGFR	NN	ORGANIZATION	egfr	nn	4	SENT_109	[p6l85t2134r274b2194],
2	tyrosine	NN	O	tyrosine	nn	4	SENT_109	[p6l301t2135r586b2214],
3	kinase	NN	O	kinase	nn	4	SENT_109	[p6l619t2129r839b2194],
4	inhibitors	NNS	O	inhibitor	_	0	SENT_109	[p6l872t2129r1207b2194],
5	through	IN	O	through	_	0	SENT_109	[p6l1236t2129r1517b2214],
6	amplification	NN	O	amplification	nn	9	SENT_109	[p6l1552t2128r2019b2213],
7	ofthe	NN	O	ofthe	nn	9	SENT_109	[p6l79t2236r283b2301],
8	MET	NN	O	met	nn	9	SENT_109	[p6l316t2243r486b2300],
9	oncogene	NN	O	oncogene	prep_through	4	SENT_109	[p6l506t2260r874b2322],
10	.	.	O	.	_	0	SENT_109	[p6l506t2260r874b2322],

1	Despite	IN	O	despite	dep	9	SENT_110	[p6l912t2243r1180b2321],
2	effective	JJ	O	effective	amod	6	SENT_110	[p6l1209t2236r1511b2301],
3	EGFR	NN	ORGANIZATION	egfr	nn	6	SENT_110	[p6l1546t2241r1734b2301],
4	tyrosine	NN	O	tyrosine	nn	6	SENT_110	[p6l1762t2243r2047b2322],
5	kinase	NN	O	kinase	nn	6	SENT_110	[p6l83t2344r303b2408],
6	inhibition	NN	O	inhibition	pobj	1	SENT_110	[p6l336t2344r692b2420],
7	,	,	O	,	_	0	SENT_110	[p6l336t2344r692b2420],
8	downstream	JJ	O	downstream	amod	9	SENT_110	[p6l725t2344r1167b2408],
9	signaling	NN	O	signaling	_	0	SENT_110	[p6l1202t2344r1522b2429],
10	through	IN	O	through	_	0	SENT_110	[p6l1548t2344r1828b2429],
11	the	DT	O	the	det	14	SENT_110	[p6l1859t2344r1970b2408],
12	P	NN	O	p	nn	14	SENT_110	[p6l85t2456r439b2515],
13	|	CD	NUMBER	|	num	14	SENT_110	[p6l85t2456r439b2515],
14	3K	NN	O	3k	prep_through	9	SENT_110	[p6l85t2456r439b2515],
15	.	.	O	.	_	0	SENT_110	[p6l85t2456r439b2515],

1	—	NN	O	—	_	0	SENT_111	[p6l85t2456r439b2515],
2	.	.	O	.	_	0	SENT_111	[p6l85t2456r439b2515],

1	AKT	NN	O	akt	nn	2	SENT_112	[p6l85t2456r439b2515],
2	pathway	NN	O	pathway	nsubj	4	SENT_112	[p6l470t2452r760b2536],
3	still	RB	O	still	advmod	4	SENT_112	[p6l790t2452r908b2516],
4	occurs	VBZ	O	occur	_	0	SENT_112	[p6l942t2474r1173b2517],
5	in	IN	O	in	_	0	SENT_112	[p6l1208t2457r1263b2515],
6	a	DT	O	a	det	10	SENT_112	[p6l1298t2474r1331b2516],
7	MET-mediated	JJ	O	met-mediated	amod	10	SENT_112	[p6l1367t2452r1908b2527],
8	,	,	O	,	_	0	SENT_112	[p6l1367t2452r1908b2527],
9	EGFR-independent	JJ	O	egfr-independent	amod	10	SENT_112	[p6l85t2559r760b2643],
10	fashion	NN	O	fashion	prep_in	4	SENT_112	[p6l787t2559r1070b2624],
11	.	.	O	.	_	0	SENT_112	[p6l787t2559r1070b2624],

1	Furthermore	RB	O	furthermore	advmod	19	SENT_113	[p6l9t2914r581b3009],
2	,	,	O	,	_	0	SENT_113	[p6l9t2914r581b3009],
3	the	DT	O	the	det	4	SENT_113	[p6l630t2914r762b2992],
4	presence	NN	O	presence	nsubjpass	19	SENT_113	[p6l804t2940r1178b3014],
5	of	IN	O	of	_	0	SENT_113	[p6l1222t2913r1322b2992],
6	specific	JJ	O	specific	amod	8	SENT_113	[p6l1347t2913r1676b3014],
7	EGFR	NN	ORGANIZATION	egfr	nn	8	SENT_113	[p6l1716t2921r1929b2994],
8	mutations	NNS	O	mutation	prep_of	4	SENT_113	[p6l1965t2940r2132b2993, p6l12t3043r299b3120],
9	leading	VBG	O	lead	partmod	8	SENT_113	[p6l330t3042r643b3143],
10	to	TO	O	to	_	0	SENT_113	[p6l671t3059r751b3120],
11	intrinsic	JJ	O	intrinsic	amod	12	SENT_113	[p6l782t3043r1135b3120],
12	activation	NN	O	activation	prep_to	9	SENT_113	[p6l1164t3043r1572b3121],
13	of	IN	O	of	_	0	SENT_113	[p6l1602t3041r1702b3120],
14	the	DT	O	the	det	15	SENT_113	[p6l1715t3042r1844b3120],
15	receptor	NN	O	receptor	prep_of	12	SENT_113	[p6l1876t3068r2133b3142, p6l12t3187r134b3248],
16	has	VBZ	O	have	aux	19	SENT_113	[p6l183t3170r327b3248],
17	been	VBN	O	be	auxpass	19	SENT_113	[p6l382t3170r583b3248],
18	consistently	RB	O	consistently	advmod	19	SENT_113	[p6l635t3170r1149b3270],
19	found	VBN	O	find	_	0	SENT_113	[p6l1197t3169r1449b3249],
20	to	TO	O	to	aux	23	SENT_113	[p6l1502t3187r1582b3248],
21	be	VB	O	be	auxpass	23	SENT_113	[p6l1636t3170r1733b3248],
22	strongly	RB	O	strongly	advmod	23	SENT_113	[p6l1787t3170r2138b3271],
23	associated	VBN	O	associate	xcomp	19	SENT_113	[p6l11t3298r455b3375],
24	with	IN	O	with	_	0	SENT_113	[p6l477t3298r672b3377],
25	a	DT	O	a	det	30	SENT_113	[p6l698t3324r742b3375],
26	better	JJR	O	better	amod	30	SENT_113	[p6l768t3298r1020b3375],
27	therapeutic	JJ	O	therapeutic	amod	30	SENT_113	[p6l1044t3298r1528b3397],
28	response	NN	O	response	nn	30	SENT_113	[p6l1554t3303r2133b3397],
29	.18	CD	NUMBER	.18	num	30	SENT_113	[p6l1554t3303r2133b3397],
30	‘	NN	O	‘	prep_with	23	SENT_113	[p6l1554t3303r2133b3397],
31	2	CD	NUMBER	2	number	32	SENT_113	[p6l1554t3303r2133b3397],
32	°	CD	NUMBER	°	num	30	SENT_113	[p6l1554t3303r2133b3397],
33	These	DT	O	these	det	34	SENT_113	[p6l8t3427r263b3505],
34	observations	NNS	O	observation	nsubj	36	SENT_113	[p6l324t3427r878b3506],
35	have	VBP	O	have	aux	36	SENT_113	[p6l941t3427r1133b3506],
36	led	VBN	O	lead	rcmod	30	SENT_113	[p6l1193t3427r1320b3505],
37	to	TO	O	to	_	0	SENT_113	[p6l1381t3444r1463b3505],
38	clinical	JJ	O	clinical	amod	39	SENT_113	[p6l1526t3427r1846b3505],
39	trials	NNS	O	trial	prep_to	36	SENT_113	[p6l1907t3427r2130b3505],
40	specifically	RB	O	specifically	advmod	41	SENT_113	[p6l13t3554r488b3655],
41	focusing	VBG	O	focus	ccomp	36	SENT_113	[p6l519t3554r884b3656],
42	on	IN	O	on	_	0	SENT_113	[p6l919t3581r1022b3633],
43	the	DT	O	the	det	44	SENT_113	[p6l1059t3555r1190b3633],
44	use	NN	O	use	prep_on	41	SENT_113	[p6l1226t3581r1364b3634],
45	of	IN	O	of	_	0	SENT_113	[p6l1401t3554r1500b3633],
46	EGFR	NN	ORGANIZATION	egfr	nn	49	SENT_113	[p6l1516t3560r1768b3638],
47	tyrosine	NN	O	tyrosine	nn	49	SENT_113	[p6l1794t3556r2133b3655],
48	kinase	NN	O	kinase	nn	49	SENT_113	[p6l11t3683r290b3763],
49	inhibitors	NNS	O	inhibitor	prep_of	44	SENT_113	[p6l329t3683r750b3761],
50	as	IN	O	as	_	0	SENT_113	[p6l792t3709r878b3761],
51	first-line	JJ	O	first-line	amod	52	SENT_113	[p6l920t3682r1289b3761],
52	therapy	NN	O	therapy	prep_as	41	SENT_113	[p6l1330t3683r1652b3783],
53	in	IN	O	in	_	0	SENT_113	[p6l1686t3684r1769b3760],
54	responsive	JJ	O	responsive	prep_in	41	SENT_113	[p6l1810t3709r2132b3783, p7l13t22r166b100],

1	subgroups	NNS	O	subgroup	_	0	SENT_114	[p7l207t21r653b122],
2	of	IN	O	of	_	0	SENT_114	[p7l696t20r795b99],
3	patients	NNS	O	patient	prep_of	1	SENT_114	[p7l815t22r1156b121],
4	with	IN	O	with	_	0	SENT_114	[p7l1193t21r1389b100],
5	N	NN	O	n	nn	6	SENT_114	[p7l1426t28r1501b100],
6	SCLC	NN	ORGANIZATION	sclc	prep_with	1	SENT_114	[p7l1504t26r1754b99],
7	.	.	O	.	_	0	SENT_114	[p7l1504t26r1754b99],

1	In	IN	O	in	dep	110	SENT_115	[p7l138t156r229b225],
2	the	DT	O	the	dep	110	SENT_115	[p7l343t149r478b226],
3	Iressa	NNP	O	Iressa	dep	110	SENT_115	[p7l591t156r850b226],
4	Pan-Asia	NNP	O	Pan-Asia	dep	110	SENT_115	[p7l962t150r1344b226],
5	Study	NNP	O	Study	dep	110	SENT_115	[p7l1459t149r1700b248],
6	(	CD	NUMBER	(	dep	110	SENT_115	[p7l1815t154r2128b239],
7	IPASS	NNP	ORGANIZATION	IPASS	dep	110	SENT_115	[p7l1815t154r2128b239],
8	)	CD	NUMBER	)	dep	110	SENT_115	[p7l1815t154r2128b239],
9	(	CD	NUMBER	(	dep	110	SENT_115	[p7l16t282r717b372],
10	NCTOO322452	NN	O	nctoo322452	dep	110	SENT_115	[p7l16t282r717b372],
11	)	NN	O	)	dep	110	SENT_115	[p7l16t282r717b372],
12	,	,	O	,	_	0	SENT_115	[p7l16t282r717b372],
13	a	DT	O	a	dep	110	SENT_115	[p7l785t303r829b354],
14	phase	NN	O	phase	dep	110	SENT_115	[p7l888t277r1136b376],
15	3	CD	NUMBER	3	dep	110	SENT_115	[p7l1199t282r1243b355],
16	trial	NN	O	trial	dep	110	SENT_115	[p7l1308t277r1485b354],
17	conducted	VBN	O	conduct	dep	110	SENT_115	[p7l1548t277r1988b356],
18	in	IN	O	in	dep	110	SENT_115	[p7l2050t278r2133b353],
19	Asia	NNP	LOCATION	Asia	dep	110	SENT_115	[p7l7t406r215b500],
20	,	,	O	,	_	0	SENT_115	[p7l7t406r215b500],
21	patients	NNS	O	patient	dep	110	SENT_115	[p7l257t406r599b505],
22	with	IN	O	with	dep	110	SENT_115	[p7l635t405r830b484],
23	advanced	JJ	O	advanced	dep	110	SENT_115	[p7l867t405r1263b484],
24	adenocarcinoma	NN	O	adenocarcinoma	dep	110	SENT_115	[p7l1300t405r2014b483],
25	of	IN	O	of	dep	110	SENT_115	[p7l2052t404r2152b483],
26	the	DT	O	the	dep	110	SENT_115	[p7l12t533r141b611],
27	lung	NN	O	lung	dep	110	SENT_115	[p7l172t533r362b634],
28	who	WP	O	who	dep	110	SENT_115	[p7l386t533r566b612],
29	had	VBD	O	have	dep	110	SENT_115	[p7l599t533r753b611],
30	not	RB	O	not	dep	110	SENT_115	[p7l783t549r924b611],
31	undergone	VBN	O	undergo	dep	110	SENT_115	[p7l950t533r1400b634],
32	previous	JJ	O	previous	dep	110	SENT_115	[p7l1431t534r1786b633],
33	chemotherapy	NN	O	chemotherapy	dep	110	SENT_115	[p7l1819t533r2132b611, p7l12t661r333b761],
34	and	CC	O	and	dep	110	SENT_115	[p7l372t661r530b739],
35	who	WP	O	who	dep	110	SENT_115	[p7l569t661r751b740],
36	were	VBD	O	be	dep	110	SENT_115	[p7l792t687r994b740],
37	either	DT	O	either	dep	110	SENT_115	[p7l1040t661r1286b739],
38	lifetime	NN	O	lifetime	dep	110	SENT_115	[p7l1326t660r1661b739],
39	nonsmokers	NNS	O	nonsmoker	dep	110	SENT_115	[p7l1705t661r2132b740, p7l12t815r132b867],
40	or	CC	O	or	dep	110	SENT_115	[p7l190t815r279b867],
41	former	JJ	O	former	dep	110	SENT_115	[p7l331t788r626b867],
42	smokers	NNS	O	smoker	dep	110	SENT_115	[p7l680t789r1037b868],
43	with	IN	O	with	dep	110	SENT_115	[p7l1089t789r1284b868],
44	a	DT	O	a	dep	110	SENT_115	[p7l1339t815r1383b867],
45	limited	JJ	O	limited	dep	110	SENT_115	[p7l1436t789r1745b867],
46	lifetime	NN	O	lifetime	dep	110	SENT_115	[p7l1798t788r2133b867],
47	tobacco	NN	O	tobacco	dep	110	SENT_115	[p7l12t917r334b995],
48	exposure	NN	O	exposure	dep	110	SENT_115	[p7l380t943r758b1017],
49	were	VBD	O	be	dep	110	SENT_115	[p7l797t943r996b996],
50	randomly	RB	O	randomly	dep	110	SENT_115	[p7l1040t917r1447b1017],
51	assigned	VBN	O	assign	dep	110	SENT_115	[p7l1486t917r1852b1018],
52	to	TO	O	to	dep	110	SENT_115	[p7l1896t933r1976b995],
53	receive	VB	O	receive	dep	110	SENT_115	[p7l2021t943r2132b995, p7l12t1046r211b1124],
54	either	CC	O	either	dep	110	SENT_115	[p7l242t1045r483b1123],
55	gefitinib	NN	O	gefitinib	dep	110	SENT_115	[p7l510t1044r873b1146],
56	or	CC	O	or	dep	110	SENT_115	[p7l906t1071r993b1123],
57	chemotherapy	NN	O	chemotherapy	dep	110	SENT_115	[p7l1021t1045r1619b1145],
58	with	IN	O	with	dep	110	SENT_115	[p7l1641t1045r1832b1124],
59	carboplatin	NN	O	carboplatin	dep	110	SENT_115	[p7l1863t1045r2132b1123, p7l9t1173r261b1273],
60	and	CC	O	and	dep	110	SENT_115	[p7l304t1173r461b1251],
61	paclitaXel	NN	O	paclitaxel	dep	110	SENT_115	[p7l503t1173r1017b1273],
62	.21	CD	NUMBER	.21	dep	110	SENT_115	[p7l503t1173r1017b1273],
63	The	DT	O	the	dep	110	SENT_115	[p7l1057t1173r1218b1251],
64	rate	NN	O	rate	dep	110	SENT_115	[p7l1262t1190r1421b1251],
65	of	IN	O	of	dep	110	SENT_115	[p7l1466t1172r1565b1251],
66	progressionfree	JJ	O	progressionfree	dep	110	SENT_115	[p7l1589t1174r2132b1274, p7l11t1300r172b1379],
67	survival	NN	O	survival	dep	110	SENT_115	[p7l212t1301r544b1380],
68	at	IN	O	at	dep	110	SENT_115	[p7l581t1318r660b1379],
69	1	CD	DURATION	1	dep	110	SENT_115	[p7l696t1306r740b1378],
70	year	NN	NUMBER	year	dep	110	SENT_115	[p7l773t1327r953b1401],
71	was	VBD	O	be	dep	110	SENT_115	[p7l983t1327r1146b1380],
72	significantly	RB	O	significantly	dep	110	SENT_115	[p7l1187t1300r1730b1402],
73	better	JJR	O	better	dep	110	SENT_115	[p7l1765t1301r2017b1379],
74	in	IN	O	in	dep	110	SENT_115	[p7l2050t1302r2133b1378],
75	the	DT	O	the	dep	110	SENT_115	[p7l12t1429r144b1507],
76	gefitinib	NN	O	gefitinib	dep	110	SENT_115	[p7l178t1428r550b1530],
77	group	NN	O	group	dep	110	SENT_115	[p7l586t1455r838b1530],
78	(	CD	PERCENT	(	dep	110	SENT_115	[p7l879t1434r1168b1520],
79	24.9	CD	PERCENT	24.9	dep	110	SENT_115	[p7l879t1434r1168b1520],
80	%	NN	PERCENT	%	dep	110	SENT_115	[p7l879t1434r1168b1520],
81	vs.	CC	O	vs.	dep	110	SENT_115	[p7l1197t1455r1306b1508],
82	6.7	CD	PERCENT	6.7	dep	110	SENT_115	[p7l1347t1434r1605b1524],
83	%	NN	PERCENT	%	dep	110	SENT_115	[p7l1347t1434r1605b1524],
84	)	CD	NUMBER	)	dep	110	SENT_115	[p7l1347t1434r1605b1524],
85	,	,	O	,	_	0	SENT_115	[p7l1347t1434r1605b1524],
86	with	IN	O	with	dep	110	SENT_115	[p7l1641t1429r1836b1508],
87	a	DT	O	a	dep	110	SENT_115	[p7l1871t1455r1915b1507],
88	hazard	NN	O	hazard	dep	110	SENT_115	[p7l1948t1429r2132b1507, p7l11t1557r149b1635],
89	ratio	NN	O	ratio	dep	110	SENT_115	[p7l194t1558r391b1635],
90	for	IN	O	for	dep	110	SENT_115	[p7l438t1556r562b1635],
91	progression	NN	O	progression	dep	110	SENT_115	[p7l603t1558r1114b1658],
92	or	CC	O	or	dep	110	SENT_115	[p7l1160t1583r1248b1635],
93	death	NN	O	death	dep	110	SENT_115	[p7l1293t1557r1529b1635],
94	of	IN	O	of	dep	110	SENT_115	[p7l1575t1556r1675b1635],
95	0.74	CD	NUMBER	0.74	dep	110	SENT_115	[p7l1703t1562r1872b1635],
96	(	CD	NUMBER	(	dep	110	SENT_115	[p7l1923t1562r2134b1648],
97	95	CD	NUMBER	95	dep	110	SENT_115	[p7l1923t1562r2134b1648],
98	°	NN	O	°	dep	110	SENT_115	[p7l1923t1562r2134b1648],
99	/	:	O	/	dep	110	SENT_115	[p7l1923t1562r2134b1648],
100	o	NN	O	o	dep	110	SENT_115	[p7l1923t1562r2134b1648],
101	CI	NN	O	ci	dep	110	SENT_115	[p7l11t1690r126b1780],
102	,	,	O	,	_	0	SENT_115	[p7l11t1690r126b1780],
103	0.65	CD	NUMBER	0.65	dep	110	SENT_115	[p7l173t1690r345b1763],
104	to	TO	O	to	dep	110	SENT_115	[p7l391t1702r473b1763],
105	0.85	CD	NUMBER	0.85	dep	110	SENT_115	[p7l516t1690r715b1780],
106	;	:	O	;	_	0	SENT_115	[p7l516t1690r715b1780],
107	P	NN	O	p	dep	110	SENT_115	[p7l760t1690r1149b1776],
108	<	JJR	O	<	dep	110	SENT_115	[p7l760t1690r1149b1776],
109	0.001	CD	NUMBER	0.001	dep	110	SENT_115	[p7l760t1690r1149b1776],
110	)	NN	O	)	_	0	SENT_115	[p7l760t1690r1149b1776],
111	.	.	O	.	_	0	SENT_115	[p7l760t1690r1149b1776],

1	Although	IN	O	although	mark	5	SENT_116	[p7l1192t1685r1600b1786],
2	overall	JJ	O	overall	amod	3	SENT_116	[p7l1642t1685r1927b1764],
3	survival	NN	O	survival	nsubj	5	SENT_116	[p7l1970t1711r2132b1764, p7l7t1813r202b1892],
4	was	VBD	O	be	cop	5	SENT_116	[p7l238t1839r399b1892],
5	similar	JJ	O	similar	advcl	13	SENT_116	[p7l444t1813r749b1891],
6	in	IN	O	in	_	0	SENT_116	[p7l786t1814r870b1890],
7	the	DT	O	the	det	10	SENT_116	[p7l911t1813r1043b1891],
8	two	CD	NUMBER	two	num	10	SENT_116	[p7l1084t1830r1242b1892],
9	study	NN	O	study	nn	10	SENT_116	[p7l1285t1813r1514b1913],
10	groups	NNS	O	group	prep_in	5	SENT_116	[p7l1550t1839r1870b1914],
11	,	,	O	,	_	0	SENT_116	[p7l1550t1839r1870b1914],
12	there	EX	O	there	expl	13	SENT_116	[p7l1917t1813r2133b1891],
13	was	VBD	O	be	_	0	SENT_116	[p7l7t1967r169b2020],
14	a	DT	O	a	det	15	SENT_116	[p7l220t1967r264b2019],
15	suggestion	NN	O	suggestion	nsubj	13	SENT_116	[p7l314t1942r779b2042],
16	of	IN	O	of	_	0	SENT_116	[p7l828t1940r928b2019],
17	improvement	NN	O	improvement	prep_of	15	SENT_116	[p7l959t1942r1532b2041],
18	in	IN	O	in	_	0	SENT_116	[p7l1575t1942r1658b2018],
19	quality	NN	O	quality	prep_in	17	SENT_116	[p7l1708t1941r2006b2041],
20	of	IN	O	of	_	0	SENT_116	[p7l2052t1940r2152b2019],
21	life	NN	O	life	prep_of	19	SENT_116	[p7l10t2068r145b2147],
22	in	IN	O	in	_	0	SENT_116	[p7l185t2070r268b2146],
23	patients	NNS	O	patient	prep_in	21	SENT_116	[p7l306t2070r648b2169],
24	treated	VBN	O	treat	partmod	23	SENT_116	[p7l690t2069r988b2147],
25	with	IN	O	with	_	0	SENT_116	[p7l1023t2069r1218b2148],
26	gefitinib	NN	O	gefitinib	prep_with	24	SENT_116	[p7l1257t2068r1652b2170],
27	.	.	O	.	_	0	SENT_116	[p7l1257t2068r1652b2170],

1	In	IN	O	in	_	0	SENT_117	[p7l138t2204r228b2273],
2	two	CD	NUMBER	two	prep_in	16	SENT_117	[p7l269t2213r426b2276],
3	randomized	VBN	O	randomize	partmod	2	SENT_117	[p7l469t2197r989b2274],
4	trials	NNS	O	trial	dobj	3	SENT_117	[p7l1031t2197r1249b2274],
5	conducted	VBN	O	conduct	partmod	4	SENT_117	[p7l1294t2197r1734b2276],
6	in	IN	O	in	_	0	SENT_117	[p7l1775t2198r1858b2273],
7	Japan	NNP	LOCATION	Japan	prep_in	5	SENT_117	[p7l1889t2204r2133b2296],
8	involving	VBG	O	involve	xcomp	5	SENT_117	[p7l11t2325r416b2426],
9	230	CD	NUMBER	230	num	12	SENT_117	[p7l467t2330r622b2404],
10	and	CC	O	and	_	0	SENT_117	[p7l678t2325r838b2403],
11	177	CD	NUMBER	177	num	12	SENT_117	[p7l896t2330r1044b2403],
12	patients	NNS	O	patient	dobj	8	SENT_117	[p7l1099t2326r1474b2425],
13	,	,	O	,	_	0	SENT_117	[p7l1099t2326r1474b2425],
14	gefitinib	NN	O	gefitinib	nsubjpass	16	SENT_117	[p7l1535t2324r1915b2426],
15	was	VBD	O	be	auxpass	16	SENT_117	[p7l1967t2351r2132b2404],
16	compared	VBN	O	compare	_	0	SENT_117	[p7l12t2453r441b2553],
17	with	IN	O	with	_	0	SENT_117	[p7l492t2453r687b2532],
18	two	CD	NUMBER	two	num	19	SENT_117	[p7l743t2470r900b2533],
19	combinations	NNS	O	combination	prep_with	16	SENT_117	[p7l958t2453r1546b2531],
20	of	IN	O	of	_	0	SENT_117	[p7l1604t2452r1703b2531],
21	platinum	NN	O	platinum	nn	24	SENT_117	[p7l1739t2453r2133b2553],
22	and	CC	O	and	_	0	SENT_117	[p7l11t2581r170b2659],
23	taxane	NN	O	taxane	nn	24	SENT_117	[p7l220t2598r509b2659],
24	agents	NNS	O	agent	prep_of	19	SENT_117	[p7l558t2598r839b2682],
25	as	IN	O	as	_	0	SENT_117	[p7l889t2607r976b2659],
26	first-line	JJ	O	first-line	amod	27	SENT_117	[p7l1026t2580r1405b2659],
27	therapy	NN	O	therapy	prep_as	16	SENT_117	[p7l1456t2581r1783b2681],
28	for	IN	O	for	_	0	SENT_117	[p7l1828t2580r1954b2659],
29	patients	NNS	O	patient	prep_for	27	SENT_117	[p7l1998t2607r2132b2681, p7l12t2711r247b2788],
30	with	IN	O	with	_	0	SENT_117	[p7l280t2710r475b2789],
31	advanced	JJ	O	advanced	amod	33	SENT_117	[p7l510t2710r906b2789],
32	N	NN	O	n	nn	33	SENT_117	[p7l939t2717r1013b2788],
33	SCLC	NN	ORGANIZATION	sclc	prep_with	29	SENT_117	[p7l1017t2715r1242b2788],
34	who	WP	O	who	nsubj	35	SENT_117	[p7l1275t2710r1457b2789],
35	carried	VBD	O	carry	rcmod	33	SENT_117	[p7l1495t2710r1795b2788],
36	activatHER1	NN	O	activather1	dobj	35	SENT_117	[p7l1829t2711r2132b2789, p8l827t1231r952b1269],

1	(	JJ	O	(	amod	3	SENT_118	[p8l977t1230r1136b1283],
2	EGFR	NN	ORGANIZATION	egfr	nn	3	SENT_118	[p8l977t1230r1136b1283],
3	)	NN	O	)	_	0	SENT_118	[p8l977t1230r1136b1283],
4	with	IN	O	with	_	0	SENT_118	[p8l1157t1227r1252b1269],
5	T790M	NN	O	t790m	nn	6	SENT_118	[p8l850t1294r1008b1334],
6	mutation	NN	O	mutation	prep_with	3	SENT_118	[p8l1032t1295r1237b1334],

1	HER1	NN	O	her1	_	0	SENT_119	[p8l112t1355r236b1393],
2	(	CD	NUMBER	(	num	4	SENT_119	[p8l261t1355r421b1407],
3	EGFR	NN	ORGANIZATION	egfr	nn	4	SENT_119	[p8l261t1355r421b1407],
4	)	NN	O	)	dep	1	SENT_119	[p8l261t1355r421b1407],
5	in	IN	O	in	_	0	SENT_119	[p8l445t1356r482b1393],
6	heterodimerization	NN	O	heterodimerization	prep_in	4	SENT_119	[p8l78t1415r514b1458],

1	Cytoplasm	NN	O	cytoplasm	_	0	SENT_120	[p8l1867t1850r2108b1906],

1	EGFR	NN	ORGANIZATION	egfr	nn	3	SENT_121	[p8l1244t2244r1416b2316],
2	TKI	NN	O	tkus	nn	3	SENT_121	[p8l1432t2277r1506b2315],
3	binding	NN	O	binding	nsubj	4	SENT_121	[p8l1217t2338r1389b2393],
4	blocked	VBD	O	block	_	0	SENT_121	[p8l1408t2338r1580b2380],

1	6	CD	NUMBER	6	_	0	SENT_122	[p8l146t2558r250b2663],
2	.	.	O	.	_	0	SENT_122	[p8l146t2558r250b2663],

1	Phosphorylation	NN	O	phosphorylation	nsubj	3	SENT_123	[p8l288t2577r659b2633],
2	Downstream	JJ	O	downstream	amod	1	SENT_123	[p8l1780t2557r2070b2596],
3	inhibited	VBD	O	inhibit	_	0	SENT_123	[p8l374t2641r572b2684],
4	Sig	NN	O	sig	dobj	3	SENT_123	[p8l1821t2618r2029b2674],
5	"	''	O	"	prep	3	SENT_123	[p8l1821t2618r2029b2674],
6	'	''	O	'	_	0	SENT_123	[p8l1821t2618r2029b2674],
7	a	DT	O	a	det	9	SENT_123	[p8l1821t2618r2029b2674],
8	““	CD	NUMBER	““	num	9	SENT_123	[p8l1821t2618r2029b2674],
9	g	NN	O	g	dep	5	SENT_123	[p8l1821t2618r2029b2674],

1	C	NN	O	c	_	0	SENT_124	[p8l44t2792r85b2842],

1	HER1	NN	O	her1	_	0	SENT_125	[p8l112t2880r236b2918],
2	(	CD	NUMBER	(	num	4	SENT_125	[p8l261t2879r421b2932],
3	EGFR	NN	ORGANIZATION	egfr	nn	4	SENT_125	[p8l261t2879r421b2932],
4	)	NN	O	)	dep	1	SENT_125	[p8l261t2879r421b2932],
5	in	IN	O	in	_	0	SENT_125	[p8l446t2880r482b2918],
6	heterodimerization	NN	O	heterodimerization	prep_in	4	SENT_125	[p8l78t2941r514b2983],

1	Phosphorylation	NN	O	phosphorylation	nsubj	2	SENT_126	[p9l292t344r662b399],
2	inhibited	VBD	O	inhibit	_	0	SENT_126	[p9l377t408r575b451],
3	Downstream	JJ	O	downstream	amod	7	SENT_126	[p9l1165t413r1455b452],
4	signaling	NN	O	signaling	nn	7	SENT_126	[p9l1206t474r1414b530],
5	ing	NN	O	ing	nn	7	SENT_126	[p9l11t692r115b766],
6	EGFR	NN	ORGANIZATION	egfr	nn	7	SENT_126	[p9l146t697r305b751],
7	mutations	NNS	O	mutation	dobj	2	SENT_126	[p9l336t692r679b750],
8	.	.	O	.	_	0	SENT_126	[p9l336t692r679b750],

1	Gefitinib	JJ	O	gefitinib	amod	2	SENT_127	[p9l719t691r1012b750],
2	signiﬁcantly	NN	O	signiﬁcantly	nsubj	3	SENT_127	[p9l1050t691r1455b766],
3	improved	VBD	O	improve	_	0	SENT_127	[p9l1487t692r1595b749, p9l10t787r226b861],
4	the	DT	O	the	det	9	SENT_127	[p9l259t787r358b845],
5	median	JJ	O	median	amod	9	SENT_127	[p9l392t787r633b845],
6	progression	NN	O	progression	nn	9	SENT_127	[p9l666t786r1194b861],
7	—	CD	NUMBER	—	num	9	SENT_127	[p9l666t786r1194b861],
8	free	JJ	O	free	amod	9	SENT_127	[p9l666t786r1194b861],
9	survival	NN	O	survival	dobj	3	SENT_127	[p9l1229t787r1493b857],
10	,	,	O	,	_	0	SENT_127	[p9l1229t787r1493b857],
11	as	IN	O	as	_	0	SENT_127	[p9l1531t806r1594b845],
12	compared	VBN	O	compare	prepc_as	3	SENT_127	[p9l12t882r330b956],
13	with	IN	O	with	pcomp	12	SENT_127	[p9l362t882r507b940],
14	carboplatin	NN	O	carboplatin	nn	17	SENT_127	[p9l543t882r912b956],
15	and	CC	O	and	_	0	SENT_127	[p9l947t882r1065b940],
16	paclitaxel	NN	O	paclitaxel	nn	17	SENT_127	[p9l1098t882r1406b956],
17	(	NN	O	(	pobj	13	SENT_127	[p9l1444t886r1594b949],
18	10.8	CD	NUMBER	10.8	dep	17	SENT_127	[p9l1444t886r1594b949],
19	vs.	CC	O	vs.	prep	18	SENT_127	[p9l8t996r89b1035],
20	5.4	CD	DURATION	5.4	num	21	SENT_127	[p9l124t981r216b1035],
21	months	NNS	NUMBER	month	dep	19	SENT_127	[p9l246t977r508b1047],
22	;	:	O	;	_	0	SENT_127	[p9l246t977r508b1047],
23	hazard	NN	O	hazard	nn	24	SENT_127	[p9l541t977r762b1035],
24	ratio	NN	O	ratio	dep	18	SENT_127	[p9l792t977r956b1047],
25	,	,	O	,	_	0	SENT_127	[p9l792t977r956b1047],
26	0.30	CD	NUMBER	0.30	appos	24	SENT_127	[p9l990t981r1141b1047],
27	;	:	O	;	_	0	SENT_127	[p9l990t981r1141b1047],
28	95	CD	PERCENT	95	number	29	SENT_127	[p9l1174t981r1311b1035],
29	%	NN	PERCENT	%	amod	30	SENT_127	[p9l1174t981r1311b1035],
30	CI	NN	O	ci	dep	18	SENT_127	[p9l1341t981r1427b1047],
31	,	,	O	,	_	0	SENT_127	[p9l1341t981r1427b1047],
32	0.22	CD	NUMBER	0.22	appos	30	SENT_127	[p9l1461t981r1595b1035],

1	N	NN	O	n	nn	3	SENT_128	[p9l558t1132r572b1147],
2	ENGLJ	NN	O	englj	nn	3	SENT_128	[p9l586t1132r664b1154],
3	MED	NN	O	med	_	0	SENT_128	[p9l679t1132r731b1147],
4	364	CD	NUMBER	364	dep	3	SENT_128	[p9l741t1126r823b1154],
5	;	:	O	;	_	0	SENT_128	[p9l741t1126r823b1154],
6	1o	CD	NUMBER	1o	num	8	SENT_128	[p9l741t1126r823b1154],
7	NEJM.ORG	NN	O	nejm.org	nn	8	SENT_128	[p9l858t1132r982b1154],
8	MARCH	NN	DATE	march	dep	4	SENT_128	[p9l1019t1132r1104b1148],
9	10,2011	CD	NUMBER	10,2011	number	10	SENT_128	[p9l1117t1132r1214b1152],
10	949	CD	NUMBER	949	dep	8	SENT_128	[p9l1960t1122r2016b1145],

1	The	DT	O	the	det	4	SENT_129	[p9l702t1165r753b1188],
2	New	NNP	O	New	nn	4	SENT_129	[p9l762t1165r824b1188],
3	England	NNP	O	England	nn	4	SENT_129	[p9l833t1165r944b1195],
4	Journal	NNP	O	Journal	_	0	SENT_129	[p9l952t1165r1050b1188],
5	of	IN	O	of	_	0	SENT_129	[p9l1060t1165r1089b1188],
6	Medicine	NNP	O	Medicine	prep_of	4	SENT_129	[p9l1095t1165r1220b1188],

1	Downloaded	VBN	O	download	_	0	SENT_130	[p9l144t1205r314b1228],
2	from	IN	O	from	_	0	SENT_130	[p9l323t1205r387b1228],
3	nejm.org	NN	O	nejm.org	prep_from	1	SENT_130	[p9l396t1205r514b1235],
4	at	IN	O	at	_	0	SENT_130	[p9l524t1209r547b1228],
5	UW-Madison	NN	O	uw-madison	prep_at	1	SENT_130	[p9l556t1205r738b1228],
6	on	IN	O	on	_	0	SENT_130	[p9l748t1212r780b1228],
7	January	NNP	DATE	January	prep_on	1	SENT_130	[p9l789t1205r892b1235],
8	5	CD	DATE	5	num	7	SENT_130	[p9l902t1205r924b1233],
9	,	,	DATE	,	_	0	SENT_130	[p9l902t1205r924b1233],
10	2014	CD	DATE	2014	num	7	SENT_130	[p9l935t1205r1007b1228],
11	.	.	O	.	_	0	SENT_130	[p9l935t1205r1007b1228],

1	For	IN	O	for	_	0	SENT_131	[p9l1018t1205r1064b1228],
2	personal	JJ	O	personal	amod	3	SENT_131	[p9l1072t1205r1185b1235],
3	use	NN	O	use	pobj	1	SENT_131	[p9l1194t1212r1237b1228],
4	only	RB	O	only	advmod	3	SENT_131	[p9l1247t1205r1312b1235],
5	.	.	O	.	_	0	SENT_131	[p9l1247t1205r1312b1235],

1	No	DT	O	no	det	3	SENT_132	[p9l1323t1205r1362b1228],
2	other	JJ	O	other	amod	3	SENT_132	[p9l1372t1205r1440b1228],
3	uses	NNS	O	use	_	0	SENT_132	[p9l1449t1212r1505b1228],
4	without	IN	O	without	_	0	SENT_132	[p9l1515t1205r1616b1228],
5	permission	NN	O	permission	prep_without	3	SENT_132	[p9l1624t1205r1777b1235],
6	.	.	O	.	_	0	SENT_132	[p9l1624t1205r1777b1235],

1	Copyright	NN	O	copyright	_	0	SENT_133	[p9l494t1246r629b1277],
2	©	CD	NUMBER	©	num	6	SENT_133	[p9l638t1246r661b1270],
3	2011	CD	DATE	2011	num	6	SENT_133	[p9l671t1246r734b1270],
4	Massachusetts	NNP	ORGANIZATION	Massachusetts	nn	6	SENT_133	[p9l746t1246r937b1270],
5	Medical	NNP	ORGANIZATION	Medical	nn	6	SENT_133	[p9l947t1246r1055b1270],
6	Society	NNP	ORGANIZATION	Society	dep	1	SENT_133	[p9l1065t1246r1170b1277],
7	.	.	O	.	_	0	SENT_133	[p9l1065t1246r1170b1277],

1	All	DT	O	all	det	2	SENT_134	[p9l1181t1246r1223b1270],
2	rights	NNS	O	rights	nsubj	3	SENT_134	[p9l1232t1246r1307b1277],
3	reserved	VBN	O	reserve	_	0	SENT_134	[p9l1316t1246r1435b1270],
4	.	.	O	.	_	0	SENT_134	[p9l1316t1246r1435b1270],

1	The	DT	O	the	det	4	SENT_135	[p9l673t1352r718b1373],
2	NEW	NNP	O	NEW	nn	4	SENT_135	[p9l737t1354r822b1373],
3	ENGLAND	NNP	O	ENGLAND	nn	4	SENT_135	[p9l841t1354r1029b1373],
4	JOURNAL	NNP	O	JOURNAL	_	0	SENT_135	[p9l1048t1354r1227b1380],
5	of	IN	O	of	_	0	SENT_135	[p9l1247t1352r1275b1379],
6	MEDICINE	NNP	O	MEDICINE	prep_of	4	SENT_135	[p9l1287t1354r1486b1373],

1	Table	NNP	O	Table	_	0	SENT_136	[p9l58t1576r198b1624],
2	1	CD	NUMBER	1	dep	1	SENT_136	[p9l218t1581r260b1624],
3	.	.	O	.	_	0	SENT_136	[p9l218t1581r260b1624],

1	Eastern	NNP	ORGANIZATION	Eastern	nn	4	SENT_137	[p9l283t1580r474b1624],
2	Cooperative	NNP	ORGANIZATION	Cooperative	nn	4	SENT_137	[p9l494t1577r808b1638],
3	Oncology	NNP	ORGANIZATION	Oncology	nn	4	SENT_137	[p9l825t1576r1077b1639],
4	Group	NNP	ORGANIZATION	Group	_	0	SENT_137	[p9l1094t1580r1260b1638],
5	(	CD	NUMBER	(	num	6	SENT_137	[p9l1281t1580r1479b1639],
6	ECOG	NN	O	ecog	dep	4	SENT_137	[p9l1281t1580r1479b1639],
7	)	CD	NUMBER	)	num	9	SENT_137	[p9l1281t1580r1479b1639],
8	Performance	NNP	O	Performance	nn	9	SENT_137	[p9l1503t1575r1834b1624],
9	Status	NNP	O	Status	dep	6	SENT_137	[p9l1851t1580r2031b1624],
10	.	.	O	.	_	0	SENT_137	[p9l1851t1580r2031b1624],

1	Description	NN	O	description	_	0	SENT_138	[p9l1037t1722r1336b1783],

1	Fully	RB	O	fully	advmod	2	SENT_139	[p9l272t1833r387b1896],
2	active	JJ	O	active	dep	6	SENT_139	[p9l404t1838r562b1890],
3	,	,	O	,	_	0	SENT_139	[p9l404t1838r562b1890],
4	able	JJ	O	able	dep	2	SENT_139	[p9l584t1833r686b1881],
5	to	TO	O	to	aux	6	SENT_139	[p9l702t1842r752b1881],
6	carry	VB	O	carry	_	0	SENT_139	[p9l771t1850r893b1896],
7	on	IN	O	on	_	0	SENT_139	[p9l910t1850r971b1881],
8	all	DT	O	all	det	10	SENT_139	[p9l993t1833r1044b1881],
9	predisease	NN	O	predisease	nn	10	SENT_139	[p9l1068t1833r1339b1896],
10	activities	NNS	O	activity	prep_on	6	SENT_139	[p9l1358t1838r1579b1881],
11	without	IN	O	without	_	0	SENT_139	[p9l1596t1833r1792b1881],
12	restriction	NN	O	restriction	prep_without	6	SENT_139	[p9l1812t1838r2066b1881],
13	Restricted	VBN	O	restrict	partmod	12	SENT_139	[p9l272t1947r526b1996],
14	in	IN	O	in	_	0	SENT_139	[p9l550t1952r592b1995],
15	physically	RB	O	physically	advmod	16	SENT_139	[p9l617t1947r866b2011],
16	strenuous	JJ	O	strenuous	amod	17	SENT_139	[p9l885t1957r1144b1996],
17	activity	NN	O	activity	prep_in	13	SENT_139	[p9l1166t1952r1347b2011],
18	but	CC	O	but	_	0	SENT_139	[p9l1367t1947r1449b1996],
19	ambulatory	JJ	O	ambulatory	amod	17	SENT_139	[p9l1469t1947r1765b2011],
20	and	CC	O	and	_	0	SENT_139	[p9l1784t1947r1876b1996],
21	able	JJ	O	able	amod	17	SENT_139	[p9l1898t1947r2003b1996],
22	to	TO	O	to	aux	23	SENT_139	[p9l2020t1957r2071b1996],
23	carry	VB	O	carry	xcomp	13	SENT_139	[p9l364t2036r488b2083],
24	out	RP	O	out	prt	23	SENT_139	[p9l507t2029r592b2068],
25	work	NN	O	work	nn	27	SENT_139	[p9l608t2019r734b2068],
26	ofa	NN	O	ofa	nn	27	SENT_139	[p9l752t2019r844b2068],
27	light	NN	O	light	dobj	23	SENT_139	[p9l867t2019r979b2083],
28	or	CC	O	or	_	0	SENT_139	[p9l997t2036r1050b2068],
29	sedentary	JJ	O	sedentary	amod	30	SENT_139	[p9l1069t2019r1321b2083],
30	nature	NN	O	nature	dobj	23	SENT_139	[p9l1341t2029r1505b2068],
31	(	CD	NUMBER	(	num	30	SENT_139	[p9l1530t2024r1651b2083],
32	e.g.	FW	O	e.g.	dep	30	SENT_139	[p9l1530t2024r1651b2083],
33	,	,	O	,	_	0	SENT_139	[p9l1530t2024r1651b2083],
34	light	JJ	O	light	amod	35	SENT_139	[p9l1676t2019r1787b2083],
35	housework	NN	O	housework	appos	27	SENT_139	[p9l1808t2019r2092b2068],
36	or	CC	O	or	_	0	SENT_139	[p9l364t2108r417b2140],
37	ofﬁce	NN	O	ofﬁce	nn	38	SENT_139	[p9l434t2091r574b2140],
38	work	NN	O	work	conj_or	35	SENT_139	[p9l592t2091r734b2155],
39	)	CD	NUMBER	)	dep	35	SENT_139	[p9l592t2091r734b2155],

1	Ambulatory	JJ	O	ambulatory	_	0	SENT_140	[p9l266t2206r573b2269],
2	and	CC	O	and	_	0	SENT_140	[p9l591t2206r683b2254],
3	capable	JJ	O	capable	conj_and	1	SENT_140	[p9l705t2206r904b2269],
4	of	IN	O	of	_	0	SENT_140	[p9l923t2205r980b2254],
5	all	DT	O	all	det	6	SENT_140	[p9l991t2206r1044b2254],
6	self-care	NN	O	self-care	prep_of	3	SENT_140	[p9l1067t2205r1282b2254],
7	but	CC	O	but	_	0	SENT_140	[p9l1303t2206r1386b2254],
8	unable	JJ	O	unable	conj_and	1	SENT_140	[p9l1407t2206r1579b2254],
9	to	TO	O	to	aux	10	SENT_140	[p9l1596t2215r1647b2254],
10	carry	VB	O	carry	dep	1	SENT_140	[p9l1667t2223r1792b2269],
11	out	RP	O	out	prt	10	SENT_140	[p9l1810t2215r1895b2254],
12	any	DT	O	any	det	14	SENT_140	[p9l1914t2223r2001b2269],
13	work	NN	O	work	nn	14	SENT_140	[p9l362t2278r488b2326],
14	activities	NNS	O	activity	dobj	10	SENT_140	[p9l507t2283r749b2335],
15	;	:	O	;	_	0	SENT_140	[p9l507t2283r749b2335],
16	up	RB	O	up	amod	14	SENT_140	[p9l773t2295r835b2341],
17	and	CC	O	and	_	0	SENT_140	[p9l855t2278r947b2326],
18	about	RB	O	about	quantmod	21	SENT_140	[p9l970t2278r1118b2326],
19	more	JJR	O	more	quantmod	21	SENT_140	[p9l1140t2295r1272b2326],
20	than	IN	O	than	quantmod	21	SENT_140	[p9l1290t2278r1403b2326],
21	50	CD	PERCENT	50	num	22	SENT_140	[p9l1427t2280r1540b2328],
22	%	NN	PERCENT	%	conj_and	14	SENT_140	[p9l1427t2280r1540b2328],
23	ofwaking	NN	O	ofwaking	nn	24	SENT_140	[p9l1559t2277r1808b2342],
24	hours	NNS	DURATION	hour	dep	14	SENT_140	[p9l1828t2278r1974b2326],

1	Capable	JJ	O	capable	_	0	SENT_141	[p9l268t2393r477b2455],
2	ofonly	RB	O	ofonly	dep	4	SENT_141	[p9l496t2392r670b2456],
3	limited	JJ	O	limited	amod	4	SENT_141	[p9l691t2393r866b2441],
4	self-care	NN	O	self-care	dep	6	SENT_141	[p9l889t2392r1118b2449],
5	;	:	O	;	_	0	SENT_141	[p9l889t2392r1118b2449],
6	confined	VBN	O	confine	dep	1	SENT_141	[p9l1140t2392r1363b2441],
7	to	TO	O	to	_	0	SENT_141	[p9l1383t2402r1434b2441],
8	bed	NN	O	bed	prep_to	6	SENT_141	[p9l1456t2393r1545b2441],
9	or	CC	O	or	_	0	SENT_141	[p9l1567t2410r1620b2441],
10	chair	NN	O	chair	prep_to	6	SENT_141	[p9l1637t2393r1766b2441],
11	more	JJR	O	more	dep	12	SENT_141	[p9l1786t2410r1918b2441],
12	than	IN	O	than	advmod	6	SENT_141	[p9l1936t2393r2050b2441],

1	50	CD	PERCENT	50	num	2	SENT_142	[p9l364t2467r478b2515],
2	%	NN	PERCENT	%	_	0	SENT_142	[p9l364t2467r478b2515],
3	ofwaking	NN	O	ofwaking	nn	4	SENT_142	[p9l497t2464r746b2528],
4	hours	NNS	DURATION	hour	dep	2	SENT_142	[p9l766t2465r912b2513],

1	Completely	RB	O	completely	_	0	SENT_143	[p9l268t2579r563b2642],
2	disabled	JJ	O	disabled	nsubj	9	SENT_143	[p9l581t2579r796b2627],
3	and	CC	O	and	_	0	SENT_143	[p9l819t2579r911b2627],
4	not	RB	O	not	neg	6	SENT_143	[p9l936t2588r1019b2627],
5	capable	JJ	O	capable	amod	6	SENT_143	[p9l1037t2579r1235b2642],
6	ofself-care	NN	O	ofself-care	nsubj	9	SENT_143	[p9l1255t2579r1552b2636],
7	;	:	O	;	_	0	SENT_143	[p9l1255t2579r1552b2636],
8	totally	RB	O	totally	advmod	9	SENT_143	[p9l1571t2579r1731b2642],
9	confined	VBN	O	confine	ccomp	1	SENT_143	[p9l1749t2579r1972b2627],
10	to	TO	O	to	_	0	SENT_143	[p9l1992t2588r2043b2627],
11	bed	NN	O	bed	prep_to	9	SENT_143	[p9l366t2651r455b2699],
12	or	CC	O	or	_	0	SENT_143	[p9l477t2668r530b2699],
13	chair	NN	O	chair	prep_to	9	SENT_143	[p9l547t2651r676b2699],

1	Dead	JJ	O	dead	_	0	SENT_144	[p9l272t2766r401b2814],
2	to	TO	O	to	_	0	SENT_144	[p9l561t3068r622b3114],
3	0.41	CD	NUMBER	0.41	prep_to	1	SENT_144	[p9l647t3060r794b3126],
4	;	:	O	;	_	0	SENT_144	[p9l647t3060r794b3126],
5	P	NN	O	p	dep	6	SENT_144	[p9l820t3060r1170b3127],
6	<	JJR	O	<	dep	1	SENT_144	[p9l820t3060r1170b3127],
7	0	CD	NUMBER	0	dep	6	SENT_144	[p9l820t3060r1170b3127],
8	.	.	O	.	_	0	SENT_144	[p9l820t3060r1170b3127],

1	O01	NN	O	o01	_	0	SENT_145	[p9l820t3060r1170b3127],
2	)	CD	NUMBER	)	num	3	SENT_145	[p9l820t3060r1170b3127],
3	,22	CD	NUMBER	,22	dep	1	SENT_145	[p9l820t3060r1170b3127],
4	and	CC	O	and	_	0	SENT_145	[p9l1195t3056r1312b3114],
5	as	IN	O	as	mark	6	SENT_145	[p9l1336t3075r1400b3114],
6	compared	VBN	O	compare	conj_and	1	SENT_145	[p9l1426t3056r1744b3130],
7	with	IN	O	with	_	0	SENT_145	[p9l1765t3056r1910b3115],
8	cispla	NN	O	cisplum	nn	10	SENT_145	[p9l1936t3056r2140b3130],
9	—	CD	NUMBER	—	num	10	SENT_145	[p9l1936t3056r2140b3130],
10	tin	NN	O	tin	prep_with	6	SENT_145	[p9l561t3152r649b3209],
11	and	CC	O	and	_	0	SENT_145	[p9l690t3151r808b3209],
12	docetaxel	NN	O	docetaxel	nn	13	SENT_145	[p9l850t3151r1152b3209],
13	(	NN	O	(	conj_and	10	SENT_145	[p9l1197t3155r1310b3218],
14	9.2	CD	NUMBER	9.2	dobj	6	SENT_145	[p9l1197t3155r1310b3218],
15	vs.	CC	O	vs.	prep	14	SENT_145	[p9l1349t3170r1430b3209],
16	6.3	CD	DURATION	6.3	num	17	SENT_145	[p9l1477t3155r1569b3209],
17	months	NNS	NUMBER	month	dep	15	SENT_145	[p9l1613t3151r1875b3221],
18	;	:	O	;	_	0	SENT_145	[p9l1613t3151r1875b3221],
19	hazard	NN	O	hazard	nn	20	SENT_145	[p9l1920t3151r2141b3209],
20	ratio	NN	O	ratio	dep	14	SENT_145	[p9l561t3247r724b3317],
21	,	,	O	,	_	0	SENT_145	[p9l561t3247r724b3317],
22	0.49	CD	NUMBER	0.49	appos	20	SENT_145	[p9l758t3250r906b3316],
23	;	:	O	;	_	0	SENT_145	[p9l758t3250r906b3316],
24	95	CD	PERCENT	95	number	25	SENT_145	[p9l938t3250r1076b3304],
25	%	NN	PERCENT	%	amod	26	SENT_145	[p9l938t3250r1076b3304],
26	CI	NN	O	ci	dep	14	SENT_145	[p9l1104t3250r1190b3317],
27	,	,	O	,	_	0	SENT_145	[p9l1104t3250r1190b3317],
28	0.34	CD	NUMBER	0.34	num	30	SENT_145	[p9l1224t3250r1357b3304],
29	to	TO	O	to	dep	30	SENT_145	[p9l1387t3258r1447b3304],
30	0.71	CD	NUMBER	0.71	appos	26	SENT_145	[p9l1478t3250r1626b3316],
31	;	:	O	;	_	0	SENT_145	[p9l1478t3250r1626b3316],
32	P	NN	O	p	dep	33	SENT_145	[p9l1657t3250r2005b3313],
33	<	JJR	O	<	dep	14	SENT_145	[p9l1657t3250r2005b3313],
34	0.001	CD	NUMBER	0.001	num	35	SENT_145	[p9l1657t3250r2005b3313],
35	)	NN	O	)	dep	33	SENT_145	[p9l1657t3250r2005b3313],
36	.23	CD	NUMBER	.23	tmod	14	SENT_145	[p9l1657t3250r2005b3313],

1	CLINICAL	JJ	O	clinical	amod	2	SENT_146	[p9l1058t3469r1460b3513],
2	USE	NN	O	use	_	0	SENT_146	[p9l1498t3469r1643b3513],

1	Erlotinib	NNP	O	Erlotinib	nsubj	2	SENT_147	[p9l560t3670r842b3728],
2	received	VBD	O	receive	_	0	SENT_147	[p9l882t3670r1140b3729],
3	approval	NN	O	approval	dobj	2	SENT_147	[p9l1179t3670r1452b3744],
4	from	IN	O	from	_	0	SENT_147	[p9l1491t3669r1648b3728],
5	the	DT	O	the	det	6	SENT_147	[p9l1687t3670r1786b3728],
6	Food	NNP	O	Food	prep_from	2	SENT_147	[p9l1825t3670r1984b3728],
7	and	CC	O	and	cc	6	SENT_147	[p9l2023t3670r2141b3728],

1	Drug	NNP	O	Drug	nn	2	SENT_148	[p10l560t22r724b92],
2	Administration	NNP	O	Administration	_	0	SENT_148	[p10l759t17r1254b75],
3	(	CD	NUMBER	(	num	4	SENT_148	[p10l1297t22r1474b84],
4	FDA	NNP	ORGANIZATION	FDA	npadvmod	2	SENT_148	[p10l1297t22r1474b84],
5	)	CD	NUMBER	)	num	4	SENT_148	[p10l1297t22r1474b84],
6	in	IN	O	in	_	0	SENT_148	[p10l1516t17r1579b74],
7	November	NNP	DATE	November	prep_in	4	SENT_148	[p10l1616t17r1947b76],
8	2004	CD	DATE	2004	num	7	SENT_148	[p10l1985t21r2141b75],
9	and	CC	O	and	_	0	SENT_148	[p10l560t112r678b170],
10	from	IN	O	from	_	0	SENT_148	[p10l699t111r856b170],
11	the	DT	O	the	det	14	SENT_148	[p10l877t112r976b170],
12	European	JJ	ORGANIZATION	european	amod	14	SENT_148	[p10l997t117r1304b186],
13	Medicines	NNP	ORGANIZATION	Medicines	nn	14	SENT_148	[p10l1323t112r1648b170],
14	Agency	NNP	ORGANIZATION	Agency	prep_from	4	SENT_148	[p10l1669t117r1904b187],
15	in	IN	O	in	_	0	SENT_148	[p10l1921t112r1983b169],
16	June	NNP	DATE	June	prep_in	14	SENT_148	[p10l1997t117r2141b179],
17	2005	CD	DATE	2005	num	16	SENT_148	[p10l561t211r712b265],
18	as	IN	O	as	_	0	SENT_148	[p10l751t226r814b265],
19	a	DT	DURATION	a	det	26	SENT_148	[p10l852t226r885b265],
20	second	JJ	DURATION	second	amod	26	SENT_148	[p10l922t207r1166b265],
21	-	:	O	-	_	0	SENT_148	[p10l922t207r1166b265],
22	or	CC	O	or	_	0	SENT_148	[p10l1204t226r1270b265],
23	third	JJ	ORDINAL	third	conj_or	20	SENT_148	[p10l1305t207r1607b265],
24	—	NN	O	—	nn	26	SENT_148	[p10l1305t207r1607b265],
25	line	NN	O	line	nn	26	SENT_148	[p10l1305t207r1607b265],
26	therapy	NN	O	therapy	prep_as	2	SENT_148	[p10l1644t207r1883b281],
27	for	IN	O	for	_	0	SENT_148	[p10l1917t206r2008b265],
28	patients	NNS	O	patient	prep_for	2	SENT_148	[p10l2042t226r2140b281, p10l561t303r737b360],
29	with	IN	O	with	_	0	SENT_148	[p10l755t302r900b361],
30	locally	RB	O	locally	advmod	31	SENT_148	[p10l919t302r1129b376],
31	advanced	VBN	O	advance	amod	34	SENT_148	[p10l1145t302r1439b361],
32	or	CC	O	or	_	0	SENT_148	[p10l1459t321r1525b360],
33	metastatic	JJ	O	metastatic	conj_or	31	SENT_148	[p10l1542t302r1875b360],
34	NSCLC	NN	O	nsclc	prep_with	2	SENT_148	[p10l1893t306r2137b361],
35	.	.	O	.	_	0	SENT_148	[p10l1893t306r2137b361],

1	Gefitinib	NNP	O	Gefitinib	nsubj	3	SENT_149	[p10l561t396r853b455],
2	initially	RB	O	initially	advmod	3	SENT_149	[p10l875t397r1124b471],
3	received	VBD	O	receive	_	0	SENT_149	[p10l1142t397r1399b456],
4	approval	NN	O	approval	dobj	3	SENT_149	[p10l1419t397r1692b471],
5	by	IN	O	by	_	0	SENT_149	[p10l1713t397r1786b471],
6	the	DT	O	the	det	7	SENT_149	[p10l1804t397r1903b455],
7	FDA	NNP	ORGANIZATION	FDA	prep_by	3	SENT_149	[p10l1923t402r2060b455],
8	in	IN	O	in	_	0	SENT_149	[p10l2079t397r2141b454],
9	2003	CD	DATE	2003	prep_in	3	SENT_149	[p10l561t496r733b550],
10	.	.	O	.	_	0	SENT_149	[p10l561t496r733b550],

1	However	RB	O	however	advmod	27	SENT_150	[p10l774t497r1073b563],
2	,	,	O	,	_	0	SENT_150	[p10l774t497r1073b563],
3	on	IN	O	on	_	0	SENT_150	[p10l1115t511r1195b550],
4	the	DT	O	the	det	5	SENT_150	[p10l1232t492r1332b550],
5	basis	NN	O	basis	prep_on	27	SENT_150	[p10l1370t492r1531b550],
6	of	IN	O	of	_	0	SENT_150	[p10l1570t491r1645b550],
7	data	NNS	O	datum	prep_of	5	SENT_150	[p10l1669t492r1808b550],
8	from	IN	O	from	_	0	SENT_150	[p10l1844t491r2002b550],
9	the	DT	O	the	det	12	SENT_150	[p10l2040t492r2140b550],
10	subsequent	JJ	O	subsequent	amod	12	SENT_150	[p10l562t587r923b661],
11	ISEL	NN	O	isel	nn	12	SENT_150	[p10l945t591r1087b645],
12	trial	NN	O	trial	prep_from	7	SENT_150	[p10l1113t587r1262b658],
13	,	,	O	,	_	0	SENT_150	[p10l1113t587r1262b658],
14	which	WDT	O	which	nsubj	17	SENT_150	[p10l1289t587r1485b646],
15	did	VBD	O	do	aux	17	SENT_150	[p10l1512t587r1612b645],
16	not	RB	O	not	neg	17	SENT_150	[p10l1638t599r1745b645],
17	show	VB	O	show	rcmod	12	SENT_150	[p10l1769t587r1936b646],
18	a	DT	O	a	det	20	SENT_150	[p10l1959t606r1992b645],
19	survival	NN	O	survival	nn	20	SENT_150	[p10l2019t606r2140b646, p10l557t682r703b741],
20	advantage	NN	O	advantage	dobj	17	SENT_150	[p10l741t682r1062b757],
21	or	CC	O	or	_	0	SENT_150	[p10l1102t701r1168b740],
22	an	DT	O	a	det	23	SENT_150	[p10l1204t701r1281b740],
23	improvement	NN	O	improvement	conj_or	20	SENT_150	[p10l1319t683r1747b756],
24	in	IN	O	in	_	0	SENT_150	[p10l1781t682r1844b739],
25	diseaserelated	JJ	O	diseaserelated	amod	26	SENT_150	[p10l1884t682r2140b740, p10l561t777r778b835],
26	symptoms	NNS	O	symptom	prep_in	17	SENT_150	[p10l802t780r1207b851],
27	,15	VBP	O	,15	_	0	SENT_150	[p10l802t780r1207b851],
28	the	DT	O	the	det	29	SENT_150	[p10l1233t777r1332b835],
29	labeling	NN	O	labeling	nsubjpass	33	SENT_150	[p10l1355t777r1615b852],
30	of	IN	O	of	_	0	SENT_150	[p10l1636t776r1711b835],
31	gefitinib	NN	O	gefitinib	prep_of	29	SENT_150	[p10l1720t776r1997b852],
32	was	VBD	O	be	auxpass	33	SENT_150	[p10l2018t796r2139b836],
33	modified	VBN	O	modify	dep	27	SENT_150	[p10l561t871r855b930],
34	to	TO	O	to	aux	35	SENT_150	[p10l880t884r941b930],
35	limit	VB	O	limit	xcomp	33	SENT_150	[p10l965t872r1121b930],
36	its	PRP$	O	its	poss	37	SENT_150	[p10l1142t872r1215b930],
37	use	NN	O	use	dobj	35	SENT_150	[p10l1241t891r1346b931],
38	to	TO	O	to	_	0	SENT_150	[p10l1371t884r1431b930],
39	patients	NNS	O	patient	prep_to	35	SENT_150	[p10l1456t872r1710b946],
40	who	WP	O	who	nsubj	43	SENT_150	[p10l1733t872r1869b931],
41	are	VBP	O	be	aux	43	SENT_150	[p10l1894t891r1990b930],
42	currently	RB	DATE	currently	advmod	43	SENT_150	[p10l2016t891r2140b931, p10l561t967r741b1041],
43	benefiting	VBG	O	benefit	rcmod	39	SENT_150	[p10l760t966r1086b1042],
44	or	CC	O	or	_	0	SENT_150	[p10l1107t986r1172b1025],
45	who	WP	O	who	nsubj	48	SENT_150	[p10l1189t967r1323b1026],
46	have	VBP	O	have	aux	48	SENT_150	[p10l1347t967r1486b1026],
47	previously	RB	DATE	previously	advmod	48	SENT_150	[p10l1507t967r1827b1041],
48	beneﬁted	VBN	O	beneﬁted	conj_or	33	SENT_150	[p10l1847t966r2141b1025],
49	from	IN	O	from	_	0	SENT_150	[p10l561t1061r715b1120],
50	gefitinib	NN	O	gefitinib	nn	51	SENT_150	[p10l738t1061r1008b1137],
51	therapy	NN	O	therapy	prep_from	48	SENT_150	[p10l1033t1062r1276b1136],
52	.	.	O	.	_	0	SENT_150	[p10l1033t1062r1276b1136],

1	In	IN	O	in	_	0	SENT_151	[p10l1303t1067r1368b1119],
2	July	NNP	DATE	July	prep_in	9	SENT_151	[p10l1384t1062r1505b1136],
3	2009	CD	DATE	2009	num	2	SENT_151	[p10l1525t1066r1691b1133],
4	,	,	O	,	_	0	SENT_151	[p10l1525t1066r1691b1133],
5	the	DT	O	the	det	8	SENT_151	[p10l1719t1062r1816b1120],
6	European	JJ	ORGANIZATION	european	amod	8	SENT_151	[p10l1839t1067r2141b1136],
7	Medicines	NNP	ORGANIZATION	Medicines	nn	8	SENT_151	[p10l559t1157r884b1215],
8	Agency	NNP	ORGANIZATION	Agency	nsubj	9	SENT_151	[p10l905t1162r1139b1232],
9	granted	VBD	O	grant	_	0	SENT_151	[p10l1157t1157r1405b1232],
10	approval	NN	O	approval	dobj	9	SENT_151	[p10l1426t1157r1700b1231],
11	for	IN	O	for	_	0	SENT_151	[p10l1721t1156r1812b1215],
12	the	DT	O	the	det	13	SENT_151	[p10l1832t1157r1931b1215],
13	use	NN	O	use	prep_for	9	SENT_151	[p10l1953t1176r2057b1216],
14	of	IN	O	of	_	0	SENT_151	[p10l2080t1156r2154b1215],
15	gefitinib	NN	O	gefitinib	prep_of	13	SENT_151	[p10l561t1251r837b1327],
16	in	IN	O	in	_	0	SENT_151	[p10l867t1252r929b1309],
17	any	DT	O	any	det	18	SENT_151	[p10l957t1271r1069b1326],
18	line	NN	O	line	prep_in	9	SENT_151	[p10l1094t1252r1212b1310],
19	of	IN	O	of	_	0	SENT_151	[p10l1242t1251r1316b1310],
20	therapy	NN	O	therapy	prep_of	18	SENT_151	[p10l1332t1252r1571b1326],
21	for	IN	O	for	_	0	SENT_151	[p10l1597t1251r1688b1310],
22	patients	NNS	O	patient	prep_for	9	SENT_151	[p10l1714t1252r1968b1326],
23	with	IN	O	with	_	0	SENT_151	[p10l1995t1252r2141b1311],
24	N	NN	O	n	nn	25	SENT_151	[p10l559t1352r615b1406],
25	SCLC	NN	ORGANIZATION	sclc	prep_with	22	SENT_151	[p10l617t1351r784b1405],
26	who	WP	O	who	nsubj	27	SENT_151	[p10l805t1347r941b1406],
27	carry	VBP	O	carry	rcmod	22	SENT_151	[p10l965t1366r1130b1421],
28	activating	VBG	O	activate	xcomp	27	SENT_151	[p10l1148t1348r1462b1422],
29	EGFR	NN	ORGANIZATION	egfr	nn	30	SENT_151	[p10l1480t1352r1638b1406],
30	mutations	NNS	O	mutation	dobj	28	SENT_151	[p10l1655t1348r1997b1406],
31	.	.	O	.	_	0	SENT_151	[p10l1655t1348r1997b1406],

1	The	DT	O	the	det	2	SENT_152	[p10l2021t1347r2141b1405],
2	approval	NN	O	approval	nsubj	7	SENT_152	[p10l560t1442r826b1516],
3	of	IN	O	of	_	0	SENT_152	[p10l846t1441r919b1500],
4	gefitinib	NN	O	gefitinib	prep_of	2	SENT_152	[p10l926t1441r1194b1517],
5	is	VBZ	O	be	cop	7	SENT_152	[p10l1215t1443r1262b1500],
6	still	RB	O	still	advmod	7	SENT_152	[p10l1286t1442r1401b1500],
7	restricted	JJ	O	restricted	_	0	SENT_152	[p10l1421t1442r1714b1500],
8	in	IN	O	in	_	0	SENT_152	[p10l1734t1442r1795b1499],
9	the	DT	O	the	det	11	SENT_152	[p10l1816t1442r1912b1500],
10	United	NNP	LOCATION	United	nn	11	SENT_152	[p10l1932t1442r2141b1500],
11	States	NNPS	LOCATION	States	prep_in	7	SENT_152	[p10l563t1541r766b1608],
12	,	,	O	,	_	0	SENT_152	[p10l563t1541r766b1608],
13	but	CC	O	but	_	0	SENT_152	[p10l800t1537r904b1596],
14	as	IN	O	as	mark	15	SENT_152	[p10l929t1556r992b1595],
15	of	IN	O	of	advcl	22	SENT_152	[p10l1024t1536r1098b1595],
16	early	JJ	DATE	early	amod	17	SENT_152	[p10l1114t1537r1267b1611],
17	2011	CD	DATE	2011	pobj	15	SENT_152	[p10l1293t1541r1461b1608],
18	,	,	O	,	_	0	SENT_152	[p10l1293t1541r1461b1608],
19	the	DT	O	the	det	20	SENT_152	[p10l1494t1537r1593b1595],
20	drug	NN	O	drug	nsubjpass	22	SENT_152	[p10l1623t1537r1775b1612],
21	is	VBZ	O	be	auxpass	22	SENT_152	[p10l1801t1538r1850b1595],
22	licensed	VBN	O	license	conj_but	7	SENT_152	[p10l1880t1537r2141b1595],
23	in	IN	O	in	_	0	SENT_152	[p10l560t1633r622b1689],
24	66	CD	NUMBER	66	num	25	SENT_152	[p10l648t1636r723b1690],
25	countries	NNS	O	country	prep_in	22	SENT_152	[p10l750t1633r1046b1690],
26	worldwide	JJ	O	worldwide	amod	29	SENT_152	[p10l1071t1632r1406b1690],
27	(	NN	O	(	nn	29	SENT_152	[p10l1435t1633r2023b1699],
28	www.iressa.com	NN	O	www.iressa.com	nn	29	SENT_152	[p10l1435t1633r2023b1699],
29	)	NN	O	)	dep	25	SENT_152	[p10l1435t1633r2023b1699],
30	.	.	O	.	_	0	SENT_152	[p10l1435t1633r2023b1699],

1	Taken	VBN	O	take	partmod	8	SENT_153	[p10l654t1727r846b1786],
2	together	RB	O	together	advmod	1	SENT_153	[p10l871t1727r1148b1802],
3	,	,	O	,	_	0	SENT_153	[p10l871t1727r1148b1802],
4	the	DT	O	the	det	7	SENT_153	[p10l1177t1727r1274b1785],
5	available	JJ	O	available	amod	7	SENT_153	[p10l1298t1727r1568b1786],
6	trial	NN	O	trial	nn	7	SENT_153	[p10l1593t1727r1722b1785],
7	data	NNS	O	datum	nsubj	8	SENT_153	[p10l1747t1727r1881b1785],
8	suggest	VBP	O	suggest	_	0	SENT_153	[p10l1905t1739r2144b1802],
9	that	IN	O	that	complm	14	SENT_153	[p10l561t1822r687b1880],
10	EGFR	NN	ORGANIZATION	egfr	nn	13	SENT_153	[p10l704t1826r892b1884],
11	tyrosine	NN	O	tyrosine	nn	13	SENT_153	[p10l907t1823r1159b1896],
12	kinase	NN	O	kinase	nn	13	SENT_153	[p10l1181t1822r1385b1881],
13	inhibitors	NNS	O	inhibitor	nsubj	14	SENT_153	[p10l1407t1822r1714b1880],
14	have	VBP	O	have	ccomp	8	SENT_153	[p10l1737t1822r1877b1881],
15	efficacy	NN	O	efficacy	dobj	14	SENT_153	[p10l1899t1821r2144b1896],
16	that	WDT	O	that	nsubj	18	SENT_153	[p10l561t1917r689b1975],
17	is	VBZ	O	be	cop	18	SENT_153	[p10l713t1917r762b1975],
18	similar	JJ	O	similar	rcmod	15	SENT_153	[p10l793t1917r1020b1975],
19	to	TO	O	to	_	0	SENT_153	[p10l1047t1929r1107b1975],
20	that	DT	O	that	prep_to	18	SENT_153	[p10l1136t1917r1264b1975],
21	of	IN	O	of	_	0	SENT_153	[p10l1289t1916r1364b1975],
22	standard	JJ	O	standard	amod	23	SENT_153	[p10l1379t1917r1661b1975],
23	chemotherapy	NN	O	chemotherapy	prep_of	20	SENT_153	[p10l1689t1917r2144b1991],
24	as	IN	O	as	_	0	SENT_153	[p10l560t2031r624b2070],
25	second	JJ	ORDINAL	second	prep_as	23	SENT_153	[p10l668t2012r912b2070],
26	-	:	O	-	_	0	SENT_153	[p10l668t2012r912b2070],
27	or	CC	O	or	_	0	SENT_153	[p10l954t2031r1020b2070],
28	third	JJ	ORDINAL	third	amod	31	SENT_153	[p10l1059t2012r1361b2070],
29	—	NN	O	—	nn	31	SENT_153	[p10l1059t2012r1361b2070],
30	line	NN	O	line	nn	31	SENT_153	[p10l1059t2012r1361b2070],
31	treatment	NN	O	treatment	dobj	14	SENT_153	[p10l1403t2024r1718b2070],
32	for	IN	O	for	_	0	SENT_153	[p10l1755t2011r1847b2070],
33	patients	NNS	O	patient	prep_for	31	SENT_153	[p10l1885t2013r2139b2086],
34	with	IN	O	with	_	0	SENT_153	[p10l557t2107r703b2166],
35	advanced	JJ	O	advanced	amod	37	SENT_153	[p10l727t2107r1021b2166],
36	N	NN	O	n	nn	37	SENT_153	[p10l1044t2112r1100b2166],
37	SCLC	NN	ORGANIZATION	sclc	prep_with	33	SENT_153	[p10l1102t2111r1288b2165],
38	.	.	O	.	_	0	SENT_153	[p10l1102t2111r1288b2165],

1	Among	IN	O	among	_	0	SENT_154	[p10l1314t2112r1552b2182],
2	patients	NNS	O	patient	nsubj	3	SENT_154	[p10l1573t2108r1827b2181],
3	receiving	VBG	O	receive	prepc_among	10	SENT_154	[p10l1853t2108r2144b2182],
4	first-line	JJ	O	first-line	amod	5	SENT_154	[p10l561t2201r836b2260],
5	therapy	NN	O	therapy	dobj	3	SENT_154	[p10l871t2202r1120b2276],
6	,	,	O	,	_	0	SENT_154	[p10l871t2202r1120b2276],
7	tyrosine	NN	O	tyrosine	nn	9	SENT_154	[p10l1159t2202r1416b2276],
8	kinase	NN	O	kinase	nn	9	SENT_154	[p10l1450t2202r1658b2261],
9	inhibitors	NNS	O	inhibitor	nsubj	10	SENT_154	[p10l1692t2202r2006b2260],
10	appear	VBP	O	appear	_	0	SENT_154	[p10l2041t2221r2140b2276, p10l560t2316r705b2371],
11	to	TO	O	to	aux	13	SENT_154	[p10l743t2309r805b2355],
12	be	VB	O	be	cop	13	SENT_154	[p10l847t2297r920b2355],
13	inferior	JJ	O	inferior	xcomp	10	SENT_154	[p10l960t2296r1209b2355],
14	to	TO	O	to	_	0	SENT_154	[p10l1248t2309r1309b2355],
15	standard	JJ	O	standard	amod	16	SENT_154	[p10l1352t2297r1640b2355],
16	chemotherapy	NN	O	chemotherapy	prep_to	13	SENT_154	[p10l1681t2297r2144b2371],
17	overall	JJ	O	overall	amod	16	SENT_154	[p10l561t2392r778b2451],
18	but	CC	O	but	_	0	SENT_154	[p10l810t2392r916b2451],
19	superior	JJ	O	superior	amod	16	SENT_154	[p10l945t2392r1214b2466],
20	for	IN	O	for	_	0	SENT_154	[p10l1244t2391r1337b2450],
21	selected	VBN	O	select	amod	22	SENT_154	[p10l1368t2392r1626b2450],
22	patients	NNS	O	patient	prep_for	13	SENT_154	[p10l1657t2393r1936b2466],
23	,	,	O	,	_	0	SENT_154	[p10l1657t2393r1936b2466],
24	especially	RB	O	especially	advmod	13	SENT_154	[p10l1972t2411r2140b2466, p10l561t2487r729b2561],
25	for	IN	O	for	_	0	SENT_154	[p10l761t2486r852b2545],
26	those	DT	O	those	prep_for	13	SENT_154	[p10l885t2487r1058b2545],
27	with	IN	O	with	_	0	SENT_154	[p10l1089t2487r1235b2546],
28	activating	VBG	O	activate	amod	30	SENT_154	[p10l1269t2488r1583b2562],
29	EGFR	NN	ORGANIZATION	egfr	nn	30	SENT_154	[p10l1614t2492r1772b2546],
30	mutations	NNS	O	mutation	prep_with	26	SENT_154	[p10l1802t2488r2137b2546],
31	.	.	O	.	_	0	SENT_154	[p10l1802t2488r2137b2546],

1	Although	IN	O	although	mark	7	SENT_155	[p10l558t2582r856b2657],
2	some	DT	O	some	det	3	SENT_155	[p10l883t2601r1047b2640],
3	differences	NNS	O	difference	nsubj	7	SENT_155	[p10l1074t2581r1419b2640],
4	in	IN	O	in	_	0	SENT_155	[p10l1446t2582r1507b2639],
5	the	DT	O	the	det	6	SENT_155	[p10l1533t2582r1630b2640],
6	trial	NN	O	trial	prep_in	3	SENT_155	[p10l1657t2582r1786b2640],
7	results	VBZ	O	result	advcl	31	SENT_155	[p10l1812t2582r2023b2641],
8	for	IN	O	for	mark	13	SENT_155	[p10l2052t2581r2144b2640],
9	erlotinib	NN	O	erlotinib	nsubj	13	SENT_155	[p10l562t2677r834b2735],
10	and	CC	O	and	_	0	SENT_155	[p10l864t2677r982b2735],
11	gefitinib	NN	O	gefitinib	conj_and	9	SENT_155	[p10l1011t2676r1288b2752],
12	have	VBP	O	have	aux	13	SENT_155	[p10l1318t2677r1459b2736],
13	led	VBN	O	lead	advcl	7	SENT_155	[p10l1488t2677r1582b2735],
14	to	TO	O	to	_	0	SENT_155	[p10l1611t2689r1672b2735],
15	differences	NNS	O	difference	prep_to	13	SENT_155	[p10l1703t2676r2050b2735],
16	in	IN	O	in	_	0	SENT_155	[p10l2079t2678r2141b2734],
17	regulatory	JJ	O	regulatory	amod	18	SENT_155	[p10l11t2946r450b3047],
18	policy	NN	O	policy	prep_in	15	SENT_155	[p10l479t2946r746b3046],
19	,	,	O	,	_	0	SENT_155	[p10l479t2946r746b3046],
20	no	DT	O	no	det	24	SENT_155	[p10l787t2972r891b3024],
21	head-to	JJ	O	head-to	amod	24	SENT_155	[p10l928t2946r1478b3024],
22	—	NN	O	—	nn	24	SENT_155	[p10l928t2946r1478b3024],
23	head	NN	O	head	nn	24	SENT_155	[p10l928t2946r1478b3024],
24	comparison	NN	O	comparison	nsubjpass	31	SENT_155	[p10l1515t2947r2015b3046],
25	of	IN	O	of	_	0	SENT_155	[p10l2052t2945r2152b3024],
26	the	DT	O	the	det	28	SENT_155	[p10l11t3074r144b3152],
27	two	CD	NUMBER	two	num	28	SENT_155	[p10l193t3090r351b3153],
28	agents	NNS	O	agent	prep_of	24	SENT_155	[p10l400t3091r676b3175],
29	has	VBZ	O	have	aux	31	SENT_155	[p10l727t3074r871b3152],
30	been	VBN	O	be	auxpass	31	SENT_155	[p10l922t3074r1124b3152],
31	conducted	VBN	O	conduct	_	0	SENT_155	[p10l1172t3074r1637b3153],
32	.	.	O	.	_	0	SENT_155	[p10l1172t3074r1637b3153],

1	Therefore	RB	O	therefore	advmod	8	SENT_156	[p10l1688t3073r2129b3169],
2	,	,	O	,	_	0	SENT_156	[p10l1688t3073r2129b3169],
3	no	DT	O	no	det	5	SENT_156	[p10l11t3228r116b3280],
4	definitive	JJ	O	definitive	amod	5	SENT_156	[p10l164t3201r570b3281],
5	conclusions	NNS	O	conclusion	nsubjpass	8	SENT_156	[p10l617t3202r1120b3281],
6	can	MD	O	can	aux	8	SENT_156	[p10l1168t3228r1317b3280],
7	be	VB	O	be	auxpass	8	SENT_156	[p10l1363t3202r1459b3280],
8	drawn	VBN	O	draw	_	0	SENT_156	[p10l1506t3202r1778b3281],
9	regarding	VBG	O	regard	_	0	SENT_156	[p10l1824t3202r2133b3303, p10l10t3331r150b3431],
10	substantive	JJ	O	substantive	amod	11	SENT_156	[p10l214t3330r698b3409],
11	differences	NNS	O	difference	prep_regarding	8	SENT_156	[p10l764t3329r1239b3408],
12	in	IN	O	in	_	0	SENT_156	[p10l1306t3331r1389b3407],
13	the	DT	O	the	det	14	SENT_156	[p10l1455t3330r1588b3408],
14	efficacy	NN	O	efficacy	prep_in	11	SENT_156	[p10l1655t3329r1991b3430],
15	of	IN	O	of	_	0	SENT_156	[p10l2052t3329r2153b3408],
16	these	DT	O	these	det	18	SENT_156	[p10l11t3458r235b3536],
17	two	CD	NUMBER	two	num	18	SENT_156	[p10l275t3474r432b3537],
18	agents	NNS	O	agent	prep_of	14	SENT_156	[p10l473t3474r774b3559],
19	.	.	O	.	_	0	SENT_156	[p10l473t3474r774b3559],

1	The	DT	O	the	det	3	SENT_157	[p10l136t3586r297b3664],
2	recommended	VBN	O	recommend	amod	3	SENT_157	[p10l332t3586r949b3664],
3	doses	NNS	O	dose	nsubj	6	SENT_157	[p10l985t3586r1222b3664],
4	are	VBP	O	be	cop	6	SENT_157	[p10l1258t3612r1387b3664],
5	150	CD	NUMBER	150	num	6	SENT_157	[p10l1426t3591r1575b3664],
6	mg	NN	O	mg	_	0	SENT_157	[p10l1611t3612r1749b3687],
7	for	IN	O	for	_	0	SENT_157	[p10l1781t3585r1904b3664],
8	erlotinib	NN	O	erlotinib	prep_for	6	SENT_157	[p10l1938t3586r2133b3664, p11l11t21r213b99],

1	and	CC	O	and	cc	2	SENT_158	[p11l249t21r406b99],
2	250	CD	NUMBER	250	num	3	SENT_158	[p11l442t26r593b99],
3	mg	NN	O	mg	nsubj	7	SENT_158	[p11l629t47r768b122],
4	for	IN	O	for	_	0	SENT_158	[p11l799t20r922b99],
5	gefitinib	NN	O	gefitinib	prep_for	3	SENT_158	[p11l954t20r1348b122],
6	,	,	O	,	_	0	SENT_158	[p11l954t20r1348b122],
7	taken	VBN	O	take	_	0	SENT_158	[p11l1389t21r1627b100],
8	orally	RB	O	orally	advmod	7	SENT_158	[p11l1663t21r1906b121],
9	once	RB	DATE	once	advmod	10	SENT_158	[p11l1937t47r2134b99],
10	daily	JJ	SET	daily	advmod	7	SENT_158	[p11l11t149r232b249],
11	.	.	O	.	_	0	SENT_158	[p11l11t149r232b249],

1	Erlotinib	NNP	O	Erlotinib	nsubj	2	SENT_159	[p11l269t149r649b227],
2	has	VBZ	O	have	_	0	SENT_159	[p11l683t149r827b227],
3	an	DT	O	a	det	5	SENT_159	[p11l861t175r964b227],
4	oral	JJ	O	oral	amod	5	SENT_159	[p11l997t149r1163b227],
5	bioavailability	NN	O	bioavailability	dobj	2	SENT_159	[p11l1196t149r1802b249],
6	of	IN	O	of	_	0	SENT_159	[p11l1832t148r1931b227],
7	60	CD	PERCENT	60	num	8	SENT_159	[p11l1946t154r2134b228],
8	%	NN	PERCENT	%	prep_of	5	SENT_159	[p11l1946t154r2134b228],
9	When	WRB	O	when	advmod	10	SENT_159	[p11l6t277r237b355],
10	taken	VBN	O	take	dep	8	SENT_159	[p11l290t277r524b356],
11	on	IN	O	on	_	0	SENT_159	[p11l577t302r682b354],
12	an	DT	O	a	det	14	SENT_159	[p11l735t302r836b354],
13	empty	JJ	O	empty	amod	14	SENT_159	[p11l890t293r1153b376],
14	stomach	NN	O	stomach	prep_on	10	SENT_159	[p11l1202t277r1580b354],
15	.	.	O	.	_	0	SENT_159	[p11l1202t277r1580b354],

1	Taken	VBN	O	take	partmod	6	SENT_160	[p11l1636t277r1894b356],
2	With	IN	O	with	_	0	SENT_160	[p11l1941t277r2134b356],
3	food	NN	O	food	prep_with	1	SENT_160	[p11l11t404r233b501],
4	,	,	O	,	_	0	SENT_160	[p11l11t404r233b501],
5	erlotinib	NN	O	erlotinib	nsubj	6	SENT_160	[p11l300t405r675b483],
6	has	VBZ	O	have	_	0	SENT_160	[p11l737t405r883b483],
7	a	DT	O	a	det	8	SENT_160	[p11l945t431r989b483],
8	bioavailability	NN	O	bioavailability	dobj	6	SENT_160	[p11l1049t405r1671b505],
9	of	IN	O	of	_	0	SENT_160	[p11l1727t404r1828b483],
10	nearly	RB	O	nearly	quantmod	11	SENT_160	[p11l1870t405r2139b505],
11	100	CD	PERCENT	100	num	12	SENT_160	[p11l14t538r273b629],
12	%	NN	PERCENT	%	prep_of	8	SENT_160	[p11l14t538r273b629],
13	,	,	O	,	_	0	SENT_160	[p11l14t538r273b629],
14	which	WDT	O	which	nsubj	15	SENT_160	[p11l314t533r577b612],
15	potentiates	VBZ	O	potentiate	rcmod	12	SENT_160	[p11l615t534r1093b633],
16	side	JJ	O	side	amod	17	SENT_160	[p11l1136t533r1300b611],
17	effects	NNS	O	effect	dobj	15	SENT_160	[p11l1340t532r1646b611],
18	.	.	O	.	_	0	SENT_160	[p11l1340t532r1646b611],

1	Therefore	RB	O	therefore	advmod	6	SENT_161	[p11l1688t532r2128b629],
2	,	,	O	,	_	0	SENT_161	[p11l1688t532r2128b629],
3	erlotinib	NN	O	erlotinib	nsubjpass	6	SENT_161	[p11l11t661r379b739],
4	should	MD	O	should	aux	6	SENT_161	[p11l425t661r712b740],
5	be	VB	O	be	auxpass	6	SENT_161	[p11l756t661r852b739],
6	taken	VBN	O	take	_	0	SENT_161	[p11l896t661r1134b740],
7	at	IN	DURATION	at	quantmod	9	SENT_161	[p11l1176t678r1255b739],
8	least	JJS	DURATION	least	mwe	7	SENT_161	[p11l1292t661r1491b739],
9	1	CD	DURATION	1	num	10	SENT_161	[p11l1533t666r1577b738],
10	hour	NN	NUMBER	hour	npadvmod	6	SENT_161	[p11l1621t661r1824b740],
11	before	IN	O	before	_	0	SENT_161	[p11l1865t660r2134b739],
12	or	CC	O	or	cc	13	SENT_161	[p11l11t814r100b867],
13	2	CD	DURATION	2	num	14	SENT_161	[p11l143t794r190b866],
14	hours	NNS	NUMBER	hour	prep_before	6	SENT_161	[p11l236t789r479b868],
15	after	IN	O	after	_	0	SENT_161	[p11l526t788r728b867],
16	a	DT	O	a	det	17	SENT_161	[p11l770t815r814b867],
17	meal	NN	O	meal	prep_after	6	SENT_161	[p11l858t789r1089b867],
18	.	.	O	.	_	0	SENT_161	[p11l858t789r1089b867],

1	In	IN	O	in	_	0	SENT_162	[p11l1139t796r1228b866],
2	contrast	NN	O	contrast	dep	1	SENT_162	[p11l1274t805r1646b884],
3	,	,	O	,	_	0	SENT_162	[p11l1274t805r1646b884],
4	food	NN	O	food	nsubj	7	SENT_162	[p11l1697t788r1893b867],
5	does	VBZ	O	do	aux	7	SENT_162	[p11l1939t789r2132b867],
6	not	RB	O	not	neg	7	SENT_162	[p11l11t933r153b995],
7	affect	VB	O	affect	ccomp	2	SENT_162	[p11l204t916r450b995],
8	the	DT	O	the	det	9	SENT_162	[p11l501t917r634b995],
9	absorption	NN	O	absorption	dobj	7	SENT_162	[p11l690t917r1157b1017],
10	of	IN	O	of	_	0	SENT_162	[p11l1215t916r1314b995],
11	gef1tinib	NN	O	gef1tinib	prep_of	2	SENT_162	[p11l1352t916r1917b1018],
12	.24	CD	NUMBER	.24	num	11	SENT_162	[p11l1352t916r1917b1018],
13	’	SYM	O	’	dep	11	SENT_162	[p11l1352t916r1917b1018],
14	-	:	O	-	_	0	SENT_162	[p11l1352t916r1917b1018],
15	’	NN	O	’	dep	2	SENT_162	[p11l1352t916r1917b1018],
16	-5	CD	NUMBER	-5	num	15	SENT_162	[p11l1352t916r1917b1018],
17	The	DT	O	the	det	19	SENT_162	[p11l1973t917r2134b995],
18	elimination	NN	O	elimination	nn	19	SENT_162	[p11l11t1045r513b1123],
19	half-life	NN	O	half-life	nsubj	24	SENT_162	[p11l575t1044r910b1123],
20	of	IN	O	of	_	0	SENT_162	[p11l972t1044r1072b1123],
21	gefitinib	NN	O	gefitinib	prep_of	19	SENT_162	[p11l1115t1044r1491b1146],
22	is	VBZ	O	be	cop	24	SENT_162	[p11l1556t1046r1623b1123],
23	48	CD	DURATION	48	num	24	SENT_162	[p11l1687t1050r1789b1123],
24	hours	NNS	NUMBER	hour	rcmod	15	SENT_162	[p11l1855t1045r2129b1140],
25	,	,	O	,	_	0	SENT_162	[p11l1855t1045r2129b1140],
26	and	CC	O	and	_	0	SENT_162	[p11l10t1173r170b1250],
27	its	PRP$	O	its	poss	29	SENT_162	[p11l211t1174r312b1250],
28	mean	JJ	O	mean	amod	29	SENT_162	[p11l355t1198r596b1250],
29	bioavailability	NN	O	bioavailability	nsubj	32	SENT_162	[p11l638t1173r1260b1272],
30	is	VBZ	O	be	cop	32	SENT_162	[p11l1296t1174r1363b1250],
31	60	CD	NUMBER	60	number	32	SENT_162	[p11l1407t1178r1623b1251],
32	°	CD	NUMBER	°	rcmod	15	SENT_162	[p11l1407t1178r1623b1251],
33	/	:	O	/	punct	15	SENT_162	[p11l1407t1178r1623b1251],
34	o.	SYM	O	o.	dep	1	SENT_162	[p11l1407t1178r1623b1251],

1	Erlotinib	NN	O	erlotinib	nsubjpass	5	SENT_163	[p11l139t1301r518b1379],
2	and	CC	O	and	_	0	SENT_163	[p11l573t1301r731b1379],
3	gefitinib	NN	O	gefitinib	nsubjpass	5	SENT_163	[p11l785t1300r1156b1402],
4	are	VBP	O	be	auxpass	5	SENT_163	[p11l1211t1327r1340b1379],
5	metabolized	VBN	O	metabolize	conj_and	5	SENT_163	[p11l1395t1301r1929b1379],
6	primarily	RB	O	primarily	advmod	5	SENT_163	[p11l1981t1302r2133b1401, p11l11t1429r296b1528],
7	by	IN	O	by	_	0	SENT_163	[p11l357t1429r455b1528],
8	CYP3A4	NN	O	cyp3a4	agent	5	SENT_163	[p11l515t1434r856b1507],
9	and	CC	O	and	_	0	SENT_163	[p11l920t1429r1080b1506],
10	to	TO	O	to	_	0	SENT_163	[p11l1145t1445r1227b1506],
11	a	DT	O	a	det	13	SENT_163	[p11l1292t1455r1337b1506],
12	lesser	JJR	O	lesser	amod	13	SENT_163	[p11l1399t1429r1649b1506],
13	extent	NN	O	extent	prep_to	5	SENT_163	[p11l1711t1445r1979b1506],
14	by	IN	O	by	_	0	SENT_163	[p11l2039t1429r2138b1528],
15	CYP3A5	NN	O	cyp3a5	prep_by	13	SENT_163	[p11l11t1562r349b1636],
16	and	CC	O	and	_	0	SENT_163	[p11l390t1557r548b1635],
17	CYP1A1	NN	O	cyp1a1	prep_by	13	SENT_163	[p11l587t1562r1131b1635],
18	.24	CD	NUMBER	.24	num	17	SENT_163	[p11l587t1562r1131b1635],
19	‘	CD	NUMBER	‘	num	20	SENT_163	[p11l587t1562r1131b1635],
20	27	CD	NUMBER	27	dep	5	SENT_163	[p11l587t1562r1131b1635],
21	The	DT	O	the	det	23	SENT_163	[p11l1167t1557r1328b1635],
22	concurrent	JJ	O	concurrent	amod	23	SENT_163	[p11l1367t1573r1838b1636],
23	use	NN	O	use	nsubjpass	51	SENT_163	[p11l1873t1583r2013b1636],
24	of	IN	O	of	_	0	SENT_163	[p11l2052t1556r2152b1635],
25	these	DT	O	these	det	26	SENT_163	[p11l11t1685r235b1763],
26	agents	NNS	O	agent	prep_of	23	SENT_163	[p11l266t1701r542b1786],
27	with	IN	O	with	_	0	SENT_163	[p11l572t1685r767b1764],
28	CYP3A4	NN	O	cyp3a4	nn	29	SENT_163	[p11l799t1690r1135b1764],
29	inhibitors	NNS	O	inhibitor	prep_with	26	SENT_163	[p11l1166t1685r1588b1763],
30	or	CC	O	or	_	0	SENT_163	[p11l1623t1710r1712b1763],
31	inducers	NNS	O	inducer	conj_or	29	SENT_163	[p11l1740t1685r2128b1780],
32	,	,	O	,	_	0	SENT_163	[p11l1740t1685r2128b1780],
33	such	JJ	O	such	_	0	SENT_163	[p11l12t1813r206b1891],
34	as	IN	O	as	_	0	SENT_163	[p11l251t1839r335b1890],
35	atazanavir	NN	O	atazanavir	prep_such_as	23	SENT_163	[p11l383t1813r850b1908],
36	,	,	O	,	_	0	SENT_163	[p11l383t1813r850b1908],
37	itraconazole	NN	O	itraconazole	conj_or	35	SENT_163	[p11l900t1813r1452b1907],
38	,	,	O	,	_	0	SENT_163	[p11l900t1813r1452b1907],
39	ritonavir	NN	O	ritonavir	conj_or	35	SENT_163	[p11l1503t1814r1892b1908],
40	,	,	O	,	_	0	SENT_163	[p11l1503t1814r1892b1908],
41	Vori	NNP	O	Vori	nn	43	SENT_163	[p11l1939t1813r2133b1891],
42	—	CD	NUMBER	—	num	43	SENT_163	[p11l1939t1813r2133b1891],
43	conazole	NN	O	conazole	conj_or	35	SENT_163	[p11l11t1940r414b2036],
44	,	,	O	,	_	0	SENT_163	[p11l11t1940r414b2036],
45	or	CC	O	or	_	0	SENT_163	[p11l456t1965r545b2018],
46	grapefruit	NN	O	grapefruit	nn	47	SENT_163	[p11l576t1939r1015b2041],
47	juice	NN	O	juice	conj_or	35	SENT_163	[p11l1032t1941r1264b2040],
48	,	,	O	,	_	0	SENT_163	[p11l1032t1941r1264b2040],
49	must	MD	O	must	aux	51	SENT_163	[p11l1305t1957r1521b2019],
50	be	VB	O	be	auxpass	51	SENT_163	[p11l1552t1940r1648b2018],
51	monitored	VBN	O	monitor	_	0	SENT_163	[p11l1683t1940r2134b2018],
52	carefully	RB	O	carefully	advmod	51	SENT_163	[p11l11t2067r411b2168],
53	,	,	O	,	_	0	SENT_163	[p11l11t2067r411b2168],
54	since	IN	O	since	mark	62	SENT_163	[p11l475t2069r694b2146],
55	dose	NN	O	dose	nn	56	SENT_163	[p11l752t2068r949b2146],
56	adjustments	NNS	O	adjustment	nsubj	62	SENT_163	[p11l1006t2068r1537b2168],
57	of	IN	O	of	_	0	SENT_163	[p11l1597t2067r1698b2146],
58	the	DT	O	the	det	59	SENT_163	[p11l1737t2068r1872b2146],
59	drug	NN	O	drug	prep_of	56	SENT_163	[p11l1930t2068r2136b2169],
60	may	MD	O	may	aux	62	SENT_163	[p11l11t2221r188b2295],
61	be	VB	O	be	cop	62	SENT_163	[p11l219t2196r313b2273],
62	necessary	JJ	O	necessary	advcl	51	SENT_163	[p11l348t2221r771b2295],
63	.	.	O	.	_	0	SENT_163	[p11l348t2221r771b2295],

1	Certain	JJ	O	certain	amod	3	SENT_164	[p11l811t2196r1125b2273],
2	CYP3A4	NN	O	cyp3a4	nn	3	SENT_164	[p11l1159t2201r1490b2274],
3	inducers	NNS	O	inducer	nsubjpass	20	SENT_164	[p11l1523t2196r1903b2290],
4	,	,	O	,	_	0	SENT_164	[p11l1523t2196r1903b2290],
5	such	JJ	O	such	_	0	SENT_164	[p11l1944t2196r2134b2275],
6	as	IN	O	as	_	0	SENT_164	[p11l10t2350r97b2402],
7	rifampicin	NN	O	rifampicin	prep_such_as	3	SENT_164	[p11l151t2323r636b2424],
8	,	,	O	,	_	0	SENT_164	[p11l151t2323r636b2424],
9	phenytoin	NN	O	phenytoin	conj_and	7	SENT_164	[p11l692t2324r1158b2424],
10	,	,	O	,	_	0	SENT_164	[p11l692t2324r1158b2424],
11	and	CC	O	and	_	0	SENT_164	[p11l1216t2324r1375b2402],
12	St.	NNP	PERSON	St.	nn	13	SENT_164	[p11l1429t2329r1533b2402],
13	John	NNP	PERSON	John	poss	15	SENT_164	[p11l1580t2324r1851b2415],
14	’s	POS	O	’s	_	0	SENT_164	[p11l1580t2324r1851b2415],
15	wort	NN	O	wort	conj_and	7	SENT_164	[p11l1901t2340r2129b2419],
16	,	,	O	,	_	0	SENT_164	[p11l1901t2340r2129b2419],
17	should	MD	O	should	aux	20	SENT_164	[p11l12t2453r294b2532],
18	not	RB	O	not	neg	20	SENT_164	[p11l329t2469r470b2531],
19	be	VB	O	be	auxpass	20	SENT_164	[p11l501t2453r596b2531],
20	used	VBN	O	use	_	0	SENT_164	[p11l632t2453r825b2532],
21	in	IN	O	in	_	0	SENT_164	[p11l860t2454r942b2530],
22	combination	NN	O	combination	prep_in	20	SENT_164	[p11l979t2453r1514b2531],
23	with	IN	O	with	_	0	SENT_164	[p11l1545t2453r1737b2532],
24	erlotinib	NN	O	erlotinib	prep_with	20	SENT_164	[p11l1773t2453r2133b2531],
25	or	CC	O	or	_	0	SENT_164	[p11l11t2606r100b2659],
26	gefitinib	NN	O	gefitinib	prep_with	20	SENT_164	[p11l150t2580r544b2682],
27	,	,	O	,	_	0	SENT_164	[p11l150t2580r544b2682],
28	since	IN	O	since	mark	32	SENT_164	[p11l604t2582r819b2659],
29	these	DT	O	these	det	30	SENT_164	[p11l873t2581r1096b2659],
30	agents	NNS	O	agent	nsubj	32	SENT_164	[p11l1149t2597r1424b2682],
31	could	MD	O	could	aux	32	SENT_164	[p11l1481t2581r1715b2660],
32	decrease	VB	O	decrease	advcl	20	SENT_164	[p11l1768t2581r2134b2659],
33	the	DT	O	the	det	34	SENT_164	[p11l11t2709r142b2787],
34	bioavailability	NN	O	bioavailability	dobj	32	SENT_164	[p11l179t2709r770b2809],
35	of	IN	O	of	_	0	SENT_164	[p11l803t2708r902b2787],
36	the	DT	O	the	det	37	SENT_164	[p11l920t2709r1050b2787],
37	drug	NN	O	drug	prep_of	34	SENT_164	[p11l1087t2709r1306b2810],
38	.	.	O	.	_	0	SENT_164	[p11l1087t2709r1306b2810],

1	Cigarette	NN	O	cigarette	nn	2	SENT_165	[p11l1348t2710r1729b2810],
2	smoking	NN	O	smoking	nsubjpass	8	SENT_165	[p11l1766t2709r2137b2810],
3	induces	VBZ	O	induce	_	0	SENT_165	[p11l10t2838r336b2917],
4	CYP1A1	NN	O	cyp1a1	dobj	3	SENT_165	[p11l379t2843r722b2916],
5	and	CC	O	and	_	0	SENT_165	[p11l762t2838r920b2916],
6	has	VBZ	O	have	aux	8	SENT_165	[p11l960t2838r1104b2916],
7	been	VBN	O	be	auxpass	8	SENT_165	[p11l1148t2838r1348b2916],
8	correlated	VBN	O	correlate	conj_and	3	SENT_165	[p11l1390t2838r1820b2916],
9	With	IN	O	with	_	0	SENT_165	[p11l1856t2838r2051b2917],
10	a	DT	O	a	det	11	SENT_165	[p11l2091t2864r2136b2916],
11	reduction	NN	O	reduction	prep_with	8	SENT_165	[p11l11t2966r420b3045],
12	in	IN	O	in	_	0	SENT_165	[p11l456t2967r540b3043],
13	erlotinib	JJ	O	erlotinib	amod	14	SENT_165	[p11l578t2966r945b3044],
14	exposure	NN	O	exposure	prep_in	11	SENT_165	[p11l984t2992r1370b3066],
15	after	IN	O	after	_	0	SENT_165	[p11l1407t2965r1610b3044],
16	a	DT	O	a	det	18	SENT_165	[p11l1643t2992r1687b3044],
17	therapeutic	JJ	O	therapeutic	amod	18	SENT_165	[p11l1724t2966r2133b3066, p11l11t3095r115b3172],
18	dose	NN	O	dose	prep_after	8	SENT_165	[p11l166t3094r463b3172],
19	.28	CD	NUMBER	.28	num	18	SENT_165	[p11l166t3094r463b3172],
20	The	DT	O	the	det	21	SENT_165	[p11l513t3094r673b3172],
21	solubility	NN	O	solubility	nsubj	29	SENT_165	[p11l727t3094r1126b3194],
22	of	IN	O	of	_	0	SENT_165	[p11l1174t3093r1273b3172],
23	both	DT	O	both	preconj	24	SENT_165	[p11l1308t3094r1505b3172],
24	erlotinib	NN	O	erlotinib	prep_of	21	SENT_165	[p11l1557t3094r1924b3172],
25	and	CC	O	and	_	0	SENT_165	[p11l1976t3094r2134b3172],
26	gefitinib	NN	O	gefitinib	prep_of	21	SENT_165	[p11l11t3221r383b3323],
27	is	VBZ	O	be	cop	29	SENT_165	[p11l419t3223r485b3300],
28	pH	NN	O	ph	nn	29	SENT_165	[p11l521t3222r1159b3322],
29	—	NN	O	—	rcmod	18	SENT_165	[p11l521t3222r1159b3322],
30	dependent	JJ	O	dependent	amod	29	SENT_165	[p11l521t3222r1159b3322],
31	.	.	O	.	_	0	SENT_165	[p11l521t3222r1159b3322],

1	Agents	NNS	O	agent	nsubj	21	SENT_166	[p11l1197t3229r1492b3323],
2	that	WDT	O	that	nsubj	3	SENT_166	[p11l1531t3222r1703b3300],
3	alter	VBP	O	alter	rcmod	1	SENT_166	[p11l1732t3222r1926b3300],
4	gastric	JJ	O	gastric	amod	5	SENT_166	[p11l1958t3248r2133b3323, p11l11t3351r154b3427],
5	pH	NN	O	ph	dobj	3	SENT_166	[p11l215t3356r366b3449],
6	,	,	O	,	_	0	SENT_166	[p11l215t3356r366b3449],
7	such	JJ	O	such	_	0	SENT_166	[p11l437t3350r631b3429],
8	as	IN	O	as	_	0	SENT_166	[p11l694t3376r779b3427],
9	H2	NN	O	h2	nn	12	SENT_166	[p11l844t3357r1351b3453],
10	—	NN	O	—	nn	12	SENT_166	[p11l844t3357r1351b3453],
11	receptor	NN	O	receptor	nn	12	SENT_166	[p11l844t3357r1351b3453],
12	antagonists	NNS	O	antagonist	prep_such_as	1	SENT_166	[p11l1411t3351r1911b3450],
13	and	CC	O	and	_	0	SENT_166	[p11l1976t3350r2134b3428],
14	proton	NN	O	proton	nn	17	SENT_166	[p11l10t3494r571b3577],
15	—	CD	NUMBER	—	num	17	SENT_166	[p11l10t3494r571b3577],
16	pump	NN	O	pump	nn	17	SENT_166	[p11l10t3494r571b3577],
17	inhibitors	NNS	O	inhibitor	conj_and	12	SENT_166	[p11l612t3478r1047b3573],
18	,	,	O	,	_	0	SENT_166	[p11l612t3478r1047b3573],
19	can	MD	O	can	aux	21	SENT_166	[p11l1094t3503r1241b3555],
20	substantially	RB	O	substantially	advmod	21	SENT_166	[p11l1282t3478r1823b3577],
21	reduce	VB	O	reduce	_	0	SENT_166	[p11l1859t3478r2134b3557],
22	the	DT	O	the	det	24	SENT_166	[p11l11t3606r146b3684],
23	plasma	NN	O	plasma	nn	24	SENT_166	[p11l195t3606r511b3706],
24	levels	NNS	O	level	dobj	21	SENT_166	[p11l558t3606r794b3685],
25	of	IN	O	of	_	0	SENT_166	[p11l847t3605r948b3684],
26	EGFR	NN	ORGANIZATION	egfr	nn	29	SENT_166	[p11l979t3611r1238b3689],
27	tyrosine	NN	O	tyrosine	nn	29	SENT_166	[p11l1278t3607r1632b3706],
28	kinase	NN	O	kinase	nn	29	SENT_166	[p11l1682t3606r1966b3685],
29	inhibitors	NNS	O	inhibitor	prep_of	24	SENT_166	[p11l2016t3607r2133b3683, p12l11t21r376b115],
30	,	,	O	,	_	0	SENT_166	[p11l2016t3607r2133b3683, p12l11t21r376b115],

1	and	CC	O	and	cc	7	SENT_167	[p12l431t21r591b98],
2	their	PRP$	O	they	poss	4	SENT_167	[p12l642t21r850b98],
3	concomitant	JJ	O	concomitant	amod	4	SENT_167	[p12l897t22r1454b98],
4	use	NN	O	use	nsubjpass	7	SENT_167	[p12l1499t47r1642b99],
5	should	MD	O	should	aux	7	SENT_167	[p12l1694t21r1986b99],
6	be	VB	O	be	auxpass	7	SENT_167	[p12l2037t21r2134b98],
7	avoided	VBN	O	avoid	_	0	SENT_167	[p12l10t149r357b228],
8	.	.	O	.	_	0	SENT_167	[p12l10t149r357b228],

1	In	IN	O	in	_	0	SENT_168	[p12l139t284r228b354],
2	keeping	VBG	O	keep	prepc_in	21	SENT_168	[p12l292t277r640b378],
3	with	IN	O	with	_	0	SENT_168	[p12l697t277r895b356],
4	the	DT	O	the	det	5	SENT_168	[p12l961t277r1095b355],
5	designs	NNS	O	design	prep_with	2	SENT_168	[p12l1161t277r1490b378],
6	of	IN	O	of	_	0	SENT_168	[p12l1558t276r1659b355],
7	published	VBN	O	publish	amod	8	SENT_168	[p12l1704t277r2134b377],
8	phase	NN	O	phase	prep_of	5	SENT_168	[p12l10t405r258b505],
9	3	CD	NUMBER	3	num	10	SENT_168	[p12l317t410r361b484],
10	trials	NNS	O	trial	nsubj	21	SENT_168	[p12l423t405r666b500],
11	,	,	O	,	_	0	SENT_168	[p12l423t405r666b500],
12	radiographic	JJ	O	radiographic	amod	13	SENT_168	[p12l730t405r1280b506],
13	assessment	NN	O	assessment	appos	10	SENT_168	[p12l1336t422r1827b483],
14	of	IN	O	of	_	0	SENT_168	[p12l1881t404r1980b483],
15	response	NN	O	response	prep_of	13	SENT_168	[p12l2020t431r2133b483, p12l12t558r307b633],
16	to	TO	O	to	_	0	SENT_168	[p12l348t549r429b611],
17	erlotinib	NN	O	erlotinib	prep_to	15	SENT_168	[p12l472t533r839b611],
18	or	CC	O	or	_	0	SENT_168	[p12l882t559r970b611],
19	gefitinib	NN	O	gefitinib	conj_or	17	SENT_168	[p12l1007t532r1379b634],
20	should	MD	O	should	aux	21	SENT_168	[p12l1423t533r1709b612],
21	occur	VB	O	occur	_	0	SENT_168	[p12l1750t559r1989b612],
22	no	DT	O	no	dep	23	SENT_168	[p12l2027t558r2132b611],
23	more	RBR	O	more	advmod	21	SENT_168	[p12l11t686r231b739],
24	frequently	RB	O	frequently	advmod	23	SENT_168	[p12l276t660r716b761],
25	than	IN	O	than	_	0	SENT_168	[p12l757t661r953b739],
26	every	DT	SET	every	det	30	SENT_168	[p12l999t687r1220b761],
27	6	CD	SET	6	number	29	SENT_168	[p12l1262t666r1308b739],
28	to	TO	SET	to	dep	29	SENT_168	[p12l1355t678r1437b739],
29	8	CD	SET	8	num	30	SENT_168	[p12l1484t666r1530b739],
30	weel	NN	O	weel	prep_than	21	SENT_168	[p12l1573t661r2134b740],
31	29	CD	NUMBER	29	number	32	SENT_168	[p12l1573t661r2134b740],
32	'31	CD	NUMBER	'31	num	30	SENT_168	[p12l1573t661r2134b740],
33	However	RB	O	however	advmod	46	SENT_168	[p12l10t796r405b885],
34	,	,	O	,	_	0	SENT_168	[p12l10t796r405b885],
35	given	VBN	O	give	prep	46	SENT_168	[p12l446t790r673b890],
36	the	DT	O	the	det	37	SENT_168	[p12l709t789r842b867],
37	potential	NN	O	potential	dep	35	SENT_168	[p12l877t789r1264b889],
38	for	IN	O	for	_	0	SENT_168	[p12l1299t788r1423b867],
39	substantial	JJ	O	substantial	amod	41	SENT_168	[p12l1457t789r1933b868],
40	side	JJ	O	side	amod	41	SENT_168	[p12l1970t789r2134b867],
41	effects	NNS	O	effect	prep_for	37	SENT_168	[p12l11t916r317b1013],
42	,	,	O	,	_	0	SENT_168	[p12l11t916r317b1013],
43	patients	NNS	O	patient	nsubjpass	46	SENT_168	[p12l354t918r695b1017],
44	should	MD	O	should	aux	46	SENT_168	[p12l732t917r1019b996],
45	be	VB	O	be	auxpass	46	SENT_168	[p12l1052t917r1148b995],
46	evaluated	VBN	O	evaluate	rcmod	30	SENT_168	[p12l1183t917r1584b996],
47	by	IN	O	by	_	0	SENT_168	[p12l1617t917r1715b1017],
48	the	DT	O	the	nsubj	49	SENT_168	[p12l1744t917r1876b995],
49	treating	VBG	O	treat	agent	46	SENT_168	[p12l1909t933r2133b995, p12l10t1046r150b1146],
50	clinician	NN	O	clinician	dobj	49	SENT_168	[p12l192t1045r562b1123],
51	at	IN	O	at	advmod	49	SENT_168	[p12l606t1061r685b1123],
52	least	JJS	O	least	pobj	51	SENT_168	[p12l724t1045r923b1123],
53	monthly	JJ	SET	monthly	advmod	51	SENT_168	[p12l963t1045r1326b1145],
54	initially	RB	O	initially	advmod	49	SENT_168	[p12l1366t1045r1700b1145],
55	and	CC	O	and	_	0	SENT_168	[p12l1740t1045r1898b1123],
56	then	RB	O	then	dep	58	SENT_168	[p12l1943t1045r2134b1123],
57	possibly	RB	O	possibly	advmod	58	SENT_168	[p12l10t1173r370b1273],
58	less	RBR	O	less	conj_and	46	SENT_168	[p12l415t1173r574b1251],
59	frequently	RB	O	frequently	advmod	21	SENT_168	[p12l625t1172r1089b1273],
60	,	,	O	,	_	0	SENT_168	[p12l625t1172r1089b1273],
61	depending	VBG	O	depend	_	0	SENT_168	[p12l1145t1173r1611b1274],
62	on	IN	O	on	prepc_depending_on	21	SENT_168	[p12l1659t1199r1765b1251],
63	the	DT	O	the	det	64	SENT_168	[p12l1816t1173r1951b1251],
64	patient	NN	O	patient	poss	66	SENT_168	[p12l1999t1199r2133b1273, p12l11t1302r269b1379],
65	’s	POS	O	’s	_	0	SENT_168	[p12l1999t1199r2133b1273, p12l11t1302r269b1379],
66	tolerance	NN	O	tolerance	pobj	21	SENT_168	[p12l317t1301r709b1379],
67	of	IN	O	of	_	0	SENT_168	[p12l756t1300r856b1379],
68	the	DT	O	the	det	69	SENT_168	[p12l883t1301r1015b1379],
69	agent	NN	O	agent	prep_of	66	SENT_168	[p12l1061t1318r1318b1402],
70	.	.	O	.	_	0	SENT_168	[p12l1061t1318r1318b1402],

1	Daily	NNP	SET	Daily	nn	2	SENT_169	[p12l1367t1301r1593b1401],
2	erlotinib	NN	O	erlotinib	nsubjpass	8	SENT_169	[p12l1634t1301r2001b1379],
3	or	CC	O	or	_	0	SENT_169	[p12l2049t1326r2138b1379],
4	gefitinib	NN	O	gefitinib	nn	5	SENT_169	[p12l11t1428r383b1530],
5	therapy	NN	O	therapy	conj_or	2	SENT_169	[p12l416t1429r738b1529],
6	should	MD	O	should	aux	8	SENT_169	[p12l767t1429r1054b1508],
7	be	VB	O	be	auxpass	8	SENT_169	[p12l1086t1429r1182b1507],
8	continued	VBN	O	continue	_	0	SENT_169	[p12l1215t1429r1645b1508],
9	for	IN	O	for	_	0	SENT_169	[p12l1676t1428r1800b1507],
10	as	RB	O	as	advmod	11	SENT_169	[p12l1828t1455r1913b1507],
11	long	JJ	O	long	prepc_for	8	SENT_169	[p12l1946t1429r2138b1530],
12	as	IN	O	as	mark	19	SENT_169	[p12l10t1583r95b1635],
13	the	DT	O	the	det	14	SENT_169	[p12l145t1557r278b1635],
14	patient	NN	O	patient	poss	17	SENT_169	[p12l323t1558r686b1657],
15	’s	POS	O	’s	_	0	SENT_169	[p12l323t1558r686b1657],
16	performance	NN	O	performance	nn	17	SENT_169	[p12l735t1556r1289b1657],
17	status	NN	O	status	nsubj	19	SENT_169	[p12l1338t1574r1589b1636],
18	is	VBZ	O	be	cop	19	SENT_169	[p12l1638t1558r1703b1635],
19	adequate	JJ	O	adequate	advcl	8	SENT_169	[p12l1752t1557r2134b1657],
20	and	CC	O	and	_	0	SENT_169	[p12l10t1685r168b1763],
21	there	EX	O	there	expl	22	SENT_169	[p12l206t1685r423b1763],
22	is	VBZ	O	be	advcl	8	SENT_169	[p12l460t1686r526b1763],
23	no	DT	O	no	det	27	SENT_169	[p12l566t1710r671b1763],
24	clinical	JJ	O	clinical	amod	27	SENT_169	[p12l710t1685r1024b1763],
25	or	CC	O	or	_	0	SENT_169	[p12l1062t1710r1151b1763],
26	radiographic	JJ	O	radiographic	amod	27	SENT_169	[p12l1185t1685r1735b1786],
27	progression	NN	O	progression	nsubj	22	SENT_169	[p12l1771t1710r2133b1786, p12l12t1814r206b1907],
28	,	,	O	,	_	0	SENT_169	[p12l1771t1710r2133b1786, p12l12t1814r206b1907],
29	since	IN	O	since	mark	36	SENT_169	[p12l250t1814r460b1890],
30	patients	NNS	O	patient	nsubjpass	36	SENT_169	[p12l495t1814r829b1912],
31	with	IN	O	with	_	0	SENT_169	[p12l863t1813r1055b1892],
32	stable	JJ	O	stable	amod	33	SENT_169	[p12l1093t1813r1335b1890],
33	disease	NN	O	disease	prep_with	30	SENT_169	[p12l1372t1813r1676b1890],
34	have	VBP	O	have	aux	36	SENT_169	[p12l1712t1813r1899b1892],
35	been	VBN	O	be	auxpass	36	SENT_169	[p12l1936t1813r2134b1890],
36	shown	VBN	O	show	dep	27	SENT_169	[p12l12t1941r294b2020],
37	to	TO	O	to	aux	38	SENT_169	[p12l345t1958r427b2019],
38	have	VB	O	have	xcomp	36	SENT_169	[p12l478t1941r668b2020],
39	a	DT	O	a	det	41	SENT_169	[p12l718t1967r762b2019],
40	clinical	JJ	O	clinical	amod	41	SENT_169	[p12l812t1941r1125b2019],
41	benefit	NN	O	benefit	dobj	38	SENT_169	[p12l1176t1940r1501b2019],
42	.	.	O	.	_	0	SENT_169	[p12l1176t1940r1501b2019],

1	Furthermore	RB	O	furthermore	advmod	4	SENT_170	[p12l1556t1941r2128b2037],
2	,	,	O	,	_	0	SENT_170	[p12l1556t1941r2128b2037],
3	data	NNS	O	datum	nsubj	4	SENT_170	[p12l11t2069r195b2147],
4	support	VBP	O	support	_	0	SENT_170	[p12l234t2086r566b2169],
5	the	DT	O	the	det	6	SENT_170	[p12l602t2069r734b2147],
6	continuation	NN	O	continuation	dobj	4	SENT_170	[p12l775t2070r1326b2148],
7	of	IN	O	of	_	0	SENT_170	[p12l1366t2068r1466b2147],
8	treatment	NN	O	treatment	prep_of	6	SENT_170	[p12l1487t2085r1911b2147],
9	even	RB	O	even	advmod	8	SENT_170	[p12l1946t2095r2135b2148],

1	950	CD	NUMBER	950	number	2	SENT_171	[p12l149t2244r206b2267],
2	N	NN	O	n	num	4	SENT_171	[p12l951t2254r964b2269],
3	ENGLJ	NN	O	englj	nn	4	SENT_171	[p12l979t2254r1057b2276],
4	MED	NN	O	med	_	0	SENT_171	[p12l1072t2254r1124b2269],
5	364	CD	NUMBER	364	num	7	SENT_171	[p12l1134t2248r1216b2276],
6	;	:	O	;	_	0	SENT_171	[p12l1134t2248r1216b2276],
7	1o	CD	NUMBER	1o	dep	4	SENT_171	[p12l1134t2248r1216b2276],
8	NEjM	NNP	O	NEjM	dep	4	SENT_171	[p12l1251t2254r1375b2276],
9	,	,	O	,	_	0	SENT_171	[p12l1251t2254r1375b2276],
10	ORG	NNP	O	ORG	nn	11	SENT_171	[p12l1251t2254r1375b2276],
11	MARCH	NNP	DATE	MARCH	appos	8	SENT_171	[p12l1412t2254r1497b2269],
12	10	CD	DATE	10	num	11	SENT_171	[p12l1510t2254r1543b2274],
13	,	,	DATE	,	_	0	SENT_171	[p12l1510t2254r1543b2274],
14	2011	CD	DATE	2011	num	11	SENT_171	[p12l1555t2254r1606b2270],

1	The	DT	O	the	det	4	SENT_172	[p12l936t2287r987b2311],
2	New	NNP	O	New	nn	4	SENT_172	[p12l996t2288r1058b2311],
3	England	NNP	O	England	nn	4	SENT_172	[p12l1067t2287r1178b2318],
4	Journal	NNP	O	Journal	_	0	SENT_172	[p12l1187t2287r1284b2311],
5	of	IN	O	of	_	0	SENT_172	[p12l1294t2287r1323b2311],
6	Medicine	NNP	O	Medicine	prep_of	4	SENT_172	[p12l1330t2287r1455b2311],

1	Downloaded	VBN	O	download	_	0	SENT_173	[p12l378t2328r548b2351],
2	from	IN	O	from	_	0	SENT_173	[p12l557t2328r622b2351],
3	nejm.org	NN	O	nejm.org	prep_from	1	SENT_173	[p12l630t2328r749b2358],
4	at	IN	O	at	_	0	SENT_173	[p12l759t2332r782b2351],
5	UW-Madison	NN	O	uw-madison	prep_at	1	SENT_173	[p12l790t2328r973b2351],
6	on	IN	O	on	_	0	SENT_173	[p12l982t2335r1015b2351],
7	January	NNP	DATE	January	prep_on	1	SENT_173	[p12l1023t2328r1126b2358],
8	5	CD	DATE	5	num	7	SENT_173	[p12l1136t2328r1159b2355],
9	,	,	DATE	,	_	0	SENT_173	[p12l1136t2328r1159b2355],
10	2014	CD	DATE	2014	num	7	SENT_173	[p12l1169t2328r1242b2351],
11	.	.	O	.	_	0	SENT_173	[p12l1169t2328r1242b2351],

1	For	IN	O	for	_	0	SENT_174	[p12l1252t2328r1299b2351],
2	personal	JJ	O	personal	amod	3	SENT_174	[p12l1307t2328r1419b2358],
3	use	NN	O	use	pobj	1	SENT_174	[p12l1428t2335r1472b2351],
4	only	RB	O	only	advmod	3	SENT_174	[p12l1481t2328r1546b2358],
5	.	.	O	.	_	0	SENT_174	[p12l1481t2328r1546b2358],

1	No	DT	O	no	det	3	SENT_175	[p12l1557t2328r1596b2351],
2	other	JJ	O	other	amod	3	SENT_175	[p12l1606t2328r1674b2351],
3	uses	NNS	O	use	_	0	SENT_175	[p12l1683t2335r1739b2351],
4	without	IN	O	without	_	0	SENT_175	[p12l1749t2328r1850b2351],
5	permission	NN	O	permission	prep_without	3	SENT_175	[p12l1858t2328r2011b2358],
6	.	.	O	.	_	0	SENT_175	[p12l1858t2328r2011b2358],

1	Copyright	NN	O	copyright	_	0	SENT_176	[p12l729t2369r863b2400],
2	©	CD	NUMBER	©	num	6	SENT_176	[p12l872t2369r896b2393],
3	2011	CD	DATE	2011	num	6	SENT_176	[p12l906t2369r968b2393],
4	Massachusetts	NNP	ORGANIZATION	Massachusetts	nn	6	SENT_176	[p12l980t2369r1171b2393],
5	Medical	NNP	ORGANIZATION	Medical	nn	6	SENT_176	[p12l1181t2369r1289b2393],
6	Society	NNP	ORGANIZATION	Society	dep	1	SENT_176	[p12l1300t2369r1405b2400],
7	.	.	O	.	_	0	SENT_176	[p12l1300t2369r1405b2400],

1	All	DT	O	all	det	2	SENT_177	[p12l1416t2369r1457b2393],
2	rights	NNS	O	rights	nsubj	3	SENT_177	[p12l1466t2369r1541b2400],
3	reserved	VBN	O	reserve	_	0	SENT_177	[p12l1551t2369r1669b2393],
4	.	.	O	.	_	0	SENT_177	[p12l1551t2369r1669b2393],

1	CLINICAL	JJ	O	clinical	amod	2	SENT_178	[p12l868t2475r1027b2494],
2	THERAPEUTICS	NNS	O	therapeutics	_	0	SENT_178	[p12l1039t2475r1292b2494],

1	if	IN	O	if	mark	7	SENT_179	[p12l11t2688r87b2767],
2	a	DT	O	a	det	3	SENT_179	[p12l104t2715r148b2767],
3	loss	NN	O	loss	nsubjpass	7	SENT_179	[p12l181t2689r345b2768],
4	of	IN	O	of	_	0	SENT_179	[p12l383t2688r483b2768],
5	response	NN	O	response	prep_of	3	SENT_179	[p12l500t2715r880b2789],
6	is	VBZ	O	be	auxpass	7	SENT_179	[p12l915t2690r981b2767],
7	documented	VBN	O	document	csubjpass	13	SENT_179	[p12l1019t2689r1575b2785],
8	,	,	O	,	_	0	SENT_179	[p12l1019t2689r1575b2785],
9	since	IN	O	since	_	0	SENT_179	[p12l1618t2690r1832b2767],
10	tumor	NN	O	tumor	nn	11	SENT_179	[p12l1868t2706r2137b2769],
11	progression	NN	O	progression	prep_since	7	SENT_179	[p12l9t2819r521b2919],
12	is	VBZ	O	be	auxpass	13	SENT_179	[p12l563t2819r629b2896],
13	accelerated	VBN	O	accelerate	_	0	SENT_179	[p12l674t2818r1149b2897],
14	to	TO	O	to	_	0	SENT_179	[p12l1192t2835r1273b2897],
15	a	DT	O	a	det	17	SENT_179	[p12l1317t2844r1362b2896],
16	greater	JJR	O	greater	amod	17	SENT_179	[p12l1403t2835r1708b2919],
17	degree	NN	O	degree	prep_to	13	SENT_179	[p12l1748t2818r2032b2919],
18	if	IN	O	if	mark	22	SENT_179	[p12l2074t2817r2152b2896],
19	the	DT	O	the	det	20	SENT_179	[p12l12t2946r144b3025],
20	agent	NN	O	agent	nsubjpass	22	SENT_179	[p12l183t2963r420b3047],
21	is	VBZ	O	be	auxpass	22	SENT_179	[p12l453t2947r519b3024],
22	discontinued	VBN	O	discontinue	advcl	13	SENT_179	[p12l561t2946r1222b3025],
23	.	.	O	.	_	0	SENT_179	[p12l561t2946r1222b3025],

1	”	NN	O	”	_	0	SENT_180	[p12l561t2946r1222b3025],

1	A	DT	O	a	det	2	SENT_181	[p12l136t3082r202b3152],
2	reduction	NN	O	reduction	nsubjpass	18	SENT_181	[p12l230t3074r630b3153],
3	in	IN	O	in	_	0	SENT_181	[p12l660t3075r742b3152],
4	the	DT	O	the	det	5	SENT_181	[p12l773t3074r904b3153],
5	dose	NN	O	dose	prep_in	2	SENT_181	[p12l935t3074r1126b3153],
6	of	IN	O	of	_	0	SENT_181	[p12l1158t3073r1257b3153],
7	erlotinib	NN	O	erlotinib	prep_of	5	SENT_181	[p12l1270t3074r1627b3153],
8	or	CC	O	or	_	0	SENT_181	[p12l1660t3100r1748b3153],
9	an	DT	O	a	det	10	SENT_181	[p12l1775t3100r1876b3152],
10	interruption	NN	O	interruption	conj_or	5	SENT_181	[p12l1907t3075r2132b3152, p12l11t3203r331b3302],
11	of	IN	O	of	_	0	SENT_181	[p12l367t3201r467b3281],
12	treatment	NN	O	treatment	prep_of	10	SENT_181	[p12l485t3219r909b3281],
13	with	IN	O	with	prep	2	SENT_181	[p12l934t3202r1130b3281],
14	either	CC	O	either	dep	13	SENT_181	[p12l1166t3202r1413b3281],
15	agent	NN	O	agent	conj	13	SENT_181	[p12l1445t3219r1681b3303],
16	should	MD	O	should	aux	18	SENT_181	[p12l1714t3202r2001b3281],
17	be	VB	O	be	auxpass	18	SENT_181	[p12l2037t3202r2133b3281],
18	considered	VBN	O	consider	_	0	SENT_181	[p12l12t3329r475b3408],
19	in	IN	O	in	_	0	SENT_181	[p12l520t3330r603b3407],
20	cases	NNS	O	case	prep_in	18	SENT_181	[p12l649t3355r871b3407],
21	of	IN	O	of	_	0	SENT_181	[p12l920t3328r1020b3408],
22	substantial	JJ	O	substantial	amod	24	SENT_181	[p12l1049t3329r1524b3408],
23	toxic	JJ	O	toxic	amod	24	SENT_181	[p12l1570t3330r1776b3408],
24	effects	NNS	O	effect	prep_of	20	SENT_181	[p12l1822t3328r2127b3425],
25	,	,	O	,	_	0	SENT_181	[p12l1822t3328r2127b3425],
26	such	JJ	O	such	_	0	SENT_181	[p12l12t3458r206b3537],
27	as	IN	O	as	_	0	SENT_181	[p12l248t3484r333b3536],
28	severe	JJ	O	severe	amod	29	SENT_181	[p12l380t3484r637b3537],
29	rash	NN	O	rash	prep_such_as	20	SENT_181	[p12l679t3458r862b3536],
30	or	CC	O	or	_	0	SENT_181	[p12l905t3484r994b3537],
31	debilitating	JJ	O	debilitating	amod	32	SENT_181	[p12l1034t3458r1533b3559],
32	diarrhea	NN	O	diarrhea	prep_such_as	20	SENT_181	[p12l1573t3458r2130b3537],
33	.24	CD	NUMBER	.24	npadvmod	34	SENT_181	[p12l1573t3458r2130b3537],
34	>	JJR	O	>	amod	29	SENT_181	[p12l1573t3458r2130b3537],
35	25	CD	NUMBER	25	dep	38	SENT_181	[p12l1573t3458r2130b3537],
36	Although	IN	O	although	dep	38	SENT_181	[p12l7t3586r415b3687],
37	there	EX	O	there	expl	38	SENT_181	[p12l483t3586r700b3664],
38	are	VBP	O	be	ccomp	34	SENT_181	[p12l768t3612r896b3665],
39	no	DT	O	no	det	41	SENT_181	[p12l965t3612r1070b3665],
40	specific	JJ	O	specific	amod	41	SENT_181	[p12l1141t3585r1471b3686],
41	recommendations	NNS	O	recommendation	nsubj	38	SENT_181	[p12l1538t3586r2132b3665, p13l12t22r223b100],

1	for	IN	O	for	_	0	SENT_182	[p13l270t20r393b100],
2	adjustment	NN	O	adjustment	prep_for	20	SENT_182	[p13l435t21r915b121],
3	of	IN	O	of	_	0	SENT_182	[p13l956t20r1056b100],
4	the	DT	O	the	det	5	SENT_182	[p13l1084t21r1216b100],
5	dose	NN	O	dose	prep_of	2	SENT_182	[p13l1262t21r1456b100],
6	of	IN	O	of	_	0	SENT_182	[p13l1503t20r1603b100],
7	gefitinib	NN	O	gefitinib	prep_of	5	SENT_182	[p13l1629t20r2000b122],
8	or	CC	O	or	_	0	SENT_182	[p13l2048t47r2137b100],
9	erlotinib	NN	O	erlotinib	prep_of	5	SENT_182	[p13l12t148r379b227],
10	in	IN	O	in	_	0	SENT_182	[p13l413t149r496b226],
11	patients	NNS	O	patient	prep_in	7	SENT_182	[p13l529t149r870b248],
12	with	IN	O	with	_	0	SENT_182	[p13l902t148r1097b228],
13	renal	JJ	O	renal	amod	14	SENT_182	[p13l1132t148r1348b226],
14	dysfunction	NN	O	dysfunction	prep_with	11	SENT_182	[p13l1383t147r1914b248],
15	,	,	O	,	_	0	SENT_182	[p13l1383t147r1914b248],
16	liver	NN	O	liver	nn	17	SENT_182	[p13l1952t148r2136b228],
17	function	NN	O	function	nsubjpass	20	SENT_182	[p13l11t275r385b356],
18	should	MD	O	should	aux	20	SENT_182	[p13l427t276r719b355],
19	be	VB	O	be	auxpass	20	SENT_182	[p13l760t276r857b355],
20	monitored	VBN	O	monitor	_	0	SENT_182	[p13l898t276r1357b355],
21	periodically	RB	O	periodically	advmod	20	SENT_182	[p13l1396t276r1918b376],
22	during	IN	O	during	_	0	SENT_182	[p13l1955t276r2132b356, p13l11t406r152b506],
23	erlotinib	NN	O	erlotinib	nn	26	SENT_182	[p13l186t405r562b484],
24	or	CC	O	or	_	0	SENT_182	[p13l600t431r690b484],
25	gefitinib	NN	O	gefitinib	nn	26	SENT_182	[p13l723t404r1104b506],
26	therapy	NN	O	therapy	prep_during	20	SENT_182	[p13l1142t405r1484b505],
27	,	,	O	,	_	0	SENT_182	[p13l1142t405r1484b505],
28	since	IN	O	since	mark	35	SENT_182	[p13l1528t406r1747b483],
29	cases	NNS	O	case	nsubjpass	35	SENT_182	[p13l1785t431r2011b483],
30	of	IN	O	of	_	0	SENT_182	[p13l2051t404r2152b484],
31	hepatic	JJ	O	hepatic	amod	32	SENT_182	[p13l11t532r328b632],
32	failure	NN	O	failure	prep_of	29	SENT_182	[p13l395t531r679b612],
33	have	VBP	O	have	aux	35	SENT_182	[p13l746t532r939b612],
34	been	VBN	O	be	auxpass	35	SENT_182	[p13l1008t532r1212b611],
35	attributed	VBN	O	attribute	advcl	20	SENT_182	[p13l1279t532r1713b612],
36	to	TO	O	to	_	0	SENT_182	[p13l1780t549r1863b611],
37	both	DT	O	both	det	38	SENT_182	[p13l1933t532r2133b611],
38	agents	NNS	O	agent	prep_to	35	SENT_182	[p13l11t666r488b762],
39	.33	CD	NUMBER	.33	number	40	SENT_182	[p13l11t666r488b762],
40	’34	CD	NUMBER	’34	num	42	SENT_182	[p13l11t666r488b762],
41	Dose	NN	O	dose	nn	42	SENT_182	[p13l531t667r745b740],
42	adjustment	NN	O	adjustment	dobj	35	SENT_182	[p13l789t661r1270b761],
43	or	CC	O	or	_	0	SENT_182	[p13l1310t687r1398b740],
44	treatment	NN	O	treatment	nn	45	SENT_182	[p13l1440t678r1863b740],
45	interruption	NN	O	interruption	dobj	35	SENT_182	[p13l1902t662r2132b739, p13l11t790r331b889],
46	should	MD	O	should	aux	48	SENT_182	[p13l375t789r662b868],
47	be	VB	O	be	auxpass	48	SENT_182	[p13l705t789r801b868],
48	considered	VBN	O	consider	rcmod	42	SENT_182	[p13l845t789r1309b868],
49	for	IN	O	for	_	0	SENT_182	[p13l1351t788r1474b868],
50	both	DT	O	both	det	51	SENT_182	[p13l1515t789r1712b868],
51	agents	NNS	O	agent	prep_for	48	SENT_182	[p13l1754t806r2030b890],
52	if	IN	O	if	mark	57	SENT_182	[p13l2074t788r2151b867],
53	the	DT	O	the	det	56	SENT_182	[p13l12t918r144b997],
54	total	JJ	O	total	amod	56	SENT_182	[p13l189t918r386b997],
55	bilirubin	NN	O	bilirubin	nn	56	SENT_182	[p13l430t918r807b997],
56	level	NN	O	level	nsubj	57	SENT_182	[p13l849t918r1039b997],
57	exceeds	VBZ	O	exceed	advcl	35	SENT_182	[p13l1083t918r1408b997],
58	three	CD	NUMBER	three	num	59	SENT_182	[p13l1454t918r1674b997],
59	times	NNS	O	time	dobj	57	SENT_182	[p13l1718t919r1954b996],
60	the	DT	O	the	det	62	SENT_182	[p13l2001t918r2133b996],
61	upper	JJ	O	upper	amod	62	SENT_182	[p13l11t1072r259b1146],
62	limit	NN	O	limit	nsubj	71	SENT_182	[p13l301t1046r510b1124],
63	of	IN	O	of	_	0	SENT_182	[p13l553t1045r653b1125],
64	the	DT	O	the	det	66	SENT_182	[p13l681t1046r814b1124],
65	normal	JJ	O	normal	amod	66	SENT_182	[p13l862t1046r1175b1125],
66	range	NN	O	range	prep_of	62	SENT_182	[p13l1221t1072r1462b1147],
67	or	CC	O	or	_	0	SENT_182	[p13l1509t1072r1598b1125],
68	the	DT	O	the	det	70	SENT_182	[p13l1642t1046r1775b1124],
69	aminotransferase	NN	O	aminotransferase	nn	70	SENT_182	[p13l1822t1047r2132b1125, p13l12t1172r498b1251],
70	levels	NNS	O	level	prep_of	62	SENT_182	[p13l552t1173r787b1253],
71	exceed	VBP	O	exceed	rcmod	59	SENT_182	[p13l845t1173r1133b1252],
72	five	CD	NUMBER	five	number	73	SENT_182	[p13l1187t1172r1343b1252],
73	times	NNS	O	time	num	76	SENT_182	[p13l1399t1174r1638b1251],
74	the	DT	O	the	det	76	SENT_182	[p13l1695t1173r1830b1251],
75	upper	JJ	O	upper	amod	76	SENT_182	[p13l1885t1199r2137b1273],
76	limit	NN	O	limit	dobj	71	SENT_182	[p13l10t1302r219b1380],
77	of	IN	O	of	_	0	SENT_182	[p13l254t1301r354b1381],
78	the	DT	O	the	det	80	SENT_182	[p13l376t1302r508b1381],
79	normal	JJ	O	normal	amod	80	SENT_182	[p13l548t1302r861b1381],
80	range	NN	O	range	prep_of	76	SENT_182	[p13l901t1308r1338b1403],
81	.24	CD	NUMBER	.24	number	82	SENT_182	[p13l901t1308r1338b1403],
82	’25	CD	NUMBER	’25	num	80	SENT_182	[p13l901t1308r1338b1403],

1	The	DT	O	the	det	2	SENT_183	[p13l136t1430r297b1508],
2	length	NN	O	length	nsubjpass	8	SENT_183	[p13l352t1430r628b1531],
3	of	IN	O	of	_	0	SENT_183	[p13l685t1429r785b1509],
4	treatment	NN	O	treatment	nn	5	SENT_183	[p13l822t1447r1246b1509],
5	interruptions	NNS	O	interruption	prep_of	2	SENT_183	[p13l1297t1431r1865b1530],
6	must	MD	O	must	aux	8	SENT_183	[p13l1922t1447r2139b1509],
7	be	VB	O	be	auxpass	8	SENT_183	[p13l12t1558r108b1637],
8	guided	VBN	O	guide	_	0	SENT_183	[p13l143t1558r438b1659],
9	by	IN	O	by	_	0	SENT_183	[p13l474t1558r571b1658],
10	the	DT	O	the	det	11	SENT_183	[p13l602t1558r735b1636],
11	patient	NN	O	patient	poss	14	SENT_183	[p13l768t1559r1131b1658],
12	’s	POS	O	’s	_	0	SENT_183	[p13l768t1559r1131b1658],
13	individual	JJ	O	individual	amod	14	SENT_183	[p13l1168t1558r1599b1637],
14	response	NN	O	response	agent	8	SENT_183	[p13l1634t1584r2014b1658],
15	to	TO	O	to	_	0	SENT_183	[p13l2050t1575r2132b1637],
16	the	DT	O	the	det	18	SENT_183	[p13l12t1685r144b1763],
17	treatment	NN	O	treatment	nn	18	SENT_183	[p13l180t1702r603b1763],
18	break	NN	O	break	prep_to	8	SENT_183	[p13l634t1685r895b1765],
19	.	.	O	.	_	0	SENT_183	[p13l634t1685r895b1765],

1	After	IN	O	after	_	0	SENT_184	[p13l932t1684r1154b1763],
2	an	DT	O	a	det	3	SENT_184	[p13l1185t1711r1288b1763],
3	interruption	NN	O	interruption	pobj	1	SENT_184	[p13l1322t1686r1848b1785],
4	in	IN	O	in	_	0	SENT_184	[p13l1882t1686r1965b1763],
5	the	DT	O	the	det	6	SENT_184	[p13l2001t1685r2133b1763],
6	administration	NN	O	administration	prep_in	3	SENT_184	[p13l11t1814r670b1893],
7	of	IN	O	of	_	0	SENT_184	[p13l714t1813r815b1893],
8	erlotinib	NN	O	erlotinib	prep_of	6	SENT_184	[p13l840t1814r1216b1893],
9	because	IN	O	because	_	0	SENT_184	[p13l1261t1814r1603b1893],
10	of	IN	O	of	_	0	SENT_184	[p13l1648t1813r1748b1893],
11	toxic	JJ	O	toxic	amod	12	SENT_184	[p13l1774t1815r1983b1893],
12	effects	NNS	O	effect	prep_because_of	6	SENT_184	[p13l2027t1813r2132b1893, p13l11t1940r228b2037],
13	,	,	O	,	_	0	SENT_184	[p13l2027t1813r2132b1893, p13l11t1940r228b2037],

1	it	PRP	O	it	nsubjpass	3	SENT_185	[p13l265t1942r323b2019],
2	is	VBZ	O	be	auxpass	3	SENT_185	[p13l350t1942r415b2019],
3	recommended	VBN	O	recommend	_	0	SENT_185	[p13l449t1941r1055b2020],
4	that	IN	O	that	complm	7	SENT_185	[p13l1088t1941r1257b2019],
5	therapy	NN	O	therapy	nsubjpass	7	SENT_185	[p13l1285t1941r1600b2041],
6	be	VB	O	be	auxpass	7	SENT_185	[p13l1628t1941r1724b2020],
7	restarted	VBN	O	restart	ccomp	3	SENT_185	[p13l1757t1941r2134b2020],
8	at	IN	O	at	_	0	SENT_185	[p13l11t2087r90b2148],
9	a	DT	O	a	det	11	SENT_185	[p13l122t2096r166b2148],
10	reduced	VBN	O	reduce	amod	11	SENT_185	[p13l203t2070r539b2149],
11	dose	NN	O	dose	prep_at	7	SENT_185	[p13l578t2070r795b2149],
12	.	.	O	.	_	0	SENT_185	[p13l578t2070r795b2149],

1	When	WRB	O	when	advmod	5	SENT_186	[p13l835t2070r1089b2148],
2	dose	NN	O	dose	nn	3	SENT_186	[p13l1128t2070r1322b2149],
3	modifications	NNS	O	modification	nsubjpass	5	SENT_186	[p13l1360t2069r1964b2149],
4	are	VBP	O	be	auxpass	5	SENT_186	[p13l2004t2096r2133b2148],
5	made	VBN	O	make	advcl	13	SENT_186	[p13l11t2198r265b2294],
6	,	,	O	,	_	0	SENT_186	[p13l11t2198r265b2294],
7	decrements	NNS	O	decrement	nsubjpass	13	SENT_186	[p13l310t2198r800b2277],
8	of	IN	O	of	_	0	SENT_186	[p13l840t2197r940b2277],
9	50	CD	NUMBER	50	num	10	SENT_186	[p13l961t2204r1058b2277],
10	mg	NN	O	mg	prep_of	7	SENT_186	[p13l1097t2224r1235b2299],
11	should	MD	O	should	aux	13	SENT_186	[p13l1271t2198r1558b2277],
12	be	VB	O	be	auxpass	13	SENT_186	[p13l1596t2198r1692b2277],
13	instituted	VBN	O	institute	dep	64	SENT_186	[p13l1729t2198r2134b2277],
14	with	IN	O	with	_	0	SENT_186	[p13l7t2326r198b2405],
15	the	DT	O	the	det	16	SENT_186	[p13l254t2326r384b2405],
16	use	NN	O	use	prep_with	13	SENT_186	[p13l440t2352r578b2405],
17	of	IN	O	of	_	0	SENT_186	[p13l634t2325r733b2405],
18	lower	JJR	O	lower	amod	21	SENT_186	[p13l768t2326r1390b2427],
19	—	NN	O	—	nn	21	SENT_186	[p13l768t2326r1390b2427],
20	strength	NN	O	strength	nn	21	SENT_186	[p13l768t2326r1390b2427],
21	tablets	NNS	O	tablet	prep_of	16	SENT_186	[p13l1445t2326r1819b2405],
22	.35	CD	NUMBER	.35	dep	27	SENT_186	[p13l1445t2326r1819b2405],
23	If	IN	O	if	dep	27	SENT_186	[p13l1878t2325r1961b2404],
24	the	DT	O	the	det	25	SENT_186	[p13l2001t2326r2133b2404],
25	decision	NN	O	decision	nsubjpass	27	SENT_186	[p13l12t2454r364b2533],
26	is	VBZ	O	be	auxpass	27	SENT_186	[p13l421t2455r486b2532],
27	made	VBN	O	make	dep	13	SENT_186	[p13l546t2454r777b2533],
28	to	TO	O	to	aux	29	SENT_186	[p13l835t2471r916b2533],
29	continue	VB	O	continue	xcomp	27	SENT_186	[p13l976t2455r1348b2533],
30	gefitinib	NN	O	gefitinib	dobj	29	SENT_186	[p13l1405t2453r1777b2555],
31	after	IN	O	after	_	0	SENT_186	[p13l1835t2453r2037b2532],
32	a	DT	O	a	det	34	SENT_186	[p13l2090t2480r2135b2532],
33	treatment	NN	O	treatment	nn	34	SENT_186	[p13l12t2598r435b2659],
34	interruption	NN	O	interruption	prep_after	29	SENT_186	[p13l479t2582r1005b2681],
35	because	IN	O	because	mark	49	SENT_186	[p13l1055t2581r1391b2661],
36	of	IN	O	of	_	0	SENT_186	[p13l1441t2580r1541b2660],
37	toxic	JJ	O	toxic	amod	38	SENT_186	[p13l1573t2582r1778b2660],
38	effects	NNS	O	effect	prep_of	49	SENT_186	[p13l1828t2580r2128b2677],
39	,	,	O	,	_	0	SENT_186	[p13l1828t2580r2128b2677],
40	the	DT	O	the	det	43	SENT_186	[p13l12t2710r142b2789],
41	original	JJ	O	original	amod	43	SENT_186	[p13l179t2710r510b2811],
42	daily	JJ	SET	daily	amod	43	SENT_186	[p13l546t2710r750b2810],
43	dose	NN	O	dose	nsubjpass	49	SENT_186	[p13l782t2710r972b2789],
44	of	IN	O	of	_	0	SENT_186	[p13l1009t2709r1108b2789],
45	250	CD	NUMBER	250	num	46	SENT_186	[p13l1125t2716r1275b2789],
46	mg	NN	O	mg	prep_of	43	SENT_186	[p13l1312t2736r1449b2811],
47	should	MD	O	should	aux	49	SENT_186	[p13l1484t2710r1765b2789],
48	be	VB	O	be	auxpass	49	SENT_186	[p13l1801t2710r1897b2789],
49	reinstituted	VBN	O	reinstitute	advcl	29	SENT_186	[p13l1934t2711r2132b2789, p13l12t2838r360b2934],
50	,	,	O	,	_	0	SENT_186	[p13l1934t2711r2132b2789, p13l12t2838r360b2934],
51	since	IN	O	since	mark	53	SENT_186	[p13l402t2839r616b2917],
52	there	EX	O	there	expl	53	SENT_186	[p13l652t2838r869b2916],
53	are	VBP	O	be	dep	27	SENT_186	[p13l903t2864r1032b2917],
54	no	DT	O	no	det	56	SENT_186	[p13l1067t2864r1172b2917],
55	consensus	NN	O	consensus	nn	56	SENT_186	[p13l1209t2864r1649b2917],
56	guidelines	NNS	O	guideline	nsubj	53	SENT_186	[p13l1686t2838r2130b2939],
57	for	IN	O	for	_	0	SENT_186	[p13l11t2965r134b3045],
58	dose	NN	O	dose	nn	59	SENT_186	[p13l175t2966r369b3045],
59	reduction	NN	O	reduction	prep_for	56	SENT_186	[p13l412t2966r821b3045],
60	and	CC	O	and	_	0	SENT_186	[p13l864t2966r1022b3045],
61	gefitinib	NN	O	gefitinib	conj_and	59	SENT_186	[p13l1064t2965r1436b3067],
62	is	VBZ	O	be	auxpass	64	SENT_186	[p13l1480t2967r1546b3044],
63	not	RB	O	not	neg	64	SENT_186	[p13l1591t2983r1734b3045],
64	supplied	VBN	O	supply	_	0	SENT_186	[p13l1773t2966r2134b3066],
65	in	IN	O	in	_	0	SENT_186	[p13l11t3095r94b3172],
66	lower	JJR	O	lower	amod	69	SENT_186	[p13l132t3094r768b3195],
67	—	NN	O	—	nn	69	SENT_186	[p13l132t3094r768b3195],
68	strength	NN	O	strength	nn	69	SENT_186	[p13l132t3094r768b3195],
69	tablets	NNS	O	tablet	prep_in	64	SENT_186	[p13l808t3094r1191b3173],
70	.25	CD	NUMBER	.25	nsubjpass	64	SENT_186	[p13l808t3094r1191b3173],

1	In	IN	O	in	_	0	SENT_187	[p13l139t3229r228b3299],
2	the	DT	O	the	det	4	SENT_187	[p13l275t3221r408b3299],
3	United	NNP	LOCATION	United	nn	4	SENT_187	[p13l456t3221r743b3300],
4	States	NNPS	LOCATION	States	prep_in	38	SENT_187	[p13l792t3227r1066b3317],
5	,	,	O	,	_	0	SENT_187	[p13l792t3227r1066b3317],
6	the	DT	O	the	det	7	SENT_187	[p13l1120t3221r1252b3299],
7	costs	NNS	O	cost	nsubj	38	SENT_187	[p13l1301t3238r1515b3300],
8	of	IN	O	of	_	0	SENT_187	[p13l1565t3220r1665b3300],
9	a	DT	DURATION	a	det	10	SENT_187	[p13l1694t3247r1738b3299],
10	month	NN	DURATION	month	poss	12	SENT_187	[p13l1784t3221r2131b3300],
11	’s	POS	O	’s	_	0	SENT_187	[p13l1784t3221r2131b3300],
12	supply	NN	O	supply	prep_of	7	SENT_187	[p13l12t3350r289b3450],
13	of	IN	O	of	_	0	SENT_187	[p13l335t3349r434b3429],
14	erlotinib	NN	O	erlotinib	nn	15	SENT_187	[p13l467t3350r834b3429],
15	(	NN	O	(	prep_of	12	SENT_187	[p13l889t3357r993b3441],
16	at	IN	O	at	_	0	SENT_187	[p13l889t3357r993b3441],
17	a	DT	O	a	det	19	SENT_187	[p13l1037t3376r1081b3428],
18	daily	JJ	SET	daily	amod	19	SENT_187	[p13l1130t3350r1338b3450],
19	dose	NN	O	dose	prep_at	15	SENT_187	[p13l1384t3350r1578b3429],
20	of	IN	O	of	_	0	SENT_187	[p13l1629t3349r1729b3429],
21	150	CD	NUMBER	150	num	23	SENT_187	[p13l1764t3356r1912b3429],
22	mg	NN	O	mg	nn	23	SENT_187	[p13l1962t3357r2128b3451],
23	)	NN	O	)	prep_of	19	SENT_187	[p13l1962t3357r2128b3451],
24	and	CC	O	and	_	0	SENT_187	[p13l11t3478r168b3557],
25	gefitinib	NN	O	gefitinib	nn	26	SENT_187	[p13l206t3477r577b3579],
26	(	NN	O	(	conj_and	12	SENT_187	[p13l622t3485r725b3569],
27	at	IN	O	at	_	0	SENT_187	[p13l622t3485r725b3569],
28	a	DT	O	a	det	30	SENT_187	[p13l758t3504r802b3556],
29	daily	JJ	SET	daily	amod	30	SENT_187	[p13l839t3478r1047b3578],
30	dose	NN	O	dose	prep_at	26	SENT_187	[p13l1081t3478r1275b3557],
31	of	IN	O	of	_	0	SENT_187	[p13l1314t3477r1414b3557],
32	250	CD	NUMBER	250	num	34	SENT_187	[p13l1434t3484r1586b3557],
33	mg	NN	O	mg	nn	34	SENT_187	[p13l1624t3485r1790b3579],
34	)	NN	O	)	prep_of	30	SENT_187	[p13l1624t3485r1790b3579],
35	are	VBP	O	be	cop	38	SENT_187	[p13l1833t3504r1961b3556],
36	approximately	RB	O	approximately	quantmod	38	SENT_187	[p13l2000t3504r2132b3578, p13l9t3605r526b3705],
37	$	$	MONEY	$	dep	38	SENT_187	[p13l613t3603r897b3701],
38	4,000	CD	MONEY	4,000	_	0	SENT_187	[p13l613t3603r897b3701],
39	and	CC	O	and	_	0	SENT_187	[p13l987t3605r1145b3684],
40	$	$	MONEY	$	conj_and	38	SENT_187	[p13l1237t3603r1542b3701],
41	1,800	CD	MONEY	1,800	number	38	SENT_187	[p13l1237t3603r1542b3701],
42	,	,	O	,	_	0	SENT_187	[p13l1237t3603r1542b3701],
43	respectively	RB	O	respectively	advmod	38	SENT_187	[p13l1637t3606r2138b3705],

1	(	NN	O	(	_	0	SENT_188	[p14l16t21r976b122],
2	WwW.drugstore.com	NNP	O	WwW.drugstore.com	dep	1	SENT_188	[p14l16t21r976b122],
3	)	CD	NUMBER	)	num	2	SENT_188	[p14l16t21r976b122],
4	.	.	O	.	_	0	SENT_188	[p14l16t21r976b122],

1	In	IN	O	in	_	0	SENT_189	[p14l1061t29r1150b99],
2	countries	NNS	O	country	prep_in	16	SENT_189	[p14l1231t22r1629b100],
3	in	IN	O	in	_	0	SENT_189	[p14l1711t22r1795b99],
4	which	WDT	O	which	rel	10	SENT_189	[p14l1871t21r2133b100],
5	both	CC	O	both	advmod	10	SENT_189	[p14l12t149r209b228],
6	agents	NNS	O	agent	nsubj	10	SENT_189	[p14l274t166r549b250],
7	are	VBP	O	be	cop	10	SENT_189	[p14l616t175r745b227],
8	currently	RB	DATE	currently	advmod	10	SENT_189	[p14l810t149r1200b249],
9	commercially	RB	O	commercially	advmod	10	SENT_189	[p14l1261t149r1846b249],
10	available	JJ	O	available	rcmod	2	SENT_189	[p14l1906t149r2132b228, p14l11t277r204b372],
11	,	,	O	,	_	0	SENT_189	[p14l1906t149r2132b228, p14l11t277r204b372],
12	erlotinib	NN	O	erlotinib	nsubj	16	SENT_189	[p14l269t277r636b355],
13	is	VBZ	O	be	cop	16	SENT_189	[p14l695t278r761b354],
14	approximately	RB	O	approximately	quantmod	15	SENT_189	[p14l821t277r1437b376],
15	20	CD	PERCENT	20	num	16	SENT_189	[p14l1491t282r1679b356],
16	%	NN	PERCENT	%	_	0	SENT_189	[p14l1491t282r1679b356],
17	more	RBR	O	more	advmod	18	SENT_189	[p14l1736t303r1956b355],
18	expensive	JJ	O	expensive	amod	16	SENT_189	[p14l2015t303r2132b355, p14l10t406r327b505],
19	than	IN	O	than	_	0	SENT_189	[p14l367t405r563b483],
20	gefitinib	NN	O	gefitinib	prep_than	16	SENT_189	[p14l603t404r997b506],
21	.	.	O	.	_	0	SENT_189	[p14l603t404r997b506],

1	ADVERSE	JJ	O	adverse	amod	2	SENT_190	[p14l560t702r1060b760],
2	EFFECTS	NNS	O	effect	_	0	SENT_190	[p14l1115t702r1578b760],

1	Erlotinib	NN	O	erlotinib	nsubj	4	SENT_191	[p14l9t918r389b997],
2	and	CC	O	and	_	0	SENT_191	[p14l437t918r594b997],
3	gefitinib	NN	O	gefitinib	conj_and	1	SENT_191	[p14l641t917r1013b1019],
4	have	VBP	O	have	_	0	SENT_191	[p14l1062t918r1252b997],
5	similar	JJ	O	similar	amod	9	SENT_191	[p14l1300t918r1606b996],
6	toxic	JJ	O	toxic	amod	9	SENT_191	[p14l1651t917r2138b997],
7	—	NN	O	—	nn	9	SENT_191	[p14l1651t917r2138b997],
8	effect	NN	O	effect	nn	9	SENT_191	[p14l1651t917r2138b997],
9	profiles	NNS	O	profile	dobj	4	SENT_191	[p14l9t1044r364b1145],
10	.	.	O	.	_	0	SENT_191	[p14l9t1044r364b1145],

1	However	RB	O	however	advmod	21	SENT_192	[p14l439t1053r834b1141],
2	,	,	O	,	_	0	SENT_192	[p14l439t1053r834b1141],
3	because	IN	O	because	mark	10	SENT_192	[p14l909t1045r1245b1125],
4	the	DT	O	the	det	6	SENT_192	[p14l1315t1045r1448b1123],
5	recommended	VBN	O	recommend	amod	6	SENT_192	[p14l1517t1045r2133b1124],
6	dose	NN	O	dose	nsubj	10	SENT_192	[p14l12t1174r206b1253],
7	of	IN	O	of	_	0	SENT_192	[p14l240t1173r340b1253],
8	erlotinib	NN	O	erlotinib	prep_of	6	SENT_192	[p14l356t1174r723b1253],
9	is	VBZ	O	be	cop	10	SENT_192	[p14l758t1175r824b1252],
10	closer	JJR	O	closer	advcl	21	SENT_192	[p14l861t1174r1113b1253],
11	to	TO	O	to	_	0	SENT_192	[p14l1144t1191r1226b1253],
12	the	DT	O	the	det	13	SENT_192	[p14l1261t1174r1394b1253],
13	maximum	NN	O	maximum	prep_to	10	SENT_192	[p14l1428t1175r1874b1253],
14	tolerated	VBD	O	tolerate	partmod	13	SENT_192	[p14l1908t1174r2132b1253, p14l11t1302r189b1381],
15	dose	NN	O	dose	dobj	14	SENT_192	[p14l227t1302r444b1398],
16	,	,	O	,	_	0	SENT_192	[p14l227t1302r444b1398],
17	it	PRP	O	it	nsubj	21	SENT_192	[p14l488t1303r546b1380],
18	is	VBZ	O	be	cop	21	SENT_192	[p14l579t1303r645b1380],
19	moderately	RB	O	moderately	advmod	21	SENT_192	[p14l685t1302r1165b1402],
20	more	RBR	O	more	advmod	21	SENT_192	[p14l1199t1328r1418b1381],
21	toxic	JJ	O	toxic	_	0	SENT_192	[p14l1457t1303r1663b1381],
22	than	IN	O	than	_	0	SENT_192	[p14l1701t1302r1897b1380],
23	gefitinib	NN	O	gefitinib	prep_than	21	SENT_192	[p14l1935t1301r2132b1403, p14l12t1430r230b1509],
24	.	.	O	.	_	0	SENT_192	[p14l1935t1301r2132b1403, p14l12t1430r230b1509],

1	Unlike	IN	O	unlike	_	0	SENT_193	[p14l262t1430r541b1509],
2	traditional	JJ	O	traditional	amod	4	SENT_193	[p14l569t1430r1013b1509],
3	cytotoxic	JJ	O	cytotoxic	amod	4	SENT_193	[p14l1041t1431r1420b1530],
4	agents	NNS	O	agent	prep_unlike	12	SENT_193	[p14l1446t1447r1740b1531],
5	,	,	O	,	_	0	SENT_193	[p14l1446t1447r1740b1531],
6	erlotinib	NN	O	erlotinib	prep_unlike	12	SENT_193	[p14l1774t1430r2132b1509],
7	and	CC	O	and	_	0	SENT_193	[p14l11t1558r170b1637],
8	gefitinib	NN	O	gefitinib	prep_unlike	12	SENT_193	[p14l216t1557r597b1659],
9	do	VBP	O	do	aux	12	SENT_193	[p14l645t1558r749b1637],
10	not	RB	O	not	neg	12	SENT_193	[p14l796t1575r941b1637],
11	typically	RB	O	typically	advmod	12	SENT_193	[p14l983t1558r1356b1658],
12	cause	VB	O	cause	_	0	SENT_193	[p14l1399t1584r1636b1637],
13	myelosup	JJ	O	myelosup	amod	15	SENT_193	[p14l1682t1558r2132b1658],
14	—	NN	O	—	nn	15	SENT_193	[p14l1682t1558r2132b1658],
15	pression	NN	O	pression	dobj	12	SENT_193	[p14l9t1712r403b1810],
16	,	,	O	,	_	0	SENT_193	[p14l9t1712r403b1810],
17	neuropathy	NN	O	neuropathy	dobj	12	SENT_193	[p14l463t1711r977b1810],
18	,	,	O	,	_	0	SENT_193	[p14l463t1711r977b1810],
19	alopecia	NN	O	alopecia	dobj	12	SENT_193	[p14l1036t1711r1422b1810],
20	,	,	O	,	_	0	SENT_193	[p14l1036t1711r1422b1810],
21	or	CC	O	or	_	0	SENT_193	[p14l1482t1737r1572b1789],
22	severe	JJ	O	severe	amod	23	SENT_193	[p14l1625t1737r1888b1790],
23	nausea	NN	O	nausea	dobj	12	SENT_193	[p14l1942t1737r2132b1790, p14l12t1843r535b1918],
24	.14	CD	NUMBER	.14	number	25	SENT_193	[p14l1942t1737r2132b1790, p14l12t1843r535b1918],
25	’	CD	NUMBER	’	nsubj	12	SENT_193	[p14l1942t1737r2132b1790, p14l12t1843r535b1918],
26	16	CD	NUMBER	16	num	81	SENT_193	[p14l1942t1737r2132b1790, p14l12t1843r535b1918],
27	>	JJR	O	>	amod	81	SENT_193	[p14l1942t1737r2132b1790, p14l12t1843r535b1918],
28	35	CD	NUMBER	35	number	29	SENT_193	[p14l1942t1737r2132b1790, p14l12t1843r535b1918],
29	’37	CD	NUMBER	’37	num	31	SENT_193	[p14l1942t1737r2132b1790, p14l12t1843r535b1918],
30	The	DT	O	the	det	31	SENT_193	[p14l562t1839r723b1917],
31	discontinuation	NN	O	discontinuation	nsubj	59	SENT_193	[p14l754t1839r1435b1918],
32	of	IN	O	of	_	0	SENT_193	[p14l1466t1838r1566b1918],
33	erlotinib	NN	O	erlotinib	nsubj	40	SENT_193	[p14l1578t1839r1945b1918],
34	and	CC	O	and	_	0	SENT_193	[p14l1976t1839r2134b1918],
35	gefitinib	NN	O	gefitinib	conj_and	33	SENT_193	[p14l11t1966r382b2068],
36	because	IN	O	because	_	0	SENT_193	[p14l434t1967r769b2046],
37	of	IN	O	of	prepc_because_of	33	SENT_193	[p14l820t1966r919b2046],
38	toxic	JJ	O	toxic	amod	39	SENT_193	[p14l951t1968r1156b2046],
39	effects	NNS	O	effect	pobj	33	SENT_193	[p14l1205t1966r1487b2045],
40	occurs	VBZ	O	occur	dep	53	SENT_193	[p14l1539t1993r1817b2046],
41	in	IN	O	in	quantmod	46	SENT_193	[p14l1868t1968r1951b2045],
42	5	CD	PERCENT	5	number	46	SENT_193	[p14l2002t1973r2134b2046],
43	%	NN	PERCENT	%	dep	46	SENT_193	[p14l2002t1973r2134b2046],
44	and	CC	O	and	_	0	SENT_193	[p14l11t2094r168b2173],
45	2	CD	PERCENT	2	conj_and	46	SENT_193	[p14l213t2099r347b2173],
46	%	NN	PERCENT	%	dobj	40	SENT_193	[p14l213t2099r347b2173],
47	of	IN	O	of	_	0	SENT_193	[p14l392t2093r492b2173],
48	patients	NNS	O	patient	prep_of	46	SENT_193	[p14l517t2095r883b2194],
49	,	,	O	,	_	0	SENT_193	[p14l517t2095r883b2194],
50	respectively	RB	O	respectively	advmod	53	SENT_193	[p14l934t2094r1621b2194],
51	.1438	CD	NUMBER	.1438	num	53	SENT_193	[p14l934t2094r1621b2194],
52	Elderly	JJ	O	elderly	amod	53	SENT_193	[p14l1667t2094r1961b2194],
53	patients	NNS	O	patient	prep_of	31	SENT_193	[p14l2001t2120r2132b2194, p14l12t2225r247b2302],
54	Who	WP	O	who	nsubjpass	56	SENT_193	[p14l276t2224r459b2303],
55	are	VBP	O	be	auxpass	56	SENT_193	[p14l490t2250r619b2302],
56	treated	VBN	O	treat	rcmod	53	SENT_193	[p14l650t2224r948b2303],
57	with	IN	O	with	_	0	SENT_193	[p14l974t2224r1169b2303],
58	erlotinib	NN	O	erlotinib	prep_with	56	SENT_193	[p14l1200t2224r1567b2303],
59	have	VBP	O	have	ccomp	27	SENT_193	[p14l1599t2224r1788b2303],
60	clinical	JJ	O	clinical	amod	61	SENT_193	[p14l1820t2224r2133b2302],
61	outcomes	NNS	O	outcome	dobj	59	SENT_193	[p14l12t2369r423b2431],
62	that	WDT	O	that	nsubj	71	SENT_193	[p14l472t2352r645b2430],
63	are	VBP	O	be	cop	64	SENT_193	[p14l687t2378r815b2430],
64	similar	JJ	O	similar	rcmod	61	SENT_193	[p14l864t2352r1170b2430],
65	to	TO	O	to	_	0	SENT_193	[p14l1214t2369r1296b2431],
66	those	DT	O	those	prep_to	64	SENT_193	[p14l1345t2352r1576b2431],
67	for	IN	O	for	_	0	SENT_193	[p14l1623t2351r1747b2431],
68	younger	JJR	O	younger	amod	69	SENT_193	[p14l1787t2378r2136b2453],
69	patients	NNS	O	patient	prep_for	66	SENT_193	[p14l9t2481r358b2580],
70	but	CC	O	but	_	0	SENT_193	[p14l405t2480r548b2559],
71	have	VBP	O	have	conj_but	64	SENT_193	[p14l587t2480r780b2559],
72	a	DT	O	a	det	74	SENT_193	[p14l824t2506r868b2558],
73	higher	JJR	O	higher	amod	74	SENT_193	[p14l911t2480r1197b2581],
74	rate	NN	O	rate	dobj	71	SENT_193	[p14l1238t2497r1401b2558],
75	of	IN	O	of	_	0	SENT_193	[p14l1446t2479r1547b2559],
76	grade	NN	O	grade	prep_of	74	SENT_193	[p14l1573t2480r1816b2581],
77	3	CD	NUMBER	3	num	76	SENT_193	[p14l1862t2486r1906b2559],
78	or	CC	O	or	_	0	SENT_193	[p14l1954t2506r2044b2559],
79	4	CD	NUMBER	4	number	80	SENT_193	[p14l2083t2487r2133b2559],
80	toxic	JJ	O	toxic	amod	81	SENT_193	[p14l12t2608r217b2686],
81	effects	NNS	O	effect	nsubj	82	SENT_193	[p14l254t2606r535b2685],
82	(	VBP	O	(	rcmod	25	SENT_193	[p14l578t2613r788b2698],
83	35	CD	PERCENT	35	num	84	SENT_193	[p14l578t2613r788b2698],
84	%	NN	PERCENT	%	nsubj	97	SENT_193	[p14l578t2613r788b2698],
85	for	IN	O	for	_	0	SENT_193	[p14l824t2606r947b2686],
86	patients	NNS	O	patient	prep_for	84	SENT_193	[p14l979t2608r1320b2707],
87	270	CD	DURATION	270	num	88	SENT_193	[p14l1357t2613r1511b2686],
88	years	NNS	NUMBER	year	npadvmod	94	SENT_193	[p14l1544t2633r1763b2707],
89	vs.	CC	O	vs.	prep	88	SENT_193	[p14l1797t2633r1906b2687],
90	18	CD	PERCENT	18	num	91	SENT_193	[p14l1952t2612r2134b2686],
91	%	NN	PERCENT	%	dep	89	SENT_193	[p14l1952t2612r2134b2686],
92	for	IN	O	for	_	0	SENT_193	[p14l11t2734r134b2814],
93	patients	NNS	O	patient	prep_for	91	SENT_193	[p14l164t2736r506b2835],
94	<	JJR	O	<	amod	86	SENT_193	[p14l545t2741r693b2814],
95	70	CD	DURATION	70	num	96	SENT_193	[p14l545t2741r693b2814],
96	years	NNS	NUMBER	year	tmod	94	SENT_193	[p14l724t2741r1073b2835],
97	)	VBP	O	)	ccomp	82	SENT_193	[p14l724t2741r1073b2835],
98	.39	CD	NUMBER	.39	dobj	97	SENT_193	[p14l724t2741r1073b2835],

1	In	IN	O	in	_	0	SENT_194	[p14l138t2872r228b2942],
2	phase	NN	O	phase	prep_in	13	SENT_194	[p14l278t2864r526b2964],
3	1	CD	NUMBER	1	num	4	SENT_194	[p14l581t2870r625b2942],
4	studies	NNS	O	study	nsubj	13	SENT_194	[p14l679t2864r978b2943],
5	of	IN	O	of	_	0	SENT_194	[p14l1033t2863r1133b2943],
6	both	DT	O	both	det	7	SENT_194	[p14l1166t2864r1364b2943],
7	agents	NNS	O	agent	prep_of	4	SENT_194	[p14l1415t2881r1715b2965],
8	,	,	O	,	_	0	SENT_194	[p14l1415t2881r1715b2965],
9	diarrhea	NN	O	diarrhea	appos	7	SENT_194	[p14l1773t2864r2135b2943],
10	was	VBD	O	be	cop	13	SENT_194	[p14l7t3018r169b3071],
11	the	DT	O	the	det	13	SENT_194	[p14l212t2992r344b3071],
12	dose	NN	O	dose	nn	13	SENT_194	[p14l385t2992r968b3093],
13	—	NN	O	—	_	0	SENT_194	[p14l385t2992r968b3093],
14	limiting	VBG	O	limit	partmod	13	SENT_194	[p14l385t2992r968b3093],
15	effect	NN	O	effect	dobj	14	SENT_194	[p14l1006t2991r1268b3071],
16	.	.	O	.	_	0	SENT_194	[p14l1006t2991r1268b3071],

1	Diarrhea	NN	O	diarrhea	nsubj	2	SENT_195	[p14l1312t2992r1691b3070],
2	occurs	VBZ	O	occur	_	0	SENT_195	[p14l1730t3018r2009b3071],
3	in	IN	O	in	_	0	SENT_195	[p14l2050t2993r2133b3070],
4	up	RB	O	up	quantmod	6	SENT_195	[p14l11t3145r114b3219],
5	to	TO	O	to	dep	6	SENT_195	[p14l154t3136r235b3198],
6	55	CD	PERCENT	55	num	7	SENT_195	[p14l275t3124r456b3198],
7	%	NN	PERCENT	%	prep_in	2	SENT_195	[p14l275t3124r456b3198],
8	of	IN	O	of	_	0	SENT_195	[p14l493t3118r593b3198],
9	patients	NNS	O	patient	prep_of	7	SENT_195	[p14l610t3120r951b3219],
10	who	WP	O	who	nsubjpass	12	SENT_195	[p14l986t3119r1169b3199],
11	are	VBP	O	be	auxpass	12	SENT_195	[p14l1207t3145r1336b3197],
12	treated	VBN	O	treat	rcmod	9	SENT_195	[p14l1374t3119r1672b3198],
13	with	IN	O	with	_	0	SENT_195	[p14l1704t3119r1900b3199],
14	erlotinib	NN	O	erlotinib	prep_with	12	SENT_195	[p14l1938t3119r2132b3198, p14l12t3248r235b3344],
15	,	,	O	,	_	0	SENT_195	[p14l1938t3119r2132b3198, p14l12t3248r235b3344],
16	with	IN	O	with	_	0	SENT_195	[p14l289t3248r484b3327],
17	severe	JJ	O	severe	amod	18	SENT_195	[p14l538t3274r795b3327],
18	diarrhea	NN	O	diarrhea	prep_with	12	SENT_195	[p14l849t3248r1211b3327],
19	occurring	VBG	O	occur	partmod	18	SENT_195	[p14l1262t3249r1684b3349],
20	in	IN	O	in	_	0	SENT_195	[p14l1732t3249r1815b3326],
21	6	CD	PERCENT	6	num	22	SENT_195	[p14l1868t3254r1999b3327],
22	%	NN	PERCENT	%	prep_in	19	SENT_195	[p14l1868t3254r1999b3327],
23	of	IN	O	of	_	0	SENT_195	[p14l2052t3247r2152b3327],
24	patients	NNS	O	patient	prep_of	22	SENT_195	[p14l9t3376r376b3475],
25	.	.	O	.	_	0	SENT_195	[p14l9t3376r376b3475],

1	The	DT	O	the	det	2	SENT_196	[p14l431t3375r592b3453],
2	incidence	NN	O	incidence	nsubjpass	28	SENT_196	[p14l645t3375r1051b3454],
3	of	IN	O	of	_	0	SENT_196	[p14l1105t3374r1205b3454],
4	diarrhea	NN	O	diarrhea	prep_of	2	SENT_196	[p14l1241t3375r1603b3454],
5	in	IN	O	in	_	0	SENT_196	[p14l1654t3376r1738b3453],
6	patients	NNS	O	patient	prep_in	4	SENT_196	[p14l1789t3376r2131b3475],
7	receiving	VBG	O	receive	partmod	6	SENT_196	[p14l11t3505r401b3605],
8	gefitinib	NN	O	gefitinib	nn	9	SENT_196	[p14l449t3503r821b3605],
9	ranges	NNS	O	range	dobj	7	SENT_196	[p14l873t3530r1156b3605],
10	from	IN	O	from	_	0	SENT_196	[p14l1209t3503r1420b3583],
11	27	CD	NUMBER	27	number	14	SENT_196	[p14l1471t3510r1569b3583],
12	to	TO	NUMBER	to	dep	14	SENT_196	[p14l1622t3521r1703b3583],
13	35	CD	NUMBER	35	number	14	SENT_196	[p14l1757t3508r2133b3583],
14	°	CD	NUMBER	°	prep_from	7	SENT_196	[p14l1757t3508r2133b3583],
15	/	:	O	/	punct	16	SENT_196	[p14l1757t3508r2133b3583],
16	o.	NN	O	o.	parataxis	7	SENT_196	[p14l1757t3508r2133b3583],
17	14	CD	NUMBER	14	num	18	SENT_196	[p14l1757t3508r2133b3583],
18	’16	CD	NUMBER	’16	dep	16	SENT_196	[p14l1757t3508r2133b3583],
19	In	IN	O	in	dep	16	SENT_196	[p14l10t3639r99b3709],
20	cases	NNS	O	case	pobj	19	SENT_196	[p14l153t3657r375b3709],
21	of	IN	O	of	_	0	SENT_196	[p14l431t3630r531b3710],
22	severe	JJ	O	severe	amod	23	SENT_196	[p14l568t3657r826b3711],
23	diarrhea	NN	O	diarrhea	prep_of	20	SENT_196	[p14l880t3631r1264b3727],
24	,	,	O	,	_	0	SENT_196	[p14l880t3631r1264b3727],
25	therapy	NN	O	therapy	dep	7	SENT_196	[p14l1324t3631r1645b3731],
26	should	MD	O	should	aux	28	SENT_196	[p14l1696t3631r1983b3711],
27	be	VB	O	be	auxpass	28	SENT_196	[p14l2037t3631r2134b3710],
28	stopped	VBN	O	stop	_	0	SENT_196	[p15l12t21r350b121],
29	for	IN	O	for	_	0	SENT_196	[p15l402t20r525b100],
30	up	RB	DURATION	up	quantmod	32	SENT_196	[p15l573t47r677b121],
31	to	TO	DURATION	to	dep	32	SENT_196	[p15l730t38r811b100],
32	14	CD	DURATION	14	num	33	SENT_196	[p15l867t27r959b100],
33	days	NNS	NUMBER	day	prep_for	28	SENT_196	[p15l1011t21r1195b121],
34	until	IN	O	until	mark	38	SENT_196	[p15l1249t21r1452b101],
35	the	DT	O	the	det	36	SENT_196	[p15l1503t21r1636b99],
36	symptoms	NNS	O	symptom	nsubj	38	SENT_196	[p15l1689t38r2131b121],
37	have	VBP	O	have	aux	38	SENT_196	[p15l11t150r201b229],
38	resolved	VBN	O	resolve	advcl	28	SENT_196	[p15l248t150r622b245],
39	;	:	O	;	_	0	SENT_196	[p15l248t150r622b245],
40	loperamide	NN	O	loperamide	nsubjpass	43	SENT_196	[p15l673t150r1159b249],
41	may	MD	O	may	aux	43	SENT_196	[p15l1206t176r1386b249],
42	be	VB	O	be	auxpass	43	SENT_196	[p15l1429t150r1526b228],
43	used	VBN	O	use	parataxis	28	SENT_196	[p15l1573t150r1770b229],
44	to	TO	O	to	aux	45	SENT_196	[p15l1818t167r1899b228],
45	control	VB	O	control	xcomp	43	SENT_196	[p15l1949t176r2132b228, p15l12t279r161b358],
46	the	DT	O	the	det	47	SENT_196	[p15l200t279r333b357],
47	diarrhea	NN	O	diarrhea	dobj	45	SENT_196	[p15l374t279r758b358],
48	.	.	O	.	_	0	SENT_196	[p15l374t279r758b358],

1	Rash	NNP	O	Rash	nsubjpass	3	SENT_197	[p15l139t406r353b490],
2	is	VBZ	O	be	auxpass	3	SENT_197	[p15l395t407r461b484],
3	reported	VBN	O	report	ccomp	33	SENT_197	[p15l507t406r873b506],
4	in	IN	O	in	_	0	SENT_197	[p15l916t407r999b484],
5	75	CD	PERCENT	75	num	6	SENT_197	[p15l1044t412r1227b486],
6	%	NN	PERCENT	%	prep_in	3	SENT_197	[p15l1044t412r1227b486],
7	of	IN	O	of	_	0	SENT_197	[p15l1270t405r1370b485],
8	patients	NNS	O	patient	prep_of	6	SENT_197	[p15l1394t407r1735b506],
9	who	WP	O	who	nsubjpass	11	SENT_197	[p15l1776t406r1959b486],
10	are	VBP	O	be	auxpass	11	SENT_197	[p15l2004t432r2133b484],
11	treated	VBN	O	treat	rcmod	8	SENT_197	[p15l12t535r310b614],
12	with	IN	O	with	_	0	SENT_197	[p15l370t535r565b614],
13	erlotinib	NN	O	erlotinib	nn	14	SENT_197	[p15l630t535r1074b614],
14	“	NN	O	“	prep_with	11	SENT_197	[p15l630t535r1074b614],
15	and	CC	O	and	_	0	SENT_197	[p15l1138t535r1296b614],
16	in	IN	O	in	_	0	SENT_197	[p15l1360t536r1443b613],
17	33	CD	PERCENT	33	num	18	SENT_197	[p15l1509t540r1690b614],
18	%	NN	PERCENT	%	conj_and	6	SENT_197	[p15l1509t540r1690b614],
19	of	IN	O	of	_	0	SENT_197	[p15l1755t534r1855b614],
20	those	DT	O	those	prep_of	18	SENT_197	[p15l1902t535r2133b614],
21	treated	VBN	O	treat	partmod	20	SENT_197	[p15l12t663r302b742],
22	with	IN	O	with	_	0	SENT_197	[p15l330t663r522b742],
23	gef1tinib	NN	O	gef1tinib	prep_with	21	SENT_197	[p15l554t662r1010b764],
24	.25	CD	NUMBER	.25	num	23	SENT_197	[p15l554t662r1010b764],
25	Among	IN	O	among	_	0	SENT_197	[p15l1043t671r1358b764],
26	such	JJ	O	such	amod	27	SENT_197	[p15l1388t663r1578b742],
27	patients	NNS	O	patient	prep_among	21	SENT_197	[p15l1609t664r1965b763],
28	,	,	O	,	_	0	SENT_197	[p15l1609t664r1965b763],
29	the	DT	O	the	det	30	SENT_197	[p15l2003t663r2133b742],
30	onset	NN	O	onset	nsubj	33	SENT_197	[p15l12t807r240b869],
31	of	IN	O	of	_	0	SENT_197	[p15l274t789r372b869],
32	rash	NN	O	rash	prep_of	30	SENT_197	[p15l392t790r571b868],
33	occurs	VBZ	O	occur	_	0	SENT_197	[p15l609t816r883b870],
34	7	CD	DURATION	7	number	36	SENT_197	[p15l924t798r969b869],
35	to	TO	DURATION	to	dep	36	SENT_197	[p15l1009t807r1089b869],
36	14	CD	DURATION	14	num	37	SENT_197	[p15l1132t796r1223b869],
37	days	NNS	NUMBER	day	tmod	33	SENT_197	[p15l1262t790r1443b890],
38	after	IN	O	after	_	0	SENT_197	[p15l1481t789r1680b868],
39	the	DT	O	the	det	40	SENT_197	[p15l1715t790r1845b868],
40	initiation	NN	O	initiation	prep_after	33	SENT_197	[p15l1882t791r2132b868, p15l12t919r181b997],
41	of	IN	O	of	_	0	SENT_197	[p15l232t917r332b997],
42	therapy	NN	O	therapy	prep_of	40	SENT_197	[p15l364t918r781b1018],
43	.	.	O	.	_	0	SENT_197	[p15l364t918r781b1018],

1	“	NN	O	“	nsubj	8	SENT_198	[p15l364t918r781b1018],
2	The	DT	O	the	det	3	SENT_198	[p15l828t918r989b996],
3	rash	NN	O	rash	dep	1	SENT_198	[p15l1039t918r1221b996],
4	is	VBZ	O	be	cop	6	SENT_198	[p15l1271t919r1337b996],
5	usually	RB	O	usually	advmod	6	SENT_198	[p15l1389t918r1697b1018],
6	follicular	JJ	O	follicular	_	0	SENT_198	[p15l1742t917r2136b998],
7	and	CC	O	and	_	0	SENT_198	[p15l11t1046r168b1125],
8	papulopustular	JJ	O	papulopustular	conj_and	6	SENT_198	[p15l216t1046r875b1146],
9	and	CC	O	and	_	0	SENT_198	[p15l921t1046r1079b1125],
10	frequently	RB	O	frequently	advmod	11	SENT_198	[p15l1128t1045r1567b1146],
11	involves	VBZ	O	involve	conj_and	6	SENT_198	[p15l1611t1046r1949b1126],
12	the	DT	O	the	det	13	SENT_198	[p15l2001t1046r2133b1124],
13	face	NN	O	face	dobj	11	SENT_198	[p15l11t1174r207b1271],
14	,	,	O	,	_	0	SENT_198	[p15l11t1174r207b1271],
15	scalp	NN	O	scalp	conj_and	13	SENT_198	[p15l267t1175r510b1275],
16	,	,	O	,	_	0	SENT_198	[p15l267t1175r510b1275],
17	chest	NN	O	chest	conj_and	13	SENT_198	[p15l570t1175r819b1271],
18	,	,	O	,	_	0	SENT_198	[p15l570t1175r819b1271],
19	and	CC	O	and	_	0	SENT_198	[p15l877t1175r1037b1254],
20	back	RB	O	back	advmod	22	SENT_198	[p15l1091t1175r1294b1254],
21	(	JJ	O	(	amod	22	SENT_198	[p15l1348t1176r1532b1276],
22	Fig	NN	O	fig	dobj	11	SENT_198	[p15l1348t1176r1532b1276],
23	.	.	O	.	_	0	SENT_198	[p15l1348t1176r1532b1276],

1	3A	NN	O	3a	_	0	SENT_199	[p15l1592t1181r1706b1254],
2	and	CC	O	and	_	0	SENT_199	[p15l1755t1175r1915b1254],
3	3B	NN	O	3b	conj_and	1	SENT_199	[p15l1969t1181r2128b1266],
4	)	NN	O	)	dep	1	SENT_199	[p15l1969t1181r2128b1266],
5	.	.	O	.	_	0	SENT_199	[p15l1969t1181r2128b1266],

1	Various	JJ	O	various	amod	2	SENT_200	[p15l7t1303r335b1382],
2	topical	JJ	O	topical	nsubjpass	17	SENT_200	[p15l403t1302r700b1402],
3	and	CC	O	and	_	0	SENT_200	[p15l764t1302r923b1381],
4	systemic	JJ	O	systemic	amod	5	SENT_200	[p15l989t1303r1364b1402],
5	preparations	NNS	O	preparation	conj_and	2	SENT_200	[p15l1427t1303r1983b1402],
6	of	IN	O	of	_	0	SENT_200	[p15l2050t1301r2152b1381],
7	antibiotics	NNS	O	antibiotic	prep_of	2	SENT_200	[p15l11t1431r475b1527],
8	,	,	O	,	_	0	SENT_200	[p15l11t1431r475b1527],
9	glucocorticoids	NNS	O	glucocorticoid	prep_of	2	SENT_200	[p15l515t1431r1185b1532],
10	,	,	O	,	_	0	SENT_200	[p15l515t1431r1185b1532],
11	and	CC	O	and	_	0	SENT_200	[p15l1225t1431r1381b1510],
12	immunomodula	NN	O	immunomodulum	nn	14	SENT_200	[p15l1415t1431r2132b1510],
13	—	NN	O	—	nn	14	SENT_200	[p15l1415t1431r2132b1510],
14	tors	NNS	O	tor	conj_and	7	SENT_200	[p15l12t1574r174b1636],
15	have	VBP	O	have	aux	17	SENT_200	[p15l210t1558r400b1637],
16	been	VBN	O	be	auxpass	17	SENT_200	[p15l435t1558r636b1636],
17	used	VBN	O	use	_	0	SENT_200	[p15l670t1558r866b1637],
18	with	IN	O	with	_	0	SENT_200	[p15l896t1558r1091b1637],
19	some	DT	O	some	det	20	SENT_200	[p15l1126t1583r1351b1636],
20	success	NN	O	success	prep_with	17	SENT_200	[p15l1386t1584r1725b1653],
21	;	:	O	;	_	0	SENT_200	[p15l1386t1584r1725b1653],
22	moisturizing	VBG	O	moisturize	nsubjpass	27	SENT_200	[p15l1764t1559r2132b1637, p15l11t1687r228b1787],
23	of	IN	O	of	_	0	SENT_200	[p15l259t1685r359b1765],
24	the	DT	O	the	det	25	SENT_200	[p15l374t1686r506b1764],
25	skin	NN	O	skin	prep_of	22	SENT_200	[p15l541t1686r722b1765],
26	is	VBZ	O	be	auxpass	27	SENT_200	[p15l754t1687r820b1764],
27	recommended	VBN	O	recommend	parataxis	17	SENT_200	[p15l855t1686r1494b1765],
28	.	.	O	.	_	0	SENT_200	[p15l855t1686r1494b1765],

1	Acne	NN	MISC	acne	nn	2	SENT_201	[p15l1530t1694r1740b1765],
2	preparations	NNS	O	preparation	nsubjpass	11	SENT_201	[p15l1772t1712r2132b1786, p15l12t1815r247b1909],
3	,	,	O	,	_	0	SENT_201	[p15l1772t1712r2132b1786, p15l12t1815r247b1909],
4	such	JJ	O	such	_	0	SENT_201	[p15l284t1814r478b1893],
5	as	IN	O	as	_	0	SENT_201	[p15l507t1840r593b1892],
6	benzoyl	NN	O	benzoyl	nn	7	SENT_201	[p15l625t1814r958b1913],
7	peroxide	NN	O	peroxide	prep_such_as	2	SENT_201	[p15l986t1814r1378b1913],
8	,	,	O	,	_	0	SENT_201	[p15l986t1814r1378b1913],
9	must	MD	O	must	aux	11	SENT_201	[p15l1414t1831r1630b1893],
10	be	VB	O	be	auxpass	11	SENT_201	[p15l1655t1814r1751b1892],
11	avoided	VBN	O	avoid	_	0	SENT_201	[p15l1781t1814r2128b1909],
12	,	,	O	,	_	0	SENT_201	[p15l1781t1814r2128b1909],
13	since	IN	O	since	mark	16	SENT_201	[p15l12t1943r232b2020],
14	they	PRP	O	they	nsubj	16	SENT_201	[p15l292t1942r478b2041],
15	may	MD	O	may	aux	16	SENT_201	[p15l534t1968r715b2041],
16	exacerbate	VB	O	exacerbate	advcl	11	SENT_201	[p15l772t1942r1231b2020],
17	this	DT	O	this	det	20	SENT_201	[p15l1291t1942r1454b2020],
18	common	JJ	O	common	amod	20	SENT_201	[p15l1517t1968r1904b2020],
19	side	NN	O	side	nn	20	SENT_201	[p15l1966t1942r2133b2020],
20	effect	NN	O	effect	dobj	16	SENT_201	[p15l12t2068r280b2148],
21	.	.	O	.	_	0	SENT_201	[p15l12t2068r280b2148],

1	In	IN	O	in	_	0	SENT_202	[p15l325t2077r415b2147],
2	patients	NNS	O	patient	prep_in	16	SENT_202	[p15l454t2070r803b2169],
3	with	IN	O	with	_	0	SENT_202	[p15l842t2069r1040b2149],
4	rash	JJ	O	rash	prep_with	2	SENT_202	[p15l1081t2069r1266b2147],
5	controlled	VBN	O	control	partmod	2	SENT_202	[p15l1308t2069r1755b2148],
6	by	IN	O	by	_	0	SENT_202	[p15l1796t2069r1894b2169],
7	topical	JJ	O	topical	amod	8	SENT_202	[p15l1931t2070r2132b2169, p15l12t2197r134b2274],
8	moisturizers	NNS	O	moisturizer	agent	5	SENT_202	[p15l199t2198r781b2292],
9	,	,	O	,	_	0	SENT_202	[p15l199t2198r781b2292],
10	treatment	NN	O	treatment	nsubj	16	SENT_202	[p15l852t2213r1284b2274],
11	with	IN	O	with	_	0	SENT_202	[p15l1340t2197r1538b2276],
12	erlotinib	NN	O	erlotinib	prep_with	10	SENT_202	[p15l1604t2197r1979b2275],
13	or	CC	O	or	_	0	SENT_202	[p15l2046t2222r2137b2275],
14	geﬁtinib	NN	O	geﬁtinib	conj_or	12	SENT_202	[p15l11t2324r382b2426],
15	can	MD	O	can	aux	16	SENT_202	[p15l420t2351r569b2403],
16	continue	VB	O	continue	_	0	SENT_202	[p15l605t2326r978b2404],
17	in	IN	O	in	_	0	SENT_202	[p15l1013t2326r1097b2403],
18	an	DT	O	a	det	20	SENT_202	[p15l1132t2351r1235b2403],
19	uninterrupted	JJ	O	uninterrupted	amod	20	SENT_202	[p15l1270t2325r1874b2425],
20	manner	NN	O	manner	prep_in	16	SENT_202	[p15l1909t2351r2132b2403, p15l11t2477r171b2530],
21	.	.	O	.	_	0	SENT_202	[p15l1909t2351r2132b2403, p15l11t2477r171b2530],

1	However	RB	O	however	advmod	21	SENT_203	[p15l227t2459r629b2547],
2	,	,	O	,	_	0	SENT_203	[p15l227t2459r629b2547],
3	in	IN	O	in	_	0	SENT_203	[p15l685t2453r769b2529],
4	those	DT	O	those	prep_in	21	SENT_203	[p15l821t2452r1057b2530],
5	with	IN	O	with	_	0	SENT_203	[p15l1103t2452r1302b2531],
6	severe	JJ	O	severe	amod	7	SENT_203	[p15l1355t2478r1618b2531],
7	rash	NN	O	rash	prep_with	4	SENT_203	[p15l1669t2452r1878b2547],
8	,	,	O	,	_	0	SENT_203	[p15l1669t2452r1878b2547],
9	dose	NN	O	dose	nn	10	SENT_203	[p15l1936t2452r2133b2530],
10	modifications	NNS	O	modification	nsubj	21	SENT_203	[p15l11t2578r615b2658],
11	of	IN	O	of	_	0	SENT_203	[p15l652t2578r752b2658],
12	erlotinib	NN	O	erlotinib	nn	15	SENT_203	[p15l769t2579r1136b2658],
13	or	CC	O	or	_	0	SENT_203	[p15l1173t2605r1261b2658],
14	treatment	NN	O	treatment	nn	15	SENT_203	[p15l1293t2596r1717b2657],
15	interruption	NN	O	interruption	prep_of	10	SENT_203	[p15l1746t2580r2132b2679, p15l12t2709r181b2787],
16	of	IN	O	of	prep	10	SENT_203	[p15l221t2707r321b2787],
17	either	CC	O	either	dep	16	SENT_203	[p15l342t2708r589b2787],
18	agent	NN	O	agent	conj	16	SENT_203	[p15l625t2725r862b2809],
19	may	MD	O	may	aux	21	SENT_203	[p15l896t2734r1075b2808],
20	be	VB	O	be	cop	21	SENT_203	[p15l1111t2708r1207b2787],
21	necessary	JJ	O	necessary	_	0	SENT_203	[p15l1246t2714r1754b2808],
22	.35	CD	NUMBER	.35	tmod	21	SENT_203	[p15l1246t2714r1754b2808],

1	Interstitial	JJ	O	interstitial	amod	3	SENT_204	[p15l138t2836r594b2914],
2	lung	NN	O	lung	nn	3	SENT_204	[p15l643t2836r836b2937],
3	disease	NN	O	disease	nsubj	12	SENT_204	[p15l884t2836r1194b2915],
4	is	VBZ	O	be	cop	12	SENT_204	[p15l1244t2837r1309b2914],
5	a	DT	O	a	det	12	SENT_204	[p15l1361t2862r1405b2914],
6	rare	JJ	O	rare	amod	12	SENT_204	[p15l1454t2862r1621b2914],
7	but	CC	O	but	cc	6	SENT_204	[p15l1672t2836r1812b2915],
8	potentially	RB	O	potentially	advmod	6	SENT_204	[p15l1855t2853r2132b2936, p15l12t2964r228b3064],
9	life	NN	O	life	npadvmod	11	SENT_204	[p15l261t2963r941b3065],
10	—	CD	NUMBER	—	num	9	SENT_204	[p15l261t2963r941b3065],
11	threatening	JJ	O	threatening	dep	6	SENT_204	[p15l261t2963r941b3065],
12	complication	NN	O	complication	conj_and	12	SENT_204	[p15l978t2964r1540b3064],
13	of	IN	O	of	_	0	SENT_204	[p15l1579t2963r1679b3043],
14	both	DT	O	both	preconj	18	SENT_204	[p15l1700t2964r1898b3043],
15	erlotinib	NN	O	erlotinib	nn	18	SENT_204	[p15l1938t2964r2132b3043, p15l12t3092r213b3171],
16	and	CC	O	and	_	0	SENT_204	[p15l254t3092r412b3171],
17	gefitinib	NN	O	gefitinib	nn	18	SENT_204	[p15l452t3091r824b3193],
18	therapy	NN	O	therapy	prep_of	12	SENT_204	[p15l866t3092r1200b3192],
19	,	,	O	,	_	0	SENT_204	[p15l866t3092r1200b3192],
20	with	IN	O	with	_	0	SENT_204	[p15l1241t3092r1436b3171],
21	an	DT	O	a	det	23	SENT_204	[p15l1476t3118r1579b3170],
22	overall	JJ	O	overall	amod	23	SENT_204	[p15l1620t3092r1906b3171],
23	incidence	NN	O	incidence	prep_with	12	SENT_204	[p15l1944t3093r2132b3170, p15l12t3219r260b3298],
24	of	IN	O	of	_	0	SENT_204	[p15l320t3218r421b3298],
25	less	JJR	O	less	mwe	26	SENT_204	[p15l461t3219r619b3297],
26	than	IN	O	than	quantmod	27	SENT_204	[p15l680t3219r880b3297],
27	1	CD	PERCENT	1	num	28	SENT_204	[p15l942t3224r1067b3299],
28	%	NN	PERCENT	%	prep_of	23	SENT_204	[p15l942t3224r1067b3299],
29	in	IN	O	in	_	0	SENT_204	[p15l1125t3220r1209b3297],
30	White	NNP	O	White	nn	31	SENT_204	[p15l1263t3219r1507b3299],
31	patients	NNS	O	patient	prep_in	28	SENT_204	[p15l1564t3220r1913b3319],
32	and	CC	O	and	_	0	SENT_204	[p15l1974t3219r2134b3298],
33	about	IN	O	about	_	0	SENT_204	[p15l11t3347r254b3427],
34	5	CD	PERCENT	5	num	35	SENT_204	[p15l297t3353r428b3427],
35	%	NN	PERCENT	%	prep_about	12	SENT_204	[p15l297t3353r428b3427],
36	in	IN	O	in	_	0	SENT_204	[p15l473t3348r556b3425],
37	Japanese	JJ	MISC	japanese	amod	38	SENT_204	[p15l592t3355r973b3447],
38	patients	NNS	O	patient	prep_in	35	SENT_204	[p15l1017t3348r1383b3447],
39	.	.	O	.	_	0	SENT_204	[p15l1017t3348r1383b3447],

1	The	DT	O	the	det	2	SENT_205	[p15l1431t3347r1592b3425],
2	risk	NN	O	risk	nsubj	18	SENT_205	[p15l1638t3347r1802b3427],
3	of	IN	O	of	_	0	SENT_205	[p15l1844t3346r1944b3426],
4	this	DT	O	this	det	6	SENT_205	[p15l1972t3347r2131b3425],
5	side	JJ	O	side	amod	6	SENT_205	[p15l12t3475r177b3554],
6	effect	NN	O	effect	prep_of	2	SENT_205	[p15l214t3474r476b3571],
7	,	,	O	,	_	0	SENT_205	[p15l214t3474r476b3571],
8	which	WDT	O	which	nsubj	10	SENT_205	[p15l514t3475r776b3555],
9	usually	RB	O	usually	advmod	10	SENT_205	[p15l812t3475r1119b3575],
10	occurs	VBZ	O	occur	rcmod	2	SENT_205	[p15l1151t3501r1430b3554],
11	within	IN	O	within	_	0	SENT_205	[p15l1463t3475r1748b3555],
12	the	DT	DURATION	the	det	14	SENT_205	[p15l1785t3475r1917b3553],
13	first	JJ	DURATION	first	amod	14	SENT_205	[p15l1954t3474r2138b3553],
14	month	NN	DURATION	month	prep_within	10	SENT_205	[p15l11t3603r300b3682],
15	of	IN	O	of	_	0	SENT_205	[p15l354t3602r455b3682],
16	therapy	NN	O	therapy	prep_of	14	SENT_205	[p15l489t3603r831b3703],
17	,	,	O	,	_	0	SENT_205	[p15l489t3603r831b3703],
18	appears	VBZ	O	appear	_	0	SENT_205	[p15l889t3629r1227b3703],
19	to	TO	O	to	aux	21	SENT_205	[p15l1282t3620r1365b3682],
20	be	VB	O	be	auxpass	21	SENT_205	[p15l1419t3603r1517b3682],
21	increased	VBN	O	increase	xcomp	18	SENT_205	[p15l1569t3603r1986b3682],
22	by	IN	O	by	_	0	SENT_205	[p15l2040t3603r2138b3703],
23	previous	JJ	O	previous	amod	24	SENT_205	[p16l9t22r372b120],
24	chemotherapy	NN	O	chemotherapy	nsubj	33	SENT_205	[p16l418t21r1042b120],
25	,	,	O	,	_	0	SENT_205	[p16l418t21r1042b120],
26	previous	JJ	O	previous	amod	28	SENT_205	[p16l1089t22r1452b120],
27	radiation	NN	O	radiation	nn	28	SENT_205	[p16l1497t21r1886b99],
28	therapy	NN	O	therapy	appos	24	SENT_205	[p16l1930t21r2132b99, p16l11t175r156b249],
29	to	TO	O	to	_	0	SENT_205	[p16l198t166r279b228],
30	the	DT	O	the	det	31	SENT_205	[p16l327t149r460b228],
31	lungs	NNS	O	lung	prep_to	28	SENT_205	[p16l505t149r762b250],
32	,	,	O	,	_	0	SENT_205	[p16l505t149r762b250],
33	preexisting	VBG	O	preexist	agent	21	SENT_205	[p16l813t150r1298b250],
34	parenchymal	JJ	O	parenchymal	amod	36	SENT_205	[p16l1339t149r1899b249],
35	lung	NN	O	lung	nn	36	SENT_205	[p16l1943t149r2137b250],
36	disease	NN	O	disease	dobj	33	SENT_205	[p16l12t277r337b373],
37	,	,	O	,	_	0	SENT_205	[p16l12t277r337b373],
38	metastatic	JJ	O	metastatic	amod	40	SENT_205	[p16l373t278r811b355],
39	lung	NN	O	lung	nn	40	SENT_205	[p16l839t277r1029b378],
40	disease	NN	O	disease	conj_and	36	SENT_205	[p16l1057t277r1382b373],
41	,	,	O	,	_	0	SENT_205	[p16l1057t277r1382b373],
42	and	CC	O	and	_	0	SENT_205	[p16l1417t277r1573b356],
43	concomitant	JJ	O	concomitant	amod	45	SENT_205	[p16l1603t278r2138b356],
44	pulmonary	JJ	O	pulmonary	amod	45	SENT_205	[p16l9t404r488b504],
45	infection	NN	O	infection	conj_and	36	SENT_205	[p16l532t403r941b483],
46	.	.	O	.	_	0	SENT_205	[p16l532t403r941b483],

1	The	DT	O	the	det	2	SENT_206	[p16l992t404r1153b482],
2	onset	NN	O	onset	nsubj	8	SENT_206	[p16l1203t421r1436b483],
3	of	IN	O	of	_	0	SENT_206	[p16l1480t403r1580b483],
4	unexplained	JJ	O	unexplained	amod	6	SENT_206	[p16l1610t404r2134b504],
5	respiratory	JJ	O	respiratory	amod	6	SENT_206	[p16l11t534r471b633],
6	symptoms	NNS	O	symptom	prep_of	2	SENT_206	[p16l509t550r944b633],
7	should	MD	O	should	aux	8	SENT_206	[p16l989t533r1270b612],
8	prompt	VB	O	prompt	_	0	SENT_206	[p16l1310t550r1626b633],
9	drug	NN	O	drug	nn	10	SENT_206	[p16l1662t533r1863b634],
10	interruption	NN	O	interruption	dobj	8	SENT_206	[p16l1901t534r2132b612, p16l11t662r331b761],
11	While	IN	O	while	mark	16	SENT_206	[p16l360t661r595b740],
12	a	DT	O	a	det	14	SENT_206	[p16l629t687r674b739],
13	diagnostic	JJ	O	diagnostic	amod	14	SENT_206	[p16l706t661r1156b762],
14	workup	NN	O	workup	nsubjpass	16	SENT_206	[p16l1184t661r1514b761],
15	is	VBZ	O	be	auxpass	16	SENT_206	[p16l1548t662r1613b739],
16	performed	VBN	O	perform	dep	8	SENT_206	[p16l1648t660r2128b761],
17	.	.	O	.	_	0	SENT_206	[p16l1648t660r2128b761],

1	Should	MD	O	should	aux	4	SENT_207	[p16l13t789r308b868],
2	interstitial	JJ	O	interstitial	amod	3	SENT_207	[p16l366t789r816b867],
3	lung	NN	O	lung	nsubj	4	SENT_207	[p16l874t789r1067b890],
4	disease	NN	O	disease	_	0	SENT_207	[p16l1124t789r1434b868],
5	be	VB	O	be	auxpass	6	SENT_207	[p16l1494t789r1591b868],
6	confirmed	VBN	O	confirm	dep	4	SENT_207	[p16l1651t788r2128b885],
7	,	,	O	,	_	0	SENT_207	[p16l1651t788r2128b885],
8	therapy	NN	O	therapy	dobj	6	SENT_207	[p16l12t917r333b1016],
9	with	IN	O	with	_	0	SENT_207	[p16l389t917r584b996],
10	EGFR	NN	ORGANIZATION	egfr	nn	11	SENT_207	[p16l647t923r902b1000],
11	tyrosine	NN	O	tyrosine	prep_with	8	SENT_207	[p16l957t918r1303b1016],
12	kinase	NN	O	kinase	nn	13	SENT_207	[p16l1367t917r1646b996],
13	inhibitors	NNS	O	inhibitor	nsubjpass	17	SENT_207	[p16l1709t917r2131b995],
14	should	MD	O	should	aux	17	SENT_207	[p16l12t1045r300b1124],
15	be	VB	O	be	auxpass	17	SENT_207	[p16l340t1045r436b1123],
16	permanently	RB	O	permanently	advmod	17	SENT_207	[p16l474t1045r1023b1144],
17	discontinued	VBN	O	discontinue	rcmod	8	SENT_207	[p16l1059t1045r1815b1124],
18	.24	CD	NUMBER	.24	num	19	SENT_207	[p16l1059t1045r1815b1124],
19	>	JJR	O	>	xcomp	17	SENT_207	[p16l1059t1045r1815b1124],
20	25	CD	NUMBER	25	dep	19	SENT_207	[p16l1059t1045r1815b1124],

1	N	NN	O	n	nn	3	SENT_208	[p16l558t1229r572b1244],
2	ENGLJ	NN	O	englj	nn	3	SENT_208	[p16l586t1229r664b1251],
3	MED	NN	O	med	_	0	SENT_208	[p16l679t1229r731b1244],
4	;	:	O	;	_	0	SENT_208	[p16l788t1229r823b1249],
5	1o	NN	O	1o	nn	7	SENT_208	[p16l788t1229r823b1249],
6	NEjM.ORG	NN	O	nejm.org	nn	7	SENT_208	[p16l858t1229r982b1251],
7	MARCH	NN	DATE	march	dep	3	SENT_208	[p16l1019t1229r1104b1244],
8	10	CD	DATE	10	dep	7	SENT_208	[p16l1117t1229r1150b1249],
9	,	,	DATE	,	_	0	SENT_208	[p16l1117t1229r1150b1249],
10	2011	CD	DATE	2011	num	11	SENT_208	[p16l1162t1229r1213b1245],
11	951	CD	NUMBER	951	appos	8	SENT_208	[p16l1959t1219r2016b1242],

1	T	NN	O	t	_	0	SENT_209	[p16l702t1263r721b1286],
2	e	SYM	O	e	dep	3	SENT_209	[p16l739t1270r753b1286],
3	ew	FW	O	ew	rcmod	1	SENT_209	[p16l786t1270r824b1286],
4	England	NNP	O	England	nn	5	SENT_209	[p16l833t1262r944b1293],
5	Journal	NNP	O	Journal	dep	1	SENT_209	[p16l952t1262r1050b1286],
6	of	IN	O	of	_	0	SENT_209	[p16l1059t1262r1088b1286],
7	Medicine	NNP	O	Medicine	prep_of	5	SENT_209	[p16l1095t1262r1220b1286],

1	Downloaded	VBN	O	download	_	0	SENT_210	[p16l144t1303r314b1326],
2	from	IN	O	from	_	0	SENT_210	[p16l323t1303r387b1326],
3	nejm.org	NN	O	nejm.org	prep_from	1	SENT_210	[p16l396t1303r514b1333],
4	at	IN	O	at	_	0	SENT_210	[p16l524t1307r547b1326],
5	UW-Madison	NN	O	uw-madison	prep_at	1	SENT_210	[p16l556t1303r738b1326],
6	on	IN	O	on	_	0	SENT_210	[p16l748t1310r780b1326],
7	January	NNP	DATE	January	prep_on	1	SENT_210	[p16l789t1303r892b1333],
8	5	CD	DATE	5	num	7	SENT_210	[p16l902t1303r924b1331],
9	,	,	DATE	,	_	0	SENT_210	[p16l902t1303r924b1331],
10	2014	CD	DATE	2014	num	7	SENT_210	[p16l935t1303r1007b1326],
11	.	.	O	.	_	0	SENT_210	[p16l935t1303r1007b1326],

1	For	IN	O	for	_	0	SENT_211	[p16l1018t1303r1064b1326],
2	personal	JJ	O	personal	amod	3	SENT_211	[p16l1072t1303r1185b1333],
3	use	NN	O	use	pobj	1	SENT_211	[p16l1194t1310r1237b1326],
4	only	RB	O	only	advmod	3	SENT_211	[p16l1247t1303r1312b1333],
5	.	.	O	.	_	0	SENT_211	[p16l1247t1303r1312b1333],

1	No	DT	O	no	det	3	SENT_212	[p16l1322t1303r1362b1326],
2	other	JJ	O	other	amod	3	SENT_212	[p16l1372t1303r1440b1326],
3	uses	NNS	O	use	_	0	SENT_212	[p16l1448t1310r1504b1326],
4	without	IN	O	without	_	0	SENT_212	[p16l1514t1303r1616b1326],
5	permission	NN	O	permission	prep_without	3	SENT_212	[p16l1624t1303r1776b1333],
6	.	.	O	.	_	0	SENT_212	[p16l1624t1303r1776b1333],

1	Copyright	NN	O	copyright	_	0	SENT_213	[p16l494t1344r629b1375],
2	©	CD	NUMBER	©	num	6	SENT_213	[p16l638t1344r661b1368],
3	2011	CD	DATE	2011	num	6	SENT_213	[p16l671t1344r734b1368],
4	Massachusetts	NNP	ORGANIZATION	Massachusetts	nn	6	SENT_213	[p16l746t1344r937b1368],
5	Medical	NNP	ORGANIZATION	Medical	nn	6	SENT_213	[p16l947t1344r1055b1368],
6	Society	NNP	ORGANIZATION	Society	dep	1	SENT_213	[p16l1065t1344r1170b1375],
7	.	.	O	.	_	0	SENT_213	[p16l1065t1344r1170b1375],

1	All	DT	O	all	det	2	SENT_214	[p16l1181t1344r1223b1368],
2	rights	NNS	O	rights	nsubj	3	SENT_214	[p16l1232t1344r1306b1375],
3	reserved	VBN	O	reserve	_	0	SENT_214	[p16l1316t1344r1435b1368],
4	.	.	O	.	_	0	SENT_214	[p16l1316t1344r1435b1368],

1	The	DT	O	the	det	4	SENT_215	[p16l673t1450r718b1471],
2	NEW	NNP	O	NEW	nn	4	SENT_215	[p16l737t1452r822b1471],
3	ENGLAND	NNP	O	ENGLAND	nn	4	SENT_215	[p16l841t1452r1029b1471],
4	JOURNAL	NNP	O	JOURNAL	_	0	SENT_215	[p16l1048t1452r1227b1478],
5	of	IN	O	of	_	0	SENT_215	[p16l1247t1450r1275b1477],
6	MEDICINE	NNP	O	MEDICINE	prep_of	4	SENT_215	[p16l1287t1452r1486b1471],

1	Figure	NNP	O	Figure	_	0	SENT_216	[p18l83t1473r303b1557],
2	3	CD	NUMBER	3	dep	1	SENT_216	[p18l331t1477r389b1536],
3	.	.	O	.	_	0	SENT_216	[p18l331t1477r389b1536],

1	Rash	NNP	O	Rash	nn	2	SENT_217	[p18l425t1472r591b1537],
2	Associated	NNP	O	Associated	_	0	SENT_217	[p18l620t1472r1011b1537],
3	with	IN	O	with	_	0	SENT_217	[p18l1041t1472r1193b1537],
4	Use	NNP	O	Use	dep	10	SENT_217	[p18l1228t1477r1362b1537],
5	of	IN	O	of	_	0	SENT_217	[p18l1388t1471r1471b1537],
6	EG	NNP	O	EG	nn	7	SENT_217	[p18l1489t1477r1584b1537],
7	FR	NN	O	fr	prep_of	4	SENT_217	[p18l1597t1477r1683b1536],
8	Tyrosine	NN	O	tyrosine	nn	9	SENT_217	[p18l1709t1473r2011b1557],
9	Kinase	NN	O	kinase	dep	4	SENT_217	[p18l83t1581r316b1645],
10	Inhibitor	NN	O	inhibitor	prep_with	2	SENT_217	[p18l348t1580r666b1645],
11	.	.	O	.	_	0	SENT_217	[p18l348t1580r666b1645],

1	The	DT	O	the	det	2	SENT_218	[p18l76t1710r209b1776],
2	rash	NN	O	rash	nsubj	3	SENT_218	[p18l243t1710r387b1776],
3	associated	VBN	O	associate	_	0	SENT_218	[p18l422t1710r798b1776],
4	with	IN	O	with	_	0	SENT_218	[p18l828t1710r977b1776],
5	the	DT	O	the	det	6	SENT_218	[p18l1008t1710r1121b1776],
6	use	NN	O	use	prep_with	3	SENT_218	[p18l1154t1733r1272b1776],
7	of	IN	O	of	_	0	SENT_218	[p18l1302t1710r1380b1776],
8	epidermal	JJ	O	epidermal	amod	11	SENT_218	[p18l1397t1710r1756b1795],
9	growth	NN	O	growth	nn	11	SENT_218	[p18l1791t1710r2038b1796],
10	factor	NN	O	factor	nn	11	SENT_218	[p18l77t1818r289b1884],
11	receptor	NN	O	receptor	prep_of	6	SENT_218	[p18l320t1831r618b1904],
12	(	CD	NUMBER	(	num	13	SENT_218	[p18l652t1824r896b1904],
13	EGFR	NN	ORGANIZATION	egfr	dobj	3	SENT_218	[p18l652t1824r896b1904],
14	)	CD	NUMBER	)	num	17	SENT_218	[p18l652t1824r896b1904],
15	tyrosine	NN	O	tyrosine	nn	17	SENT_218	[p18l931t1825r1219b1905],
16	kinase	NN	O	kinase	nn	17	SENT_218	[p18l1252t1819r1475b1884],
17	inhibitors	NNS	O	inhibitor	nsubj	19	SENT_218	[p18l1507t1819r1846b1884],
18	typically	RB	O	typically	advmod	19	SENT_218	[p18l1875t1825r2033b1905, p18l79t1927r235b2013],
19	affects	VBZ	O	affect	rcmod	13	SENT_218	[p18l264t1926r502b1993],
20	the	DT	O	the	det	23	SENT_218	[p18l532t1927r644b1993],
21	face	NN	O	face	nn	23	SENT_218	[p18l672t1926r816b1993],
22	(	CD	NUMBER	(	num	23	SENT_218	[p18l853t1927r1070b2013],
23	Panel	NN	O	panel	nsubj	25	SENT_218	[p18l853t1927r1070b2013],
24	A	DT	O	a	det	25	SENT_218	[p18l1101t1931r1173b2013],
25	)	NN	O	)	xcomp	19	SENT_218	[p18l1101t1931r1173b2013],
26	and	CC	O	and	_	0	SENT_218	[p18l1211t1927r1337b1993],
27	torso	NN	O	torso	nn	31	SENT_218	[p18l1369t1939r1554b1993],
28	(	CD	NUMBER	(	num	31	SENT_218	[p18l1592t1927r1808b2013],
29	Panel	NN	O	panel	nn	31	SENT_218	[p18l1592t1927r1808b2013],
30	B	NN	O	b	nn	31	SENT_218	[p18l1848t1933r1934b2013],
31	)	NN	O	)	conj_and	25	SENT_218	[p18l1848t1933r1934b2013],
32	.	.	O	.	_	0	SENT_218	[p18l1848t1933r1934b2013],

1	The	DT	O	the	det	3	SENT_219	[p18l1964t1927r2098b1993],
2	onset	NN	O	onset	nn	3	SENT_219	[p18l79t2048r278b2101],
3	ofthis	NN	O	ofthi	nsubj	8	SENT_219	[p18l307t2035r530b2101],
4	reversible	JJ	O	reversible	amod	6	SENT_219	[p18l566t2036r910b2101],
5	maculopapular	JJ	O	maculopapular	amod	6	SENT_219	[p18l944t2036r1488b2121],
6	rash	NN	O	rash	dep	3	SENT_219	[p18l1518t2036r1663b2101],
7	usually	RB	O	usually	advmod	8	SENT_219	[p18l1701t2036r1947b2122],
8	occurs	VBZ	O	occur	_	0	SENT_219	[p18l1976t2059r2077b2101, p18l79t2167r225b2210],
9	within	IN	O	within	_	0	SENT_219	[p18l252t2145r466b2210],
10	2	CD	DURATION	2	num	11	SENT_219	[p18l499t2150r535b2209],
11	weeks	NNS	NUMBER	week	prep_within	8	SENT_219	[p18l562t2145r777b2210],
12	after	IN	O	after	_	0	SENT_219	[p18l809t2144r971b2209],
13	the	DT	O	the	det	15	SENT_219	[p18l994t2145r1105b2209],
14	initiation	NN	O	initiation	nn	15	SENT_219	[p18l1137t2150r1443b2209],
15	oftherapy	NN	O	oftherapy	prep_after	8	SENT_219	[p18l1476t2144r1847b2230],
16	.	.	O	.	_	0	SENT_219	[p18l1476t2144r1847b2230],

1	Histologic	JJ	O	histologic	amod	2	SENT_220	[p18l1884t2150r2097b2209, p18l82t2253r246b2339],
2	examination	NN	O	examination	nsubj	3	SENT_220	[p18l273t2258r712b2318],
3	reveals	VBZ	O	reveal	_	0	SENT_220	[p18l749t2253r992b2318],
4	neutrophilic	JJ	O	neutrophilic	amod	7	SENT_220	[p18l1027t2253r1459b2338],
5	infiltration	NN	O	infiltration	nn	7	SENT_220	[p18l1490t2252r1863b2318],
6	ofthe	NN	O	ofthe	nn	7	SENT_220	[p18l1897t2252r2104b2318],
7	dermis	NN	O	dermi	dobj	3	SENT_220	[p18l79t2361r349b2438],
8	,	,	O	,	_	0	SENT_220	[p18l79t2361r349b2438],
9	involving	VBG	O	involve	partmod	3	SENT_220	[p18l386t2361r711b2447],
10	most	RBS	O	most	advmod	11	SENT_220	[p18l743t2374r924b2426],
11	prominently	RB	O	prominently	advmod	9	SENT_220	[p18l957t2361r1396b2447],
12	the	DT	O	the	det	17	SENT_220	[p18l1422t2361r1536b2426],
13	infundibular	JJ	O	infundibular	amod	17	SENT_220	[p18l1569t2361r2012b2426],
14	portion	NN	O	portion	nn	17	SENT_220	[p18l83t2476r344b2555],
15	ofthe	NN	O	ofthe	nn	17	SENT_220	[p18l378t2469r586b2535],
16	hair	NN	O	hair	nn	17	SENT_220	[p18l619t2470r753b2535],
17	follicles	NNS	O	follicle	dobj	9	SENT_220	[p18l779t2469r1076b2535],
18	.	.	O	.	_	0	SENT_220	[p18l779t2469r1076b2535],

1	(	NN	O	(	nn	2	SENT_221	[p18l1118t2470r1606b2556],
2	Photographs	NNS	O	photograph	_	0	SENT_221	[p18l1118t2470r1606b2556],
3	courtesy	NN	O	courtesy	dep	2	SENT_221	[p18l1638t2482r1939b2555],
4	of	IN	O	of	_	0	SENT_221	[p18l1965t2469r2042b2535],
5	Dr.	NNP	O	Dr.	nn	7	SENT_221	[p18l84t2584r178b2643],
6	Barbara	NNP	PERSON	Barbara	nn	7	SENT_221	[p18l215t2578r481b2644],
7	Melosky	NNP	PERSON	Melosky	prep_of	3	SENT_221	[p18l516t2578r820b2664],
8	,	,	O	,	_	0	SENT_221	[p18l516t2578r820b2664],
9	University	NNP	ORGANIZATION	University	appos	7	SENT_221	[p18l856t2584r1208b2664],
10	of	IN	ORGANIZATION	of	_	0	SENT_221	[p18l1235t2577r1311b2644],
11	British	NNP	ORGANIZATION	British	nn	14	SENT_221	[p18l1332t2578r1551b2644],
12	Columbia	NNP	ORGANIZATION	Columbia	nn	14	SENT_221	[p18l1584t2578r1973b2663],
13	.	.	O	.	_	0	SENT_221	[p18l1584t2578r1973b2663],
14	)	NN	O	)	prep_of	9	SENT_221	[p18l1584t2578r1973b2663],

1	AREAS	NNS	O	area	_	0	SENT_222	[p18l371t3014r724b3072],
2	OF	IN	O	of	_	0	SENT_222	[p18l779t3014r909b3072],
3	UNCERTAINTY	NN	O	uncertainty	prep_of	1	SENT_222	[p18l962t3014r1774b3072],

1	The	DT	O	the	det	5	SENT_223	[p18l7t3243r168b3320],
2	relatively	RB	O	relatively	advmod	3	SENT_223	[p18l216t3243r602b3342],
3	low	JJ	O	low	amod	5	SENT_223	[p18l645t3243r801b3322],
4	response	NN	O	response	nn	5	SENT_223	[p18l845t3268r1226b3342],
5	rates	NNS	O	rate	nsubj	6	SENT_223	[p18l1274t3259r1477b3320],
6	achieved	VBN	O	achieve	_	0	SENT_223	[p18l1527t3243r1895b3322],
7	with	IN	O	with	_	0	SENT_223	[p18l1939t3243r2134b3322],
8	the	DT	O	the	det	10	SENT_223	[p18l11t3371r144b3448],
9	EGFR	NN	ORGANIZATION	egfr	nn	10	SENT_223	[p18l210t3376r466b3454],
10	tyrosine	NN	O	tyrosine	prep_with	6	SENT_223	[p18l523t3372r869b3470],
11	kinase	NN	O	kinase	nn	12	SENT_223	[p18l936t3371r1215b3450],
12	inhibitors	NNS	O	inhibitor	nsubj	20	SENT_223	[p18l1282t3371r1728b3466],
13	,	,	O	,	_	0	SENT_223	[p18l1282t3371r1728b3466],
14	coupled	VBN	O	couple	partmod	12	SENT_223	[p18l1801t3371r2134b3470],
15	With	IN	O	with	_	0	SENT_223	[p18l6t3499r202b3578],
16	their	PRP$	O	they	poss	18	SENT_223	[p18l234t3499r438b3577],
17	high	JJ	O	high	amod	18	SENT_223	[p18l468t3499r663b3600],
18	cost	NN	O	cost	prep_with	14	SENT_223	[p18l695t3515r890b3594],
19	,	,	O	,	_	0	SENT_223	[p18l695t3515r890b3594],
20	highlights	VBZ	O	highlight	rcmod	10	SENT_223	[p18l928t3499r1370b3600],
21	the	DT	O	the	det	22	SENT_223	[p18l1406t3499r1538b3577],
22	need	NN	O	need	dobj	20	SENT_223	[p18l1571t3499r1771b3577],
23	to	TO	O	to	aux	24	SENT_223	[p18l1804t3515r1886b3577],
24	identify	VB	O	identify	infmod	22	SENT_223	[p18l1919t3499r2133b3577, p18l11t3626r158b3727],
25	a	DT	O	a	det	26	SENT_223	[p18l184t3653r228b3705],
26	priori	FW	O	priori	nsubj	28	SENT_223	[p18l257t3628r498b3727],
27	a	DT	O	a	det	28	SENT_223	[p18l528t3653r573b3705],
28	subgroup	NN	O	subgroup	xcomp	24	SENT_223	[p18l603t3627r1007b3728],
29	of	IN	O	of	_	0	SENT_223	[p18l1041t3626r1140b3705],
30	patients	NNS	O	patient	prep_of	28	SENT_223	[p18l1152t3628r1493b3727],
31	who	WP	O	who	nsubj	33	SENT_223	[p18l1522t3627r1705b3706],
32	may	MD	O	may	aux	33	SENT_223	[p18l1738t3653r1917b3727],
33	have	VB	O	have	rcmod	30	SENT_223	[p18l1944t3627r2134b3706],
34	a	DT	O	a	det	36	SENT_223	[p19l10t47r55b99],
35	clinical	JJ	O	clinical	amod	36	SENT_223	[p19l92t21r406b99],
36	benefit	NN	O	benefit	dobj	33	SENT_223	[p19l444t20r749b99],
37	from	IN	O	from	_	0	SENT_223	[p19l783t20r993b99],
38	these	DT	O	these	det	39	SENT_223	[p19l1033t21r1255b99],
39	agents	NNS	O	agent	prep_from	36	SENT_223	[p19l1294t38r1595b122],
40	.	.	O	.	_	0	SENT_223	[p19l1294t38r1595b122],

1	The	DT	O	the	det	2	SENT_224	[p19l1635t21r1796b99],
2	assessment	NN	O	assessment	nsubj	12	SENT_224	[p19l1834t47r2133b99, p19l11t166r232b227],
3	of	IN	O	of	_	0	SENT_224	[p19l272t148r371b227],
4	EGFR	NN	ORGANIZATION	egfr	nn	6	SENT_224	[p19l395t156r607b229],
5	mutational	JJ	O	mutational	amod	6	SENT_224	[p19l644t149r1117b228],
6	status	NN	O	status	prep_of	2	SENT_224	[p19l1162t166r1414b228],
7	is	VBZ	O	be	cop	12	SENT_224	[p19l1460t150r1525b227],
8	currently	RB	DATE	currently	advmod	12	SENT_224	[p19l1572t149r1961b249],
9	the	DT	O	the	det	12	SENT_224	[p19l2002t149r2134b227],
10	most	RBS	O	most	advmod	11	SENT_224	[p19l11t294r227b355],
11	reliable	JJ	O	reliable	amod	12	SENT_224	[p19l263t277r577b355],
12	predictor	NN	O	predictor	_	0	SENT_224	[p19l616t277r1011b377],
13	of	IN	O	of	_	0	SENT_224	[p19l1050t276r1149b355],
14	response	NN	O	response	prep_of	12	SENT_224	[p19l1171t303r1552b377],
15	and	CC	O	and	_	0	SENT_224	[p19l1592t277r1749b355],
16	of	IN	O	of	_	0	SENT_224	[p19l1790t276r1890b355],
17	clinical	JJ	O	clinical	amod	18	SENT_224	[p19l1913t277r2133b355, p19l12t405r131b483],
18	benefit	NN	O	benefit	prep_of	12	SENT_224	[p19l171t404r496b483],
19	.	.	O	.	_	0	SENT_224	[p19l171t404r496b483],

1	It	PRP	O	it	nsubj	2	SENT_225	[p19l540t412r604b483],
2	remains	VBZ	O	remain	_	0	SENT_225	[p19l638t406r986b483],
3	to	TO	O	to	aux	5	SENT_225	[p19l1027t422r1108b483],
4	be	VB	O	be	auxpass	5	SENT_225	[p19l1149t405r1246b483],
5	shown	VBN	O	show	xcomp	2	SENT_225	[p19l1286t405r1568b484],
6	whether	IN	O	whether	complm	36	SENT_225	[p19l1602t405r1957b484],
7	upfront	JJ	O	upfront	amod	8	SENT_225	[p19l1993t431r2133b505, p19l11t532r227b611],
8	assessment	NN	O	assessment	nsubj	36	SENT_225	[p19l268t550r758b611],
9	of	IN	O	of	_	0	SENT_225	[p19l801t532r900b611],
10	the	DT	O	the	det	13	SENT_225	[p19l930t533r1062b611],
11	EGFR	NN	ORGANIZATION	egfr	nn	13	SENT_225	[p19l1108t540r1320b612],
12	mutational	JJ	O	mutational	amod	13	SENT_225	[p19l1360t533r1833b612],
13	status	NN	O	status	prep_of	8	SENT_225	[p19l1881t549r2131b612],
14	for	IN	O	for	_	0	SENT_225	[p19l11t660r134b739],
15	all	DT	O	all	det	16	SENT_225	[p19l165t661r269b739],
16	patients	NNS	O	patient	prep_for	13	SENT_225	[p19l301t662r642b761],
17	with	IN	O	with	_	0	SENT_225	[p19l674t661r869b740],
18	advanced	JJ	O	advanced	amod	20	SENT_225	[p19l903t661r1299b740],
19	N	NN	O	n	nn	20	SENT_225	[p19l1331t668r1406b740],
20	SCLC	NN	ORGANIZATION	sclc	prep_with	16	SENT_225	[p19l1409t666r1633b739],
21	and	CC	O	and	_	0	SENT_225	[p19l1669t661r1827b739],
22	subsequent	JJ	O	subsequent	amod	23	SENT_225	[p19l1862t661r2133b740, p19l12t805r254b888],
23	treatment	NN	O	treatment	conj_and	13	SENT_225	[p19l300t805r724b866],
24	with	IN	O	with	_	0	SENT_225	[p19l765t789r960b868],
25	an	DT	O	a	det	29	SENT_225	[p19l1010t814r1113b866],
26	EGFR	NN	ORGANIZATION	egfr	nn	29	SENT_225	[p19l1162t794r1418b871],
27	tyrosine	NN	O	tyrosine	nn	29	SENT_225	[p19l1459t790r1805b888],
28	kinase	NN	O	kinase	nn	29	SENT_225	[p19l1855t789r2134b868],
29	inhibitor	NN	O	inhibitor	prep_with	23	SENT_225	[p19l11t917r392b995],
30	for	IN	O	for	_	0	SENT_225	[p19l446t916r569b995],
31	patients	NNS	O	patient	prep_for	29	SENT_225	[p19l620t918r962b1017],
32	carrying	VBG	O	carry	partmod	31	SENT_225	[p19l1021t918r1384b1018],
33	EGFR	NN	ORGANIZATION	egfr	nn	34	SENT_225	[p19l1435t924r1647b996],
34	mutations	NNS	O	mutation	dobj	32	SENT_225	[p19l1697t918r2132b996],
35	will	MD	O	will	aux	36	SENT_225	[p19l7t1045r174b1124],
36	result	VB	O	result	ccomp	5	SENT_225	[p19l220t1045r468b1124],
37	in	IN	O	in	_	0	SENT_225	[p19l509t1046r593b1122],
38	an	DT	O	a	det	41	SENT_225	[p19l638t1071r742b1123],
39	overall	JJ	O	overall	amod	41	SENT_225	[p19l789t1045r1080b1124],
40	survival	NN	O	survival	nn	41	SENT_225	[p19l1127t1045r1467b1124],
41	advantage	NN	O	advantage	prep_in	36	SENT_225	[p19l1511t1045r1975b1146],
42	,	,	O	,	_	0	SENT_225	[p19l1511t1045r1975b1146],
43	although	IN	O	although	mark	49	SENT_225	[p19l2025t1045r2133b1123, p19l12t1173r320b1274],
44	this	DT	O	this	det	45	SENT_225	[p19l364t1173r524b1251],
45	approach	NN	O	approach	nsubjpass	49	SENT_225	[p19l568t1173r964b1273],
46	has	VBZ	O	have	aux	49	SENT_225	[p19l1007t1173r1151b1251],
47	already	RB	O	already	advmod	49	SENT_225	[p19l1197t1173r1508b1273],
48	been	VBN	O	be	auxpass	49	SENT_225	[p19l1548t1173r1749b1251],
49	adopted	VBN	O	adopt	advcl	2	SENT_225	[p19l1792t1173r2134b1273],
50	by	IN	O	by	_	0	SENT_225	[p19l12t1301r109b1400],
51	some	DT	O	some	det	52	SENT_225	[p19l140t1326r364b1378],
52	clinicians	NNS	O	clinician	agent	49	SENT_225	[p19l400t1301r836b1378],
53	.	.	O	.	_	0	SENT_225	[p19l400t1301r836b1378],

1	The	DT	O	the	det	3	SENT_226	[p19l136t1429r297b1507],
2	skin	NN	O	skin	nn	3	SENT_226	[p19l333t1429r513b1508],
3	toxicity	NN	O	toxicity	nsubjpass	9	SENT_226	[p19l548t1430r865b1529],
4	of	IN	O	of	_	0	SENT_226	[p19l896t1428r996b1507],
5	EGFR	NN	ORGANIZATION	egfr	nn	6	SENT_226	[p19l1010t1434r1266b1512],
6	inhibition	NN	O	inhibition	prep_of	3	SENT_226	[p19l1289t1429r1718b1507],
7	has	VBZ	O	have	aux	9	SENT_226	[p19l1752t1429r1896b1507],
8	been	VBN	O	be	auxpass	9	SENT_226	[p19l1933t1429r2134b1507],
9	associated	VBN	O	associate	dep	28	SENT_226	[p19l11t1557r442b1635],
10	with	IN	O	with	_	0	SENT_226	[p19l468t1557r659b1636],
11	improved	VBN	O	improve	amod	27	SENT_226	[p19l690t1557r1083b1657],
12	overall	JJ	O	overall	amod	27	SENT_226	[p19l1115t1557r1392b1636],
13	and	CC	O	and	_	0	SENT_226	[p19l1421t1557r1576b1635],
14	progressionfree	JJ	O	progressionfree	amod	15	SENT_226	[p19l1606t1558r2132b1658, p19l11t1684r173b1763],
15	survival	NN	O	survival	conj_and	12	SENT_226	[p19l220t1685r552b1764],
16	in	IN	O	in	_	0	SENT_226	[p19l595t1686r680b1762],
17	unselected	JJ	O	unselected	amod	18	SENT_226	[p19l724t1685r1180b1764],
18	patients	NNS	O	patient	prep_in	15	SENT_226	[p19l1224t1686r1565b1785],
19	(	CD	NUMBER	(	npadvmod	20	SENT_226	[p19l1617t1685r1951b1786],
20	though	IN	O	though	advmod	18	SENT_226	[p19l1617t1685r1951b1786],
21	not	RB	O	not	neg	18	SENT_226	[p19l1996t1702r2139b1763],
22	specifically	RB	O	specifically	advmod	18	SENT_226	[p19l12t1812r500b1913],
23	in	IN	O	in	_	0	SENT_226	[p19l527t1814r610b1890],
24	patients	NNS	O	patient	prep_in	18	SENT_226	[p19l641t1814r982b1913],
25	with	IN	O	with	_	0	SENT_226	[p19l1011t1813r1206b1892],
26	EGFR	NN	ORGANIZATION	egfr	prep_with	24	SENT_226	[p19l1237t1820r1449b1893],
27	mutations	NNS	O	mutation	prep_with	9	SENT_226	[p19l1475t1814r2134b1904],
28	)	VBP	O	)	_	0	SENT_226	[p19l1475t1814r2134b1904],
29	.41	CD	NUMBER	.41	dobj	28	SENT_226	[p19l1475t1814r2134b1904],
30	»	CD	NUMBER	»	number	31	SENT_226	[p19l1475t1814r2134b1904],
31	42	CD	NUMBER	42	nsubj	28	SENT_226	[p19l1475t1814r2134b1904],
32	Although	IN	O	although	mark	39	SENT_226	[p19l7t1941r422b2042],
33	the	DT	O	the	det	34	SENT_226	[p19l479t1941r614b2019],
34	reasons	NNS	O	reason	nsubj	39	SENT_226	[p19l672t1967r1005b2019],
35	for	IN	O	for	_	0	SENT_226	[p19l1064t1940r1189b2019],
36	this	DT	O	this	det	37	SENT_226	[p19l1245t1941r1407b2019],
37	association	NN	O	association	prep_for	34	SENT_226	[p19l1466t1942r1961b2019],
38	remain	VBP	O	remain	cop	39	SENT_226	[p19l2018t1967r2133b2019, p19l11t2070r232b2147],
39	unclear	JJ	O	unclear	advcl	42	SENT_226	[p19l279t2069r618b2164],
40	,	,	O	,	_	0	SENT_226	[p19l279t2069r618b2164],
41	commonly	RB	O	commonly	advmod	42	SENT_226	[p19l670t2069r1130b2169],
42	cited	VBD	O	cite	rcmod	31	SENT_226	[p19l1174t2069r1376b2147],
43	hypotheses	NNS	O	hypothesis	nsubj	44	SENT_226	[p19l1423t2069r1904b2169],
44	suggest	VBP	O	suggest	ccomp	42	SENT_226	[p19l1955t2095r2133b2170, p19l11t2213r187b2298],
45	that	IN	O	that	complm	53	SENT_226	[p19l216t2197r388b2275],
46	the	DT	O	the	det	48	SENT_226	[p19l418t2197r550b2275],
47	skin	NN	O	skin	nn	48	SENT_226	[p19l586t2197r766b2276],
48	toxicity	NN	O	toxicity	nsubj	53	SENT_226	[p19l801t2198r1117b2297],
49	is	VBZ	O	be	cop	53	SENT_226	[p19l1146t2198r1212b2275],
50	a	DT	O	a	det	53	SENT_226	[p19l1247t2223r1291b2275],
51	surrogate	JJ	O	surrogate	amod	53	SENT_226	[p19l1326t2214r1732b2298],
52	pharmacodynamic	JJ	O	pharmacodynamic	amod	53	SENT_226	[p19l1765t2197r2133b2297, p19l12t2325r481b2425],
53	indicator	NN	O	indicator	ccomp	44	SENT_226	[p19l510t2325r900b2403],
54	of	IN	O	of	_	0	SENT_226	[p19l929t2324r1029b2403],
55	effective	JJ	O	effective	amod	57	SENT_226	[p19l1042t2324r1400b2404],
56	EGFR	NN	ORGANIZATION	egfr	nn	57	SENT_226	[p19l1430t2330r1686b2408],
57	inhibition	NN	O	inhibition	prep_of	53	SENT_226	[p19l1705t2325r2134b2403],
58	at	IN	O	at	_	0	SENT_226	[p19l10t2469r89b2530],
59	the	DT	O	the	det	61	SENT_226	[p19l132t2453r264b2530],
60	tumor	NN	O	tumor	nn	61	SENT_226	[p19l313t2469r580b2532],
61	level	NN	O	level	prep_at	57	SENT_226	[p19l624t2453r813b2532],
62	or	CC	O	or	_	0	SENT_226	[p19l860t2478r948b2530],
63	that	IN	O	that	complm	70	SENT_226	[p19l994t2453r1166b2530],
64	the	DT	O	the	det	66	SENT_226	[p19l1208t2453r1341b2530],
65	skin	NN	O	skin	nn	66	SENT_226	[p19l1390t2453r1570b2532],
66	toxicity	NN	O	toxicity	nsubj	70	SENT_226	[p19l1618t2454r1935b2552],
67	is	VBZ	O	be	cop	70	SENT_226	[p19l1977t2454r2043b2530],
68	a	DT	O	a	det	70	SENT_226	[p19l2092t2479r2136b2530],
69	surrogate	JJ	O	surrogate	amod	70	SENT_226	[p19l12t2598r419b2682],
70	indicator	NN	O	indicator	conj_or	53	SENT_226	[p19l478t2581r868b2659],
71	of	IN	O	of	_	0	SENT_226	[p19l925t2580r1025b2659],
72	an	DT	O	a	det	74	SENT_226	[p19l1065t2607r1169b2659],
73	immune	JJ	O	immune	amod	74	SENT_226	[p19l1226t2581r1871b2660],
74	—	NN	O	—	prep_of	70	SENT_226	[p19l1226t2581r1871b2660],
75	based	VBN	O	base	partmod	74	SENT_226	[p19l1226t2581r1871b2660],
76	local	JJ	O	local	amod	78	SENT_226	[p19l1929t2581r2134b2659],
77	inflammatory	JJ	O	inflammatory	amod	78	SENT_226	[p19l10t2708r632b2809],
78	reaction	NN	O	reaction	dobj	75	SENT_226	[p19l679t2710r1035b2787],
79	at	IN	O	at	_	0	SENT_226	[p19l1086t2726r1166b2787],
80	the	DT	O	the	det	82	SENT_226	[p19l1212t2709r1347b2787],
81	tumor	NN	O	tumor	nn	82	SENT_226	[p19l1399t2726r1672b2788],
82	level	NN	O	level	prep_at	75	SENT_226	[p19l1719t2709r1912b2788],
83	that	WDT	O	that	nsubj	84	SENT_226	[p19l1964t2709r2139b2787],
84	provides	VBZ	O	provide	rcmod	82	SENT_226	[p19l10t2837r370b2936],
85	antitumor	NN	O	antitumor	nn	86	SENT_226	[p19l422t2838r859b2916],
86	activity	NN	O	activity	dobj	84	SENT_226	[p19l906t2838r1229b2936],
87	.	.	O	.	_	0	SENT_226	[p19l906t2838r1229b2936],

1	Prospective	JJ	O	prospective	amod	2	SENT_227	[p19l1283t2838r1773b2936],
2	investigation	NN	O	investigation	nsubjpass	19	SENT_227	[p19l1822t2838r2133b2916, p19l11t2966r283b3066],
3	of	IN	O	of	_	0	SENT_227	[p19l341t2964r441b3043],
4	a	DT	O	a	det	5	SENT_227	[p19l478t2991r522b3043],
5	correlation	NN	O	correlation	prep_of	2	SENT_227	[p19l579t2965r1049b3043],
6	between	IN	O	between	_	0	SENT_227	[p19l1106t2965r1464b3044],
7	the	DT	O	the	det	8	SENT_227	[p19l1521t2965r1654b3043],
8	effects	NNS	O	effect	prep_between	5	SENT_227	[p19l1712t2964r1993b3043],
9	of	IN	O	of	_	0	SENT_227	[p19l2053t2964r2153b3043],
10	EGFR	NN	ORGANIZATION	egfr	nn	11	SENT_227	[p19l10t3099r266b3177],
11	inhibition	NN	O	inhibition	prep_of	8	SENT_227	[p19l294t3094r722b3172],
12	in	IN	O	in	_	0	SENT_227	[p19l762t3095r845b3171],
13	the	DT	O	the	det	17	SENT_227	[p19l885t3094r1018b3172],
14	skin	NN	O	skin	nn	17	SENT_227	[p19l1059t3094r1240b3173],
15	and	CC	O	and	_	0	SENT_227	[p19l1278t3094r1436b3172],
16	tumor	NN	O	tumor	nn	17	SENT_227	[p19l1476t3110r1744b3173],
17	tissue	NN	O	tissue	prep_in	11	SENT_227	[p19l1781t3095r2027b3173],
18	is	VBZ	O	be	auxpass	19	SENT_227	[p19l2066t3095r2131b3172],
19	warranted	VBN	O	warrant	_	0	SENT_227	[p19l6t3223r473b3302],
20	.	.	O	.	_	0	SENT_227	[p19l6t3223r473b3302],

1	Deletions	NNS	O	deletion	nsubjpass	27	SENT_228	[p19l139t3351r537b3428],
2	in	IN	O	in	_	0	SENT_228	[p19l573t3352r655b3427],
3	exon	NN	O	exon	prep_in	1	SENT_228	[p19l691t3376r888b3428],
4	19	CD	NUMBER	19	num	3	SENT_228	[p19l927t3356r1021b3428],
5	and	CC	O	and	_	0	SENT_228	[p19l1056t3351r1213b3428],
6	the	DT	O	the	det	9	SENT_228	[p19l1248t3351r1378b3428],
7	L858R	NN	O	l858r	nn	9	SENT_228	[p19l1412t3356r1689b3433],
8	point	NN	O	point	nn	9	SENT_228	[p19l1711t3352r1937b3450],
9	mutation	NN	O	mutation	nsubjpass	27	SENT_228	[p19l1967t3376r2133b3429, p19l11t3480r263b3557],
10	in	IN	O	in	_	0	SENT_228	[p19l308t3480r391b3556],
11	exon	NN	O	exon	prep_in	9	SENT_228	[p19l437t3504r637b3557],
12	21	CD	NUMBER	21	num	11	SENT_228	[p19l682t3484r804b3575],
13	,	,	O	,	_	0	SENT_228	[p19l682t3484r804b3575],
14	the	DT	O	the	det	16	SENT_228	[p19l855t3479r987b3557],
15	most	RBS	O	most	advmod	16	SENT_228	[p19l1033t3495r1249b3557],
16	common	JJ	O	common	appos	1	SENT_228	[p19l1290t3504r1671b3557],
17	activating	VBG	O	activate	partmod	16	SENT_228	[p19l1715t3480r2138b3580],
18	EGFR	NN	ORGANIZATION	egfr	nn	19	SENT_228	[p19l9t3613r218b3686],
19	mutations	NNS	O	mutation	dobj	17	SENT_228	[p19l243t3608r669b3685],
20	in	IN	O	in	_	0	SENT_228	[p19l701t3608r784b3683],
21	N	NN	O	n	nn	22	SENT_228	[p19l813t3614r887b3685],
22	SCLC	NN	ORGANIZATION	sclc	prep_in	17	SENT_228	[p19l890t3612r1135b3701],
23	,	,	O	,	_	0	SENT_228	[p19l890t3612r1135b3701],
24	have	VBP	O	have	aux	27	SENT_228	[p19l1172t3607r1358b3685],
25	both	DT	O	both	advmod	27	SENT_228	[p19l1390t3607r1585b3684],
26	been	VBN	O	be	auxpass	27	SENT_228	[p19l1616t3607r1815b3684],
27	associated	VBN	O	associate	_	0	SENT_228	[p19l1846t3608r2133b3684, p20l11t23r188b100],

1	with	IN	O	with	_	0	SENT_229	[p20l233t23r428b102],
2	improved	VBN	O	improve	amod	3	SENT_229	[p20l476t23r880b122],
3	outcomes	NNS	O	outcome	prep_with	17	SENT_229	[p20l929t39r1340b102],
4	with	IN	O	with	_	0	SENT_229	[p20l1386t23r1582b102],
5	erlotinib	NN	O	erlotinib	nn	8	SENT_229	[p20l1631t23r1998b100],
6	or	CC	O	or	_	0	SENT_229	[p20l2048t48r2137b100],
7	gefitinib	NN	O	gefitinib	conj_or	5	SENT_229	[p20l11t150r383b252],
8	therapy	NN	O	therapy	prep_with	3	SENT_229	[p20l428t151r1040b251],
9	.22	CD	NUMBER	.22	npadvmod	10	SENT_229	[p20l428t151r1040b251],
10	>	JJR	O	>	amod	8	SENT_229	[p20l428t151r1040b251],
11	43	CD	NUMBER	43	num	12	SENT_229	[p20l428t151r1040b251],
12	’44	CD	NUMBER	’44	tmod	3	SENT_229	[p20l428t151r1040b251],
13	However	RB	O	however	advmod	12	SENT_229	[p20l1082t158r1477b246],
14	,	,	O	,	_	0	SENT_229	[p20l1082t158r1477b246],
15	patients	NNS	O	patient	nsubj	17	SENT_229	[p20l1525t152r1866b251],
16	eventually	RB	O	eventually	advmod	17	SENT_229	[p20l1913t177r2133b230, p20l11t279r254b378],
17	acquire	VB	O	acquire	_	0	SENT_229	[p20l290t280r604b378],
18	resistance	NN	O	resistance	dobj	17	SENT_229	[p20l644t280r1073b356],
19	to	TO	O	to	_	0	SENT_229	[p20l1114t295r1196b356],
20	these	DT	O	these	det	24	SENT_229	[p20l1238t279r1462b356],
21	EGFR	NN	ORGANIZATION	egfr	nn	24	SENT_229	[p20l1501t284r1757b361],
22	tyrosine	NN	O	tyrosine	nn	24	SENT_229	[p20l1788t280r2134b378],
23	kinase	NN	O	kinase	nn	24	SENT_229	[p20l11t407r284b486],
24	inhibitors	NNS	O	inhibitor	prep_to	17	SENT_229	[p20l317t407r753b502],
25	,	,	O	,	_	0	SENT_229	[p20l317t407r753b502],
26	with	IN	O	with	_	0	SENT_229	[p20l788t407r980b486],
27	a	DT	O	a	det	29	SENT_229	[p20l1013t433r1057b485],
28	median	JJ	O	median	amod	29	SENT_229	[p20l1090t407r1407b485],
29	time	NN	O	time	prep_with	24	SENT_229	[p20l1442t408r1631b485],
30	to	TO	O	to	_	0	SENT_229	[p20l1665t424r1745b485],
31	progression	NN	O	progression	prep_to	29	SENT_229	[p20l1779t433r2133b508, p20l12t536r182b613],
32	of	IN	O	of	_	0	SENT_229	[p20l211t534r309b613],
33	approximately	RB	O	approximately	quantmod	34	SENT_229	[p20l320t535r911b635],
34	12	CD	DURATION	12	num	35	SENT_229	[p20l939t540r1035b612],
35	months	NNS	NUMBER	month	prep_of	31	SENT_229	[p20l1065t535r1567b613],
36	.44	CD	NUMBER	.44	number	37	SENT_229	[p20l1065t535r1567b613],
37	»	CD	NUMBER	»	num	35	SENT_229	[p20l1065t535r1567b613],
38	45	CD	NUMBER	45	nsubjpass	51	SENT_229	[p20l1065t535r1567b613],
39	In	IN	O	in	_	0	SENT_229	[p20l1599t542r1686b612],
40	50	CD	NUMBER	50	number	42	SENT_229	[p20l1718t540r1813b613],
41	to	TO	O	to	dep	42	SENT_229	[p20l1843t551r1922b613],
42	70	CD	PERCENT	70	num	43	SENT_229	[p20l1954t540r2134b614],
43	%	NN	PERCENT	%	prep_in	38	SENT_229	[p20l1954t540r2134b614],
44	of	IN	O	of	_	0	SENT_229	[p20l11t662r112b741],
45	cases	NNS	O	case	prep_of	43	SENT_229	[p20l137t689r384b758],
46	,	,	O	,	_	0	SENT_229	[p20l137t689r384b758],
47	this	DT	O	this	det	48	SENT_229	[p20l433t663r593b741],
48	phenomenon	NN	O	phenomenon	appos	45	SENT_229	[p20l637t663r1205b763],
49	can	MD	O	can	aux	51	SENT_229	[p20l1249t689r1397b741],
50	be	VB	O	be	auxpass	51	SENT_229	[p20l1442t663r1538b741],
51	explained	VBN	O	explain	rcmod	31	SENT_229	[p20l1582t663r1997b763],
52	by	IN	O	by	_	0	SENT_229	[p20l2041t663r2138b763],
53	the	DT	O	the	det	54	SENT_229	[p20l11t791r146b869],
54	acquisition	NN	O	acquisition	dep	63	SENT_229	[p20l201t792r685b891],
55	of	IN	O	of	_	0	SENT_229	[p20l740t790r841b869],
56	a	DT	O	a	det	58	SENT_229	[p20l877t817r921b869],
57	secondary	JJ	O	secondary	amod	58	SENT_229	[p20l975t791r1422b891],
58	EGFR	NN	ORGANIZATION	egfr	prep_of	54	SENT_229	[p20l1470t798r1686b871],
59	mutation	NN	O	mutation	dep	63	SENT_229	[p20l1734t792r2134b870],
60	(	CD	NUMBER	(	num	59	SENT_229	[p20l16t925r262b1009],
61	most	RBS	O	most	advmod	62	SENT_229	[p20l16t925r262b1009],
62	commonly	RB	O	commonly	advmod	63	SENT_229	[p20l308t919r768b1018],
63	T79OM	NN	O	t79om	dep	67	SENT_229	[p20l808t924r1111b996],
64	in	IN	O	in	_	0	SENT_229	[p20l1161t920r1244b995],
65	exon	NN	O	exon	prep_in	63	SENT_229	[p20l1294t944r1494b996],
66	20	CD	NUMBER	20	num	67	SENT_229	[p20l1542t924r1669b1009],
67	)	CD	NUMBER	)	agent	51	SENT_229	[p20l1542t924r1669b1009],
68	or	CC	O	or	_	0	SENT_229	[p20l1724t944r1813b996],
69	by	IN	O	by	_	0	SENT_229	[p20l1860t919r1957b1018],
70	the	DT	O	the	det	71	SENT_229	[p20l2002t919r2134b996],
71	amplification	NN	O	amplification	agent	51	SENT_229	[p20l10t1046r608b1147],
72	of	IN	O	of	_	0	SENT_229	[p20l655t1046r756b1125],
73	the	DT	O	the	det	75	SENT_229	[p20l785t1047r920b1125],
74	MET	NN	O	met	nn	75	SENT_229	[p20l966t1053r1164b1126],
75	oncogene	NN	O	oncogene	prep_of	71	SENT_229	[p20l1202t1052r1824b1148],
76	,45	CD	NUMBER	,45	num	77	SENT_229	[p20l1202t1052r1824b1148],
77	’49	CD	NUMBER	’49	dep	51	SENT_229	[p20l1202t1052r1824b1148],
78	which	WDT	O	which	nsubj	79	SENT_229	[p20l1866t1047r2134b1126],
79	implies	VBZ	O	imply	dep	17	SENT_229	[p20l10t1175r325b1275],
80	that	IN	O	that	complm	98	SENT_229	[p20l366t1175r538b1253],
81	in	IN	O	in	_	0	SENT_229	[p20l569t1176r653b1252],
82	30	CD	NUMBER	30	number	85	SENT_229	[p20l691t1180r789b1254],
83	to	TO	O	to	dep	85	SENT_229	[p20l828t1192r909b1253],
84	50	CD	NUMBER	50	number	85	SENT_229	[p20l950t1180r1135b1254],
85	°	CD	NUMBER	°	prep_in	98	SENT_229	[p20l950t1180r1135b1254],
86	/	:	O	/	punct	87	SENT_229	[p20l950t1180r1135b1254],
87	o	NN	O	o	dep	85	SENT_229	[p20l950t1180r1135b1254],
88	of	IN	O	of	_	0	SENT_229	[p20l1172t1174r1272b1253],
89	patients	NNS	O	patient	prep_of	87	SENT_229	[p20l1290t1176r1656b1275],
90	,	,	O	,	_	0	SENT_229	[p20l1290t1176r1656b1275],
91	the	DT	O	the	det	92	SENT_229	[p20l1699t1175r1832b1253],
92	mechanisms	NNS	O	mechanism	nsubj	98	SENT_229	[p20l1869t1175r2133b1253, p20l10t1304r305b1381],
93	of	IN	O	of	_	0	SENT_229	[p20l343t1302r440b1381],
94	resistance	NN	O	resistance	prep_of	92	SENT_229	[p20l455t1304r864b1381],
95	are	VBP	O	be	cop	98	SENT_229	[p20l899t1329r1023b1381],
96	unknown	JJ	O	unknown	amod	98	SENT_229	[p20l1057t1303r1459b1382],
97	(	NN	O	(	nn	98	SENT_229	[p20l1497t1304r1668b1404],
98	Fig	NN	O	fig	ccomp	79	SENT_229	[p20l1497t1304r1668b1404],
99	.	.	O	.	_	0	SENT_229	[p20l1497t1304r1668b1404],

1	2	CD	NUMBER	2	num	2	SENT_230	[p20l1708t1308r1804b1394],
2	)	CD	NUMBER	)	_	0	SENT_230	[p20l1708t1308r1804b1394],
3	.	.	O	.	_	0	SENT_230	[p20l1708t1308r1804b1394],

1	Several	JJ	O	several	amod	2	SENT_231	[p20l1846t1303r2134b1382],
2	agents	NNS	O	agent	nsubjpass	15	SENT_231	[p20l10t1448r286b1532],
3	with	IN	O	with	prep	2	SENT_231	[p20l321t1431r516b1510],
4	in	FW	O	in	nn	5	SENT_231	[p20l552t1432r636b1508],
5	vitro	FW	O	vitro	dep	6	SENT_231	[p20l668t1432r866b1510],
6	activity	NN	O	activity	dep	3	SENT_231	[p20l904t1432r1213b1531],
7	against	IN	O	against	_	0	SENT_231	[p20l1245t1432r1561b1532],
8	EGFR	NN	ORGANIZATION	egfr	nn	9	SENT_231	[p20l1590t1437r1803b1510],
9	T79OM	NN	O	t79om	prep_against	3	SENT_231	[p20l1830t1436r2133b1509],
10	or	CC	O	or	_	0	SENT_231	[p20l12t1584r100b1637],
11	MET	NN	O	met	nn	12	SENT_231	[p20l144t1564r351b1637],
12	kinases	NNS	O	kinase	prep_against	3	SENT_231	[p20l397t1559r718b1638],
13	are	VBP	O	be	aux	15	SENT_231	[p20l769t1585r898b1637],
14	being	VBG	O	be	auxpass	15	SENT_231	[p20l949t1559r1189b1660],
15	evaluated	VBN	O	evaluate	_	0	SENT_231	[p20l1237t1559r1638b1638],
16	in	IN	O	in	_	0	SENT_231	[p20l1687t1560r1770b1636],
17	clinical	JJ	O	clinical	amod	18	SENT_231	[p20l1821t1559r2134b1637],
18	trials	NNS	O	trial	prep_in	15	SENT_231	[p20l11t1687r231b1765],
19	for	IN	O	for	_	0	SENT_231	[p20l272t1686r395b1765],
20	patients	NNS	O	patient	prep_for	18	SENT_231	[p20l429t1688r771b1787],
21	with	IN	O	with	_	0	SENT_231	[p20l807t1687r1002b1766],
22	N	NN	O	n	nn	23	SENT_231	[p20l1039t1694r1115b1766],
23	SCLC	NN	ORGANIZATION	sclc	prep_with	15	SENT_231	[p20l1118t1692r1342b1765],
24	in	IN	O	in	_	0	SENT_231	[p20l1382t1688r1466b1764],
25	Whom	WP	O	whom	det	26	SENT_231	[p20l1500t1687r1771b1766],
26	therapy	NN	O	therapy	rel	33	SENT_231	[p20l1811t1687r2138b1787],
27	With	IN	O	with	_	0	SENT_231	[p20l6t1815r198b1894],
28	EGFR	NN	ORGANIZATION	egfr	nn	29	SENT_231	[p20l230t1820r482b1898],
29	tyrosine	NN	O	tyrosine	prep_with	26	SENT_231	[p20l505t1816r842b1915],
30	kinase	NN	O	kinase	nn	31	SENT_231	[p20l876t1815r1148b1894],
31	inhibitors	NNS	O	inhibitor	nsubj	33	SENT_231	[p20l1181t1815r1591b1893],
32	has	VBZ	O	have	aux	33	SENT_231	[p20l1626t1815r1768b1893],
33	failed	VBN	O	fail	rcmod	23	SENT_231	[p20l1804t1814r2134b1893],
34	.5	CD	NUMBER	.5	number	35	SENT_231	[p20l1804t1814r2134b1893],
35	°	CD	NUMBER	°	num	37	SENT_231	[p20l1804t1814r2134b1893],
36	Recent	JJ	O	recent	amod	37	SENT_231	[p20l139t1949r438b2026],
37	data	NNS	O	datum	nsubj	38	SENT_231	[p20l488t1943r675b2021],
38	suggest	VBP	O	suggest	ccomp	33	SENT_231	[p20l730t1960r1063b2044],
39	improved	VBN	O	improve	amod	40	SENT_231	[p20l1113t1943r1524b2043],
40	progression952	NN	O	progression952	dobj	38	SENT_231	[p20l1577t1944r2132b2044, p20l149t2119r206b2142],

1	N	NN	O	n	nn	3	SENT_232	[p20l951t2129r964b2144],
2	ENGLJ	NN	O	englj	nn	3	SENT_232	[p20l979t2129r1057b2151],
3	MED	NN	O	med	_	0	SENT_232	[p20l1072t2129r1124b2144],
4	364	CD	NUMBER	364	num	6	SENT_232	[p20l1134t2123r1216b2151],
5	;	:	O	;	_	0	SENT_232	[p20l1134t2123r1216b2151],
6	1o	CD	NUMBER	1o	dep	3	SENT_232	[p20l1134t2123r1216b2151],
7	NEjM	NNP	O	NEjM	dep	6	SENT_232	[p20l1251t2129r1375b2151],
8	,	,	O	,	_	0	SENT_232	[p20l1251t2129r1375b2151],
9	ORG	NNP	O	ORG	nn	10	SENT_232	[p20l1251t2129r1375b2151],
10	MARCH	NNP	DATE	MARCH	appos	7	SENT_232	[p20l1412t2129r1497b2145],
11	1	CD	DATE	1	dep	10	SENT_232	[p20l1510t2129r1516b2144],
12	,	,	O	,	_	0	SENT_232	[p20l1540t2141r1543b2149],

1	The	DT	O	the	det	4	SENT_233	[p20l936t2162r987b2186],
2	New	NNP	O	New	nn	4	SENT_233	[p20l996t2163r1058b2186],
3	England	NNP	O	England	nn	4	SENT_233	[p20l1067t2162r1178b2193],
4	Journal	NNP	O	Journal	_	0	SENT_233	[p20l1187t2162r1284b2186],
5	of	IN	O	of	_	0	SENT_233	[p20l1294t2162r1323b2186],
6	Medicine	NNP	O	Medicine	prep_of	4	SENT_233	[p20l1330t2162r1455b2186],

1	Downloaded	VBN	O	download	_	0	SENT_234	[p20l378t2203r548b2226],
2	from	IN	O	from	_	0	SENT_234	[p20l557t2203r622b2226],
3	nejm.org	NN	O	nejm.org	prep_from	1	SENT_234	[p20l630t2203r748b2233],
4	at	IN	O	at	_	0	SENT_234	[p20l759t2206r782b2226],
5	UW-Madison	NN	O	uw-madison	prep_at	1	SENT_234	[p20l790t2203r973b2226],
6	on	IN	O	on	_	0	SENT_234	[p20l982t2210r1015b2226],
7	January	NNP	DATE	January	prep_on	1	SENT_234	[p20l1023t2203r1126b2233],
8	5	CD	DATE	5	num	7	SENT_234	[p20l1136t2203r1159b2230],
9	,	,	DATE	,	_	0	SENT_234	[p20l1136t2203r1159b2230],
10	2014	CD	DATE	2014	num	7	SENT_234	[p20l1169t2203r1242b2226],
11	.	.	O	.	_	0	SENT_234	[p20l1169t2203r1242b2226],

1	For	IN	O	for	_	0	SENT_235	[p20l1252t2203r1299b2226],
2	personal	JJ	O	personal	amod	3	SENT_235	[p20l1307t2203r1419b2233],
3	use	NN	O	use	pobj	1	SENT_235	[p20l1428t2210r1472b2226],
4	only	RB	O	only	advmod	3	SENT_235	[p20l1481t2203r1546b2233],
5	.	.	O	.	_	0	SENT_235	[p20l1481t2203r1546b2233],

1	No	DT	O	no	det	3	SENT_236	[p20l1557t2203r1596b2226],
2	other	JJ	O	other	amod	3	SENT_236	[p20l1606t2203r1674b2226],
3	uses	NNS	O	use	_	0	SENT_236	[p20l1683t2210r1739b2226],
4	without	IN	O	without	_	0	SENT_236	[p20l1749t2203r1850b2226],
5	permission	NN	O	permission	prep_without	3	SENT_236	[p20l1858t2203r2011b2233],
6	.	.	O	.	_	0	SENT_236	[p20l1858t2203r2011b2233],

1	Copyright	NN	O	copyright	_	0	SENT_237	[p20l729t2244r863b2275],
2	©	CD	NUMBER	©	num	6	SENT_237	[p20l872t2244r896b2268],
3	2011	CD	DATE	2011	num	6	SENT_237	[p20l906t2244r968b2268],
4	Massachusetts	NNP	ORGANIZATION	Massachusetts	nn	6	SENT_237	[p20l980t2244r1171b2268],
5	Medical	NNP	ORGANIZATION	Medical	nn	6	SENT_237	[p20l1181t2244r1289b2268],
6	Society	NNP	ORGANIZATION	Society	dep	1	SENT_237	[p20l1300t2244r1405b2275],
7	.	.	O	.	_	0	SENT_237	[p20l1300t2244r1405b2275],

1	All	DT	O	all	det	2	SENT_238	[p20l1416t2244r1457b2268],
2	rights	NNS	O	rights	nsubj	3	SENT_238	[p20l1466t2244r1541b2275],
3	reserved	VBN	O	reserve	_	0	SENT_238	[p20l1551t2244r1669b2268],
4	.	.	O	.	_	0	SENT_238	[p20l1551t2244r1669b2268],

1	CLINICAL	JJ	O	clinical	amod	2	SENT_239	[p20l868t2350r1027b2369],
2	THERAPEUTICS	NNS	O	therapeutics	_	0	SENT_239	[p20l1039t2350r1292b2369],

1	free	JJ	O	free	amod	2	SENT_240	[p20l11t2563r176b2642],
2	survival	NN	O	survival	_	0	SENT_240	[p20l215t2564r554b2644],
3	with	IN	O	with	_	0	SENT_240	[p20l587t2564r785b2644],
4	erlotinib	NN	O	erlotinib	nn	5	SENT_240	[p20l823t2564r1199b2643],
5	therapy	NN	O	therapy	prep_with	2	SENT_240	[p20l1238t2564r1567b2664],
6	in	IN	O	in	_	0	SENT_240	[p20l1599t2565r1683b2642],
7	combination	NN	O	combination	prep_in	2	SENT_240	[p20l1721t2564r2132b2643, p20l11t2694r180b2772],
8	With	IN	O	with	_	0	SENT_240	[p20l228t2693r424b2772],
9	other	JJ	O	other	prep_with	2	SENT_240	[p20l476t2693r704b2772],
10	targeted	VBN	O	target	partmod	2	SENT_240	[p20l753t2693r1108b2794],
11	agents	NNS	O	agent	dobj	10	SENT_240	[p20l1160t2710r1460b2794],
12	.	.	O	.	_	0	SENT_240	[p20l1160t2710r1460b2794],

1	In	IN	O	in	_	0	SENT_241	[p20l1516t2701r1605b2771],
2	the	DT	O	the	det	7	SENT_241	[p20l1658t2693r1790b2772],
3	ATLAS	NN	O	atla	nn	7	SENT_241	[p20l1838t2699r2130b2772],
4	trial	NN	O	trial	nn	7	SENT_241	[p20l11t2821r193b2899],
5	(	CD	NUMBER	(	num	7	SENT_241	[p20l266t2827r975b2916],
6	NCTOO257608	NN	O	nctoo257608	nn	7	SENT_241	[p20l266t2827r975b2916],
7	)	NN	O	)	prep_in	34	SENT_241	[p20l266t2827r975b2916],
8	,	,	O	,	_	0	SENT_241	[p20l266t2827r975b2916],
9	patients	NNS	O	patient	appos	7	SENT_241	[p20l1048t2822r1396b2920],
10	With	IN	O	with	_	0	SENT_241	[p20l1463t2821r1662b2900],
11	advanced	JJ	O	advanced	amod	13	SENT_241	[p20l1730t2821r2133b2900],
12	N	NN	O	n	nn	13	SENT_241	[p20l9t2956r83b3027],
13	SCLC	NN	ORGANIZATION	sclc	prep_with	9	SENT_241	[p20l87t2954r311b3027],
14	who	WP	O	who	nsubj	15	SENT_241	[p20l342t2948r525b3028],
15	had	VBD	O	have	rcmod	9	SENT_241	[p20l560t2948r717b3027],
16	stable	JJ	O	stable	amod	19	SENT_241	[p20l751t2948r999b3027],
17	or	CC	O	or	_	0	SENT_241	[p20l1034t2974r1122b3027],
18	improved	JJ	O	improved	conj_or	16	SENT_241	[p20l1152t2948r1556b3048],
19	disease	NN	O	disease	dobj	15	SENT_241	[p20l1591t2948r1901b3027],
20	after	IN	O	after	_	0	SENT_241	[p20l1934t2947r2135b3026],
21	treatment	NN	O	treatment	prep_after	15	SENT_241	[p20l11t3094r435b3155],
22	with	IN	O	with	_	0	SENT_241	[p20l475t3077r670b3156],
23	chemotherapy	NN	O	chemotherapy	prep_with	15	SENT_241	[p20l720t3077r1330b3176],
24	plus	CC	O	plus	prep	23	SENT_241	[p20l1373t3077r1549b3176],
25	the	DT	O	the	det	29	SENT_241	[p20l1601t3077r1733b3155],
26	vascular	JJ	O	vascular	amod	29	SENT_241	[p20l1778t3077r2136b3156],
27	endothelial	JJ	O	endothelial	amod	29	SENT_241	[p20l12t3205r496b3284],
28	growth	NN	O	growth	nn	29	SENT_241	[p20l529t3205r843b3306],
29	factor	NN	O	factor	dep	24	SENT_241	[p20l877t3204r1128b3284],
30	inhibitor	NN	O	inhibitor	nn	31	SENT_241	[p20l1157t3205r1539b3284],
31	bevacizumab	NN	O	bevacizumab	nsubjpass	34	SENT_241	[p20l1571t3205r2132b3284],
32	were	VBD	O	be	auxpass	34	SENT_241	[p20l7t3359r208b3412],
33	randomly	RB	O	randomly	advmod	34	SENT_241	[p20l251t3333r665b3433],
34	assigned	VBN	O	assign	_	0	SENT_241	[p20l702t3333r1076b3434],
35	to	TO	O	to	aux	36	SENT_241	[p20l1119t3350r1200b3412],
36	receive	VB	O	receive	xcomp	34	SENT_241	[p20l1244t3334r1533b3412],
37	maintenance	NN	O	maintenance	nn	38	SENT_241	[p20l1575t3334r2133b3411],
38	therapy	NN	O	therapy	dobj	36	SENT_241	[p20l11t3461r332b3560],
39	with	IN	O	with	_	0	SENT_241	[p20l365t3461r560b3540],
40	bevacizumab	NN	O	bevacizumab	prep_with	36	SENT_241	[p20l603t3461r1163b3540],
41	with	IN	O	with	_	0	SENT_241	[p20l1201t3461r1396b3540],
42	or	CC	O	or	_	0	SENT_241	[p20l1439t3487r1527b3539],
43	without	IN	O	without	_	0	SENT_241	[p20l1561t3461r1901b3540],
44	erlotinib	NN	O	erlotinib	prep_without	36	SENT_241	[p20l1938t3461r2132b3539, p20l11t3589r235b3668],
45	.	.	O	.	_	0	SENT_241	[p20l1938t3461r2132b3539, p20l11t3589r235b3668],

1	Progression	NN	O	progression	dep	123	SENT_242	[p20l278t3588r985b3690],
2	—	CD	NUMBER	—	dep	123	SENT_242	[p20l278t3588r985b3690],
3	free	JJ	O	free	dep	123	SENT_242	[p20l278t3588r985b3690],
4	survival	NN	O	survival	dep	123	SENT_242	[p20l1025t3589r1357b3668],
5	was	VBD	O	be	dep	123	SENT_242	[p20l1390t3615r1552b3668],
6	significantly	RB	O	significantly	dep	123	SENT_242	[p20l1594t3588r2137b3690],
7	longer	RBR	O	longer	dep	123	SENT_242	[p21l10t20r284b121],
8	in	IN	O	in	dep	123	SENT_242	[p21l327t21r410b98],
9	the	DT	O	the	dep	123	SENT_242	[p21l457t20r589b98],
10	bevacizumab	NN	O	bevacizumab	dep	123	SENT_242	[p21l636t20r1629b99],
11	—	NN	O	—	dep	123	SENT_242	[p21l636t20r1629b99],
12	erlotinib	NN	O	erlotinib	dep	123	SENT_242	[p21l636t20r1629b99],
13	group	NN	O	group	dep	123	SENT_242	[p21l1676t46r1929b121],
14	(	CD	NUMBER	(	dep	123	SENT_242	[p21l1980t26r2131b111],
15	4.8	CD	DURATION	4.8	dep	123	SENT_242	[p21l1980t26r2131b111],
16	months	NNS	NUMBER	month	dep	123	SENT_242	[p21l11t148r357b239],
17	)	RB	O	)	dep	123	SENT_242	[p21l11t148r357b239],
18	than	IN	O	than	dep	123	SENT_242	[p21l399t148r593b226],
19	in	IN	O	in	dep	123	SENT_242	[p21l629t149r710b226],
20	the	DT	O	the	dep	123	SENT_242	[p21l747t148r878b227],
21	bevacizumab	NN	O	bevacizumab	dep	123	SENT_242	[p21l916t148r1846b248],
22	—	NN	O	—	dep	123	SENT_242	[p21l916t148r1846b248],
23	placebo	NN	O	placebo	dep	123	SENT_242	[p21l916t148r1846b248],
24	group	NN	O	group	dep	123	SENT_242	[p21l1884t174r2132b249],
25	(	CD	NUMBER	(	dep	123	SENT_242	[p21l16t282r168b367],
26	3.7	CD	DURATION	3.7	dep	123	SENT_242	[p21l16t282r168b367],
27	months	NNS	NUMBER	month	dep	123	SENT_242	[p21l213t276r564b372],
28	;	:	O	;	_	0	SENT_242	[p21l213t276r564b372],
29	hazard	NN	O	hazard	dep	123	SENT_242	[p21l613t276r909b355],
30	ratio	NN	O	ratio	dep	123	SENT_242	[p21l953t277r1150b355],
31	for	IN	O	for	dep	123	SENT_242	[p21l1195t275r1318b355],
32	death	NN	O	death	dep	123	SENT_242	[p21l1360t276r1597b355],
33	or	CC	O	or	dep	123	SENT_242	[p21l1642t302r1731b355],
34	progression	NN	O	progression	dep	123	SENT_242	[p21l1770t302r2132b377, p21l12t404r211b498],
35	,	,	O	,	_	0	SENT_242	[p21l1770t302r2132b377, p21l12t404r211b498],
36	0.72	CD	NUMBER	0.72	dep	123	SENT_242	[p21l253t409r451b498],
37	;	:	O	;	_	0	SENT_242	[p21l253t409r451b498],
38	95	CD	NUMBER	95	dep	123	SENT_242	[p21l492t408r675b482],
39	°	CD	NUMBER	°	dep	123	SENT_242	[p21l492t408r675b482],
40	/	:	O	/	dep	123	SENT_242	[p21l492t408r675b482],
41	o	NN	O	o	dep	123	SENT_242	[p21l492t408r675b482],
42	CI	NN	O	ci	dep	123	SENT_242	[p21l711t409r826b498],
43	,	,	O	,	_	0	SENT_242	[p21l711t409r826b498],
44	0.59	CD	NUMBER	0.59	dep	123	SENT_242	[p21l868t409r1043b481],
45	to	TO	O	to	dep	123	SENT_242	[p21l1081t419r1163b481],
46	0.88	CD	NUMBER	0.88	dep	123	SENT_242	[p21l1200t409r1404b498],
47	;	:	O	;	_	0	SENT_242	[p21l1200t409r1404b498],
48	P	NN	O	p	dep	123	SENT_242	[p21l1442t408r1939b493],
49	=	JJ	O	=	dep	123	SENT_242	[p21l1442t408r1939b493],
50	O.	NNP	O	O.	dep	123	SENT_242	[p21l1442t408r1939b493],
51	OO1	NN	O	oo1	dep	123	SENT_242	[p21l1442t408r1939b493],
52	)	CD	NUMBER	)	dep	123	SENT_242	[p21l1442t408r1939b493],
53	.51	CD	NUMBER	.51	dep	123	SENT_242	[p21l1442t408r1939b493],
54	The	DT	O	the	dep	123	SENT_242	[p21l1972t403r2133b480],
55	phase	NN	O	phase	dep	123	SENT_242	[p21l9t531r258b631],
56	3	CD	NUMBER	3	dep	123	SENT_242	[p21l297t537r340b610],
57	BETA	NN	O	beta	dep	123	SENT_242	[p21l379t537r617b609],
58	Lung	NN	O	lung	dep	123	SENT_242	[p21l650t539r870b632],
59	Trial	NN	O	trial	dep	123	SENT_242	[p21l901t531r1104b609],
60	(	CD	NUMBER	(	dep	123	SENT_242	[p21l1146t537r1841b627],
61	NCTOO130728	NN	O	nctoo130728	dep	123	SENT_242	[p21l1146t537r1841b627],
62	)	NN	O	)	dep	123	SENT_242	[p21l1146t537r1841b627],
63	,	,	O	,	_	0	SENT_242	[p21l1146t537r1841b627],
64	investigating	VBG	O	investigate	dep	123	SENT_242	[p21l1884t532r2132b610, p21l11t660r350b760],
65	the	DT	O	the	dep	123	SENT_242	[p21l398t659r531b737],
66	benefits	NNS	O	benefit	dep	123	SENT_242	[p21l582t658r927b738],
67	of	IN	O	of	dep	123	SENT_242	[p21l981t658r1080b738],
68	the	DT	O	the	dep	123	SENT_242	[p21l1114t659r1246b737],
69	addition	NN	O	addition	dep	123	SENT_242	[p21l1297t659r1653b738],
70	of	IN	O	of	dep	123	SENT_242	[p21l1706t658r1805b738],
71	bevaci	FW	O	bevaci	dep	123	SENT_242	[p21l1838t659r2132b738],
72	—	FW	O	—	dep	123	SENT_242	[p21l1838t659r2132b738],
73	zumab	NN	O	zumab	dep	123	SENT_242	[p21l11t786r306b865],
74	to	TO	O	to	dep	123	SENT_242	[p21l364t803r446b865],
75	erlotinib	VB	O	erlotinib	dep	123	SENT_242	[p21l503t786r879b865],
76	for	IN	O	for	dep	123	SENT_242	[p21l936t785r1061b865],
77	second	JJ	ORDINAL	second	dep	123	SENT_242	[p21l1115t786r1616b865],
78	—	NN	O	—	dep	123	SENT_242	[p21l1115t786r1616b865],
79	line	NN	O	line	dep	123	SENT_242	[p21l1115t786r1616b865],
80	therapy	NN	O	therapy	dep	123	SENT_242	[p21l1671t786r2000b886],
81	of	IN	O	of	dep	123	SENT_242	[p21l2051t785r2152b865],
82	advanced	JJ	O	advanced	dep	123	SENT_242	[p21l10t915r408b994],
83	NSCLC	NNP	LOCATION	NSCLC	dep	123	SENT_242	[p21l439t921r767b1011],
84	,	,	O	,	_	0	SENT_242	[p21l439t921r767b1011],
85	showed	VBD	O	show	dep	123	SENT_242	[p21l808t915r1130b994],
86	a	DT	O	a	dep	123	SENT_242	[p21l1163t941r1207b993],
87	doubling	NN	O	doubling	dep	123	SENT_242	[p21l1240t915r1626b1016],
88	of	IN	O	of	dep	123	SENT_242	[p21l1657t914r1757b994],
89	progression	NN	O	progression	dep	123	SENT_242	[p21l1770t941r2132b1016, p21l12t1041r385b1121],
90	—	CD	NUMBER	—	dep	123	SENT_242	[p21l1770t941r2132b1016, p21l12t1041r385b1121],
91	free	JJ	O	free	dep	123	SENT_242	[p21l1770t941r2132b1016, p21l12t1041r385b1121],
92	survival	NN	O	survival	dep	123	SENT_242	[p21l423t1042r754b1122],
93	from	IN	O	from	dep	123	SENT_242	[p21l790t1041r1000b1121],
94	combination	NN	O	combination	dep	123	SENT_242	[p21l1038t1042r1584b1121],
95	therapy	NN	O	therapy	dep	123	SENT_242	[p21l1621t1042r1943b1142],
96	(	CD	NUMBER	(	dep	123	SENT_242	[p21l1979t1048r2133b1133],
97	3.4	CD	DURATION	3.4	dep	123	SENT_242	[p21l1979t1048r2133b1133],
98	months	NNS	NUMBER	month	dep	123	SENT_242	[p21l11t1171r388b1266],
99	)	RB	O	)	dep	123	SENT_242	[p21l11t1171r388b1266],
100	,	,	O	,	_	0	SENT_242	[p21l11t1171r388b1266],
101	as	IN	O	as	dep	123	SENT_242	[p21l435t1197r521b1249],
102	compared	VBN	O	compare	dep	123	SENT_242	[p21l565t1171r992b1270],
103	with	IN	O	with	dep	123	SENT_242	[p21l1030t1171r1225b1250],
104	erlotinib	NN	O	erlotinib	dep	123	SENT_242	[p21l1267t1171r1634b1249],
105	monother	NN	O	monother	dep	123	SENT_242	[p21l1677t1171r2132b1249],
106	—	CD	NUMBER	—	dep	123	SENT_242	[p21l1677t1171r2132b1249],
107	apy	NN	O	apy	dep	123	SENT_242	[p21l10t1324r154b1398],
108	(	CD	NUMBER	(	dep	123	SENT_242	[p21l187t1304r334b1389],
109	1.7	CD	DURATION	1.7	dep	123	SENT_242	[p21l187t1304r334b1389],
110	months	NNS	NUMBER	month	dep	123	SENT_242	[p21l368t1298r713b1394],
111	,	,	O	,	_	0	SENT_242	[p21l368t1298r713b1394],
112	P	NN	O	p	dep	123	SENT_242	[p21l750t1304r1106b1389],
113	<	JJR	O	<	dep	123	SENT_242	[p21l750t1304r1106b1389],
114	0.001	CD	NUMBER	0.001	dep	123	SENT_242	[p21l750t1304r1106b1389],
115	)	NN	O	)	dep	123	SENT_242	[p21l750t1304r1106b1389],
116	but	CC	O	but	dep	123	SENT_242	[p21l1146t1298r1283b1378],
117	no	DT	O	no	dep	123	SENT_242	[p21l1311t1324r1416b1377],
118	benefit	NN	O	benefit	dep	123	SENT_242	[p21l1450t1297r1749b1377],
119	in	IN	O	in	dep	123	SENT_242	[p21l1776t1299r1858b1376],
120	terms	NNS	O	term	dep	123	SENT_242	[p21l1892t1315r2131b1376],
121	of	IN	O	of	dep	123	SENT_242	[p21l12t1426r110b1506],
122	overall	JJ	O	overall	dep	123	SENT_242	[p21l134t1427r413b1506],
123	survival	NN	O	survival	_	0	SENT_242	[p21l456t1427r875b1506],
124	.	.	O	.	_	0	SENT_242	[p21l456t1427r875b1506],

1	”	NN	O	”	nn	3	SENT_243	[p21l456t1427r875b1506],
2	Further	JJ	O	further	amod	3	SENT_243	[p21l916t1427r1235b1506],
3	research	NN	O	research	nsubjpass	5	SENT_243	[p21l1273t1427r1627b1506],
4	is	VBZ	O	be	auxpass	5	SENT_243	[p21l1668t1428r1733b1505],
5	warranted	VBN	O	warrant	_	0	SENT_243	[p21l1771t1444r2132b1506, p21l12t1554r108b1633],
6	to	TO	O	to	aux	7	SENT_243	[p21l162t1571r243b1633],
7	define	VB	O	define	xcomp	5	SENT_243	[p21l298t1553r568b1633],
8	the	DT	O	the	det	9	SENT_243	[p21l622t1554r755b1632],
9	role	NN	O	role	dobj	7	SENT_243	[p21l809t1554r968b1633],
10	of	IN	O	of	_	0	SENT_243	[p21l1022t1553r1122b1633],
11	EGFR	NN	ORGANIZATION	egfr	nn	14	SENT_243	[p21l1156t1560r1412b1638],
12	tyrosine	NN	O	tyrosine	nn	14	SENT_243	[p21l1455t1555r1801b1654],
13	kinase	NN	O	kinase	nn	14	SENT_243	[p21l1854t1554r2133b1634],
14	inhibitors	NNS	O	inhibitor	prep_of	9	SENT_243	[p21l10t1683r432b1762],
15	in	IN	O	in	_	0	SENT_243	[p21l493t1684r576b1761],
16	combination	NN	O	combination	prep_in	14	SENT_243	[p21l636t1683r1182b1762],
17	with	IN	O	with	_	0	SENT_243	[p21l1238t1683r1434b1762],
18	other	JJ	O	other	prep_with	7	SENT_243	[p21l1494t1683r1721b1762],
19	targeted	VBN	O	target	partmod	18	SENT_243	[p21l1778t1683r2133b1784],
20	agents	NNS	O	agent	dobj	19	SENT_243	[p21l10t1828r286b1912],
21	in	IN	O	in	_	0	SENT_243	[p21l327t1812r410b1889],
22	patients	NNS	O	patient	prep_in	20	SENT_243	[p21l448t1812r790b1911],
23	with	IN	O	with	_	0	SENT_243	[p21l827t1811r1022b1890],
24	NSCLC	NN	ORGANIZATION	nsclc	prep_with	19	SENT_243	[p21l1059t1817r1387b1890],
25	.	.	O	.	_	0	SENT_243	[p21l1059t1817r1387b1890],

1	The	DT	O	the	det	3	SENT_244	[p21l136t1938r297b2016],
2	combined	JJ	O	combined	amod	3	SENT_244	[p21l351t1938r776b2017],
3	effects	NNS	O	effect	nsubjpass	20	SENT_244	[p21l830t1937r1111b2016],
4	of	IN	O	of	_	0	SENT_244	[p21l1168t1937r1267b2017],
5	the	DT	O	the	det	9	SENT_244	[p21l1302t1938r1435b2016],
6	EGFR	NN	ORGANIZATION	egfr	nn	9	SENT_244	[p21l1488t1944r1743b2022],
7	tyrosine	NN	O	tyrosine	nn	9	SENT_244	[p21l1787t1939r2133b2038],
8	kinase	NN	O	kinase	nn	9	SENT_244	[p21l11t2067r290b2146],
9	inhibitors	NNS	O	inhibitor	prep_of	3	SENT_244	[p21l347t2067r768b2145],
10	and	CC	O	and	_	0	SENT_244	[p21l828t2067r986b2145],
11	radiotherapy	NN	O	radiotherapy	prep_of	3	SENT_244	[p21l1044t2067r1590b2166],
12	as	IN	O	as	_	0	SENT_244	[p21l1644t2093r1729b2145],
13	primary	JJ	O	primary	amod	14	SENT_244	[p21l1787t2068r2138b2166],
14	treatment	NN	O	treatment	prep_as	11	SENT_244	[p21l11t2212r435b2273],
15	of	IN	O	of	_	0	SENT_244	[p21l473t2194r573b2274],
16	NSCLC	NNP	O	NSCLC	prep_of	14	SENT_244	[p21l595t2201r897b2274],
17	are	VBP	O	be	aux	20	SENT_244	[p21l942t2221r1070b2273],
18	currently	RB	DATE	currently	advmod	20	SENT_244	[p21l1114t2195r1503b2295],
19	being	VBG	O	be	auxpass	20	SENT_244	[p21l1542t2195r1782b2296],
20	investigated	VBN	O	investigate	_	0	SENT_244	[p21l1821t2196r2132b2274, p21l11t2323r267b2424],
21	.	.	O	.	_	0	SENT_244	[p21l1821t2196r2132b2274, p21l11t2323r267b2424],

1	On	IN	O	on	_	0	SENT_245	[p21l316t2329r442b2402],
2	the	DT	O	the	det	3	SENT_245	[p21l485t2323r618b2401],
3	basis	NN	O	basis	prep_on	14	SENT_245	[p21l662t2323r873b2402],
4	of	IN	O	of	_	0	SENT_245	[p21l919t2322r1018b2402],
5	the	DT	O	the	det	7	SENT_245	[p21l1044t2323r1176b2401],
6	limited	JJ	O	limited	amod	7	SENT_245	[p21l1218t2323r1527b2402],
7	data	NNS	O	datum	prep_of	3	SENT_245	[p21l1570t2323r1752b2402],
8	that	WDT	O	that	nsubj	11	SENT_245	[p21l1794t2323r1966b2401],
9	are	VBP	O	be	cop	11	SENT_245	[p21l2004t2349r2133b2401],
10	currently	RB	DATE	currently	advmod	11	SENT_245	[p21l12t2451r401b2550],
11	available	JJ	O	available	rcmod	7	SENT_245	[p21l429t2451r824b2546],
12	,	,	O	,	_	0	SENT_245	[p21l429t2451r824b2546],
13	it	PRP	O	it	nsubj	14	SENT_245	[p21l862t2452r921b2528],
14	appears	VBZ	O	appear	_	0	SENT_245	[p21l948t2477r1280b2550],
15	that	IN	O	that	complm	22	SENT_245	[p21l1316t2451r1488b2529],
16	no	DT	O	no	det	20	SENT_245	[p21l1516t2477r1622b2529],
17	substantial	JJ	O	substantial	amod	20	SENT_245	[p21l1658t2451r2134b2530],
18	additional	JJ	O	additional	amod	20	SENT_245	[p21l10t2579r447b2658],
19	toxic	JJ	O	toxic	amod	20	SENT_245	[p21l488t2580r694b2658],
20	effects	NNS	O	effect	nsubjpass	22	SENT_245	[p21l736t2578r1016b2658],
21	are	VBP	O	be	auxpass	22	SENT_245	[p21l1059t2605r1188b2657],
22	associated	VBN	O	associate	ccomp	14	SENT_245	[p21l1230t2579r1674b2658],
23	with	IN	O	with	_	0	SENT_245	[p21l1711t2579r1906b2658],
24	concomitant	JJ	O	concomitant	amod	25	SENT_245	[p21l1948t2605r2132b2658, p21l12t2708r401b2785],
25	therapy	NN	O	therapy	prep_with	22	SENT_245	[p21l436t2707r758b2806],
26	with	IN	O	with	_	0	SENT_245	[p21l790t2707r985b2786],
27	EGFR	NN	ORGANIZATION	egfr	nn	30	SENT_245	[p21l1025t2713r1280b2790],
28	tyrosine	NN	O	tyrosine	nn	30	SENT_245	[p21l1311t2708r1657b2806],
29	kinase	NN	O	kinase	nn	30	SENT_245	[p21l1698t2707r1977b2786],
30	inhibitors	NNS	O	inhibitor	prep_with	22	SENT_245	[p21l2018t2708r2132b2784, p21l11t2835r342b2914],
31	during	IN	O	during	_	0	SENT_245	[p21l385t2835r674b2936],
32	radiotherapy	NN	O	radiotherapy	prep_during	22	SENT_245	[p21l710t2835r1444b2935],
33	.53	CD	NUMBER	.53	num	32	SENT_245	[p21l710t2835r1444b2935],
34	»	CD	NUMBER	»	number	35	SENT_245	[p21l710t2835r1444b2935],
35	54	CD	NUMBER	54	dep	32	SENT_245	[p21l710t2835r1444b2935],

1	GUIDELINES	NNS	O	guideline	_	0	SENT_246	[p21l719t3131r1423b3190],

1	The	DT	O	the	det	5	SENT_247	[p21l7t3348r168b3426],
2	National	NNP	ORGANIZATION	National	nn	5	SENT_247	[p21l233t3348r606b3427],
3	Comprehensive	NNP	ORGANIZATION	Comprehensive	nn	5	SENT_247	[p21l673t3348r1333b3447],
4	Cancer	NNP	ORGANIZATION	Cancer	nn	5	SENT_247	[p21l1400t3354r1698b3426],
5	Network	NNP	ORGANIZATION	Network	nsubj	9	SENT_247	[p21l1761t3348r2138b3427],
6	(	CD	NUMBER	(	num	7	SENT_247	[p21l16t3482r352b3567],
7	NCCN	NNP	ORGANIZATION	NCCN	dep	5	SENT_247	[p21l16t3482r352b3567],
8	)	CD	NUMBER	)	num	7	SENT_247	[p21l16t3482r352b3567],
9	recognizes	VBZ	O	recognize	_	0	SENT_247	[p21l416t3477r880b3577],
10	erlotinib	NN	O	erlotinib	dobj	9	SENT_247	[p21l942t3476r1309b3555],
11	as	IN	O	as	_	0	SENT_247	[p21l1368t3502r1453b3554],
12	an	DT	O	a	det	13	SENT_247	[p21l1513t3502r1617b3554],
13	option	NN	O	option	prep_as	9	SENT_247	[p21l1676t3477r1955b3576],
14	for	IN	O	for	_	0	SENT_247	[p21l2013t3475r2136b3555],
15	second	JJ	ORDINAL	second	amod	16	SENT_247	[p21l12t3604r340b3682],
16	—	NN	O	—	prep_for	13	SENT_247	[p21l12t3604r340b3682],
17	and	CC	O	and	_	0	SENT_247	[p21l390t3604r548b3682],
18	third	JJ	ORDINAL	third	amod	21	SENT_247	[p21l597t3604r1003b3682],
19	—	NN	O	—	nn	21	SENT_247	[p21l597t3604r1003b3682],
20	line	NN	O	line	nn	21	SENT_247	[p21l597t3604r1003b3682],
21	therapy	NN	O	therapy	prep_as	9	SENT_247	[p21l1053t3604r1374b3703],
22	in	IN	O	in	_	0	SENT_247	[p21l1419t3605r1502b3681],
23	patients	NNS	O	patient	prep_in	21	SENT_247	[p21l1549t3605r1891b3703],
24	with	IN	O	with	_	0	SENT_247	[p21l1938t3604r2133b3683],
25	advanced	JJ	O	advanced	amod	26	SENT_247	[p22l10t21r406b101],
26	NSCLC	NNP	O	NSCLC	prep_with	23	SENT_247	[p22l469t27r771b101],
27	who	WP	O	who	nsubj	28	SENT_247	[p22l834t21r1017b101],
28	have	VBP	O	have	rcmod	21	SENT_247	[p22l1083t21r1273b100],
29	an	DT	O	a	det	32	SENT_247	[p22l1338t47r1440b99],
30	ECOG	NN	O	ecog	nn	32	SENT_247	[p22l1504t27r1770b100],
31	performance	NN	O	performance	nn	32	SENT_247	[p22l1835t20r2132b121, p22l11t175r293b227],
32	status	NN	O	status	dobj	28	SENT_247	[p22l331t166r582b229],
33	of	IN	O	of	_	0	SENT_247	[p22l621t148r720b228],
34	O	NN	O	o	prep_of	32	SENT_247	[p22l738t155r785b228],
35	to	TO	O	to	_	0	SENT_247	[p22l822t166r904b228],
36	3	CD	NUMBER	3	prep_to	28	SENT_247	[p22l942t155r1011b228],
37	.	.	O	.	_	0	SENT_247	[p22l942t155r1011b228],

1	For	IN	O	for	_	0	SENT_248	[p22l1050t157r1193b228],
2	patients	NNS	O	patient	prep_for	16	SENT_248	[p22l1224t150r1566b249],
3	with	IN	O	with	_	0	SENT_248	[p22l1600t149r1795b229],
4	NSCLC	NN	O	nsclc	prep_with	2	SENT_248	[p22l1828t155r2130b228],
5	who	WP	O	who	nsubjpass	7	SENT_248	[p22l7t278r189b357],
6	are	VBP	O	be	auxpass	7	SENT_248	[p22l234t304r363b356],
7	known	VBN	O	know	rcmod	2	SENT_248	[p22l407t278r705b357],
8	to	TO	O	to	aux	9	SENT_248	[p22l750t295r831b356],
9	carry	VB	O	carry	xcomp	7	SENT_248	[p22l878t304r1099b377],
10	an	DT	O	a	det	12	SENT_248	[p22l1138t304r1241b356],
11	EGFR	NN	ORGANIZATION	egfr	nn	12	SENT_248	[p22l1284t284r1497b357],
12	mutation	NN	O	mutation	dobj	9	SENT_248	[p22l1534t279r1950b373],
13	,	,	O	,	_	0	SENT_248	[p22l1534t279r1950b373],
14	the	DT	O	the	det	15	SENT_248	[p22l2000t278r2133b356],
15	NCCN	NN	ORGANIZATION	nccn	nsubj	16	SENT_248	[p22l8t412r286b485],
16	suggests	VBZ	O	suggest	_	0	SENT_248	[p22l335t423r701b507],
17	erlotinib	JJ	O	erlotinib	amod	18	SENT_248	[p22l753t406r1120b485],
18	monotherapy	NN	O	monotherapy	dobj	16	SENT_248	[p22l1170t406r1744b506],
19	as	IN	O	as	_	0	SENT_248	[p22l1788t432r1873b484],
20	firstline	NN	O	firstline	nn	21	SENT_248	[p22l1924t405r2132b484, p22l10t534r168b612],
21	therapy	NN	O	therapy	prep_as	16	SENT_248	[p22l208t534r529b633],
22	and	CC	O	and	cc	21	SENT_248	[p22l563t534r720b612],
23	even	RB	O	even	advmod	21	SENT_248	[p22l759t560r948b613],
24	reserves	NNS	O	reserve	nn	25	SENT_248	[p22l986t560r1329b613],
25	erlotinib	NN	O	erlotinib	dep	21	SENT_248	[p22l1370t534r1737b612],
26	as	IN	O	as	_	0	SENT_248	[p22l1776t560r1862b612],
27	a	DT	O	a	det	30	SENT_248	[p22l1902t560r1946b612],
28	salvage	NN	O	salvage	nn	30	SENT_248	[p22l1984t534r2132b612, p22l7t688r196b763],
29	treatment	NN	O	treatment	nn	30	SENT_248	[p22l245t679r669b740],
30	option	NN	O	option	prep_as	25	SENT_248	[p22l714t663r992b762],
31	in	IN	O	in	_	0	SENT_248	[p22l1040t663r1123b740],
32	this	DT	O	this	det	33	SENT_248	[p22l1173t662r1332b740],
33	subgroup	NN	O	subgroup	prep_in	30	SENT_248	[p22l1384t662r1787b763],
34	among	IN	O	among	_	0	SENT_248	[p22l1837t688r2137b763],
35	patients	NNS	O	patient	prep_among	33	SENT_248	[p22l9t790r350b889],
36	with	IN	O	with	_	0	SENT_248	[p22l385t789r580b869],
37	an	DT	O	a	det	40	SENT_248	[p22l616t815r719b867],
38	ECOG	NN	O	ecog	nn	40	SENT_248	[p22l754t795r1020b868],
39	performance	NN	O	performance	nn	40	SENT_248	[p22l1056t788r1611b889],
40	status	NN	O	status	prep_with	35	SENT_248	[p22l1649t806r1901b868],
41	of	IN	O	of	_	0	SENT_248	[p22l1939t788r2040b868],
42	4	CD	NUMBER	4	prep_of	40	SENT_248	[p22l2056t796r2128b868],
43	.	.	O	.	_	0	SENT_248	[p22l2056t796r2128b868],

1	Furthermore	RB	O	furthermore	advmod	5	SENT_249	[p22l9t918r581b1014],
2	,	,	O	,	_	0	SENT_249	[p22l9t918r581b1014],
3	the	DT	O	the	det	4	SENT_249	[p22l616t918r749b996],
4	NCCN	NNP	ORGANIZATION	NCCN	nsubj	5	SENT_249	[p22l776t924r1053b997],
5	recognizes	VBZ	O	recognize	_	0	SENT_249	[p22l1081t919r1546b1019],
6	erlotinib	NN	O	erlotinib	dobj	5	SENT_249	[p22l1578t918r1944b997],
7	as	IN	O	as	_	0	SENT_249	[p22l1974t944r2059b996],
8	a	DT	O	a	det	10	SENT_249	[p22l2090t944r2134b996],
9	maintenance	NN	O	maintenance	nn	10	SENT_249	[p22l11t1047r568b1124],
10	agent	NN	O	agent	prep_as	5	SENT_249	[p22l601t1063r837b1147],
11	for	IN	O	for	_	0	SENT_249	[p22l865t1045r989b1125],
12	patients	NNS	O	patient	prep_for	10	SENT_249	[p22l1017t1047r1359b1146],
13	with	IN	O	with	_	0	SENT_249	[p22l1389t1046r1585b1125],
14	stable	JJ	O	stable	amod	17	SENT_249	[p22l1619t1046r1866b1125],
15	or	CC	O	or	_	0	SENT_249	[p22l1900t1072r1989b1125],
16	responsive	JJ	O	responsive	conj_or	14	SENT_249	[p22l2019t1072r2132b1124, p22l12t1174r376b1273],
17	disease	NN	O	disease	prep_with	12	SENT_249	[p22l428t1173r739b1252],
18	after	IN	O	after	_	0	SENT_249	[p22l789t1172r991b1251],
19	f1rst	CD	NUMBER	f1rst	num	20	SENT_249	[p22l1039t1172r1408b1251],
20	—	CD	NUMBER	—	prep_after	17	SENT_249	[p22l1039t1172r1408b1251],
21	line	NN	O	line	nn	23	SENT_249	[p22l1039t1172r1408b1251],
22	platinum	NN	O	platinum	nn	23	SENT_249	[p22l1458t1173r2133b1273],
23	—	NN	O	—	tmod	17	SENT_249	[p22l1458t1173r2133b1273],
24	based	VBN	O	base	partmod	23	SENT_249	[p22l1458t1173r2133b1273],
25	chemotherapy	NN	O	chemotherapy	dobj	24	SENT_249	[p22l12t1302r708b1401],
26	.55	CD	NUMBER	.55	num	25	SENT_249	[p22l12t1302r708b1401],

1	Although	IN	O	although	mark	11	SENT_250	[p22l136t1430r550b1531],
2	evidence	NN	O	evidence	nsubj	11	SENT_250	[p22l609t1430r982b1509],
3	supporting	VBG	O	support	partmod	2	SENT_250	[p22l1041t1431r1527b1531],
4	the	DT	O	the	det	5	SENT_250	[p22l1581t1430r1716b1508],
5	value	NN	O	value	dobj	3	SENT_250	[p22l1769t1430r1992b1509],
6	of	IN	O	of	_	0	SENT_250	[p22l2051t1429r2152b1509],
7	EGFR	NN	ORGANIZATION	egfr	nn	9	SENT_250	[p22l9t1564r225b1638],
8	mutational	JJ	O	mutational	amod	9	SENT_250	[p22l265t1558r747b1637],
9	analysis	NN	O	analysis	prep_of	5	SENT_250	[p22l793t1558r1140b1658],
10	is	VBZ	O	be	cop	11	SENT_250	[p22l1188t1559r1256b1636],
11	growing	VBG	O	grow	advcl	18	SENT_250	[p22l1304t1559r1695b1659],
12	,	,	O	,	_	0	SENT_250	[p22l1304t1559r1695b1659],
13	no	DT	O	no	det	14	SENT_250	[p22l1747t1584r1854b1637],
14	study	NN	O	study	nsubj	18	SENT_250	[p22l1904t1558r2138b1658],
15	to	TO	O	to	_	0	SENT_250	[p22l11t1703r94b1765],
16	date	NN	O	date	prep_to	14	SENT_250	[p22l146t1686r323b1765],
17	has	VBZ	O	have	aux	18	SENT_250	[p22l372t1686r516b1764],
18	shown	VBN	O	show	_	0	SENT_250	[p22l568t1686r849b1765],
19	a	DT	O	a	det	20	SENT_250	[p22l897t1712r941b1764],
20	benefit	NN	O	benefit	dobj	18	SENT_250	[p22l988t1685r1293b1765],
21	in	IN	O	in	_	0	SENT_250	[p22l1335t1687r1419b1764],
22	overall	JJ	O	overall	amod	23	SENT_250	[p22l1467t1686r1753b1765],
23	survival	NN	O	survival	prep_in	20	SENT_250	[p22l1802t1686r2134b1765],
24	from	IN	O	from	_	0	SENT_250	[p22l11t1813r221b1893],
25	treatment	NN	O	treatment	nn	26	SENT_250	[p22l268t1831r692b1893],
26	selection	NN	O	selection	prep_from	18	SENT_250	[p22l735t1814r1114b1893],
27	on	IN	O	on	_	0	SENT_250	[p22l1161t1840r1266b1893],
28	the	DT	O	the	det	29	SENT_250	[p22l1314t1814r1447b1892],
29	basis	NN	O	basis	prep_on	18	SENT_250	[p22l1494t1814r1705b1893],
30	of	IN	O	of	_	0	SENT_250	[p22l1755t1813r1854b1893],
31	mutational	JJ	O	mutational	amod	32	SENT_250	[p22l1883t1831r2132b1893, p22l11t1941r261b2020],
32	status	NN	O	status	prep_of	29	SENT_250	[p22l303t1958r579b2020],
33	.	.	O	.	_	0	SENT_250	[p22l303t1958r579b2020],

1	Therefore	RB	O	therefore	advmod	4	SENT_251	[p22l622t1940r1062b2037],
2	,	,	O	,	_	0	SENT_251	[p22l622t1940r1062b2037],
3	there	EX	O	there	expl	4	SENT_251	[p22l1109t1941r1326b2019],
4	is	VBZ	O	be	_	0	SENT_251	[p22l1366t1942r1432b2019],
5	no	DT	O	no	det	7	SENT_251	[p22l1475t1967r1581b2020],
6	current	JJ	DATE	current	amod	7	SENT_251	[p22l1624t1958r1938b2020],
7	recommendation	NN	O	recommendation	nsubj	4	SENT_251	[p22l1974t1967r2132b2019, p22l12t2069r622b2148],
8	for	IN	O	for	_	0	SENT_251	[p22l657t2068r781b2148],
9	routine	JJ	O	routine	amod	11	SENT_251	[p22l813t2070r1125b2149],
10	mutational	JJ	O	mutational	amod	11	SENT_251	[p22l1160t2069r1637b2149],
11	analysis	NN	O	analysis	prep_for	7	SENT_251	[p22l1671t2069r2014b2169],
12	in	IN	O	in	_	0	SENT_251	[p22l2050t2070r2134b2147],
13	patients	NNS	O	patient	prep_in	11	SENT_251	[p22l9t2198r354b2297],
14	with	IN	O	with	_	0	SENT_251	[p22l400t2197r597b2277],
15	advanced	JJ	O	advanced	amod	16	SENT_251	[p22l644t2197r1043b2277],
16	NSCLC	NNP	O	NSCLC	prep_with	13	SENT_251	[p22l1089t2203r1419b2276],
17	.	.	O	.	_	0	SENT_251	[p22l1089t2203r1419b2276],

1	However	RB	O	however	advmod	21	SENT_252	[p22l1472t2205r1870b2293],
2	,	,	O	,	_	0	SENT_252	[p22l1472t2205r1870b2293],
3	if	IN	O	if	mark	8	SENT_252	[p22l1923t2196r2000b2275],
4	an	DT	O	a	det	6	SENT_252	[p22l2029t2223r2133b2275],
5	EGFR	NN	ORGANIZATION	egfr	nn	6	SENT_252	[p22l9t2332r224b2405],
6	mutation	NN	O	mutation	nsubjpass	8	SENT_252	[p22l262t2327r662b2405],
7	is	VBZ	O	be	auxpass	8	SENT_252	[p22l706t2327r773b2403],
8	known	VBN	O	know	advcl	21	SENT_252	[p22l819t2326r1121b2405],
9	to	TO	O	to	aux	10	SENT_252	[p22l1166t2342r1248b2404],
10	exist	VB	O	exist	xcomp	8	SENT_252	[p22l1295t2327r1521b2421],
11	,	,	O	,	_	0	SENT_252	[p22l1295t2327r1521b2421],
12	therapy	NN	O	therapy	nsubjpass	21	SENT_252	[p22l1571t2326r1899b2425],
13	with	IN	O	with	_	0	SENT_252	[p22l1935t2326r2133b2405],
14	an	DT	O	a	det	18	SENT_252	[p22l10t2480r114b2531],
15	EGFR	NN	ORGANIZATION	egfr	nn	18	SENT_252	[p22l151t2460r401b2537],
16	tyrosine	NN	O	tyrosine	nn	18	SENT_252	[p22l422t2455r754b2553],
17	kinase	NN	O	kinase	nn	18	SENT_252	[p22l786t2454r1053b2533],
18	inhibitor	NN	O	inhibitor	prep_with	12	SENT_252	[p22l1085t2454r1449b2532],
19	should	MD	O	should	aux	21	SENT_252	[p22l1480t2454r1756b2533],
20	be	VB	O	be	auxpass	21	SENT_252	[p22l1789t2454r1883b2532],
21	instituted	VBN	O	institute	_	0	SENT_252	[p22l1914t2455r2132b2532, p22l11t2583r425b2662],
22	.21	CD	NUMBER	.21	num	23	SENT_252	[p22l1914t2455r2132b2532, p22l11t2583r425b2662],
23	>	JJR	O	>	dobj	21	SENT_252	[p22l1914t2455r2132b2532, p22l11t2583r425b2662],
24	55	CD	NUMBER	55	dep	23	SENT_252	[p22l1914t2455r2132b2532, p22l11t2583r425b2662],

1	RECOMMENDATIONS	NNS	O	recommendation	_	0	SENT_253	[p22l491t2879r1654b2940],

1	The	DT	O	the	det	2	SENT_254	[p22l7t3098r170b3176],
2	use	NN	O	use	nsubjpass	10	SENT_254	[p22l240t3124r382b3177],
3	of	IN	O	of	_	0	SENT_254	[p22l453t3097r554b3177],
4	EGFR	NN	ORGANIZATION	egfr	nn	7	SENT_254	[p22l604t3104r863b3182],
5	tyrosine	NN	O	tyrosine	nn	7	SENT_254	[p22l923t3099r1276b3198],
6	kinase	NN	O	kinase	nn	7	SENT_254	[p22l1346t3098r1630b3178],
7	inhibitors	NNS	O	inhibitor	prep_of	2	SENT_254	[p22l1699t3098r2131b3177],
8	should	MD	O	should	aux	10	SENT_254	[p22l12t3226r299b3306],
9	be	VB	O	be	auxpass	10	SENT_254	[p22l345t3226r442b3305],
10	considered	VBN	O	consider	_	0	SENT_254	[p22l488t3226r951b3305],
11	in	IN	O	in	_	0	SENT_254	[p22l996t3227r1079b3304],
12	the	DT	O	the	det	13	SENT_254	[p22l1125t3226r1258b3304],
13	case	NN	O	case	prep_in	10	SENT_254	[p22l1305t3252r1484b3304],
14	of	IN	O	of	_	0	SENT_254	[p22l1531t3225r1631b3305],
15	the	DT	O	the	det	16	SENT_254	[p22l1659t3226r1791b3304],
16	patient	NN	O	patient	prep_of	13	SENT_254	[p22l1836t3227r2138b3326],
17	presented	VBN	O	present	partmod	16	SENT_254	[p22l9t3355r428b3455],
18	in	IN	O	in	_	0	SENT_254	[p22l478t3356r562b3433],
19	the	DT	O	the	det	20	SENT_254	[p22l613t3355r745b3433],
20	vignette	NN	O	vignette	prep_in	17	SENT_254	[p22l792t3356r1161b3456],
21	,	,	O	,	_	0	SENT_254	[p22l792t3356r1161b3456],
22	who	WP	O	who	nsubj	23	SENT_254	[p22l1213t3355r1396b3434],
23	has	VBZ	O	have	rcmod	20	SENT_254	[p22l1448t3355r1592b3433],
24	progressive	JJ	O	progressive	amod	26	SENT_254	[p22l1644t3356r2133b3456],
25	metastatic	JJ	O	metastatic	amod	26	SENT_254	[p22l11t3484r457b3561],
26	NSCLC	NN	O	nsclc	dobj	23	SENT_254	[p22l489t3489r791b3562],
27	despite	IN	O	despite	_	0	SENT_254	[p22l829t3483r1129b3582],
28	treatment	NN	O	treatment	prep_despite	23	SENT_254	[p22l1164t3499r1588b3561],
29	with	IN	O	with	_	0	SENT_254	[p22l1613t3483r1808b3562],
30	a	DT	O	a	det	33	SENT_254	[p22l1842t3509r1886b3561],
31	standard	JJ	O	standard	amod	33	SENT_254	[p22l1920t3499r2132b3561, p22l12t3611r206b3690],
32	chemotherapeutic	JJ	O	chemotherapeutic	amod	33	SENT_254	[p22l238t3611r1012b3711],
33	regimen	NN	O	regimen	prep_with	28	SENT_254	[p22l1043t3612r1422b3712],
34	.	.	O	.	_	0	SENT_254	[p22l1043t3612r1422b3712],

1	We	PRP	O	we	nsubj	2	SENT_255	[p22l1455t3619r1587b3689],
2	recommend	VBP	O	recommend	_	0	SENT_255	[p22l1619t3611r2133b3690],
3	that	IN	O	that	complm	5	SENT_255	[p23l11t20r184b98],
4	she	PRP	O	she	nsubj	5	SENT_255	[p23l225t20r363b98],
5	begin	VB	O	begin	ccomp	2	SENT_255	[p23l409t20r651b121],
6	erlotinib	NN	O	erlotinib	nn	7	SENT_255	[p23l696t20r1062b99],
7	monotherapy	NN	O	monotherapy	dobj	5	SENT_255	[p23l1109t20r1683b120],
8	at	IN	O	at	_	0	SENT_255	[p23l1723t37r1802b98],
9	a	DT	O	a	det	11	SENT_255	[p23l1841t46r1885b98],
10	daily	JJ	SET	daily	amod	11	SENT_255	[p23l1930t20r2137b120],
11	dose	NN	O	dose	prep_at	5	SENT_255	[p23l12t148r206b227],
12	of	IN	O	of	_	0	SENT_255	[p23l242t147r341b227],
13	150	CD	NUMBER	150	num	14	SENT_255	[p23l361t154r510b227],
14	mg	NN	O	mg	prep_of	11	SENT_255	[p23l546t174r704b249],
15	.	.	O	.	_	0	SENT_255	[p23l546t174r704b249],

1	Given	VBN	O	give	_	0	SENT_256	[p23l744t149r988b227],
2	the	DT	O	the	det	3	SENT_256	[p23l1023t148r1156b226],
3	fact	NN	O	fact	dep	1	SENT_256	[p23l1191t147r1350b226],
4	that	IN	O	that	complm	8	SENT_256	[p23l1380t148r1552b226],
5	erlotinib	NN	O	erlotinib	nsubjpass	8	SENT_256	[p23l1583t148r1950b227],
6	has	VBZ	O	have	aux	8	SENT_256	[p23l1987t148r2130b226],
7	been	VBN	O	be	auxpass	8	SENT_256	[p23l12t276r212b355],
8	shown	VBN	O	show	dep	3	SENT_256	[p23l250t276r532b355],
9	to	TO	O	to	aux	11	SENT_256	[p23l568t293r649b355],
10	be	VB	O	be	cop	11	SENT_256	[p23l688t276r784b355],
11	beneficial	JJ	O	beneficial	xcomp	8	SENT_256	[p23l821t275r1243b355],
12	as	IN	O	as	_	0	SENT_256	[p23l1279t302r1364b354],
13	second	JJ	ORDINAL	second	amod	16	SENT_256	[p23l1404t276r1893b355],
14	—	NN	O	—	nn	16	SENT_256	[p23l1404t276r1893b355],
15	line	NN	O	line	nn	16	SENT_256	[p23l1404t276r1893b355],
16	therapy	NN	O	therapy	prep_as	11	SENT_256	[p23l1930t276r2132b355, p23l10t430r158b503],

1	in	IN	O	in	_	0	SENT_257	[p23l210t405r295b481],
2	unselected	JJ	O	unselected	amod	3	SENT_257	[p23l352t404r818b483],
3	patients	NNS	O	patient	prep_in	14	SENT_257	[p23l874t405r1248b503],
4	,	,	O	,	_	0	SENT_257	[p23l874t405r1248b503],
5	treatment	NN	O	treatment	nsubj	14	SENT_257	[p23l1312t420r1745b482],
6	without	IN	O	without	_	0	SENT_257	[p23l1793t404r2138b483],
7	assessment	NN	O	assessment	prep_without	5	SENT_257	[p23l10t549r504b610],
8	of	IN	O	of	_	0	SENT_257	[p23l542t531r642b611],
9	the	DT	O	the	det	12	SENT_257	[p23l666t532r799b610],
10	EGFR	NN	ORGANIZATION	egfr	nn	12	SENT_257	[p23l840t539r1053b612],
11	mutational	JJ	O	mutational	amod	12	SENT_257	[p23l1089t532r1562b611],
12	status	NN	O	status	prep_of	7	SENT_257	[p23l1606t549r1858b611],
13	is	VBZ	O	be	cop	14	SENT_257	[p23l1902t533r1968b610],
14	acceptable	JJ	O	acceptable	_	0	SENT_257	[p23l2012t558r2132b610, p23l12t660r392b760],
15	.	.	O	.	_	0	SENT_257	[p23l2012t558r2132b610, p23l12t660r392b760],

1	Special	JJ	O	special	amod	2	SENT_258	[p23l446t660r754b760],
2	instruction	NN	O	instruction	nsubj	3	SENT_258	[p23l798t661r1287b739],
3	needs	VBZ	O	need	_	0	SENT_258	[p23l1333t660r1580b739],
4	to	TO	O	to	aux	6	SENT_258	[p23l1628t677r1711b739],
5	be	VB	O	be	auxpass	6	SENT_258	[p23l1759t660r1856b739],
6	given	VBN	O	give	xcomp	3	SENT_258	[p23l1902t661r2133b761],
7	regarding	VBG	O	regard	_	0	SENT_258	[p23l11t788r434b889],
8	the	DT	O	the	det	9	SENT_258	[p23l471t788r603b866],
9	anticipation	NN	O	anticipation	prep_regarding	6	SENT_258	[p23l643t789r1158b888],
10	of	IN	O	of	prep	9	SENT_258	[p23l1198t787r1298b867],
11	and	CC	O	and	_	0	SENT_258	[p23l1319t788r1476b867],
12	treatment	NN	O	treatment	nn	13	SENT_258	[p23l1516t805r1940b866],
13	recommendations	NNS	O	recommendation	conj_and	9	SENT_258	[p23l1974t814r2132b866, p23l12t915r660b994],
14	for	IN	O	for	_	0	SENT_258	[p23l708t914r831b994],
15	rash	NN	O	rash	prep_for	13	SENT_258	[p23l874t915r1056b993],
16	and	CC	O	and	_	0	SENT_258	[p23l1102t915r1260b994],
17	diarrhea	NN	O	diarrhea	prep_for	13	SENT_258	[p23l1307t915r1690b1011],
18	,	,	O	,	_	0	SENT_258	[p23l1307t915r1690b1011],
19	the	DT	O	the	det	23	SENT_258	[p23l1743t915r1876b993],
20	most	RBS	O	most	advmod	21	SENT_258	[p23l1922t932r2138b994],
21	common	JJ	O	common	amod	23	SENT_258	[p23l12t1070r393b1123],
22	adverse	JJ	O	adverse	amod	23	SENT_258	[p23l439t1044r754b1123],
23	effects	NNS	O	effect	appos	15	SENT_258	[p23l801t1043r1083b1122],
24	of	IN	O	of	_	0	SENT_258	[p23l1132t1043r1231b1123],
25	erlotinib	NN	O	erlotinib	prep_of	23	SENT_258	[p23l1261t1044r1650b1123],
26	.	.	O	.	_	0	SENT_258	[p23l1261t1044r1650b1123],

1	Restaging	VBG	O	restage	amod	2	SENT_259	[p23l1700t1045r2136b1145],
2	studies	NNS	O	study	nsubjpass	5	SENT_259	[p23l12t1172r312b1251],
3	should	MD	O	should	aux	5	SENT_259	[p23l347t1172r634b1251],
4	be	VB	O	be	auxpass	5	SENT_259	[p23l666t1172r763b1251],
5	conducted	VBN	O	conduct	_	0	SENT_259	[p23l795t1172r1236b1251],
6	before	IN	O	before	_	0	SENT_259	[p23l1269t1171r1537b1251],
7	the	DT	O	the	det	8	SENT_259	[p23l1570t1172r1702b1251],
8	initiation	NN	O	initiation	prep_before	5	SENT_259	[p23l1734t1173r2133b1251],
9	of	IN	O	of	_	0	SENT_259	[p23l12t1298r112b1378],
10	therapy	NN	O	therapy	prep_of	8	SENT_259	[p23l125t1299r447b1399],
11	and	CC	O	and	_	0	SENT_259	[p23l473t1299r630b1378],
12	6	CD	DURATION	6	number	14	SENT_259	[p23l662t1305r709b1378],
13	to	TO	DURATION	to	dep	14	SENT_259	[p23l741t1316r823b1378],
14	8	CD	DURATION	8	num	15	SENT_259	[p23l857t1305r901b1378],
15	weeks	NNS	NUMBER	week	prep_before	5	SENT_259	[p23l930t1299r1192b1379],
16	after	IN	O	after	_	0	SENT_259	[p23l1224t1298r1427b1377],
17	the	DT	O	the	det	18	SENT_259	[p23l1455t1299r1588b1377],
18	initiation	NN	O	initiation	prep_after	5	SENT_259	[p23l1619t1300r2018b1378],
19	to	TO	O	to	aux	20	SENT_259	[p23l2050t1316r2132b1378],
20	evaluate	VB	O	evaluate	infmod	18	SENT_259	[p23l12t1428r357b1507],
21	the	DT	O	the	det	22	SENT_259	[p23l415t1428r548b1507],
22	patient	NN	O	patient	dobj	20	SENT_259	[p23l604t1429r906b1528],
23	for	IN	O	for	_	0	SENT_259	[p23l958t1427r1081b1507],
24	response	NN	O	response	prep_for	22	SENT_259	[p23l1135t1454r1539b1528],
25	.	.	O	.	_	0	SENT_259	[p23l1135t1454r1539b1528],

1	Single	JJ	O	single	amod	4	SENT_260	[p23l1604t1428r2138b1529],
2	—	JJ	O	—	amod	4	SENT_260	[p23l1604t1428r2138b1529],
3	agent	NN	O	agent	nn	4	SENT_260	[p23l1604t1428r2138b1529],
4	treatment	NN	O	treatment	nsubj	8	SENT_260	[p23l11t1574r435b1636],
5	with	IN	O	with	_	0	SENT_260	[p23l481t1557r677b1636],
6	erlotinib	NN	O	erlotinib	prep_with	4	SENT_260	[p23l733t1557r1100b1636],
7	should	MD	O	should	aux	8	SENT_260	[p23l1159t1557r1445b1636],
8	continue	VB	O	continue	_	0	SENT_260	[p23l1502t1558r1875b1636],
9	until	IN	O	until	mark	14	SENT_260	[p23l1931t1557r2134b1636],
10	progression	NN	O	progression	nsubjpass	14	SENT_260	[p23l9t1686r521b1786],
11	of	IN	O	of	_	0	SENT_260	[p23l556t1684r656b1764],
12	disease	NN	O	disease	prep_of	10	SENT_260	[p23l673t1685r983b1764],
13	is	VBZ	O	be	auxpass	14	SENT_260	[p23l1017t1686r1083b1763],
14	documented	VBN	O	document	advcl	8	SENT_260	[p23l1120t1685r1677b1764],
15	.	.	O	.	_	0	SENT_260	[p23l1120t1685r1677b1764],

1	Dr.	NNP	O	Dr.	nn	2	SENT_261	[p23l95t1870r192b1924],
2	Pérez-Soler	NNP	PERSON	Pérez-Soler	nsubj	3	SENT_261	[p23l226t1863r595b1924],
3	reports	VBZ	O	report	_	0	SENT_261	[p23l624t1878r859b1940],
4	receiving	VBG	O	receive	xcomp	3	SENT_261	[p23l892t1866r1191b1940],
5	consulting	NN	O	consulting	nn	8	SENT_261	[p23l1220t1865r1572b1940],
6	and	CC	O	and	_	0	SENT_261	[p23l1600t1865r1720b1924],
7	lecture	NN	O	lecture	nn	8	SENT_261	[p23l1751t1865r1974b1925],
8	fees	NNS	O	fee	dobj	4	SENT_261	[p23l2006t1864r2132b1924],
9	and	CC	O	and	_	0	SENT_261	[p23l9t1952r130b2011],
10	payment	NN	O	payment	dobj	4	SENT_261	[p23l160t1965r444b2027],
11	for	IN	O	for	_	0	SENT_261	[p23l472t1951r567b2011],
12	the	DT	O	the	det	13	SENT_261	[p23l596t1952r697b2010],
13	development	NN	O	development	prep_for	4	SENT_261	[p23l729t1952r1150b2027],
14	of	IN	O	of	_	0	SENT_261	[p23l1178t1951r1254b2011],
15	educational	JJ	O	educational	amod	16	SENT_261	[p23l1272t1952r1656b2012],
16	presentations	NNS	O	presentation	prep_of	13	SENT_261	[p23l1686t1953r2133b2027],
17	from	IN	O	from	_	0	SENT_261	[p23l10t2038r170b2098],
18	Genentech/Roche	NNP	O	Genentech/Roche	prep_from	4	SENT_261	[p23l203t2039r803b2106],
19	.	.	O	.	_	0	SENT_261	[p23l203t2039r803b2106],

1	No	DT	O	no	det	4	SENT_262	[p23l839t2044r934b2099],
2	other	JJ	O	other	amod	4	SENT_262	[p23l969t2039r1143b2098],
3	potential	JJ	O	potential	amod	4	SENT_262	[p23l1173t2039r1471b2114],
4	conflict	NN	O	conflict	nsubjpass	12	SENT_262	[p23l1504t2038r1762b2098],
5	of	IN	O	of	_	0	SENT_262	[p23l1792t2038r1868b2098],
6	interest	NN	O	interest	prep_of	4	SENT_262	[p23l1887t2040r2138b2098],
7	relevant	JJ	O	relevant	amod	6	SENT_262	[p23l10t2126r272b2186],
8	to	TO	O	to	_	0	SENT_262	[p23l293t2139r355b2185],
9	this	DT	O	this	det	10	SENT_262	[p23l382t2126r504b2184],
10	article	NN	O	article	prep_to	7	SENT_262	[p23l531t2126r736b2184],
11	was	VBD	O	be	auxpass	12	SENT_262	[p23l758t2145r882b2186],
12	reported	VBN	O	report	_	0	SENT_262	[p23l909t2126r1208b2201],
13	.	.	O	.	_	0	SENT_262	[p23l909t2126r1208b2201],

1	Disclosure	NN	O	disclosure	nsubj	2	SENT_263	[p23l95t2213r442b2273],
2	forms	VBZ	O	form	_	0	SENT_263	[p23l475t2212r667b2272],
3	provided	VBN	O	provide	csubj	8	SENT_263	[p23l701t2213r987b2288],
4	by	IN	O	by	_	0	SENT_263	[p23l1021t2213r1095b2288],
5	the	DT	O	the	det	6	SENT_263	[p23l1124t2213r1226b2271],
6	authors	NNS	O	author	prep_by	3	SENT_263	[p23l1258t2213r1505b2273],
7	are	VBP	O	be	cop	8	SENT_263	[p23l1539t2232r1637b2271],
8	available	JJ	O	available	ccomp	2	SENT_263	[p23l1670t2213r1955b2273],
9	with	IN	O	with	_	0	SENT_263	[p23l1985t2213r2134b2273],
10	the	DT	O	the	det	12	SENT_263	[p23l11t2300r112b2359],
11	full	JJ	O	full	amod	12	SENT_263	[p23l137t2299r251b2360],
12	text	NN	O	text	prep_with	8	SENT_263	[p23l276t2313r399b2358],
13	of	IN	O	of	_	0	SENT_263	[p23l421t2299r497b2359],
14	this	DT	O	this	det	15	SENT_263	[p23l509t2300r631b2358],
15	article	NN	O	article	prep_of	12	SENT_263	[p23l657t2300r863b2359],
16	at	IN	O	at	_	0	SENT_263	[p23l888t2313r949b2358],
17	NEJM.org	NN	O	nejm.org	prep_at	15	SENT_263	[p23l968t2305r1307b2375],
18	.	.	O	.	_	0	SENT_263	[p23l968t2305r1307b2375],

1	REFERENCES	NNS	O	reference	_	0	SENT_264	[p23l96t2456r263b2473],
2	1	CD	NUMBER	1	num	1	SENT_264	[p23l95t2492r114b2512],
3	.	.	O	.	_	0	SENT_264	[p23l95t2492r114b2512],

1	Jemal	NNP	PERSON	Jemal	nn	2	SENT_265	[p23l141t2489r214b2516],
2	A	NNP	PERSON	A	ccomp	12	SENT_265	[p23l224t2491r250b2517],
3	,	,	O	,	_	0	SENT_265	[p23l224t2491r250b2517],
4	ie	FW	O	ie	nn	6	SENT_265	[p23l278t2489r299b2512],
5	el	FW	O	el	nn	6	SENT_265	[p23l317t2489r338b2512],
6	R	NN	O	r	appos	2	SENT_265	[p23l348t2491r374b2517],
7	,	,	O	,	_	0	SENT_265	[p23l348t2491r374b2517],
8	,	,	O	,	_	0	SENT_265	[p23l440t2508r444b2517],
9	Ward	NNP	PERSON	Ward	nn	10	SENT_265	[p23l456t2489r524b2513],
10	E.	NNP	O	E.	nsubj	12	SENT_265	[p23l535t2491r558b2513],
11	Can	MD	O	can	aux	12	SENT_265	[p23l571t2491r629b2513],
12	—	VB	O	—	_	0	SENT_265	[p23l571t2491r629b2513],
13	PaclitaXel	NN	O	paclitaxel	nn	15	SENT_265	[p23l668t2489r950b2519],
14	—	NN	O	—	nn	15	SENT_265	[p23l668t2489r950b2519],
15	carboplatin	NN	O	carboplatin	dobj	12	SENT_265	[p23l668t2489r950b2519],
16	alone	RB	O	alone	dep	22	SENT_265	[p23l959t2489r1028b2513],
17	or	CC	O	or	_	0	SENT_265	[p23l1038t2497r1064b2513],
18	with	IN	O	with	conj_or	16	SENT_265	[p23l1071t2489r1129b2513],
19	beva	NN	O	beva	pobj	18	SENT_265	[p23l1139t2489r1205b2513],
20	—	CD	NUMBER	—	num	19	SENT_265	[p23l1139t2489r1205b2513],
21	coma	NN	O	coma	nn	22	SENT_265	[p23l1244t2497r1313b2513],
22	viruses	NNS	O	virus	nsubj	24	SENT_265	[p23l1324t2489r1414b2513],
23	speciﬁcally	RB	O	speciﬁcally	advmod	24	SENT_265	[p23l1429t2489r1574b2519],
24	blocks	VBZ	O	block	rcmod	15	SENT_265	[p23l1586t2489r1667b2513],
25	binding	NN	O	binding	nn	27	SENT_265	[p23l1681t2489r1781b2519],
26	cer	NN	O	cer	nn	27	SENT_265	[p23l94t2534r131b2549],
27	Statistics	NNS	O	statistics	dobj	24	SENT_265	[p23l140t2526r259b2554],
28	,	,	O	,	_	0	SENT_265	[p23l140t2526r259b2554],
29	.	.	O	.	_	0	SENT_265	[p23l330t2545r334b2550],

1	CA	NNP	O	CA	nn	2	SENT_266	[p23l345t2528r382b2550],
2	ancer	NN	O	ancer	_	0	SENT_266	[p23l409t2528r494b2553],
3	]	CD	NUMBER	]	num	4	SENT_266	[p23l409t2528r494b2553],
4	Clin	NNP	O	Clin	dep	2	SENT_266	[p23l502t2526r554b2550],
5	2010	CD	DATE	2010	num	4	SENT_266	[p23l563t2528r629b2554],
6	;	:	O	;	_	0	SENT_266	[p23l563t2528r629b2554],
7	cizumab	NN	O	cizumab	dep	2	SENT_266	[p23l669t2526r778b2550],
8	for	IN	O	for	_	0	SENT_266	[p23l791t2526r828b2550],
9	non	JJ	O	non	amod	15	SENT_266	[p23l840t2526r1032b2550],
10	—	JJ	O	—	amod	15	SENT_266	[p23l840t2526r1032b2550],
11	small	JJ	O	small	amod	15	SENT_266	[p23l840t2526r1032b2550],
12	—	NN	O	—	nn	15	SENT_266	[p23l840t2526r1032b2550],
13	cell	NN	O	cell	nn	15	SENT_266	[p23l840t2526r1032b2550],
14	lung	NN	O	lung	nn	15	SENT_266	[p23l1044t2526r1102b2556],
15	cancer	NN	O	cancer	prep_for	7	SENT_266	[p23l1114t2534r1203b2549],
16	.	.	O	.	_	0	SENT_266	[p23l1114t2534r1203b2549],

1	e	SYM	O	e	dep	2	SENT_267	[p23l1277t2534r1288b2549],
2	idermal	JJ	O	idermal	_	0	SENT_267	[p23l1306t2526r1402b2550],
3	growth	NN	O	growth	nn	4	SENT_267	[p23l1410t2526r1502b2556],
4	factor	NN	O	factor	dobj	2	SENT_267	[p23l1510t2526r1583b2550],
5	to	TO	O	to	_	0	SENT_267	[p23l1591t2531r1614b2550],
6	cells	NNS	O	cell	prep_to	2	SENT_267	[p23l1623t2526r1685b2550],
7	.	.	O	.	_	0	SENT_267	[p23l1623t2526r1685b2550],

1	Nature	NNP	O	Nature	_	0	SENT_268	[p23l1694t2528r1780b2550],
2	60:277	CD	NUMBER	60:277	number	3	SENT_268	[p23l94t2565r240b2587],
3	-300	CD	NUMBER	-300	num	1	SENT_268	[p23l94t2565r240b2587],
4	.	.	O	.	_	0	SENT_268	[p23l94t2565r240b2587],

1	N	NN	O	n	nsubj	2	SENT_269	[p23l668t2565r690b2587],
2	EnglJMed	VBD	O	engljm	_	0	SENT_269	[p23l699t2563r838b2593],
3	2006	CD	DATE	2006	dobj	2	SENT_269	[p23l848t2565r947b2591],
4	;	:	O	;	_	0	SENT_269	[p23l848t2565r947b2591],
5	35	CD	NUMBER	35	num	7	SENT_269	[p23l848t2565r947b2591],
6	:	:	O	:	_	0	SENT_269	[p23l965t2573r970b2587],
7	42-50	CD	NUMBER	42-50	dep	3	SENT_269	[p23l1003t2565r1078b2587],
8	.	.	O	.	_	0	SENT_269	[p23l1003t2565r1078b2587],

1	;	:	O	;	_	0	SENT_270	[p23l1306t2565r1444b2591],
2	264:26	CD	NUMBER	264:26	_	0	SENT_270	[p23l1306t2565r1444b2591],
3	—	CD	NUMBER	—	num	4	SENT_270	[p23l1306t2565r1444b2591],
4	31	CD	NUMBER	31	dep	2	SENT_270	[p23l1306t2565r1444b2591],
5	.	.	O	.	_	0	SENT_270	[p23l1306t2565r1444b2591],

1	2	LS	NUMBER	2	_	0	SENT_271	[p23l93t2603r115b2623],
2	.	.	O	.	_	0	SENT_271	[p23l93t2603r115b2623],

1	Schiller	NNP	PERSON	Schiller	nn	2	SENT_272	[p23l144t2600r243b2624],
2	JH	NNP	O	JH	_	0	SENT_272	[p23l252t2602r293b2628],
3	,	,	O	,	_	0	SENT_272	[p23l252t2602r293b2628],
4	Harrington	NNP	PERSON	Harrington	nn	5	SENT_272	[p23l307t2600r456b2630],
5	D	NNP	O	D	appos	2	SENT_272	[p23l468t2602r495b2628],
6	,	,	O	,	_	0	SENT_272	[p23l468t2602r495b2628],
7	Belani	NNP	PERSON	Belani	nn	8	SENT_272	[p23l508t2600r591b2623],
8	C	NNP	O	C	appos	2	SENT_272	[p23l603t2602r628b2628],
9	,	,	O	,	_	0	SENT_272	[p23l603t2602r628b2628],
10	4	CD	NUMBER	4	appos	2	SENT_272	[p23l668t2603r689b2623],
11	.	.	O	.	_	0	SENT_272	[p23l668t2603r689b2623],

1	ational	JJ	O	ational	amod	5	SENT_273	[p23l741t2600r829b2624],
2	Institutes	NNP	O	Institutes	nn	5	SENT_273	[p23l839t2600r960b2624],
3	Health	NNP	O	Health	nn	5	SENT_273	[p23l1004t2600r1097b2628],
4	,	,	O	,	_	0	SENT_273	[p23l1004t2600r1097b2628],
5	Nation	NNP	O	Nation	_	0	SENT_273	[p23l1108t2601r1205b2624],
6	—	CD	NUMBER	—	number	7	SENT_273	[p23l1108t2601r1205b2624],
7	6	CD	NUMBER	6	num	5	SENT_273	[p23l1244t2603r1264b2624],
8	.	.	O	.	_	0	SENT_273	[p23l1244t2603r1264b2624],

1	Herbst	NNP	ORGANIZATION	Herbst	nn	2	SENT_274	[p23l1294t2600r1380b2624],
2	RS	NN	ORGANIZATION	r	_	0	SENT_274	[p23l1387t2602r1429b2628],
3	,	,	O	,	_	0	SENT_274	[p23l1387t2602r1429b2628],
4	Heymach	NNP	O	Heymach	nn	5	SENT_274	[p23l1439t2600r1559b2630],
5	JV	NNP	O	JV	appos	2	SENT_274	[p23l1565t2602r1599b2628],
6	,	,	O	,	_	0	SENT_274	[p23l1565t2602r1599b2628],
7	Lippman	NNP	PERSON	Lippman	nn	8	SENT_274	[p23l1609t2600r1723b2630],
8	SM	NNP	O	SM	appos	5	SENT_274	[p23l1733t2602r1778b2624],
9	.	.	O	.	_	0	SENT_274	[p23l1733t2602r1778b2624],

1	et	FW	O	et	_	0	SENT_275	[p23l94t2642r117b2660],
2	al.	FW	O	al.	dep	1	SENT_275	[p23l130t2637r159b2661],
3	.	.	O	.	_	0	SENT_275	[p23l130t2637r159b2661],

1	Comparison	NN	O	comparison	_	0	SENT_276	[p23l174t2637r331b2667],
2	of	IN	O	of	_	0	SENT_276	[p23l345t2637r375b2661],
3	four	CD	NUMBER	four	num	5	SENT_276	[p23l383t2637r437b2661],
4	chem	NN	O	chem	nn	5	SENT_276	[p23l450t2637r518b2660],
5	erapy	NN	O	erapy	prep_of	1	SENT_276	[p23l563t2645r631b2667],
6	a	DT	O	a	det	7	SENT_276	[p23l669t2645r682b2660],
7	ancer	NN	O	ancer	dep	1	SENT_276	[p23l721t2645r791b2660],
8	Institute	NNP	O	Institute	nn	10	SENT_276	[p23l801t2638r909b2661],
9	Web	NN	O	web	nn	10	SENT_276	[p23l920t2637r975b2661],
10	site	NN	O	site	dep	7	SENT_276	[p23l987t2638r1037b2661],
11	.	.	O	.	_	0	SENT_276	[p23l987t2638r1037b2661],

1	(	NN	O	(	nn	2	SENT_277	[p23l1051t2637r1206b2667],
2	http	NN	O	http	_	0	SENT_277	[p23l1051t2637r1206b2667],
3	:	:	O	:	_	0	SENT_277	[p23l1051t2637r1206b2667],
4	/	:	O	/	punct	8	SENT_277	[p23l1051t2637r1206b2667],
5	Iwww	NNP	O	Iwww	nn	8	SENT_277	[p23l1051t2637r1206b2667],
6	Lung	NN	O	lung	nn	8	SENT_277	[p23l1244t2639r1309b2667],
7	ccccc	NN	O	ccccc	nn	8	SENT_277	[p23l1316t2645r1387b2660],
8	r.	NN	O	r.	dep	15	SENT_277	[p23l1389t2645r1405b2660],
9	N	NN	O	n	dep	8	SENT_277	[p23l1414t2639r1436b2661],
10	EnglJMed	JJ	O	engljmed	amod	9	SENT_277	[p23l1444t2637r1579b2667],
11	2008	CD	DATE	2008	tmod	10	SENT_277	[p23l1587t2639r1780b2665, p23l94t2675r167b2704],
12	;	:	O	;	_	0	SENT_277	[p23l1587t2639r1780b2665, p23l94t2675r167b2704],
13	359:1367	CD	NUMBER	359:1367	num	14	SENT_277	[p23l1587t2639r1780b2665, p23l94t2675r167b2704],
14	regim	NN	O	regim	dep	9	SENT_277	[p23l1587t2639r1780b2665, p23l94t2675r167b2704],
15	ns	NNS	O	n	nsubj	18	SENT_277	[p23l181t2682r209b2697],
16	for	IN	O	for	_	0	SENT_277	[p23l217t2674r253b2698],
17	advan	NN	O	advan	prep_for	15	SENT_277	[p23l260t2674r332b2698],
18	ed	VBD	O	ed	dep	2	SENT_277	[p23l346t2674r374b2698],
19	non	JJ	O	non	amod	20	SENT_277	[p23l382t2674r550b2698],
20	—	JJ	O	—	amod	24	SENT_277	[p23l382t2674r550b2698],
21	small	JJ	O	small	amod	24	SENT_277	[p23l382t2674r550b2698],
22	—	NN	O	—	nn	24	SENT_277	[p23l382t2674r550b2698],
23	ce	NN	O	ce	nn	24	SENT_277	[p23l382t2674r550b2698],
24	ung	NN	O	ung	dobj	18	SENT_277	[p23l583t2682r631b2704],
25	.	.	O	.	_	0	SENT_277	[p23l670t2676r826b2704],

1	cancer	NN	O	cancer	_	0	SENT_278	[p23l670t2676r826b2704],
2	.	.	O	.	_	0	SENT_278	[p23l670t2676r826b2704],

1	gov.	NN	O	gov.	_	0	SENT_279	[p23l670t2676r826b2704],
2	)	CD	NUMBER	)	number	3	SENT_279	[p23l670t2676r826b2704],
3	80	CD	NUMBER	80	num	1	SENT_279	[p23l1244t2676r1281b2698],
4	.	.	O	.	_	0	SENT_279	[p23l1244t2676r1281b2698],

1	ccccc	NN	O	ccccc	nn	3	SENT_280	[p23l94t2719r165b2734],
2	r.	NN	O	r.	nn	3	SENT_280	[p23l167t2719r183b2735],
3	NEngl	NN	O	nengl	nsubj	5	SENT_280	[p23l194t2711r364b2741],
4	]	CD	NUMBER	]	dep	3	SENT_280	[p23l194t2711r364b2741],
5	Med	VBD	O	med	_	0	SENT_280	[p23l194t2711r364b2741],
6	2002	CD	DATE	2002	dobj	5	SENT_280	[p23l374t2713r560b2739],
7	;	:	O	;	_	0	SENT_280	[p23l374t2713r560b2739],
8	346:92	CD	NUMBER	346:92	number	9	SENT_280	[p23l374t2713r560b2739],
9	—	CD	NUMBER	—	dep	6	SENT_280	[p23l374t2713r560b2739],
10	8	CD	NUMBER	8	dep	9	SENT_280	[p23l374t2713r560b2739],
11	.	.	O	.	_	0	SENT_280	[p23l374t2713r560b2739],

1	5	CD	NUMBER	5	_	0	SENT_281	[p23l669t2714r689b2734],
2	.	.	O	.	_	0	SENT_281	[p23l669t2714r689b2734],

1	Todaro	NNP	PERSON	Todaro	nn	3	SENT_282	[p23l718t2711r808b2735],
2	G	NNP	O	G	nn	3	SENT_282	[p23l832t2713r868b2739],
3	]	NNS	O	]	_	0	SENT_282	[p23l832t2713r868b2739],
4	,	,	O	,	_	0	SENT_282	[p23l832t2713r868b2739],
5	DeLarco	NNP	O	DeLarco	nn	6	SENT_282	[p23l892t2713r998b2735],
6	IE	NN	O	ie	appos	3	SENT_282	[p23l1018t2713r1053b2739],
7	,	,	O	,	_	0	SENT_282	[p23l1018t2713r1053b2739],
8	Cohen	NNP	PERSON	Cohen	nn	9	SENT_282	[p23l1078t2711r1159b2735],
9	S.	NNP	O	S.	appos	3	SENT_282	[p23l1183t2713r1203b2735],
10	7	CD	NUMBER	7	dep	9	SENT_282	[p23l1245t2714r1262b2734],
11	.	.	O	.	_	0	SENT_282	[p23l1245t2714r1262b2734],

1	Salomon	NNP	O	Salomon	nn	2	SENT_283	[p23l1295t2711r1406b2735],
2	DS	NN	O	d	_	0	SENT_283	[p23l1420t2713r1462b2739],
3	,	,	O	,	_	0	SENT_283	[p23l1420t2713r1462b2739],
4	Brandt	NNP	PERSON	Brandt	nn	5	SENT_283	[p23l1478t2711r1565b2735],
5	R	NNP	PERSON	R	appos	2	SENT_283	[p23l1578t2713r1603b2739],
6	,	,	O	,	_	0	SENT_283	[p23l1578t2713r1603b2739],
7	Ciar	NNP	O	Ciar	appos	2	SENT_283	[p23l1619t2712r1672b2735],
8	ie	FW	O	ie	nn	10	SENT_283	[p23l1690t2712r1711b2734],
9	lo	FW	O	lo	nn	10	SENT_283	[p23l1721t2711r1744b2735],
10	F	NN	O	f	dep	7	SENT_283	[p23l1759t2713r1779b2739],
11	,	,	O	,	_	0	SENT_283	[p23l1759t2713r1779b2739],
12	3	CD	NUMBER	3	appos	2	SENT_283	[p23l94t2751r114b2771],
13	.	.	O	.	_	0	SENT_283	[p23l94t2751r114b2771],

1	Sandler	NNP	O	Sandler	nn	2	SENT_284	[p23l144t2748r242b2772],
2	A	NNP	O	A	_	0	SENT_284	[p23l258t2750r284b2776],
3	,	,	O	,	_	0	SENT_284	[p23l258t2750r284b2776],
4	Gray	NNP	ORGANIZATION	Gray	nn	5	SENT_284	[p23l303t2750r364b2778],
5	R	NNP	ORGANIZATION	R	appos	2	SENT_284	[p23l380t2750r406b2776],
6	,	,	O	,	_	0	SENT_284	[p23l380t2750r406b2776],
7	Perry	NNP	PERSON	Perry	nn	8	SENT_284	[p23l425t2750r493b2778],
8	M	NNP	O	M	appos	2	SENT_284	[p23l508t2750r540b2776],
9	,	,	O	,	_	0	SENT_284	[p23l508t2750r540b2776],
10	et	FW	O	et	nn	11	SENT_284	[p23l560t2753r583b2771],
11	al.	FW	O	al.	appos	2	SENT_284	[p23l599t2748r628b2771],
12	.	.	O	.	_	0	SENT_284	[p23l599t2748r628b2771],

1	Transformation	NN	O	transformation	_	0	SENT_285	[p23l668t2748r871b2772],
2	by	IN	O	by	dep	1	SENT_285	[p23l881t2748r909b2778],
3	murine	JJ	O	murine	pobj	2	SENT_285	[p23l918t2748r1010b2772],
4	and	CC	O	and	_	0	SENT_285	[p23l1020t2748r1066b2772],
5	feline	JJ	O	feline	amod	7	SENT_285	[p23l1076t2748r1147b2771],
6	sar	JJ	O	sar	amod	7	SENT_285	[p23l1158t2756r1205b2771],
7	—	NN	O	—	conj_and	3	SENT_285	[p23l1158t2756r1205b2771],
8	Normanno	NNP	O	Normanno	nn	10	SENT_285	[p23l1243t2750r1384b2772],
9	N.	NNP	O	N.	nn	10	SENT_285	[p23l1398t2750r1426b2772],
10	Epidermal	NNP	O	Epidermal	nsubj	11	SENT_285	[p23l1442t2748r1574b2778],
11	grow	VB	O	grow	rcmod	7	SENT_285	[p23l1588t2756r1654b2778],
12	actor	NN	O	actor	dobj	11	SENT_285	[p23l1707t2753r1780b2772],
13	—	IN	O	—	prep	11	SENT_285	[p23l1707t2753r1780b2772],

1	N	NN	O	n	nn	3	SENT_286	[p23l609t2863r622b2878],
2	ENGLJ	NN	O	englj	nn	3	SENT_286	[p23l637t2863r715b2885],
3	MED	NN	O	med	_	0	SENT_286	[p23l730t2863r782b2878],
4	364	CD	NUMBER	364	num	6	SENT_286	[p23l792t2857r874b2885],
5	;	:	O	;	_	0	SENT_286	[p23l792t2857r874b2885],
6	1o	CD	NUMBER	1o	dep	3	SENT_286	[p23l792t2857r874b2885],
7	NEJM	NNP	O	NEJM	dep	6	SENT_286	[p23l909t2863r1033b2885],
8	,	,	O	,	_	0	SENT_286	[p23l909t2863r1033b2885],
9	ORG	NNP	O	ORG	nn	10	SENT_286	[p23l909t2863r1033b2885],
10	MARCH	NNP	DATE	MARCH	appos	7	SENT_286	[p23l1070t2863r1155b2878],
11	10	CD	DATE	10	num	10	SENT_286	[p23l1168t2863r1201b2883],
12	,	,	DATE	,	_	0	SENT_286	[p23l1168t2863r1201b2883],
13	2011	CD	DATE	2011	num	10	SENT_286	[p23l1212t2863r1264b2879],
14	953	CD	NUMBER	953	dep	3	SENT_286	[p23l2010t2853r2066b2876],

1	The	DT	O	the	det	4	SENT_287	[p23l752t2920r803b2944],
2	New	NNP	O	New	nn	4	SENT_287	[p23l812t2921r874b2944],
3	England	NNP	O	England	nn	4	SENT_287	[p23l884t2920r994b2951],
4	Journal	NNP	O	Journal	_	0	SENT_287	[p23l1003t2920r1100b2944],
5	of	IN	O	of	_	0	SENT_287	[p23l1110t2920r1139b2944],
6	Medicine	NNP	O	Medicine	prep_of	4	SENT_287	[p23l1146t2920r1271b2944],

1	Downloaded	VBN	O	download	_	0	SENT_288	[p23l194t2961r364b2984],
2	from	IN	O	from	_	0	SENT_288	[p23l373t2961r438b2984],
3	nejm.org	NN	O	nejm.org	prep_from	1	SENT_288	[p23l446t2961r565b2991],
4	at	IN	O	at	_	0	SENT_288	[p23l575t2965r598b2984],
5	UW-Madison	NN	O	uw-madison	prep_at	1	SENT_288	[p23l607t2961r789b2984],
6	on	IN	O	on	_	0	SENT_288	[p23l799t2968r831b2984],
7	January	NNP	DATE	January	prep_on	1	SENT_288	[p23l840t2961r942b2991],
8	5	CD	DATE	5	num	7	SENT_288	[p23l952t2961r975b2988],
9	,	,	DATE	,	_	0	SENT_288	[p23l952t2961r975b2988],
10	2014	CD	DATE	2014	num	7	SENT_288	[p23l986t2961r1058b2984],
11	.	.	O	.	_	0	SENT_288	[p23l986t2961r1058b2984],

1	For	IN	O	for	_	0	SENT_289	[p23l1068t2961r1115b2984],
2	personal	JJ	O	personal	amod	3	SENT_289	[p23l1123t2961r1235b2991],
3	use	NN	O	use	pobj	1	SENT_289	[p23l1245t2968r1288b2984],
4	only	RB	O	only	advmod	3	SENT_289	[p23l1298t2961r1362b2991],
5	.	.	O	.	_	0	SENT_289	[p23l1298t2961r1362b2991],

1	No	DT	O	no	det	3	SENT_290	[p23l1373t2961r1413b2984],
2	other	JJ	O	other	amod	3	SENT_290	[p23l1423t2961r1491b2984],
3	uses	NNS	O	use	_	0	SENT_290	[p23l1499t2968r1555b2984],
4	without	IN	O	without	_	0	SENT_290	[p23l1565t2961r1667b2984],
5	permission	NN	O	permission	prep_without	3	SENT_290	[p23l1675t2961r1827b2991],
6	.	.	O	.	_	0	SENT_290	[p23l1675t2961r1827b2991],

1	Copyright	NN	O	copyright	_	0	SENT_291	[p23l545t3002r679b3033],
2	©	CD	NUMBER	©	num	6	SENT_291	[p23l689t3002r712b3026],
3	2011	CD	DATE	2011	num	6	SENT_291	[p23l722t3002r784b3026],
4	Massachusetts	NNP	ORGANIZATION	Massachusetts	nn	6	SENT_291	[p23l796t3002r988b3026],
5	Medical	NNP	ORGANIZATION	Medical	nn	6	SENT_291	[p23l997t3002r1106b3026],
6	Society	NNP	ORGANIZATION	Society	dep	1	SENT_291	[p23l1116t3002r1221b3033],
7	.	.	O	.	_	0	SENT_291	[p23l1116t3002r1221b3033],

1	All	DT	O	all	det	2	SENT_292	[p23l1232t3002r1273b3026],
2	rights	NNS	O	rights	nsubj	3	SENT_292	[p23l1283t3002r1357b3033],
3	reserved	VBN	O	reserve	_	0	SENT_292	[p23l1367t3002r1486b3026],
4	.	.	O	.	_	0	SENT_292	[p23l1367t3002r1486b3026],

1	The	DT	O	the	det	4	SENT_293	[p23l673t3108r718b3129],
2	NEW	NNP	O	NEW	nn	4	SENT_293	[p23l737t3110r822b3129],
3	ENGLAND	NNP	O	ENGLAND	nn	4	SENT_293	[p23l841t3110r1029b3129],
4	JOURNAL	NNP	O	JOURNAL	_	0	SENT_293	[p23l1048t3110r1227b3136],
5	of	IN	O	of	_	0	SENT_293	[p23l1247t3108r1275b3135],
6	MEDICINE	NNP	O	MEDICINE	prep_of	4	SENT_293	[p23l1287t3110r1486b3129],

1	related	JJ	O	related	amod	2	SENT_294	[p23l19t3433r363b3524],
2	peptides	NNS	O	peptide	_	0	SENT_294	[p23l395t3433r821b3548],
3	and	CC	O	and	_	0	SENT_294	[p23l856t3433r1041b3524],
4	their	PRP$	O	they	poss	5	SENT_294	[p23l1076t3433r1314b3524],
5	receptors	NNS	O	receptor	conj_and	2	SENT_294	[p23l1345t3453r1811b3548],
6	in	IN	O	in	_	0	SENT_294	[p23l1846t3435r1943b3522],
7	human	JJ	O	human	amod	8	SENT_294	[p23l1979t3433r2139b3524, p23l19t3612r242b3673],
8	malignancies	NNS	O	malignancy	prep_in	5	SENT_294	[p23l280t3582r987b3699],
9	.	.	O	.	_	0	SENT_294	[p23l280t3582r987b3699],

1	Crit	NNP	O	Crit	_	0	SENT_295	[p23l1032t3584r1221b3673],
2	Rev	NN	O	rev	nn	4	SENT_295	[p23l1252t3590r1436b3679],
3	Oncol	NN	O	oncol	nn	4	SENT_295	[p23l1470t3582r1767b3673],
4	Hematol	NN	O	hematol	dep	1	SENT_295	[p23l1805t3590r2139b3673, p24l19t23r150b114],

1	1995	CD	DATE	1995	_	0	SENT_296	[p24l193t31r1035b132],
2	;	:	O	;	_	0	SENT_296	[p24l193t31r1035b132],
3	19:183	CD	NUMBER	19:183	number	4	SENT_296	[p24l193t31r1035b132],
4	-232	CD	NUMBER	-232	dep	1	SENT_296	[p24l193t31r1035b132],
5	.	.	O	.	_	0	SENT_296	[p24l193t31r1035b132],

1	8	CD	NUMBER	8	_	0	SENT_297	[p24l17t182r98b263],
2	.	.	O	.	_	0	SENT_297	[p24l17t182r98b263],

1	Yarden	NNP	PERSON	Yarden	nn	2	SENT_298	[p24l213t172r561b263],
2	Y	NN	PERSON	y	_	0	SENT_298	[p24l593t180r676b283],
3	,	,	O	,	_	0	SENT_298	[p24l593t180r676b283],
4	Sliwkowski	NNP	O	Sliwkowski	nn	5	SENT_298	[p24l721t172r1292b264],
5	MX	NNP	O	MX	appos	2	SENT_298	[p24l1323t180r1524b263],
6	.	.	O	.	_	0	SENT_298	[p24l1323t180r1524b263],

1	Untangling	VBG	O	untangle	_	0	SENT_299	[p24l1565t172r2145b289],
2	the	DT	O	the	det	5	SENT_299	[p24l19t321r175b412],
3	ErbB	NN	O	erbb	nn	5	SENT_299	[p24l217t321r456b412],
4	signaling	NN	O	signaling	nn	5	SENT_299	[p24l504t321r979b438],
5	network	NN	O	network	dobj	1	SENT_299	[p24l1019t321r1460b412],
6	.	.	O	.	_	0	SENT_299	[p24l1019t321r1460b412],

1	Nat	NNP	O	Nat	nn	5	SENT_300	[p24l1509t329r1690b412],
2	Rev	NN	O	rev	nn	5	SENT_300	[p24l1727t329r1910b418],
3	Mol	NNP	O	Mol	nn	5	SENT_300	[p24l1947t321r2141b412],
4	Cell	NNP	O	Cell	nn	5	SENT_300	[p24l19t470r213b561],
5	Biol	NNP	O	Biol	_	0	SENT_300	[p24l251t470r446b561],
6	2001	CD	DATE	2001	num	5	SENT_300	[p24l486t478r1199b579],
7	;	:	O	;	_	0	SENT_300	[p24l486t478r1199b579],
8	2:127	CD	NUMBER	2:127	number	9	SENT_300	[p24l486t478r1199b579],
9	—	CD	NUMBER	—	dep	5	SENT_300	[p24l486t478r1199b579],
10	37	CD	NUMBER	37	dep	9	SENT_300	[p24l486t478r1199b579],
11	.	.	O	.	_	0	SENT_300	[p24l486t478r1199b579],

1	9	CD	NUMBER	9	_	0	SENT_301	[p24l19t631r94b710],
2	.	.	O	.	_	0	SENT_301	[p24l19t631r94b710],

1	Schlessinger	NNP	O	Schlessinger	nn	3	SENT_302	[p24l219t619r840b736],
2	J.	NNP	O	J.	nn	3	SENT_302	[p24l860t629r926b724],
3	Cell	NNP	O	Cell	nsubj	4	SENT_302	[p24l969t619r1159b710],
4	signaling	NN	O	signaling	_	0	SENT_302	[p24l1197t619r1662b736],
5	by	IN	O	by	_	0	SENT_302	[p24l1694t619r1806b734],
6	receptor	NN	O	receptor	nn	8	SENT_302	[p24l1836t649r2139b734, p24l19t788r161b859],
7	tyrosine	NN	O	tyrosine	nn	8	SENT_302	[p24l195t770r593b883],
8	kinases	NNS	O	kinase	prep_by	4	SENT_302	[p24l631t768r1030b860],
9	.	.	O	.	_	0	SENT_302	[p24l631t768r1030b860],

1	Cell	NN	O	cell	_	0	SENT_303	[p24l1074t768r1264b859],
2	2000	CD	DATE	2000	num	1	SENT_303	[p24l1301t776r2127b877],
3	;	:	O	;	_	0	SENT_303	[p24l1301t776r2127b877],
4	103:211	CD	NUMBER	103:211	number	5	SENT_303	[p24l1301t776r2127b877],
5	-25	CD	NUMBER	-25	dep	1	SENT_303	[p24l1301t776r2127b877],
6	.	.	O	.	_	0	SENT_303	[p24l1301t776r2127b877],

1	10	CD	NUMBER	10	_	0	SENT_304	[p24l23t927r152b1008],
2	.	.	O	.	_	0	SENT_304	[p24l23t927r152b1008],

1	Zhang	NNP	PERSON	Zhang	nn	2	SENT_305	[p24l215t917r539b1034],
2	X	NNP	PERSON	X	_	0	SENT_305	[p24l565t925r661b1028],
3	,	,	O	,	_	0	SENT_305	[p24l565t925r661b1028],
4	Gureasko	NNP	PERSON	Gureasko	nn	5	SENT_305	[p24l702t917r1181b1008],
5	J	NNP	PERSON	J	appos	2	SENT_305	[p24l1206t925r1272b1028],
6	,	,	O	,	_	0	SENT_305	[p24l1206t925r1272b1028],
7	Shen	NNP	O	Shen	nn	8	SENT_305	[p24l1315t917r1553b1008],
8	K	NNP	O	K	appos	2	SENT_305	[p24l1587t925r1688b1028],
9	,	,	O	,	_	0	SENT_305	[p24l1587t925r1688b1028],
10	et	FW	O	et	nn	11	SENT_305	[p24l1729t937r1820b1008],
11	al.	FW	O	al.	appos	2	SENT_305	[p24l1848t917r1961b1008],
12	.	.	O	.	_	0	SENT_305	[p24l1848t917r1961b1008],

1	An	DT	O	a	det	3	SENT_306	[p24l1997t925r2141b1006],
2	allosteric	JJ	O	allosteric	amod	3	SENT_306	[p24l19t1065r484b1156],
3	mechanism	NN	O	mechanism	_	0	SENT_306	[p24l520t1065r1108b1156],
4	for	IN	O	for	_	0	SENT_306	[p24l1145t1065r1290b1156],
5	activation	NN	O	activation	prep_for	3	SENT_306	[p24l1322t1067r1814b1156],
6	of	IN	O	of	_	0	SENT_306	[p24l1852t1065r1969b1156],
7	the	DT	O	the	det	9	SENT_306	[p24l1985t1065r2141b1156],
8	kinase	NN	O	kinase	nn	9	SENT_306	[p24l19t1214r346b1305],
9	domain	NN	O	domain	prep_of	3	SENT_306	[p24l397t1214r783b1305],
10	of	IN	O	of	_	0	SENT_306	[p24l836t1214r952b1305],
11	epidermal	JJ	O	epidermal	amod	14	SENT_306	[p24l983t1214r1490b1329],
12	growth	NN	O	growth	nn	14	SENT_306	[p24l1539t1214r1908b1331],
13	factor	NN	O	factor	nn	14	SENT_306	[p24l1959t1214r2139b1305, p24l19t1383r163b1454],
14	receptor	NN	O	receptor	prep_of	3	SENT_306	[p24l199t1383r641b1478],
15	.	.	O	.	_	0	SENT_306	[p24l199t1383r641b1478],

1	Cell	NN	O	cell	_	0	SENT_307	[p24l686t1363r882b1454],
2	2006	CD	DATE	2006	num	1	SENT_307	[p24l920t1371r1836b1474],
3	;	:	O	;	_	0	SENT_307	[p24l920t1371r1836b1474],
4	12S	CD	NUMBER	12s	number	5	SENT_307	[p24l920t1371r1836b1474],
5	:1137	CD	NUMBER	:1137	dep	1	SENT_307	[p24l920t1371r1836b1474],
6	—	NN	O	—	dep	5	SENT_307	[p24l920t1371r1836b1474],
7	49	CD	NUMBER	49	num	6	SENT_307	[p24l920t1371r1836b1474],
8	.	.	O	.	_	0	SENT_307	[p24l920t1371r1836b1474],

1	11	CD	NUMBER	11	_	0	SENT_308	[p24l23t1524r152b1603],
2	.	.	O	.	_	0	SENT_308	[p24l23t1524r152b1603],

1	Hanahan	NN	PERSON	hanahan	nn	2	SENT_309	[p24l217t1512r684b1603],
2	D	NN	O	d	_	0	SENT_309	[p24l735t1520r839b1623],
3	,	,	O	,	_	0	SENT_309	[p24l735t1520r839b1623],
4	Weinberg	NNP	PERSON	Weinberg	nn	5	SENT_309	[p24l894t1512r1385b1629],
5	RA	NN	O	ra	appos	2	SENT_309	[p24l1434t1520r1613b1609],
6	.	.	O	.	_	0	SENT_309	[p24l1434t1520r1613b1609],

1	The	DT	O	the	det	2	SENT_310	[p24l1670t1512r1856b1603],
2	hallmarks	NNS	O	hallmark	_	0	SENT_310	[p24l1911t1512r2139b1603, p24l19t1661r332b1752],
3	of	IN	O	of	_	0	SENT_310	[p24l375t1661r492b1752],
4	cancer	NN	O	cancer	prep_of	2	SENT_310	[p24l511t1691r862b1752],
5	.	.	O	.	_	0	SENT_310	[p24l511t1691r862b1752],

1	Cell	NN	O	cell	_	0	SENT_311	[p24l909t1661r1104b1752],
2	2000	CD	DATE	2000	num	1	SENT_311	[p24l1143t1669r1929b1770],
3	;	:	O	;	_	0	SENT_311	[p24l1143t1669r1929b1770],
4	100:5770	CD	NUMBER	100:5770	dep	1	SENT_311	[p24l1143t1669r1929b1770],
5	.	.	O	.	_	0	SENT_311	[p24l1143t1669r1929b1770],

1	12	CD	NUMBER	12	_	0	SENT_312	[p24l23t1822r156b1901],
2	.	.	O	.	_	0	SENT_312	[p24l23t1822r156b1901],

1	Mendelsohn	NNP	PERSON	Mendelsohn	nn	2	SENT_313	[p24l213t1810r838b1901],
2	J	NNP	PERSON	J	_	0	SENT_313	[p24l872t1820r938b1921],
3	,	,	O	,	_	0	SENT_313	[p24l872t1820r938b1921],
4	Baselga	NNP	O	Baselga	nn	9	SENT_313	[p24l989t1810r1373b1927],
5	J.	NNP	O	J.	nn	9	SENT_313	[p24l1405t1820r1472b1915],
6	The	NNP	O	The	nn	9	SENT_313	[p24l1519t1810r1708b1901],
7	EGF	NN	ORGANIZATION	egf	nn	9	SENT_313	[p24l1751t1818r1959b1901],
8	receptor	NN	O	receptor	nn	9	SENT_313	[p24l2006t1840r2139b1901, p24l21t1979r338b2074],
9	family	NN	O	family	appos	2	SENT_313	[p24l379t1959r702b2074],
10	as	IN	O	as	_	0	SENT_313	[p24l742t1989r841b2050],
11	targets	NNS	O	target	prep_as	9	SENT_313	[p24l890t1979r1237b2076],
12	for	IN	O	for	_	0	SENT_313	[p24l1286t1959r1429b2050],
13	cancer	NN	O	cancer	nn	14	SENT_313	[p24l1472t1989r1801b2050],
14	therapy	NN	O	therapy	prep_for	11	SENT_313	[p24l1844t1959r2139b2050, p24l17t2138r150b2223],
15	.	.	O	.	_	0	SENT_313	[p24l1844t1959r2139b2050, p24l17t2138r150b2223],

1	Oncogene	NN	O	oncogene	_	0	SENT_314	[p24l197t2116r700b2225],
2	2000	CD	DATE	2000	num	1	SENT_314	[p24l741t2116r1605b2219],
3	;	:	O	;	_	0	SENT_314	[p24l741t2116r1605b2219],
4	19:6	CD	NUMBER	19:6	num	5	SENT_314	[p24l741t2116r1605b2219],
5	S50	NN	O	s50	dep	1	SENT_314	[p24l741t2116r1605b2219],
6	—	CD	NUMBER	—	number	7	SENT_314	[p24l741t2116r1605b2219],
7	65	CD	NUMBER	65	dep	5	SENT_314	[p24l741t2116r1605b2219],
8	.	.	O	.	_	0	SENT_314	[p24l741t2116r1605b2219],

1	13	CD	NUMBER	13	_	0	SENT_315	[p24l23t2269r152b2348],
2	.	.	O	.	_	0	SENT_315	[p24l23t2269r152b2348],

1	Sordella	NN	O	sordellum	nn	2	SENT_316	[p24l219t2257r627b2348],
2	R	NN	O	r	_	0	SENT_316	[p24l658t2265r759b2366],
3	,	,	O	,	_	0	SENT_316	[p24l658t2265r759b2366],
4	Bell	NNP	ORGANIZATION	Bell	nn	5	SENT_316	[p24l797t2257r989b2348],
5	DW	NNP	ORGANIZATION	DW	appos	2	SENT_316	[p24l1019t2265r1223b2368],
6	,	,	O	,	_	0	SENT_316	[p24l1019t2265r1223b2368],
7	Haber	NNP	ORGANIZATION	Haber	nn	8	SENT_316	[p24l1262t2257r1571b2348],
8	DA	NNP	ORGANIZATION	DA	appos	2	SENT_316	[p24l1599t2265r1779b2368],
9	,	,	O	,	_	0	SENT_316	[p24l1599t2265r1779b2368],
10	Settleman	NNP	O	Settleman	nn	12	SENT_316	[p24l1822t2257r2139b2348, p24l19t2436r242b2497],
11	J.	NNP	O	J.	nn	12	SENT_316	[p24l280t2416r346b2511],
12	Gefitinib	NNP	O	Gefitinib	appos	2	SENT_316	[p24l401t2406r1468b2523],
13	—	CD	NUMBER	—	num	16	SENT_316	[p24l401t2406r1468b2523],
14	sensitizing	VBG	O	sensitize	amod	16	SENT_316	[p24l401t2406r1468b2523],
15	EGFR	NN	ORGANIZATION	egfr	nn	16	SENT_316	[p24l1511t2414r1811b2503],
16	mutations	NNS	O	mutation	nsubj	20	SENT_316	[p24l1846t2426r2139b2497, p24l19t2557r268b2646],
17	in	IN	O	in	_	0	SENT_316	[p24l308t2557r405b2644],
18	lung	NN	O	lung	nn	19	SENT_316	[p24l440t2555r667b2672],
19	cancer	NN	O	cancer	prep_in	16	SENT_316	[p24l702t2585r1031b2646],
20	activate	VBP	O	activate	rcmod	12	SENT_316	[p24l1064t2557r1444b2646],
21	anti	JJ	O	anti	amod	23	SENT_316	[p24l1480t2557r2139b2670],
22	—	NN	O	—	nn	23	SENT_316	[p24l1480t2557r2139b2670],
23	apoptot	NN	O	apoptot	dobj	20	SENT_316	[p24l1480t2557r2139b2670],
24	—	CD	NUMBER	—	num	26	SENT_316	[p24l1480t2557r2139b2670],
25	ic	JJ	O	ic	amod	26	SENT_316	[p24l19t2706r100b2795],
26	pathways	NNS	O	pathway	dep	23	SENT_316	[p24l136t2704r635b2819],
27	.	.	O	.	_	0	SENT_316	[p24l136t2704r635b2819],

1	Science	NNP	O	Science	_	0	SENT_317	[p24l684t2706r1051b2795],
2	2004	CD	DATE	2004	num	1	SENT_317	[p24l1092t2712r1931b2813],
3	;	:	O	;	_	0	SENT_317	[p24l1092t2712r1931b2813],
4	30	CD	NUMBER	30	dep	1	SENT_317	[p24l1092t2712r1931b2813],
5	'	''	O	'	_	0	SENT_317	[p24l1092t2712r1931b2813],
6	3:1163	CD	NUMBER	3:1163	dep	4	SENT_317	[p24l1092t2712r1931b2813],
7	—	NN	O	—	dep	4	SENT_317	[p24l1092t2712r1931b2813],
8	7	CD	NUMBER	7	num	7	SENT_317	[p24l1092t2712r1931b2813],
9	.	.	O	.	_	0	SENT_317	[p24l1092t2712r1931b2813],

1	14	CD	NUMBER	14	_	0	SENT_318	[p24l23t2865r154b2944],
2	.	.	O	.	_	0	SENT_318	[p24l23t2865r154b2944],

1	Shepherd	NNP	ORGANIZATION	Shepherd	nn	2	SENT_319	[p24l219t2853r686b2968],
2	FA	NNP	ORGANIZATION	FA	_	0	SENT_319	[p24l730t2861r886b2964],
3	,	,	O	,	_	0	SENT_319	[p24l730t2861r886b2964],
4	Rodrigues	NNP	PERSON	Rodrigues	nn	6	SENT_319	[p24l936t2853r1454b2970],
5	Pereira	NNP	PERSON	Pereira	nn	6	SENT_319	[p24l1500t2855r1852b2944],
6	J	NNP	PERSON	J	appos	2	SENT_319	[p24l1883t2863r1949b2964],
7	,	,	O	,	_	0	SENT_319	[p24l1883t2863r1949b2964],
8	Ciuleanu	NNP	O	Ciuleanu	nn	9	SENT_319	[p24l2000t2855r2139b2944, p24l19t3002r358b3093],
9	T	NN	O	t	appos	2	SENT_319	[p24l425t3010r516b3113],
10	,	,	O	,	_	0	SENT_319	[p24l425t3010r516b3113],
11	et	FW	O	et	nn	12	SENT_319	[p24l595t3022r684b3093],
12	al.	FW	O	al.	appos	2	SENT_319	[p24l749t3002r864b3093],
13	.	.	O	.	_	0	SENT_319	[p24l749t3002r864b3093],

1	Erlotinib	NNP	O	Erlotinib	nsubj	4	SENT_320	[p24l941t3002r1389b3093],
2	in	IN	O	in	prep	1	SENT_320	[p24l1460t3004r1557b3091],
3	previously	RB	DATE	previously	pcomp	2	SENT_320	[p24l1628t3002r2145b3117],
4	treated	VBN	O	treat	_	0	SENT_320	[p24l19t3151r363b3242],
5	non	JJ	O	non	amod	8	SENT_320	[p24l397t3151r1136b3242],
6	—	JJ	O	—	amod	8	SENT_320	[p24l397t3151r1136b3242],
7	small	JJ	O	small	amod	8	SENT_320	[p24l397t3151r1136b3242],
8	—	NN	O	—	tmod	4	SENT_320	[p24l397t3151r1136b3242],
9	cell	NN	O	cell	nn	11	SENT_320	[p24l397t3151r1136b3242],
10	lung	NN	O	lung	nn	11	SENT_320	[p24l1167t3151r1391b3268],
11	cancer	NN	O	cancer	dep	8	SENT_320	[p24l1420t3181r1765b3242],
12	.	.	O	.	_	0	SENT_320	[p24l1420t3181r1765b3242],

1	N	NN	O	n	nn	3	SENT_321	[p24l1801t3159r1888b3242],
2	Engl	NNP	O	Engl	nn	3	SENT_321	[p24l1917t3151r2141b3268],
3	J	NNP	O	J	nsubj	4	SENT_321	[p24l7t3310r51b3405],
4	Med	VBD	O	med	_	0	SENT_321	[p24l84t3300r302b3391],
5	2005	CD	DATE	2005	dobj	4	SENT_321	[p24l341t3308r1193b3409],
6	;	:	O	;	_	0	SENT_321	[p24l341t3308r1193b3409],
7	3	CD	NUMBER	3	num	8	SENT_321	[p24l341t3308r1193b3409],
8	§	NN	O	§	dep	5	SENT_321	[p24l341t3308r1193b3409],
9	3:123	CD	NUMBER	3:123	number	10	SENT_321	[p24l341t3308r1193b3409],
10	—	CD	NUMBER	—	num	11	SENT_321	[p24l341t3308r1193b3409],
11	32	CD	NUMBER	32	dep	8	SENT_321	[p24l341t3308r1193b3409],
12	.	.	O	.	_	0	SENT_321	[p24l341t3308r1193b3409],

1	15	CD	NUMBER	15	_	0	SENT_322	[p24l23t3461r152b3540],
2	.	.	O	.	_	0	SENT_322	[p24l23t3461r152b3540],

1	Thatcher	NNP	PERSON	Thatcher	nn	2	SENT_323	[p24l213t3449r666b3540],
2	N	NNP	O	N	_	0	SENT_323	[p24l706t3457r815b3560],
3	,	,	O	,	_	0	SENT_323	[p24l706t3457r815b3560],
4	Chang	NNP	PERSON	Chang	nn	5	SENT_323	[p24l866t3449r1195b3566],
5	A	NNP	O	A	appos	2	SENT_323	[p24l1232t3457r1335b3560],
6	,	,	O	,	_	0	SENT_323	[p24l1232t3457r1335b3560],
7	Parikh	NNP	ORGANIZATION	Parikh	nn	8	SENT_323	[p24l1385t3449r1718b3541],
8	P	NN	ORGANIZATION	p	appos	2	SENT_323	[p24l1761t3457r1838b3560],
9	,	,	O	,	_	0	SENT_323	[p24l1761t3457r1838b3560],
10	et	FW	O	et	nn	11	SENT_323	[p24l1891t3469r1981b3540],
11	al.	FW	O	al.	appos	2	SENT_323	[p24l2020t3449r2135b3540],
12	.	.	O	.	_	0	SENT_323	[p24l2020t3449r2135b3540],

1	Gefitinib	NN	O	gefitinib	_	0	SENT_324	[p24l19t3598r482b3689],
2	plus	CC	O	plus	dep	1	SENT_324	[p24l518t3598r724b3713],
3	best	JJS	O	best	dep	4	SENT_324	[p24l763t3598r971b3689],
4	supportive	JJ	O	supportive	amod	5	SENT_324	[p24l1002t3600r1530b3713],
5	care	NN	O	care	dep	2	SENT_324	[p24l1567t3628r1773b3689],
6	in	IN	O	in	prep	5	SENT_324	[p24l1808t3600r1906b3687],
7	previously	RB	DATE	previously	pcomp	6	SENT_324	[p24l1939t3628r2139b3713, p25l15t24r360b139],

1	treated	JJ	O	treated	amod	2	SENT_325	[p25l395t24r738b115],
2	patients	NNS	O	patient	_	0	SENT_325	[p25l775t26r1167b139],
3	with	IN	O	with	_	0	SENT_325	[p25l1205t24r1429b115],
4	refractory	JJ	O	refractory	amod	10	SENT_325	[p25l1468t24r1957b139],
5	advanced	JJ	O	advanced	amod	10	SENT_325	[p25l1990t24r2139b115, p25l15t173r362b264],
6	non-small	JJ	O	non-small	amod	10	SENT_325	[p25l395t173r1126b264],
7	—	NN	O	—	nn	10	SENT_325	[p25l395t173r1126b264],
8	cell	NN	O	cell	nn	10	SENT_325	[p25l395t173r1126b264],
9	lung	NN	O	lung	nn	10	SENT_325	[p25l1157t173r1383b290],
10	cancer	NN	O	cancer	prep_with	2	SENT_325	[p25l1412t203r1767b264],
11	:	:	O	:	_	0	SENT_325	[p25l1412t203r1767b264],
12	results	NNS	O	result	dep	2	SENT_325	[p25l1804t173r2137b264],
13	from	IN	O	from	_	0	SENT_325	[p25l19t322r265b413],
14	a	DT	O	a	prep_from	12	SENT_325	[p25l332t352r383b413],
15	randomised	VBN	O	randomise	partmod	14	SENT_325	[p25l449t322r1080b433],
16	,	,	O	,	_	0	SENT_325	[p25l449t322r1080b433],
17	placebo	NN	O	placebo	nn	18	SENT_325	[p25l1153t322r2134b437],
18	—	NN	O	—	appos	14	SENT_325	[p25l1153t322r2134b437],
19	controlled	VBN	O	control	partmod	18	SENT_325	[p25l1153t322r2134b437],
20	,	,	O	,	_	0	SENT_325	[p25l1153t322r2134b437],
21	multicentre	JJ	O	multicentre	amod	22	SENT_325	[p25l19t471r603b562],
22	study	NN	O	study	appos	14	SENT_325	[p25l648t471r918b586],
23	(	CD	NUMBER	(	num	26	SENT_325	[p25l959t479r1294b576],
24	Lressa	NNP	O	Lressa	nn	26	SENT_325	[p25l959t479r1294b576],
25	Survival	NNP	O	Survival	nn	26	SENT_325	[p25l1337t471r1737b562],
26	Evaluation	NN	O	evaluation	dep	22	SENT_325	[p25l1777t471r2139b562, p25l19t622r219b711],
27	in	IN	O	in	_	0	SENT_325	[p25l286t622r383b709],
28	Lung	NN	O	lung	nn	30	SENT_325	[p25l448t630r706b737],
29	Cancer	NN	O	cancer	nn	30	SENT_325	[p25l769t628r1177b725],
30	)	NN	O	)	prep_in	26	SENT_325	[p25l769t628r1177b725],
31	.	.	O	.	_	0	SENT_325	[p25l769t628r1177b725],

1	Lancet	NNP	O	Lancet	nn	2	SENT_326	[p25l1250t628r1587b711],
2	2OOS	NN	O	2oo	_	0	SENT_326	[p25l1650t628r2135b729],
3	;	:	O	;	_	0	SENT_326	[p25l1650t628r2135b729],
4	366	CD	NUMBER	366	num	6	SENT_326	[p25l1650t628r2135b729],
5	:	:	O	:	_	0	SENT_326	[p25l1650t628r2135b729],
6	527-37	CD	NUMBER	527-37	dep	2	SENT_326	[p25l23t776r421b859],
7	.	.	O	.	_	0	SENT_326	[p25l23t776r421b859],

1	16	CD	NUMBER	16	_	0	SENT_327	[p25l23t929r154b1008],
2	.	.	O	.	_	0	SENT_327	[p25l23t929r154b1008],

1	Kim	NNP	PERSON	Kim	nn	2	SENT_328	[p25l217t919r431b1010],
2	ES	NN	O	e	_	0	SENT_328	[p25l480t925r629b1028],
3	,	,	O	,	_	0	SENT_328	[p25l480t925r629b1028],
4	Hirsh	NNP	PERSON	Hirsh	nn	5	SENT_328	[p25l686t917r971b1008],
5	V	NNP	PERSON	V	appos	2	SENT_328	[p25l1018t925r1104b1028],
6	,	,	O	,	_	0	SENT_328	[p25l1018t925r1104b1028],
7	Mok	NNP	ORGANIZATION	Mok	nn	8	SENT_328	[p25l1157t917r1387b1008],
8	T	NN	ORGANIZATION	t	appos	2	SENT_328	[p25l1428t925r1518b1028],
9	,	,	O	,	_	0	SENT_328	[p25l1428t925r1518b1028],
10	et	FW	O	et	nn	11	SENT_328	[p25l1577t937r1666b1008],
11	al.	FW	O	al.	appos	2	SENT_328	[p25l1711t917r1825b1008],
12	.	.	O	.	_	0	SENT_328	[p25l1711t917r1825b1008],

1	Gefi	JJ	O	gefi	amod	3	SENT_329	[p25l1883t917r2139b1008],
2	—	NN	O	—	nn	3	SENT_329	[p25l1883t917r2139b1008],
3	tinib	NN	O	tinib	nsubj	8	SENT_329	[p25l19t1066r252b1157],
4	versus	CC	O	versus	prep	3	SENT_329	[p25l284t1096r591b1157],
5	docetaxel	NN	O	docetaxel	dep	4	SENT_329	[p25l629t1066r1096b1157],
6	in	IN	O	in	prep	5	SENT_329	[p25l1130t1068r1226b1155],
7	previously	RB	DATE	previously	pcomp	6	SENT_329	[p25l1260t1066r1765b1181],
8	treated	VBN	O	treat	_	0	SENT_329	[p25l1797t1066r2141b1157],
9	non	JJ	O	non	amod	10	SENT_329	[p25l19t1215r765b1306],
10	—	JJ	O	—	amod	17	SENT_329	[p25l19t1215r765b1306],
11	small	JJ	O	small	amod	17	SENT_329	[p25l19t1215r765b1306],
12	—	NN	O	—	nn	17	SENT_329	[p25l19t1215r765b1306],
13	cell	NN	O	cell	nn	17	SENT_329	[p25l19t1215r765b1306],
14	lung	NN	O	lung	nn	17	SENT_329	[p25l813t1215r1043b1332],
15	cancer	NN	O	cancer	nn	17	SENT_329	[p25l1088t1245r1425b1306],
16	(	CD	NUMBER	(	num	17	SENT_329	[p25l1476t1223r2135b1320],
17	INTEREST	NN	O	interest	nsubj	18	SENT_329	[p25l1476t1223r2135b1320],
18	)	CD	NUMBER	)	xcomp	8	SENT_329	[p25l1476t1223r2135b1320],
19	:	:	O	:	_	0	SENT_329	[p25l1476t1223r2135b1320],
20	a	DT	O	a	det	24	SENT_329	[p25l19t1394r69b1455],
21	randomised	JJ	O	randomised	amod	24	SENT_329	[p25l114t1364r706b1455],
22	phase	NN	O	phase	nn	24	SENT_329	[p25l745t1364r1031b1479],
23	LIL	NN	O	lil	nn	24	SENT_329	[p25l1070t1372r1187b1453],
24	trial	NN	O	trial	dep	18	SENT_329	[p25l1227t1364r1458b1455],
25	.	.	O	.	_	0	SENT_329	[p25l1227t1364r1458b1455],

1	Lancet	NNP	O	Lancet	_	0	SENT_330	[p25l1503t1372r1834b1455],
2	2008	CD	DATE	2008	num	1	SENT_330	[p25l1870t1372r2135b1473],
3	;	:	O	;	_	0	SENT_330	[p25l1870t1372r2135b1473],
4	372:1809	CD	NUMBER	372:1809	number	5	SENT_330	[p25l21t1520r654b1603],
5	—	CD	NUMBER	—	dep	1	SENT_330	[p25l21t1520r654b1603],
6	18	CD	NUMBER	18	dep	5	SENT_330	[p25l21t1520r654b1603],
7	.	.	O	.	_	0	SENT_330	[p25l21t1520r654b1603],

1	17	CD	NUMBER	17	_	0	SENT_331	[p25l23t1673r144b1752],
2	.	.	O	.	_	0	SENT_331	[p25l23t1673r144b1752],

1	Fukuoka	NNP	LOCATION	Fukuoka	nn	2	SENT_332	[p25l215t1661r655b1752],
2	M	NNP	O	M	_	0	SENT_332	[p25l684t1669r811b1772],
3	,	,	O	,	_	0	SENT_332	[p25l684t1669r811b1772],
4	Yano	NNP	PERSON	Yano	nn	5	SENT_332	[p25l848t1669r1094b1752],
5	S	NNP	O	S	appos	2	SENT_332	[p25l1133t1669r1213b1770],
6	,	,	O	,	_	0	SENT_332	[p25l1133t1669r1213b1770],
7	Giaccone	NNP	PERSON	Giaccone	nn	8	SENT_332	[p25l1254t1663r1716b1752],
8	G	NNP	O	G	appos	2	SENT_332	[p25l1751t1669r1858b1772],
9	,	,	O	,	_	0	SENT_332	[p25l1751t1669r1858b1772],
10	et	FW	O	et	nn	11	SENT_332	[p25l1901t1681r1991b1752],
11	al.	FW	O	al.	appos	2	SENT_332	[p25l2020t1661r2133b1752],
12	.	.	O	.	_	0	SENT_332	[p25l2020t1661r2133b1752],

1	Multi	JJ	O	multi	amod	2	SENT_333	[p25l15t1810r959b1901],
2	—	NN	O	—	nsubj	12	SENT_333	[p25l15t1810r959b1901],
3	institutional	JJ	O	institutional	amod	5	SENT_333	[p25l15t1810r959b1901],
4	randomized	JJ	O	randomized	amod	5	SENT_333	[p25l1028t1810r1639b1901],
5	phase	NN	O	phase	dep	2	SENT_333	[p25l1705t1810r1997b1925],
6	LI	NN	O	li	nn	7	SENT_333	[p25l2066t1818r2141b1899],
7	trial	NN	O	trial	dep	2	SENT_333	[p25l19t1959r229b2050],
8	of	IN	O	of	_	0	SENT_333	[p25l266t1959r383b2050],
9	gefitinib	NN	O	gefitinib	prep_of	7	SENT_333	[p25l397t1959r835b2076],
10	for	IN	O	for	prep	9	SENT_333	[p25l874t1959r1019b2050],
11	previously	RB	DATE	previously	pcomp	10	SENT_333	[p25l1050t1959r1567b2074],
12	treated	VBN	O	treat	_	0	SENT_333	[p25l1599t1959r1949b2050],
13	patients	NNS	O	patient	dobj	12	SENT_333	[p25l1985t1989r2139b2074, p25l19t2110r298b2199],
14	with	IN	O	with	_	0	SENT_333	[p25l345t2108r573b2199],
15	advanced	JJ	O	advanced	amod	17	SENT_333	[p25l623t2108r1088b2199],
16	non	JJ	O	non	amod	17	SENT_333	[p25l1139t2108r1868b2199],
17	—	NN	O	—	prep_with	12	SENT_333	[p25l1139t2108r1868b2199],
18	small	JJ	O	small	amod	22	SENT_333	[p25l1139t2108r1868b2199],
19	—	NN	O	—	nn	22	SENT_333	[p25l1139t2108r1868b2199],
20	cell	NN	O	cell	nn	22	SENT_333	[p25l1139t2108r1868b2199],
21	lung	NN	O	lung	nn	22	SENT_333	[p25l1917t2108r2145b2225],
22	cancer	NN	O	cancer	dep	17	SENT_333	[p25l20t2287r371b2348],
23	.	.	O	.	_	0	SENT_333	[p25l20t2287r371b2348],

1	T	NN	O	t	nn	3	SENT_334	[p25l407t2265r450b2362],
2	Clin	NN	O	clin	nn	3	SENT_334	[p25l486t2257r694b2348],
3	Oncol	NN	O	oncol	_	0	SENT_334	[p25l733t2257r1031b2348],
4	2003	CD	DATE	2003	dep	3	SENT_334	[p25l1070t2265r1931b2366],
5	;	:	O	;	_	0	SENT_334	[p25l1070t2265r1931b2366],
6	21:2237	CD	NUMBER	21:2237	number	7	SENT_334	[p25l1070t2265r1931b2366],
7	—	CD	NUMBER	—	dep	3	SENT_334	[p25l1070t2265r1931b2366],
8	46	CD	NUMBER	46	dep	7	SENT_334	[p25l1070t2265r1931b2366],
9	.	.	O	.	_	0	SENT_334	[p25l1070t2265r1931b2366],

1	18	CD	NUMBER	18	_	0	SENT_335	[p25l23t2416r156b2497],
2	.	.	O	.	_	0	SENT_335	[p25l23t2416r156b2497],

1	Lynch	NNP	PERSON	Lynch	nn	3	SENT_336	[p25l215t2406r512b2521],
2	T	NN	O	t	nn	3	SENT_336	[p25l563t2414r694b2517],
3	]	NN	O	]	_	0	SENT_336	[p25l563t2414r694b2517],
4	,	,	O	,	_	0	SENT_336	[p25l563t2414r694b2517],
5	Bell	NNP	ORGANIZATION	Bell	nn	6	SENT_336	[p25l753t2406r944b2497],
6	DW	NNP	ORGANIZATION	DW	appos	3	SENT_336	[p25l997t2414r1199b2517],
7	,	,	O	,	_	0	SENT_336	[p25l997t2414r1199b2517],
8	Sordella	NNP	PERSON	Sordella	nn	9	SENT_336	[p25l1262t2406r1670b2497],
9	R	NNP	PERSON	R	appos	3	SENT_336	[p25l1721t2414r1821b2517],
10	,	,	O	,	_	0	SENT_336	[p25l1721t2414r1821b2517],
11	et	FW	O	et	nn	12	SENT_336	[p25l1882t2426r1973b2497],
12	al.	FW	O	al.	appos	3	SENT_336	[p25l2020t2406r2134b2497],
13	.	.	O	.	_	0	SENT_336	[p25l2020t2406r2134b2497],

1	Activating	VBG	O	activate	amod	2	SENT_337	[p25l15t2557r546b2672],
2	mutations	NNS	O	mutation	_	0	SENT_337	[p25l618t2557r1138b2646],
3	in	IN	O	in	_	0	SENT_337	[p25l1215t2557r1314b2644],
4	the	DT	O	the	det	7	SENT_337	[p25l1389t2555r1547b2646],
5	epidermal	JJ	O	epidermal	amod	7	SENT_337	[p25l1624t2555r2141b2670],
6	growth	NN	O	growth	nn	7	SENT_337	[p25l19t2704r381b2821],
7	factor	NN	O	factor	prep_in	2	SENT_337	[p25l421t2704r710b2795],
8	receptor	NN	O	receptor	nn	10	SENT_337	[p25l747t2724r1157b2819],
9	underlying	VBG	O	underlie	amod	10	SENT_337	[p25l1193t2704r1731b2821],
10	responsiveness	NN	O	responsiveness	dep	2	SENT_337	[p25l1767t2734r2139b2819, p25l21t2855r425b2944],
11	of	IN	O	of	_	0	SENT_337	[p25l472t2853r587b2944],
12	non	JJ	O	non	amod	18	SENT_337	[p25l609t2853r1365b2944],
13	—	JJ	O	—	amod	18	SENT_337	[p25l609t2853r1365b2944],
14	small	JJ	O	small	amod	18	SENT_337	[p25l609t2853r1365b2944],
15	—	NN	O	—	nn	18	SENT_337	[p25l609t2853r1365b2944],
16	cell	NN	O	cell	nn	18	SENT_337	[p25l609t2853r1365b2944],
17	lung	NN	O	lung	nn	18	SENT_337	[p25l1407t2853r1634b2970],
18	cancer	NN	O	cancer	prep_of	10	SENT_337	[p25l1674t2883r2003b2944],
19	to	TO	O	to	_	0	SENT_337	[p25l2044t2873r2139b2944],
20	gefitinib	NN	O	gefitinib	prep_to	10	SENT_337	[p25l19t3002r484b3119],
21	.	.	O	.	_	0	SENT_337	[p25l19t3002r484b3119],

1	N	NN	O	n	nn	2	SENT_338	[p25l522t3010r609b3093],
2	EnglJ	NN	O	englj	nsubj	3	SENT_338	[p25l640t3002r934b3119],
3	Med	VBD	O	med	_	0	SENT_338	[p25l961t3002r1179b3093],
4	2004	CD	DATE	2004	dobj	3	SENT_338	[p25l1214t3010r2134b3113],
5	;	:	O	;	_	0	SENT_338	[p25l1214t3010r2134b3113],
6	350:2129	CD	NUMBER	350:2129	number	7	SENT_338	[p25l1214t3010r2134b3113],
7	—	CD	NUMBER	—	dep	4	SENT_338	[p25l1214t3010r2134b3113],
8	39	CD	NUMBER	39	dep	7	SENT_338	[p25l1214t3010r2134b3113],
9	.	.	O	.	_	0	SENT_338	[p25l1214t3010r2134b3113],

1	19	CD	NUMBER	19	_	0	SENT_339	[p25l23t3163r150b3242],
2	.	.	O	.	_	0	SENT_339	[p25l23t3163r150b3242],

1	Paez	NNP	PERSON	Paez	nn	2	SENT_340	[p25l215t3159r441b3242],
2	TG	NN	PERSON	tg	_	0	SENT_340	[p25l470t3159r623b3262],
3	,	,	O	,	_	0	SENT_340	[p25l470t3159r623b3262],
4	Iéinne	NNP	ORGANIZATION	Iéinne	nn	5	SENT_340	[p25l658t3159r946b3256],
5	PA	NN	ORGANIZATION	pa	appos	2	SENT_340	[p25l985t3159r1141b3262],
6	,	,	O	,	_	0	SENT_340	[p25l985t3159r1141b3262],
7	Lee	NNP	PERSON	Lee	nn	8	SENT_340	[p25l1185t3159r1355b3242],
8	JC	NNP	PERSON	JC	appos	2	SENT_340	[p25l1383t3159r1526b3262],
9	,	,	O	,	_	0	SENT_340	[p25l1383t3159r1526b3262],
10	et	FW	O	et	nn	11	SENT_340	[p25l1573t3171r1662b3242],
11	al.	FW	O	al.	appos	2	SENT_340	[p25l1696t3151r1811b3242],
12	.	.	O	.	_	0	SENT_340	[p25l1696t3151r1811b3242],

1	EGER	NN	ORGANIZATION	eger	nn	2	SENT_341	[p25l1854t3159r2153b3248],
2	mutations	NNS	O	mutation	_	0	SENT_341	[p25l19t3302r540b3391],
3	in	IN	O	in	_	0	SENT_341	[p25l627t3302r724b3389],
4	lung	NN	O	lung	nn	5	SENT_341	[p25l809t3300r1039b3417],
5	cancer	NN	O	cancer	prep_in	2	SENT_341	[p25l1121t3330r1484b3391],
6	:	:	O	:	_	0	SENT_341	[p25l1121t3330r1484b3391],
7	correlation	NN	O	correlation	dep	2	SENT_341	[p25l1575t3300r2141b3391],
8	with	IN	O	with	_	0	SENT_341	[p25l15t3449r243b3540],
9	clinical	JJ	O	clinical	amod	10	SENT_341	[p25l292t3449r662b3540],
10	response	NN	O	response	prep_with	7	SENT_341	[p25l712t3479r1159b3564],
11	to	TO	O	to	_	0	SENT_341	[p25l1209t3469r1304b3540],
12	gefitinib	NN	O	gefitinib	nn	13	SENT_341	[p25l1355t3449r1793b3566],
13	therapy	NN	O	therapy	prep_to	10	SENT_341	[p25l1844t3449r2139b3540, p25l17t3628r150b3713],
14	.	.	O	.	_	0	SENT_341	[p25l1844t3449r2139b3540, p25l17t3628r150b3713],

1	Science	NNP	O	Science	_	0	SENT_342	[p25l199t3600r567b3689],
2	2004	CD	DATE	2004	num	1	SENT_342	[p25l607t3606r1581b3707],
3	;	:	O	;	_	0	SENT_342	[p25l607t3606r1581b3707],
4	304:1497	CD	NUMBER	304:1497	number	5	SENT_342	[p25l607t3606r1581b3707],
5	—	CD	NUMBER	—	dep	1	SENT_342	[p25l607t3606r1581b3707],
6	500	CD	NUMBER	500	dep	5	SENT_342	[p25l607t3606r1581b3707],
7	.	.	O	.	_	0	SENT_342	[p25l607t3606r1581b3707],

1	20	CD	NUMBER	20	_	0	SENT_343	[p26l17t34r156b115],
2	.	.	O	.	_	0	SENT_343	[p26l17t34r156b115],

1	Rosell	NNP	PERSON	Rosell	nn	2	SENT_344	[p26l215t24r530b121],
2	R	NNP	PERSON	R	_	0	SENT_344	[p26l585t32r686b135],
3	,	,	O	,	_	0	SENT_344	[p26l585t32r686b135],
4	Moran	NNP	PERSON	Moran	nn	5	SENT_344	[p26l746t32r1078b115],
5	T	NN	O	t	appos	2	SENT_344	[p26l1133t32r1221b135],
6	,	,	O	,	_	0	SENT_344	[p26l1133t32r1221b135],
7	Queralt	NN	O	queralt	nn	8	SENT_344	[p26l1286t24r1664b137],
8	C	NN	O	c	appos	2	SENT_344	[p26l1717t32r1814b133],
9	,	,	O	,	_	0	SENT_344	[p26l1717t32r1814b133],
10	et	FW	O	et	nn	11	SENT_344	[p26l1878t44r1969b115],
11	al.	FW	O	al.	appos	2	SENT_344	[p26l2020t24r2134b115],
12	.	.	O	.	_	0	SENT_344	[p26l2020t24r2134b115],

1	Screening	VBG	O	screen	_	0	SENT_345	[p26l21t175r520b290],
2	for	IN	O	for	_	0	SENT_345	[p26l553t173r698b264],
3	epidermal	JJ	O	epidermal	amod	7	SENT_345	[p26l731t173r1239b288],
4	growth	NN	O	growth	nn	7	SENT_345	[p26l1274t173r1642b290],
5	factor	NN	O	factor	nn	7	SENT_345	[p26l1680t173r1973b264],
6	receptor	NN	O	receptor	nn	7	SENT_345	[p26l2006t203r2139b264, p26l21t342r338b437],
7	mutations	NNS	O	mutation	prep_for	1	SENT_345	[p26l375t324r884b413],
8	in	IN	O	in	_	0	SENT_345	[p26l926t324r1023b411],
9	lung	NN	O	lung	nn	10	SENT_345	[p26l1062t322r1288b439],
10	cancer	NN	O	cancer	prep_in	7	SENT_345	[p26l1326t352r1678b413],
11	.	.	O	.	_	0	SENT_345	[p26l1326t352r1678b413],

1	N	NN	O	n	nn	3	SENT_346	[p26l1721t330r1808b413],
2	Engll	NNP	O	Engll	nn	3	SENT_346	[p26l1844t322r2143b439],
3	Med	NNP	O	Med	_	0	SENT_346	[p26l15t471r233b562],
4	2009	CD	DATE	2009	num	3	SENT_346	[p26l272t479r1126b580],
5	;	:	O	;	_	0	SENT_346	[p26l272t479r1126b580],
6	362:958	CD	NUMBER	362:958	number	7	SENT_346	[p26l272t479r1126b580],
7	—	CD	NUMBER	—	dep	3	SENT_346	[p26l272t479r1126b580],
8	67	CD	NUMBER	67	dep	7	SENT_346	[p26l272t479r1126b580],
9	.	.	O	.	_	0	SENT_346	[p26l272t479r1126b580],

1	21	CD	NUMBER	21	_	0	SENT_347	[p26l17t632r154b711],
2	.	.	O	.	_	0	SENT_347	[p26l17t632r154b711],

1	Mok	NN	O	mok	nn	2	SENT_348	[p26l213t620r442b711],
2	TS	NN	O	t	_	0	SENT_348	[p26l468t628r623b731],
3	,	,	O	,	_	0	SENT_348	[p26l468t628r623b731],
4	Wu	NNP	PERSON	Wu	nn	5	SENT_348	[p26l660t628r831b711],
5	YL	NNP	PERSON	YL	appos	2	SENT_348	[p26l860t628r1015b731],
6	,	,	O	,	_	0	SENT_348	[p26l860t628r1015b731],
7	Thongprasert	NNP	O	Thongprasert	nn	8	SENT_348	[p26l1054t620r1749b737],
8	S	NNP	O	S	appos	2	SENT_348	[p26l1781t628r1858b731],
9	,	,	O	,	_	0	SENT_348	[p26l1781t628r1858b731],
10	et	FW	O	et	nn	11	SENT_348	[p26l1901t640r1991b711],
11	al.	FW	O	al.	appos	2	SENT_348	[p26l2020t620r2134b711],
12	.	.	O	.	_	0	SENT_348	[p26l2020t620r2134b711],

1	Gefitinib	NN	O	gefitinib	_	0	SENT_349	[p26l19t769r472b860],
2	or	CC	O	or	_	0	SENT_349	[p26l517t799r619b860],
3	carboplatin	NN	O	carboplatin	conj_or	1	SENT_349	[p26l658t769r1765b884],
4	—	CD	NUMBER	—	num	5	SENT_349	[p26l658t769r1765b884],
5	paclitaxel	NN	O	paclitaxel	dep	1	SENT_349	[p26l658t769r1765b884],
6	in	IN	O	in	_	0	SENT_349	[p26l1806t771r1902b858],
7	pulmonary	JJ	O	pulmonary	amod	8	SENT_349	[p26l1943t769r2139b884, p26l19t948r411b1033],
8	adenocarcinoma	NN	O	adenocarcinoma	prep_in	5	SENT_349	[p26l468t918r1334b1009],
9	.	.	O	.	_	0	SENT_349	[p26l468t918r1334b1009],

1	N	NN	O	n	nn	3	SENT_350	[p26l1401t926r1486b1009],
2	Engl	NN	O	engl	nn	3	SENT_350	[p26l1545t918r1773b1035],
3	T	NN	O	t	nsubj	4	SENT_350	[p26l1824t926r1866b1023],
4	Med	VBD	O	med	_	0	SENT_350	[p26l1923t918r2141b1009],

1	22	CD	NUMBER	22	_	0	SENT_351	[p26l17t1228r158b1307],
2	.	.	O	.	_	0	SENT_351	[p26l17t1228r158b1307],

1	Maemondo	NNP	O	Maemondo	nn	2	SENT_352	[p26l213t1216r781b1307],
2	M	NNP	O	M	_	0	SENT_352	[p26l823t1226r949b1327],
3	,	,	O	,	_	0	SENT_352	[p26l823t1226r949b1327],
4	Tnoue	NNP	O	Tnoue	nn	5	SENT_352	[p26l997t1224r1282b1307],
5	A	NNP	O	A	appos	2	SENT_352	[p26l1321t1226r1424b1327],
6	,	,	O	,	_	0	SENT_352	[p26l1321t1226r1424b1327],
7	Kobayashi	NNP	LOCATION	Kobayashi	nn	8	SENT_352	[p26l1474t1216r1991b1331],
8	K	NNP	LOCATION	K	appos	2	SENT_352	[p26l2034t1224r2134b1327],
9	,	,	O	,	_	0	SENT_352	[p26l2034t1224r2134b1327],
10	et	FW	O	et	nn	11	SENT_352	[p26l20t1385r110b1456],
11	al.	FW	O	al.	appos	2	SENT_352	[p26l145t1365r259b1456],
12	.	.	O	.	_	0	SENT_352	[p26l145t1365r259b1456],

1	Gefitinib	NNP	O	Gefitinib	nsubj	11	SENT_353	[p26l306t1365r769b1456],
2	or	CC	O	or	_	0	SENT_353	[p26l812t1395r916b1456],
3	chemotherapy	NN	O	chemotherapy	nsubj	11	SENT_353	[p26l953t1365r1670b1480],
4	for	IN	O	for	_	0	SENT_353	[p26l1707t1365r1852b1456],
5	nonsmall	JJ	O	nonsmall	amod	9	SENT_353	[p26l1888t1395r2145b1456, p26l21t1514r514b1605],
6	—	NN	O	—	nn	9	SENT_353	[p26l1888t1395r2145b1456, p26l21t1514r514b1605],
7	cell	NN	O	cell	nn	9	SENT_353	[p26l1888t1395r2145b1456, p26l21t1514r514b1605],
8	lung	NN	O	lung	nn	9	SENT_353	[p26l622t1514r849b1631],
9	cancer	NN	O	cancer	prep_for	3	SENT_353	[p26l955t1544r1286b1605],
10	with	IN	O	with	prep	9	SENT_353	[p26l1387t1514r1615b1605],
11	mutated	VBN	O	mutate	_	0	SENT_353	[p26l1725t1514r2141b1605],
12	EGFR	NN	ORGANIZATION	egfr	dobj	11	SENT_353	[p26l17t1671r334b1760],
13	.	.	O	.	_	0	SENT_353	[p26l17t1671r334b1760],

1	N	NN	O	n	nn	2	SENT_354	[p26l377t1671r464b1754],
2	EnglJ	NN	O	englj	nsubj	3	SENT_354	[p26l500t1663r799b1780],
3	Med	VBD	O	med	_	0	SENT_354	[p26l832t1663r1050b1754],
4	2010	CD	DATE	2010	dobj	3	SENT_354	[p26l1090t1671r1953b1772],
5	;	:	O	;	_	0	SENT_354	[p26l1090t1671r1953b1772],
6	362:2380	CD	NUMBER	362:2380	number	7	SENT_354	[p26l1090t1671r1953b1772],
7	—	CD	NUMBER	—	dep	4	SENT_354	[p26l1090t1671r1953b1772],
8	8	CD	NUMBER	8	dep	7	SENT_354	[p26l1090t1671r1953b1772],
9	.	.	O	.	_	0	SENT_354	[p26l1090t1671r1953b1772],

1	23	CD	NUMBER	23	_	0	SENT_355	[p26l17t1824r154b1903],
2	.	.	O	.	_	0	SENT_355	[p26l17t1824r154b1903],

1	Mitsudomi	JJ	ORGANIZATION	mitsudomi	amod	2	SENT_356	[p26l213t1812r767b1903],
2	T	NN	ORGANIZATION	t	_	0	SENT_356	[p26l797t1820r886b1923],
3	,	,	O	,	_	0	SENT_356	[p26l797t1820r886b1923],
4	Morita	NNP	PERSON	Morita	nn	5	SENT_356	[p26l924t1814r1264b1903],
5	S	NNP	O	S	appos	2	SENT_356	[p26l1298t1820r1377b1923],
6	,	,	O	,	_	0	SENT_356	[p26l1298t1820r1377b1923],
7	Yatabe	NNP	PERSON	Yatabe	nn	8	SENT_356	[p26l1414t1812r1745b1903],
8	Y	NN	PERSON	y	appos	2	SENT_356	[p26l1775t1822r1860b1923],
9	,	,	O	,	_	0	SENT_356	[p26l1775t1822r1860b1923],
10	et	FW	O	et	nn	11	SENT_356	[p26l1901t1832r1991b1903],
11	al.	FW	O	al.	appos	2	SENT_356	[p26l2020t1812r2133b1903],
12	.	.	O	.	_	0	SENT_356	[p26l2020t1812r2133b1903],

1	Gefitinib	JJ	O	gefitinib	_	0	SENT_357	[p26l19t1961r472b2052],
2	versus	CC	O	versus	prep	1	SENT_357	[p26l504t1991r811b2052],
3	cisplatin	NN	O	cisplatin	dep	2	SENT_357	[p26l848t1961r1270b2076],
4	plus	CC	O	plus	_	0	SENT_357	[p26l1303t1961r1506b2076],
5	docetaxel	NN	O	docetaxel	conj_plus	1	SENT_357	[p26l1543t1961r2011b2052],
6	in	IN	O	in	_	0	SENT_357	[p26l2044t1963r2141b2050],
7	patients	NNS	O	patient	prep_in	5	SENT_357	[p26l17t2112r419b2225],
8	with	IN	O	with	_	0	SENT_357	[p26l470t2110r700b2201],
9	non	JJ	O	non	amod	15	SENT_357	[p26l753t2110r1484b2201],
10	—	JJ	O	—	amod	15	SENT_357	[p26l753t2110r1484b2201],
11	small	JJ	O	small	amod	15	SENT_357	[p26l753t2110r1484b2201],
12	—	NN	O	—	nn	15	SENT_357	[p26l753t2110r1484b2201],
13	cell	NN	O	cell	nn	15	SENT_357	[p26l753t2110r1484b2201],
14	lung	NN	O	lung	nn	15	SENT_357	[p26l1537t2110r1763b2227],
15	cancer	NN	O	cancer	prep_with	7	SENT_357	[p26l1814t2140r2143b2201],
16	harbouring	VBG	O	harbour	partmod	15	SENT_357	[p26l19t2259r597b2376],
17	mutations	NNS	O	mutation	dobj	16	SENT_357	[p26l662t2261r1171b2350],
18	of	IN	O	of	_	0	SENT_357	[p26l1244t2259r1361b2350],
19	the	DT	O	the	det	25	SENT_357	[p26l1408t2259r1563b2350],
20	epidermal	JJ	O	epidermal	amod	25	SENT_357	[p26l1634t2259r2141b2374],
21	growth	NN	O	growth	nn	25	SENT_357	[p26l19t2408r387b2525],
22	factor	NN	O	factor	nn	25	SENT_357	[p26l431t2408r726b2499],
23	receptor	NN	O	receptor	nn	25	SENT_357	[p26l765t2428r1185b2523],
24	(	NN	O	(	nn	25	SENT_357	[p26l1230t2416r1973b2513],
25	WJTOG3405	NN	O	wjtog3405	prep_of	17	SENT_357	[p26l1230t2416r1973b2513],
26	)	CD	NUMBER	)	dep	25	SENT_357	[p26l1230t2416r1973b2513],
27	:	:	O	:	_	0	SENT_357	[p26l1230t2416r1973b2513],
28	an	DT	O	a	det	30	SENT_357	[p26l2020t2438r2141b2499],
29	open	JJ	O	open	amod	30	SENT_357	[p26l13t2682r132b2724],
30	label	NN	O	label	dep	1	SENT_357	[p26l171t2668r300b2722],
31	,	,	O	,	_	0	SENT_357	[p26l171t2668r300b2722],
32	randomised	JJ	O	randomised	amod	33	SENT_357	[p26l343t2668r635b2712],
33	phase	NN	O	phase	appos	30	SENT_357	[p26l674t2668r815b2724],
34	3	CD	NUMBER	3	num	35	SENT_357	[p26l856t2672r880b2713],
35	trial	NN	O	trial	dep	33	SENT_357	[p26l922t2668r1037b2712],
36	.	.	O	.	_	0	SENT_357	[p26l922t2668r1037b2712],

1	Lancet	NNP	O	Lancet	nn	2	SENT_358	[p26l12t2742r175b2782],
2	Oncol	NNP	O	Oncol	_	0	SENT_358	[p26l192t2738r336b2782],
3	2010	CD	DATE	2010	num	2	SENT_358	[p26l355t2742r707b2791],
4	;	:	O	;	_	0	SENT_358	[p26l355t2742r707b2791],
5	11:121	CD	NUMBER	11:121	number	6	SENT_358	[p26l355t2742r707b2791],
6	—	CD	NUMBER	—	dep	2	SENT_358	[p26l355t2742r707b2791],
7	8	CD	NUMBER	8	dep	6	SENT_358	[p26l355t2742r707b2791],
8	.	.	O	.	_	0	SENT_358	[p26l355t2742r707b2791],

1	24	CD	NUMBER	24	_	0	SENT_359	[p26l12t2815r80b2853],
2	.	.	O	.	_	0	SENT_359	[p26l12t2815r80b2853],

1	Tarceva	NNP	O	Tarceva	nn	3	SENT_360	[p26l107t2813r297b2854],
2	(	CD	NUMBER	(	num	3	SENT_360	[p26l343t2809r588b2860],
3	erlotinib	NN	O	erlotinib	_	0	SENT_360	[p26l343t2809r588b2860],
4	)	NN	O	)	nn	6	SENT_360	[p26l343t2809r588b2860],
5	package	NN	O	package	nn	6	SENT_360	[p26l634t2809r835b2866],
6	insert	NN	O	insert	dep	3	SENT_360	[p26l879t2810r1037b2853],
7	.	.	O	.	_	0	SENT_360	[p26l879t2810r1037b2853],

1	(	NN	O	(	nn	3	SENT_361	[p26l15t2880r961b2937],
2	httpzllwww.gene.com	NN	O	httpzllwww.gene.com	nn	3	SENT_361	[p26l15t2880r961b2937],
3	lgene/products	NNS	O	lgene/products	nsubj	4	SENT_361	[p26l15t2880r961b2937],
4	]	VBP	O	]	_	0	SENT_361	[p26l15t2880r961b2937],
5	informationloncologyltarceva	NN	O	informationloncologyltarceva	dobj	4	SENT_361	[p26l13t2951r773b3008],
6	.	.	O	.	_	0	SENT_361	[p26l13t2951r773b3008],
7	)	SYM	O	)	dep	4	SENT_361	[p26l13t2951r773b3008],

1	25	CD	NUMBER	25	_	0	SENT_362	[p26l12t3028r76b3066],
2	.	.	O	.	_	0	SENT_362	[p26l12t3028r76b3066],

1	Iressa	NNP	O	Iressa	_	0	SENT_363	[p26l108t3022r496b3079],
2	(	CD	NUMBER	(	num	1	SENT_363	[p26l108t3022r496b3079],
3	gef1tinib	CD	NUMBER	gef1tinib	num	6	SENT_363	[p26l108t3022r496b3079],
4	)	NN	O	)	nn	6	SENT_363	[p26l108t3022r496b3079],
5	package	NN	O	package	nn	6	SENT_363	[p26l512t3022r703b3079],
6	insert	NN	O	insert	dep	1	SENT_363	[p26l716t3023r864b3066],
7	.	.	O	.	_	0	SENT_363	[p26l716t3023r864b3066],

1	(	NN	O	(	_	0	SENT_364	[p26l884t3022r1039b3078],
2	httpzll	NN	O	httpzll	nn	3	SENT_364	[p26l884t3022r1039b3078],
3	www1	NN	O	www1	dep	1	SENT_364	[p26l10t3093r1025b3149],
4	.	.	O	.	_	0	SENT_364	[p26l10t3093r1025b3149],

1	astrazeneca—us.com/pi/iressa.pdf	NN	O	astrazeneca—us.com/pi/iressa.pdf	_	0	SENT_365	[p26l10t3093r1025b3149],
2	)	CD	NUMBER	)	number	3	SENT_365	[p26l10t3093r1025b3149],
3	26	CD	NUMBER	26	num	1	SENT_365	[p26l12t3171r80b3209],
4	.	.	O	.	_	0	SENT_365	[p26l12t3171r80b3209],

1	Rudin	NNP	PERSON	Rudin	nn	2	SENT_366	[p26l108t3165r256b3212],
2	CM	NN	O	cm	_	0	SENT_366	[p26l273t3169r369b3219],
3	,	,	O	,	_	0	SENT_366	[p26l273t3169r369b3219],
4	Liu	NNP	PERSON	Liu	nn	5	SENT_366	[p26l388t3166r464b3210],
5	W	NNP	PERSON	W	appos	2	SENT_366	[p26l478t3169r539b3219],
6	,	,	O	,	_	0	SENT_366	[p26l478t3169r539b3219],
7	Desai	NNP	PERSON	Desai	nn	8	SENT_366	[p26l558t3166r694b3209],
8	A	NNP	O	A	appos	2	SENT_366	[p26l708t3169r758b3219],
9	,	,	O	,	_	0	SENT_366	[p26l708t3169r758b3219],
10	et	FW	O	et	nn	11	SENT_366	[p26l778t3174r822b3209],
11	al.	FW	O	al.	appos	2	SENT_366	[p26l836t3165r891b3209],
12	.	.	O	.	_	0	SENT_366	[p26l836t3165r891b3209],

1	Pharmacogenomic	JJ	PERSON	pharmacogenomic	amod	4	SENT_367	[p26l910t3165r1039b3209, p26l13t3236r351b3292],
2	and	CC	O	and	_	0	SENT_367	[p26l369t3235r457b3279],
3	pharmacokinetic	JJ	O	pharmacokinetic	conj_and	1	SENT_367	[p26l474t3235r884b3291],
4	determinants	NNS	O	determinant	_	0	SENT_367	[p26l903t3235r1039b3279, p26l13t3308r215b3351],
5	of	IN	O	of	_	0	SENT_367	[p26l236t3307r292b3351],
6	erlotinib	NN	O	erlotinib	nn	7	SENT_367	[p26l301t3307r511b3351],
7	toxicity	NN	O	toxicity	prep_of	4	SENT_367	[p26l531t3308r720b3363],
8	.	.	O	.	_	0	SENT_367	[p26l531t3308r720b3363],

1	J	NNP	O	J	nn	3	SENT_368	[p26l737t3311r758b3358],
2	Clin	NNP	O	Clin	nn	3	SENT_368	[p26l776t3307r877b3351],
3	Oncol	NNP	O	Oncol	_	0	SENT_368	[p26l896t3307r1040b3351],
4	2008	CD	DATE	2008	num	3	SENT_368	[p26l13t3382r421b3431],
5	;	:	O	;	_	0	SENT_368	[p26l13t3382r421b3431],
6	26:1119	CD	NUMBER	26:1119	number	7	SENT_368	[p26l13t3382r421b3431],
7	—	CD	NUMBER	—	dep	3	SENT_368	[p26l13t3382r421b3431],
8	27	CD	NUMBER	27	dep	7	SENT_368	[p26l13t3382r421b3431],
9	.	.	O	.	_	0	SENT_368	[p26l13t3382r421b3431],

1	27	CD	NUMBER	27	_	0	SENT_369	[p26l12t3454r74b3492],
2	.	.	O	.	_	0	SENT_369	[p26l12t3454r74b3492],

1	Li	NNP	PERSON	Li	nn	2	SENT_370	[p26l108t3449r153b3492],
2	J	NNP	PERSON	J	_	0	SENT_370	[p26l169t3452r201b3502],
3	,	,	O	,	_	0	SENT_370	[p26l169t3452r201b3502],
4	Zhao	NNP	PERSON	Zhao	nn	5	SENT_370	[p26l224t3448r345b3492],
5	M	NNP	O	M	appos	2	SENT_370	[p26l366t3452r427b3502],
6	,	,	O	,	_	0	SENT_370	[p26l366t3452r427b3502],
7	He	PRP	O	he	dep	8	SENT_370	[p26l451t3452r517b3492],
8	P	NN	O	p	appos	2	SENT_370	[p26l538t3452r576b3502],
9	,	,	O	,	_	0	SENT_370	[p26l538t3452r576b3502],
10	Hidalgo	NNP	PERSON	Hidalgo	nn	11	SENT_370	[p26l600t3448r795b3505],
11	M	NNP	O	M	appos	2	SENT_370	[p26l816t3452r877b3502],
12	,	,	O	,	_	0	SENT_370	[p26l816t3452r877b3502],
13	Baker	NNP	LOCATION	Baker	nn	14	SENT_370	[p26l901t3448r1041b3493],
14	SD	NN	LOCATION	sd	appos	2	SENT_370	[p26l14t3523r91b3563],
15	.	.	O	.	_	0	SENT_370	[p26l14t3523r91b3563],

1	Differential	JJ	O	differential	amod	2	SENT_371	[p26l121t3519r407b3563],
2	metabolism	NN	O	metabolism	_	0	SENT_371	[p26l435t3519r725b3563],
3	of	IN	O	of	_	0	SENT_371	[p26l753t3519r810b3563],
4	gefitinib	NN	O	gefitinib	prep_of	2	SENT_371	[p26l827t3519r1039b3576],
5	and	CC	O	and	_	0	SENT_371	[p26l13t3590r102b3634],
6	erlotinib	NN	O	erlotinib	conj_and	4	SENT_371	[p26l122t3590r332b3635],
7	by	IN	O	by	_	0	SENT_371	[p26l353t3590r408b3646],
8	human	JJ	O	human	amod	11	SENT_371	[p26l425t3590r598b3635],
9	cytochrome	NN	O	cytochrome	nn	11	SENT_371	[p26l618t3590r906b3646],
10	P450	NN	O	p450	nn	11	SENT_371	[p26l925t3594r1040b3635],
11	enzymes	NNS	O	enzyme	prep_by	2	SENT_371	[p26l13t3675r239b3717],
12	.	.	O	.	_	0	SENT_371	[p26l13t3675r239b3717],

1	Clin	NNP	O	Clin	nn	3	SENT_372	[p26l260t3661r361b3706],
2	Cancer	NNP	O	Cancer	nn	3	SENT_372	[p26l379t3665r548b3705],
3	Res	NNP	O	Res	_	0	SENT_372	[p26l564t3665r649b3708],
4	2007	CD	DATE	2007	num	3	SENT_372	[p26l669t3665r1037b3715],
5	;	:	O	;	_	0	SENT_372	[p26l669t3665r1037b3715],
6	13:3731	CD	NUMBER	13:3731	num	7	SENT_372	[p26l669t3665r1037b3715],
7	—	NN	O	—	dep	3	SENT_372	[p26l669t3665r1037b3715],
8	7	CD	NUMBER	7	dep	7	SENT_372	[p26l669t3665r1037b3715],
9	.	.	O	.	_	0	SENT_372	[p26l669t3665r1037b3715],

1	28	CD	NUMBER	28	_	0	SENT_373	[p26l12t3738r80b3778],
2	.	.	O	.	_	0	SENT_373	[p26l12t3738r80b3778],

1	Hamilton	NNP	PERSON	Hamilton	nn	2	SENT_374	[p26l108t3733r345b3777],
2	M	NNP	O	M	_	0	SENT_374	[p26l365t3737r426b3787],
3	,	,	O	,	_	0	SENT_374	[p26l365t3737r426b3787],
4	Wolf	NNP	PERSON	Wolf	nn	5	SENT_374	[p26l448t3733r613b3787],
5	]	NNP	O	]	appos	2	SENT_374	[p26l448t3733r613b3787],
6	,	,	O	,	_	0	SENT_374	[p26l448t3733r613b3787],
7	Rusk	NNP	PERSON	Rusk	nn	8	SENT_374	[p26l637t3733r760b3780],
8	J	NNP	O	J	appos	2	SENT_374	[p26l774t3737r806b3787],
9	,	,	O	,	_	0	SENT_374	[p26l774t3737r806b3787],
10	et	FW	O	et	nn	11	SENT_374	[p26l831t3742r875b3777],
11	al.	FW	O	al.	appos	2	SENT_374	[p26l894t3733r949b3777],
12	.	.	O	.	_	0	SENT_374	[p26l894t3733r949b3777],

1	Ef	NN	O	ef	_	0	SENT_375	[p26l973t3733r1039b3777],
2	38	CD	NUMBER	38	dep	1	SENT_375	[p26l1115t2673r1181b2713],
3	.	.	O	.	_	0	SENT_375	[p26l1115t2673r1181b2713],

1	Shah	NNP	O	Shah	nn	2	SENT_376	[p26l1212t2668r1331b2712],
2	NT	NNP	O	NT	_	0	SENT_376	[p26l1349t2672r1435b2722],
3	,	,	O	,	_	0	SENT_376	[p26l1349t2672r1435b2722],
4	Kris	NNP	PERSON	Kris	nn	5	SENT_376	[p26l1457t2669r1557b2714],
5	MG	NN	PERSON	mg	appos	2	SENT_376	[p26l1575t2672r1677b2722],
6	,	,	O	,	_	0	SENT_376	[p26l1575t2672r1677b2722],
7	Pao	NNP	O	Pao	nn	8	SENT_376	[p26l1698t2672r1783b2712],
8	W	NNP	O	W	appos	2	SENT_376	[p26l1801t2672r1862b2722],
9	,	,	O	,	_	0	SENT_376	[p26l1801t2672r1862b2722],
10	et	FW	O	et	nn	11	SENT_376	[p26l1884t2678r1928b2712],
11	al.	FW	O	al.	appos	2	SENT_376	[p26l1943t2668r1998b2712],
12	.	.	O	.	_	0	SENT_376	[p26l1943t2668r1998b2712],

1	Practical	NNP	O	Practical	nn	2	SENT_377	[p26l2019t2672r2141b2712, p26l1115t2738r1220b2782],
2	management	NN	O	management	nsubj	9	SENT_377	[p26l1248t2747r1570b2795],
3	of	IN	O	of	_	0	SENT_377	[p26l1596t2738r1652b2783],
4	patients	NNS	O	patient	prep_of	2	SENT_377	[p26l1670t2739r1865b2794],
5	with	IN	O	with	_	0	SENT_377	[p26l1892t2738r2002b2783],
6	nonsmall-cell	JJ	O	nonsmall-cell	amod	8	SENT_377	[p26l2031t2752r2141b2783, p26l1116t2809r1355b2853],
7	lung	NN	O	lung	nn	8	SENT_377	[p26l1380t2809r1490b2866],
8	cancer	NN	O	cancer	prep_with	4	SENT_377	[p26l1514t2823r1674b2853],
9	treated	VBN	O	treat	_	0	SENT_377	[p26l1699t2809r1869b2854],
10	with	IN	O	with	_	0	SENT_377	[p26l1892t2809r2003b2854],
11	gefitinib	NN	O	gefitinib	prep_with	9	SENT_377	[p26l2029t2809r2141b2866, p26l1115t2880r1243b2925],
12	.	.	O	.	_	0	SENT_377	[p26l2029t2809r2141b2866, p26l1115t2880r1243b2925],

1	J	NNP	O	J	nn	3	SENT_378	[p26l1260t2884r1281b2931],
2	Clin	NNP	O	Clin	nn	3	SENT_378	[p26l1299t2880r1400b2924],
3	Oncol	NNP	O	Oncol	_	0	SENT_378	[p26l1419t2880r1563b2925],
4	2005	CD	DATE	2005	num	3	SENT_378	[p26l1582t2884r1960b2933],
5	;	:	O	;	_	0	SENT_378	[p26l1582t2884r1960b2933],
6	23:165	CD	NUMBER	23:165	number	7	SENT_378	[p26l1582t2884r1960b2933],
7	-74	CD	NUMBER	-74	dep	3	SENT_378	[p26l1582t2884r1960b2933],
8	.	.	O	.	_	0	SENT_378	[p26l1582t2884r1960b2933],

1	39	CD	NUMBER	39	_	0	SENT_379	[p26l1115t2956r1179b2995],
2	.	.	O	.	_	0	SENT_379	[p26l1115t2956r1179b2995],

1	Wheatley	NNP	PERSON	Wheatley	_	0	SENT_380	[p26l1209t2951r1576b3007],
2	.	.	O	.	_	0	SENT_380	[p26l1209t2951r1576b3007],

1	—	NN	O	—	_	0	SENT_381	[p26l1209t2951r1576b3007],
2	.	.	O	.	_	0	SENT_381	[p26l1209t2951r1576b3007],

1	Price	NN	O	price	nn	2	SENT_382	[p26l1209t2951r1576b3007],
2	P	NN	O	p	_	0	SENT_382	[p26l1595t2955r1632b3005],
3	,	,	O	,	_	0	SENT_382	[p26l1595t2955r1632b3005],
4	Ding	NNP	PERSON	Ding	nn	5	SENT_382	[p26l1654t2952r1775b3008],
5	K	NNP	PERSON	K	appos	2	SENT_382	[p26l1792t2955r1841b3005],
6	,	,	O	,	_	0	SENT_382	[p26l1792t2955r1841b3005],
7	Seymour	NNP	PERSON	Seymour	nn	8	SENT_382	[p26l1865t2955r2079b3007],
8	L	NNP	PERSON	L	appos	2	SENT_382	[p26l2096t2955r2139b3005],
9	,	,	O	,	_	0	SENT_382	[p26l2096t2955r2139b3005],
10	et	FW	O	et	nn	11	SENT_382	[p26l1115t3032r1159b3066],
11	al.	FW	O	al.	appos	2	SENT_382	[p26l1186t3022r1242b3066],
12	.	.	O	.	_	0	SENT_382	[p26l1186t3022r1242b3066],

1	Erlotinib	NNP	O	Erlotinib	_	0	SENT_383	[p26l1274t3022r1491b3067],
2	for	IN	O	for	_	0	SENT_383	[p26l1522t3022r1592b3067],
3	advanced	JJ	O	advanced	amod	8	SENT_383	[p26l1620t3022r1845b3067],
4	non	JJ	O	non	amod	8	SENT_383	[p26l1875t3022r2141b3067, p26l1116t3093r1199b3137],
5	—	NN	O	—	nn	8	SENT_383	[p26l1875t3022r2141b3067, p26l1116t3093r1199b3137],
6	smallcell	NN	O	smallcell	nn	8	SENT_383	[p26l1875t3022r2141b3067, p26l1116t3093r1199b3137],
7	lung	NN	O	lung	nn	8	SENT_383	[p26l1216t3093r1326b3150],
8	cancer	NN	O	cancer	prep_for	1	SENT_383	[p26l1343t3107r1502b3137],
9	in	IN	O	in	_	0	SENT_383	[p26l1519t3094r1566b3137],
10	the	DT	O	the	det	11	SENT_383	[p26l1584t3093r1660b3137],
11	elderly	JJ	O	elderly	prep_in	1	SENT_383	[p26l1678t3093r1851b3149],
12	:	:	O	:	_	0	SENT_383	[p26l1678t3093r1851b3149],
13	an	DT	O	a	det	14	SENT_383	[p26l1871t3108r1929b3137],
14	analysis	NN	O	analysis	dep	1	SENT_383	[p26l1947t3093r2141b3149],
15	of	IN	O	of	_	0	SENT_383	[p26l1116t3165r1171b3209],
16	the	DT	O	the	det	19	SENT_383	[p26l1180t3165r1254b3209],
17	National	NNP	ORGANIZATION	National	nn	19	SENT_383	[p26l1272t3165r1478b3210],
18	Cancer	NNP	ORGANIZATION	Cancer	nn	19	SENT_383	[p26l1497t3169r1663b3209],
19	Institute	NNP	ORGANIZATION	Institute	prep_of	14	SENT_383	[p26l1679t3166r1880b3210],
20	of	IN	ORGANIZATION	of	_	0	SENT_383	[p26l1900t3165r1956b3209],
21	Canada	NNP	ORGANIZATION	Canada	prep_of	19	SENT_383	[p26l1964t3165r2143b3209],
22	Clinical	JJ	ORGANIZATION	clinical	amod	26	SENT_383	[p26l1115t3235r1305b3280],
23	Trials	NNPS	ORGANIZATION	Trials	nn	26	SENT_383	[p26l1325t3235r1465b3279],
24	Group	NNP	ORGANIZATION	Group	nn	26	SENT_383	[p26l1489t3239r1642b3291],
25	Study	NNP	ORGANIZATION	Study	nn	26	SENT_383	[p26l1666t3235r1801b3291],
26	BR	NNP	O	BR	dep	14	SENT_383	[p26l1821t3239r1979b3282],
27	.21	CD	NUMBER	.21	num	26	SENT_383	[p26l1821t3239r1979b3282],
28	.	.	O	.	_	0	SENT_383	[p26l1821t3239r1979b3282],

1	J	NNP	O	J	nn	3	SENT_384	[p26l1999t3239r2020b3286],
2	Clin	NNP	O	Clin	nn	3	SENT_384	[p26l2042t3235r2142b3280],
3	Oncol	NNP	O	Oncol	_	0	SENT_384	[p26l1115t3307r1259b3351],
4	2008	CD	DATE	2008	num	3	SENT_384	[p26l1278t3311r1659b3360],
5	;	:	O	;	_	0	SENT_384	[p26l1278t3311r1659b3360],
6	26:2350	CD	NUMBER	26:2350	number	7	SENT_384	[p26l1278t3311r1659b3360],
7	-7	CD	NUMBER	-7	dep	3	SENT_384	[p26l1278t3311r1659b3360],
8	.	.	O	.	_	0	SENT_384	[p26l1278t3311r1659b3360],

1	40	CD	NUMBER	40	_	0	SENT_385	[p26l1114t3383r1182b3422],
2	.	.	O	.	_	0	SENT_385	[p26l1114t3383r1182b3422],

1	Boone	NNP	PERSON	Boone	nn	2	SENT_386	[p26l1210t3382r1363b3422],
2	SL	NNP	O	SL	_	0	SENT_386	[p26l1388t3382r1457b3432],
3	,	,	O	,	_	0	SENT_386	[p26l1388t3382r1457b3432],
4	Rademaker	NNP	PERSON	Rademaker	nn	5	SENT_386	[p26l1482t3378r1762b3425],
5	A	NNP	O	A	appos	2	SENT_386	[p26l1781t3382r1831b3432],
6	,	,	O	,	_	0	SENT_386	[p26l1781t3382r1831b3432],
7	Liu	NNP	PERSON	Liu	nn	8	SENT_386	[p26l1856t3379r1932b3423],
8	D	NNP	O	D	appos	5	SENT_386	[p26l1954t3382r2004b3432],
9	,	,	O	,	_	0	SENT_386	[p26l1954t3382r2004b3432],
10	Pfeffer	NNP	PERSON	Pfeffer	nn	11	SENT_386	[p26l2030t3378r2141b3422, p26l1115t3448r1181b3492],
11	C	NNP	O	C	appos	5	SENT_386	[p26l1209t3452r1256b3502],
12	,	,	O	,	_	0	SENT_386	[p26l1209t3452r1256b3502],
13	Mauro	NNP	PERSON	Mauro	nn	14	SENT_386	[p26l1287t3452r1446b3493],
14	DJ	NNP	PERSON	DJ	appos	5	SENT_386	[p26l1475t3452r1543b3502],
15	,	,	O	,	_	0	SENT_386	[p26l1475t3452r1543b3502],
16	Lacouture	NNP	PERSON	Lacouture	nn	17	SENT_386	[p26l1575t3452r1818b3493],
17	ME	NNP	O	ME	appos	5	SENT_386	[p26l1846t3452r1941b3492],
18	.	.	O	.	_	0	SENT_386	[p26l1846t3452r1941b3492],

1	Impact	NN	O	impact	nsubj	7	SENT_387	[p26l1973t3452r2145b3504],
2	and	CC	O	and	_	0	SENT_387	[p26l1115t3519r1204b3563],
3	management	NN	O	management	conj_and	1	SENT_387	[p26l1229t3529r1550b3576],
4	of	IN	O	of	_	0	SENT_387	[p26l1573t3519r1629b3563],
5	skin	NN	O	skin	nn	6	SENT_387	[p26l1645t3519r1747b3564],
6	toxicity	NN	O	toxicity	prep_of	1	SENT_387	[p26l1772t3520r1953b3575],
7	associated	VBN	O	associate	_	0	SENT_387	[p26l1975t3520r2141b3563, p26l1115t3590r1216b3634],
8	with	IN	O	with	_	0	SENT_387	[p26l1248t3590r1358b3635],
9	anti	JJ	O	anti	amod	10	SENT_387	[p26l1392t3590r1755b3646],
10	—	NN	O	—	prep_with	7	SENT_387	[p26l1392t3590r1755b3646],
11	epidermal	JJ	O	epidermal	amod	15	SENT_387	[p26l1392t3590r1755b3646],
12	growth	NN	O	growth	nn	15	SENT_387	[p26l1789t3590r1967b3647],
13	factor	NN	O	factor	nn	15	SENT_387	[p26l2001t3590r2144b3635],
14	receptor	NN	O	receptor	nn	15	SENT_387	[p26l1115t3670r1318b3717],
15	therapy	NN	O	therapy	dep	10	SENT_387	[p26l1332t3661r1526b3717],
16	:	:	O	:	_	0	SENT_387	[p26l1332t3661r1526b3717],
17	survey	NN	O	survey	nn	18	SENT_387	[p26l1545t3676r1701b3717],
18	results	NNS	O	result	dep	10	SENT_387	[p26l1714t3661r1890b3706],
19	.	.	O	.	_	0	SENT_387	[p26l1714t3661r1890b3706],

1	Oncology	NNP	O	Oncology	_	0	SENT_388	[p26l1909t3661r2145b3718],
2	2007	CD	DATE	2007	num	1	SENT_388	[p26l1115t3737r1461b3786],
3	;	:	O	;	_	0	SENT_388	[p26l1115t3737r1461b3786],
4	72:152	CD	NUMBER	72:152	number	5	SENT_388	[p26l1115t3737r1461b3786],
5	—	CD	NUMBER	—	dep	1	SENT_388	[p26l1115t3737r1461b3786],
6	9	CD	NUMBER	9	dep	5	SENT_388	[p26l1115t3737r1461b3786],
7	.	.	O	.	_	0	SENT_388	[p26l1115t3737r1461b3786],

1	fects	NNS	O	fect	_	0	SENT_389	[p27l13t15r125b59],
2	of	IN	O	of	_	0	SENT_389	[p27l153t15r209b60],
3	smoking	NN	O	smoking	prep_of	1	SENT_389	[p27l225t15r439b72],
4	on	IN	O	on	_	0	SENT_389	[p27l463t29r523b59],
5	the	DT	O	the	det	6	SENT_389	[p27l549t15r624b59],
6	pharmacokinetics	NNS	O	pharmacokinetic	prep_on	1	SENT_389	[p27l649t15r1039b71, p27l13t87r75b130],
7	of	IN	O	of	_	0	SENT_389	[p27l98t86r155b130],
8	erlotinib	NN	O	erlotinib	prep_of	6	SENT_389	[p27l166t86r389b131],
9	.	.	O	.	_	0	SENT_389	[p27l166t86r389b131],

1	Clin	NNP	O	Clin	nn	3	SENT_390	[p27l413t86r513b131],
2	Cancer	NNP	O	Cancer	nn	3	SENT_390	[p27l534t90r704b131],
3	Res	NNP	O	Res	_	0	SENT_390	[p27l723t90r808b133],
4	2006	CD	DATE	2006	num	3	SENT_390	[p27l831t90r1038b140],
5	;	:	O	;	_	0	SENT_390	[p27l831t90r1038b140],
6	12	CD	NUMBER	12	num	8	SENT_390	[p27l831t90r1038b140],
7	:	:	O	:	_	0	SENT_390	[p27l831t90r1038b140],
8	2166-71	CD	NUMBER	2166-71	dep	3	SENT_390	[p27l13t162r216b202],
9	.	.	O	.	_	0	SENT_390	[p27l13t162r216b202],

1	29	CD	NUMBER	29	_	0	SENT_391	[p27l12t233r78b272],
2	.	.	O	.	_	0	SENT_391	[p27l12t233r78b272],

1	Herbst	NNP	ORGANIZATION	Herbst	nn	2	SENT_392	[p27l108t228r274b272],
2	RS	NN	ORGANIZATION	r	_	0	SENT_392	[p27l295t232r374b282],
3	,	,	O	,	_	0	SENT_392	[p27l295t232r374b282],
4	Prager	NN	PERSON	prager	nn	5	SENT_392	[p27l402t232r560b285],
5	D	NN	PERSON	d	appos	2	SENT_392	[p27l584t232r634b282],
6	,	,	O	,	_	0	SENT_392	[p27l584t232r634b282],
7	Hermann	NNP	PERSON	Hermann	nn	8	SENT_392	[p27l662t232r896b272],
8	R	NNP	PERSON	R	appos	2	SENT_392	[p27l921t232r970b282],
9	,	,	O	,	_	0	SENT_392	[p27l921t232r970b282],
10	et	FW	O	et	nn	11	SENT_392	[p27l999t237r1043b272],
11	al.	FW	O	al.	appos	2	SENT_392	[p27l13t299r68b343],
12	.	.	O	.	_	0	SENT_392	[p27l13t299r68b343],

1	TRIBUTE	NN	O	tribute	_	0	SENT_393	[p27l89t303r337b346],
2	:	:	O	:	_	0	SENT_393	[p27l89t303r337b346],
3	a	DT	O	a	det	6	SENT_393	[p27l359t314r384b343],
4	phase	NN	O	phase	nn	6	SENT_393	[p27l403t299r544b355],
5	III	CD	NUMBER	iii	num	6	SENT_393	[p27l564t303r621b343],
6	trial	NN	O	trial	dep	1	SENT_393	[p27l641t299r742b343],
7	of	IN	O	of	_	0	SENT_393	[p27l763t299r819b343],
8	erlotinib	NN	O	erlotinib	nn	9	SENT_393	[p27l830t299r1039b344],
9	hydrochloride	NN	O	hydrochloride	prep_of	6	SENT_393	[p27l13t370r354b426],
10	(	CD	NUMBER	(	num	14	SENT_393	[p27l395t374r612b421],
11	OSI	NNP	O	OSI	amod	14	SENT_393	[p27l395t374r612b421],
12	—	CD	NUMBER	—	num	11	SENT_393	[p27l395t374r612b421],
13	774	CD	NUMBER	774	dep	11	SENT_393	[p27l395t374r612b421],
14	)	NN	O	)	dep	9	SENT_393	[p27l395t374r612b421],
15	combined	VBN	O	combine	partmod	9	SENT_393	[p27l653t370r894b415],
16	with	IN	O	with	_	0	SENT_393	[p27l929t370r1040b415],
17	carboplatin	NN	O	carboplatin	nn	20	SENT_393	[p27l13t442r295b498],
18	and	CC	O	and	_	0	SENT_393	[p27l320t442r410b486],
19	paclitaxel	NN	O	paclitaxel	nn	20	SENT_393	[p27l434t442r669b498],
20	chemotherapy	NN	O	chemotherapy	prep_with	15	SENT_393	[p27l695t442r1042b498],
21	in	IN	O	in	_	0	SENT_393	[p27l13t513r60b556],
22	advanced	JJ	O	advanced	amod	27	SENT_393	[p27l89t512r315b557],
23	non	JJ	O	non	amod	27	SENT_393	[p27l345t512r699b556],
24	—	NN	O	—	nn	27	SENT_393	[p27l345t512r699b556],
25	small-cell	NN	O	small-cell	nn	27	SENT_393	[p27l345t512r699b556],
26	lung	NN	O	lung	nn	27	SENT_393	[p27l728t512r838b569],
27	cancer	NN	O	cancer	prep_in	15	SENT_393	[p27l867t526r1037b556],
28	.	.	O	.	_	0	SENT_393	[p27l867t526r1037b556],

1	J	NNP	O	J	nn	3	SENT_394	[p27l7t588r28b635],
2	Clin	NNP	O	Clin	nn	3	SENT_394	[p27l46t584r147b628],
3	Oncol	NNP	O	Oncol	_	0	SENT_394	[p27l166t584r310b628],
4	2005	CD	DATE	2005	num	3	SENT_394	[p27l329t588r712b637],
5	;	:	O	;	_	0	SENT_394	[p27l329t588r712b637],
6	23:5892	CD	NUMBER	23:5892	number	7	SENT_394	[p27l329t588r712b637],
7	-9	CD	NUMBER	-9	dep	3	SENT_394	[p27l329t588r712b637],
8	.	.	O	.	_	0	SENT_394	[p27l329t588r712b637],

1	30	CD	NUMBER	30	_	0	SENT_395	[p27l13t659r79b698],
2	.	.	O	.	_	0	SENT_395	[p27l13t659r79b698],

1	Giaccone	NNP	PERSON	Giaccone	nn	2	SENT_396	[p27l109t655r333b698],
2	G	NNP	PERSON	G	_	0	SENT_396	[p27l356t658r409b708],
3	,	,	O	,	_	0	SENT_396	[p27l356t658r409b708],
4	Herbst	NNP	ORGANIZATION	Herbst	nn	5	SENT_396	[p27l434t654r600b699],
5	RS	NN	ORGANIZATION	r	appos	2	SENT_396	[p27l619t658r698b708],
6	,	,	O	,	_	0	SENT_396	[p27l619t658r698b708],
7	Manegold	NNP	ORGANIZATION	Manegold	nn	8	SENT_396	[p27l723t654r967b711],
8	C	NNP	ORGANIZATION	C	appos	2	SENT_396	[p27l990t658r1037b708],
9	,	,	O	,	_	0	SENT_396	[p27l990t658r1037b708],
10	et	FW	O	et	nn	11	SENT_396	[p27l13t735r57b769],
11	al.	FW	O	al.	appos	2	SENT_396	[p27l73t725r128b769],
12	.	.	O	.	_	0	SENT_396	[p27l73t725r128b769],

1	Gefitinib	NNP	O	Gefitinib	_	0	SENT_397	[p27l151t725r374b770],
2	in	IN	O	in	_	0	SENT_397	[p27l394t726r441b769],
3	combination	NN	O	combination	prep_in	1	SENT_397	[p27l461t725r771b770],
4	with	IN	O	with	_	0	SENT_397	[p27l788t725r899b770],
5	gemcitabine	NN	O	gemcitabine	prep_with	3	SENT_397	[p27l917t740r1039b782, p27l13t797r206b841],
6	and	CC	O	and	_	0	SENT_397	[p27l236t797r325b841],
7	cisplatin	NN	O	cisplatin	conj_and	5	SENT_397	[p27l356t797r565b853],
8	in	IN	O	in	_	0	SENT_397	[p27l595t798r643b841],
9	advanced	JJ	O	advanced	amod	12	SENT_397	[p27l673t797r898b842],
10	nonsmall-cell	JJ	O	nonsmall-cell	amod	12	SENT_397	[p27l929t811r1039b841, p27l14t867r247b911],
11	lung	NN	O	lung	nn	12	SENT_397	[p27l267t867r375b924],
12	cancer	NN	O	cancer	prep_in	1	SENT_397	[p27l394t882r562b911],
13	:	:	O	:	_	0	SENT_397	[p27l394t882r562b911],
14	a	DT	O	a	det	17	SENT_397	[p27l585t882r610b911],
15	phase	NN	O	phase	nn	17	SENT_397	[p27l629t867r768b923],
16	III	CD	NUMBER	iii	num	17	SENT_397	[p27l788t871r844b911],
17	trial	NN	O	trial	dep	1	SENT_397	[p27l865t867r964b911],
18	—	CD	NUMBER	—	num	19	SENT_397	[p27l982t892r1042b897],
19	INTACT	NN	O	intact	dep	17	SENT_397	[p27l12t942r214b983],
20	1	CD	NUMBER	1	dep	19	SENT_397	[p27l234t942r272b982],
21	.	.	O	.	_	0	SENT_397	[p27l234t942r272b982],

1	J	NNP	O	J	nn	3	SENT_398	[p27l289t942r310b989],
2	Clin	NNP	O	Clin	nn	3	SENT_398	[p27l328t938r428b982],
3	Oncol	NNP	O	Oncol	_	0	SENT_398	[p27l447t938r591b983],
4	2004	CD	DATE	2004	num	3	SENT_398	[p27l610t942r998b991],
5	;	:	O	;	_	0	SENT_398	[p27l610t942r998b991],
6	22:777	CD	NUMBER	22:777	number	7	SENT_398	[p27l610t942r998b991],
7	-84	CD	NUMBER	-84	dep	3	SENT_398	[p27l610t942r998b991],
8	.	.	O	.	_	0	SENT_398	[p27l610t942r998b991],

1	31	CD	NUMBER	31	_	0	SENT_399	[p27l13t1015r78b1053],
2	.	.	O	.	_	0	SENT_399	[p27l13t1015r78b1053],

1	Herbst	NNP	ORGANIZATION	Herbst	nn	2	SENT_400	[p27l108t1009r277b1054],
2	RS	NN	ORGANIZATION	r	_	0	SENT_400	[p27l300t1013r380b1063],
3	,	,	O	,	_	0	SENT_400	[p27l300t1013r380b1063],
4	Giaccone	NNP	PERSON	Giaccone	nn	5	SENT_400	[p27l410t1010r638b1053],
5	G	NNP	PERSON	G	appos	2	SENT_400	[p27l665t1013r718b1063],
6	,	,	O	,	_	0	SENT_400	[p27l665t1013r718b1063],
7	Schiller	NNP	PERSON	Schiller	nn	8	SENT_400	[p27l749t1009r939b1054],
8	JH	NNP	O	JH	appos	2	SENT_400	[p27l958t1013r1037b1063],
9	,	,	O	,	_	0	SENT_400	[p27l958t1013r1037b1063],
10	et	FW	O	et	nn	11	SENT_400	[p27l13t1090r58b1125],
11	al.	FW	O	al.	appos	2	SENT_400	[p27l72t1081r128b1125],
12	.	.	O	.	_	0	SENT_400	[p27l72t1081r128b1125],

1	Geﬁtinib	NNP	O	Geﬁtinib	_	0	SENT_401	[p27l148t1081r372b1125],
2	in	IN	O	in	_	0	SENT_401	[p27l389t1082r436b1125],
3	combination	NN	O	combination	prep_in	1	SENT_401	[p27l453t1081r764b1125],
4	with	IN	O	with	_	0	SENT_401	[p27l779t1081r889b1126],
5	paclitaxel	NN	O	paclitaxel	prep_with	3	SENT_401	[p27l905t1081r1039b1137, p27l13t1152r129b1196],
6	and	CC	O	and	_	0	SENT_401	[p27l160t1152r249b1196],
7	carboplatin	NN	O	carboplatin	conj_and	5	SENT_401	[p27l281t1152r562b1208],
8	in	IN	O	in	_	0	SENT_401	[p27l593t1153r641b1196],
9	advanced	JJ	O	advanced	amod	12	SENT_401	[p27l672t1152r897b1197],
10	nonsmall-cell	JJ	O	nonsmall-cell	amod	12	SENT_401	[p27l928t1166r1039b1196, p27l14t1222r247b1266],
11	lung	NN	O	lung	nn	12	SENT_401	[p27l267t1222r375b1279],
12	cancer	NN	O	cancer	prep_in	1	SENT_401	[p27l394t1237r562b1266],
13	:	:	O	:	_	0	SENT_401	[p27l394t1237r562b1266],
14	a	DT	O	a	det	17	SENT_401	[p27l585t1237r610b1266],
15	phase	NN	O	phase	nn	17	SENT_401	[p27l629t1222r768b1278],
16	III	CD	NUMBER	iii	num	17	SENT_401	[p27l788t1226r844b1266],
17	trial	NN	O	trial	dep	1	SENT_401	[p27l865t1222r964b1266],
18	—	CD	NUMBER	—	num	19	SENT_401	[p27l982t1247r1042b1252],
19	INTACT	NN	O	intact	dep	17	SENT_401	[p27l12t1297r214b1338],
20	2	CD	NUMBER	2	dep	19	SENT_401	[p27l232t1297r272b1337],
21	.	.	O	.	_	0	SENT_401	[p27l232t1297r272b1337],

1	J	NNP	O	J	nn	3	SENT_402	[p27l289t1297r310b1344],
2	Clin	NNP	O	Clin	nn	3	SENT_402	[p27l328t1293r428b1337],
3	Oncol	NNP	O	Oncol	_	0	SENT_402	[p27l448t1293r592b1338],
4	2004	CD	DATE	2004	num	3	SENT_402	[p27l611t1297r998b1346],
5	;	:	O	;	_	0	SENT_402	[p27l611t1297r998b1346],
6	22:785	CD	NUMBER	22:785	number	7	SENT_402	[p27l611t1297r998b1346],
7	-94	CD	NUMBER	-94	dep	3	SENT_402	[p27l611t1297r998b1346],
8	.	.	O	.	_	0	SENT_402	[p27l611t1297r998b1346],

1	32	CD	NUMBER	32	_	0	SENT_403	[p27l13t1370r79b1408],
2	.	.	O	.	_	0	SENT_403	[p27l13t1370r79b1408],

1	Riely	NNP	PERSON	Riely	nn	3	SENT_404	[p27l108t1364r230b1420],
2	G	NNP	O	G	nn	3	SENT_404	[p27l248t1368r317b1418],
3	]	NNS	O	]	_	0	SENT_404	[p27l248t1368r317b1418],
4	,	,	O	,	_	0	SENT_404	[p27l248t1368r317b1418],
5	Kris	NNP	PERSON	Kris	nn	6	SENT_404	[p27l340t1365r440b1410],
6	MG	NN	PERSON	mg	appos	3	SENT_404	[p27l461t1368r563b1418],
7	,	,	O	,	_	0	SENT_404	[p27l461t1368r563b1418],
8	Zhao	NNP	PERSON	Zhao	nn	9	SENT_404	[p27l586t1364r707b1409],
9	B	NNP	PERSON	B	appos	3	SENT_404	[p27l728t1368r773b1418],
10	,	,	O	,	_	0	SENT_404	[p27l728t1368r773b1418],
11	et	FW	O	et	nn	12	SENT_404	[p27l798t1374r841b1408],
12	al.	FW	O	al.	appos	3	SENT_404	[p27l859t1364r915b1408],
13	.	.	O	.	_	0	SENT_404	[p27l859t1364r915b1408],

1	Prospective	JJ	O	prospective	amod	2	SENT_405	[p27l938t1368r1039b1409, p27l14t1436r207b1491],
2	assessment	NN	O	assessment	_	0	SENT_405	[p27l247t1445r527b1479],
3	of	IN	O	of	_	0	SENT_405	[p27l565t1435r621b1480],
4	discontinuation	NN	O	discontinuation	prep_of	2	SENT_405	[p27l652t1435r1040b1480],
5	and	CC	O	and	_	0	SENT_405	[p27l13t1506r102b1550],
6	reinitiation	NN	O	reinitiation	prep_of	2	SENT_405	[p27l118t1507r394b1551],
7	of	IN	O	of	_	0	SENT_405	[p27l410t1506r467b1550],
8	erlotinib	NN	O	erlotinib	prep_of	2	SENT_405	[p27l473t1506r683b1550],
9	or	CC	O	or	_	0	SENT_405	[p27l700t1520r750b1551],
10	gefitinib	NN	O	gefitinib	prep_of	2	SENT_405	[p27l764t1506r976b1563],
11	in	IN	O	in	_	0	SENT_405	[p27l993t1507r1040b1550],
12	patients	NNS	O	patient	prep_in	2	SENT_405	[p27l12t1579r207b1634],
13	with	IN	O	with	_	0	SENT_405	[p27l227t1578r338b1623],
14	acquired	VBN	O	acquire	amod	15	SENT_405	[p27l360t1578r571b1634],
15	resistance	NN	O	resistance	prep_with	2	SENT_405	[p27l592t1579r837b1622],
16	to	TO	O	to	_	0	SENT_405	[p27l859t1588r905b1622],
17	erlotinib	NN	O	erlotinib	prep_to	2	SENT_405	[p27l928t1578r1039b1622, p27l13t1648r128b1693],
18	or	CC	O	or	_	0	SENT_405	[p27l147t1662r197b1692],
19	gefitinib	NN	O	gefitinib	conj_or	17	SENT_405	[p27l213t1648r425b1705],
20	followed	VBN	O	follow	partmod	2	SENT_405	[p27l444t1648r655b1693],
21	by	IN	O	by	_	0	SENT_405	[p27l673t1648r728b1704],
22	the	DT	O	the	det	23	SENT_405	[p27l744t1648r819b1692],
23	addition	NN	O	addition	agent	20	SENT_405	[p27l837t1648r1040b1693],
24	of	IN	O	of	_	0	SENT_405	[p27l13t1720r70b1764],
25	everolimus	NN	O	everolimus	prep_of	23	SENT_405	[p27l88t1720r368b1765],
26	.	.	O	.	_	0	SENT_405	[p27l88t1720r368b1765],

1	Clin	NNP	O	Clin	nn	3	SENT_406	[p27l399t1720r499b1764],
2	Cancer	NNP	O	Cancer	nn	3	SENT_406	[p27l527t1724r697b1764],
3	Res	NNP	O	Res	_	0	SENT_406	[p27l722t1724r807b1767],
4	2007	CD	DATE	2007	num	3	SENT_406	[p27l837t1724r1037b1773],
5	;	:	O	;	_	0	SENT_406	[p27l837t1724r1037b1773],
6	13	CD	NUMBER	13	num	8	SENT_406	[p27l837t1724r1037b1773],
7	:	:	O	:	_	0	SENT_406	[p27l837t1724r1037b1773],
8	5150-5	CD	NUMBER	5150-5	dep	3	SENT_406	[p27l14t1794r189b1835],
9	.	.	O	.	_	0	SENT_406	[p27l14t1794r189b1835],

1	33	CD	NUMBER	33	_	0	SENT_407	[p27l13t1867r77b1905],
2	.	.	O	.	_	0	SENT_407	[p27l13t1867r77b1905],

1	Miller	NNP	ORGANIZATION	Miller	nn	2	SENT_408	[p27l107t1861r255b1905],
2	AA	NNP	ORGANIZATION	AA	_	0	SENT_408	[p27l276t1865r364b1915],
3	,	,	O	,	_	0	SENT_408	[p27l276t1865r364b1915],
4	Murry	NNP	PERSON	Murry	nn	5	SENT_408	[p27l389t1865r542b1917],
5	DJ	NNP	PERSON	DJ	appos	2	SENT_408	[p27l563t1865r630b1915],
6	,	,	O	,	_	0	SENT_408	[p27l563t1865r630b1915],
7	Owzar	NNP	O	Owzar	nn	8	SENT_408	[p27l657t1865r819b1906],
8	K	NNP	O	K	appos	2	SENT_408	[p27l841t1865r890b1915],
9	,	,	O	,	_	0	SENT_408	[p27l841t1865r890b1915],
10	et	FW	O	et	nn	11	SENT_408	[p27l917t1870r961b1905],
11	al.	FW	O	al.	appos	2	SENT_408	[p27l981t1861r1037b1905],
12	.	.	O	.	_	0	SENT_408	[p27l981t1861r1037b1905],

1	Phase	NN	O	phase	nn	2	SENT_409	[p27l12t1933r152b1977],
2	I	NN	O	i	_	0	SENT_409	[p27l173t1937r189b1977],
3	and	CC	O	and	_	0	SENT_409	[p27l210t1933r299b1977],
4	pharmacokinetic	JJ	O	pharmacokinetic	amod	5	SENT_409	[p27l319t1933r738b1989],
5	study	NN	O	study	conj_and	2	SENT_409	[p27l759t1933r890b1989],
6	of	IN	O	of	_	0	SENT_409	[p27l909t1933r966b1977],
7	erlotinib	NN	O	erlotinib	prep_of	2	SENT_409	[p27l977t1948r1039b1977, p27l12t2003r175b2048],
8	for	IN	O	for	_	0	SENT_409	[p27l201t2003r271b2048],
9	solid	JJ	O	solid	amod	10	SENT_409	[p27l295t2003r412b2047],
10	tumors	NNS	O	tumor	prep_for	7	SENT_409	[p27l438t2012r612b2048],
11	in	IN	O	in	_	0	SENT_409	[p27l638t2004r686b2047],
12	patients	NNS	O	patient	prep_in	10	SENT_409	[p27l710t2004r905b2059],
13	with	IN	O	with	_	0	SENT_409	[p27l929t2003r1040b2048],
14	hepatic	JJ	O	hepatic	amod	17	SENT_409	[p27l13t2074r193b2130],
15	or	CC	O	or	_	0	SENT_409	[p27l238t2088r289b2119],
16	renal	JJ	O	renal	conj_or	14	SENT_409	[p27l331t2074r457b2118],
17	dysfunction	NN	O	dysfunction	prep_with	12	SENT_409	[p27l502t2074r812b2130],
18	:	:	O	:	_	0	SENT_409	[p27l502t2074r812b2130],
19	CALGB	NN	O	calgb	dep	2	SENT_409	[p27l859t2078r1039b2119],
20	60101	CD	NUMBER	60101	dep	19	SENT_409	[p27l13t2150r169b2190],
21	.	.	O	.	_	0	SENT_409	[p27l13t2150r169b2190],

1	J	NNP	O	J	nn	3	SENT_410	[p27l186t2150r207b2197],
2	Clin	NNP	O	Clin	nn	3	SENT_410	[p27l224t2146r325b2190],
3	Oncol	NNP	O	Oncol	_	0	SENT_410	[p27l344t2146r488b2190],
4	2007	CD	DATE	2007	num	3	SENT_410	[p27l507t2150r922b2199],
5	;	:	O	;	_	0	SENT_410	[p27l507t2150r922b2199],
6	25:3055	CD	NUMBER	25:3055	number	7	SENT_410	[p27l507t2150r922b2199],
7	—	CD	NUMBER	—	dep	3	SENT_410	[p27l507t2150r922b2199],
8	60	CD	NUMBER	60	dep	7	SENT_410	[p27l507t2150r922b2199],
9	.	.	O	.	_	0	SENT_410	[p27l507t2150r922b2199],

1	34	CD	NUMBER	34	_	0	SENT_411	[p27l13t2223r79b2261],
2	.	.	O	.	_	0	SENT_411	[p27l13t2223r79b2261],

1	Liu	NNP	PERSON	Liu	nn	2	SENT_412	[p27l108t2218r183b2262],
2	W	NNP	O	W	_	0	SENT_412	[p27l203t2221r263b2271],
3	,	,	O	,	_	0	SENT_412	[p27l203t2221r263b2271],
4	Makrauer	NNP	O	Makrauer	nn	5	SENT_412	[p27l287t2217r524b2262],
5	F	NN	O	f	appos	2	SENT_412	[p27l543t2221r581b2271],
6	,	,	O	,	_	0	SENT_412	[p27l543t2221r581b2271],
7	Qamar	NNP	ORGANIZATION	Qamar	nn	8	SENT_412	[p27l606t2221r775b2272],
8	AA	NNP	ORGANIZATION	AA	appos	2	SENT_412	[p27l793t2221r881b2271],
9	,	,	O	,	_	0	SENT_412	[p27l793t2221r881b2271],
10	Janne	NNP	PERSON	Janne	nn	11	SENT_412	[p27l900t2221r1040b2268],
11	PA	NN	PERSON	pa	appos	2	SENT_412	[p27l12t2291r88b2341],
12	,	,	O	,	_	0	SENT_412	[p27l12t2291r88b2341],
13	Odze	NN	O	odze	nn	14	SENT_412	[p27l119t2287r245b2331],
14	RD.	NN	O	rd.	appos	2	SENT_412	[p27l272t2291r362b2334],
15	.	.	O	.	_	0	SENT_412	[p27l272t2291r362b2334],

1	Fulminant	JJ	O	fulminant	amod	3	SENT_413	[p27l392t2287r652b2332],
2	hepatic	JJ	O	hepatic	amod	3	SENT_413	[p27l677t2287r854b2343],
3	failure	NN	O	failure	_	0	SENT_413	[p27l881t2287r1040b2332],
4	secondary	JJ	O	secondary	dep	3	SENT_413	[p27l14t2359r263b2415],
5	to	TO	O	to	_	0	SENT_413	[p27l277t2368r323b2403],
6	erlotinib	NN	O	erlotinib	prep_to	4	SENT_413	[p27l342t2359r564b2403],
7	.	.	O	.	_	0	SENT_413	[p27l342t2359r564b2403],

1	Clin	NNP	O	Clin	nn	3	SENT_414	[p27l585t2359r685b2403],
2	Gastroenterol	NNP	O	Gastroenterol	nn	3	SENT_414	[p27l702t2359r1040b2403],
3	Hepatol	NNP	O	Hepatol	_	0	SENT_414	[p27l13t2429r205b2485],
4	2007	CD	DATE	2007	num	3	SENT_414	[p27l223t2433r567b2482],
5	;	:	O	;	_	0	SENT_414	[p27l223t2433r567b2482],
6	5:917	CD	NUMBER	5:917	number	7	SENT_414	[p27l223t2433r567b2482],
7	-20	CD	NUMBER	-20	dep	3	SENT_414	[p27l223t2433r567b2482],
8	.	.	O	.	_	0	SENT_414	[p27l223t2433r567b2482],

1	35	CD	NUMBER	35	_	0	SENT_415	[p27l13t2506r77b2544],
2	.	.	O	.	_	0	SENT_415	[p27l13t2506r77b2544],

1	Gridelli	NN	PERSON	gridellus	nn	2	SENT_416	[p27l109t2500r295b2545],
2	C	NN	PERSON	c	_	0	SENT_416	[p27l321t2504r368b2554],
3	,	,	O	,	_	0	SENT_416	[p27l321t2504r368b2554],
4	Maione	NNP	PERSON	Maione	nn	5	SENT_416	[p27l396t2501r577b2545],
5	P	NN	O	p	appos	2	SENT_416	[p27l603t2504r641b2554],
6	,	,	O	,	_	0	SENT_416	[p27l603t2504r641b2554],
7	Amoroso	NNP	PERSON	Amoroso	nn	8	SENT_416	[p27l668t2504r893b2545],
8	D	NNP	O	D	appos	2	SENT_416	[p27l919t2504r969b2554],
9	,	,	O	,	_	0	SENT_416	[p27l919t2504r969b2554],
10	et	FW	O	et	nn	11	SENT_416	[p27l999t2509r1043b2544],
11	al.	FW	O	al.	appos	2	SENT_416	[p27l13t2571r68b2615],
12	.	.	O	.	_	0	SENT_416	[p27l13t2571r68b2615],

1	Clinical	JJ	O	clinical	amod	2	SENT_417	[p27l92t2571r282b2615],
2	significance	NN	O	significance	_	0	SENT_417	[p27l304t2571r602b2628],
3	and	CC	O	and	_	0	SENT_417	[p27l623t2571r713b2615],
4	treatment	NN	O	treatment	conj_and	2	SENT_417	[p27l734t2580r975b2615],
5	of	IN	O	of	_	0	SENT_417	[p27l994t2571r1050b2615],
6	skin	NN	O	skin	nn	7	SENT_417	[p27l14t2643r116b2688],
7	rash	NN	O	rash	prep_of	2	SENT_417	[p27l135t2643r238b2687],
8	from	IN	O	from	_	0	SENT_417	[p27l257t2643r376b2687],
9	erlotinib	NN	O	erlotinib	prep_from	7	SENT_417	[p27l395t2643r605b2687],
10	in	IN	O	in	_	0	SENT_417	[p27l624t2644r671b2687],
11	non-small	JJ	O	non-small	amod	15	SENT_417	[p27l690t2643r938b2687],
12	cell	NN	O	cell	nn	15	SENT_417	[p27l957t2643r1040b2687],
13	lung	NN	O	lung	nn	15	SENT_417	[p27l12t2713r122b2770],
14	cancer	NN	O	cancer	nn	15	SENT_417	[p27l137t2728r297b2757],
15	patients	NNS	O	patient	prep_in	9	SENT_417	[p27l311t2714r520b2769],
16	:	:	O	:	_	0	SENT_417	[p27l311t2714r520b2769],
17	results	NNS	O	result	dep	2	SENT_417	[p27l539t2713r701b2758],
18	of	IN	O	of	_	0	SENT_417	[p27l719t2713r775b2758],
19	an	DT	O	a	det	21	SENT_417	[p27l781t2727r839b2757],
20	Experts	NNS	O	expert	nn	21	SENT_417	[p27l855t2717r1039b2769],
21	Panel	NNP	O	Panel	prep_of	17	SENT_417	[p27l12t2784r144b2828],
22	Meeting	VBG	O	meet	partmod	21	SENT_417	[p27l173t2785r387b2841],
23	.	.	O	.	_	0	SENT_417	[p27l173t2785r387b2841],

1	Crit	NNP	O	Crit	nn	4	SENT_418	[p27l420t2785r512b2829],
2	Rev	NN	O	rev	nn	4	SENT_418	[p27l539t2788r628b2831],
3	Oncol	NNP	O	Oncol	nn	4	SENT_418	[p27l657t2784r801b2829],
4	Hematol	NNP	O	Hematol	_	0	SENT_418	[p27l831t2784r1040b2828],
5	2008	CD	DATE	2008	num	4	SENT_418	[p27l13t2859r404b2909],
6	;	:	O	;	_	0	SENT_418	[p27l13t2859r404b2909],
7	66:155	CD	NUMBER	66:155	number	8	SENT_418	[p27l13t2859r404b2909],
8	—	CD	NUMBER	—	dep	4	SENT_418	[p27l13t2859r404b2909],
9	62	CD	NUMBER	62	dep	8	SENT_418	[p27l13t2859r404b2909],
10	.	.	O	.	_	0	SENT_418	[p27l13t2859r404b2909],

1	36	CD	NUMBER	36	_	0	SENT_419	[p27l13t2932r80b2971],
2	.	.	O	.	_	0	SENT_419	[p27l13t2932r80b2971],

1	Shepherd	NNP	ORGANIZATION	Shepherd	nn	2	SENT_420	[p27l110t2926r341b2982],
2	FA	NNP	ORGANIZATION	FA	_	0	SENT_420	[p27l360t2930r437b2980],
3	,	,	O	,	_	0	SENT_420	[p27l360t2930r437b2980],
4	Dancey	NNP	PERSON	Dancey	nn	5	SENT_420	[p27l460t2930r643b2982],
5	J	NNP	PERSON	J	appos	2	SENT_420	[p27l656t2930r689b2980],
6	,	,	O	,	_	0	SENT_420	[p27l656t2930r689b2980],
7	Ramlau	NNP	O	Ramlau	nn	8	SENT_420	[p27l712t2926r905b2973],
8	R	NNP	O	R	appos	2	SENT_420	[p27l925t2930r974b2980],
9	,	,	O	,	_	0	SENT_420	[p27l925t2930r974b2980],
10	et	FW	O	et	nn	11	SENT_420	[p27l999t2935r1043b2970],
11	al.	FW	O	al.	appos	2	SENT_420	[p27l13t2998r69b3042],
12	prospective	JJ	O	prospective	amod	14	SENT_420	[p27l90t2999r376b3054],
13	randomized	JJ	O	randomized	amod	14	SENT_420	[p27l395t2998r696b3042],
14	trial	NN	O	trial	dep	11	SENT_420	[p27l716t2998r820b3042],
15	of	IN	O	of	_	0	SENT_420	[p27l839t2998r896b3042],
16	docetaxel	NN	O	docetaxel	prep_of	2	SENT_420	[p27l906t2998r1039b3042, p27l13t3069r126b3113],
17	versus	CC	O	versus	_	0	SENT_420	[p27l138t3084r286b3114],
18	best	JJS	O	best	dep	19	SENT_420	[p27l302t3069r400b3113],
19	supportive	JJ	O	supportive	amod	20	SENT_420	[p27l413t3070r662b3125],
20	care	NN	O	care	conj_versus	2	SENT_420	[p27l677t3084r775b3113],
21	in	IN	O	in	_	0	SENT_420	[p27l789t3070r835b3113],
22	patients	NNS	O	patient	prep_in	20	SENT_420	[p27l849t3070r1039b3125],
23	with	IN	O	with	_	0	SENT_420	[p27l10t3139r119b3184],
24	non	JJ	O	non	amod	28	SENT_420	[p27l137t3139r483b3183],
25	—	JJ	O	—	amod	28	SENT_420	[p27l137t3139r483b3183],
26	small-cell	NN	O	small-cell	nn	28	SENT_420	[p27l137t3139r483b3183],
27	lung	NN	O	lung	nn	28	SENT_420	[p27l500t3139r608b3196],
28	cancer	NN	O	cancer	prep_with	22	SENT_420	[p27l625t3153r781b3183],
29	previously	RB	DATE	previously	advmod	30	SENT_420	[p27l797t3139r1042b3195],
30	treated	VBN	O	treat	partmod	22	SENT_420	[p27l13t3211r183b3255],
31	with	IN	O	with	_	0	SENT_420	[p27l200t3211r310b3256],
32	platinum	NN	O	platinum	nn	33	SENT_420	[p27l328t3211r713b3267],
33	—	NN	O	—	prep_with	30	SENT_420	[p27l328t3211r713b3267],
34	based	VBN	O	base	partmod	2	SENT_420	[p27l328t3211r713b3267],
35	chemotherapy	NN	O	chemotherapy	dobj	34	SENT_420	[p27l732t3211r1039b3255, p27l12t3296r76b3337],
36	.	.	O	.	_	0	SENT_420	[p27l732t3211r1039b3255, p27l12t3296r76b3337],

1	J	NNP	O	J	nn	3	SENT_421	[p27l93t3285r114b3332],
2	Clin	NNP	O	Clin	nn	3	SENT_421	[p27l132t3281r233b3326],
3	Oncol	NNP	O	Oncol	_	0	SENT_421	[p27l252t3281r396b3325],
4	2000	CD	DATE	2000	num	3	SENT_421	[p27l415t3285r857b3335],
5	;	:	O	;	_	0	SENT_421	[p27l415t3285r857b3335],
6	18:2095	CD	NUMBER	18:2095	number	7	SENT_421	[p27l415t3285r857b3335],
7	-103	CD	NUMBER	-103	dep	3	SENT_421	[p27l415t3285r857b3335],
8	.	.	O	.	_	0	SENT_421	[p27l415t3285r857b3335],

1	37	CD	NUMBER	37	_	0	SENT_422	[p27l13t3358r74b3396],
2	.	.	O	.	_	0	SENT_422	[p27l13t3358r74b3396],

1	Hanna	NNP	PERSON	Hanna	nn	2	SENT_423	[p27l108t3356r276b3396],
2	N	NNP	PERSON	N	_	0	SENT_423	[p27l299t3356r353b3406],
3	,	,	O	,	_	0	SENT_423	[p27l299t3356r353b3406],
4	Shepherd	NNP	O	Shepherd	nn	5	SENT_423	[p27l383t3352r613b3408],
5	F	NN	O	f	appos	2	SENT_423	[p27l638t3356r677b3406],
6	,	,	O	,	_	0	SENT_423	[p27l638t3356r677b3406],
7	Fossella	NNP	PERSON	Fossella	nn	8	SENT_423	[p27l705t3352r906b3397],
8	F	NN	O	f	appos	2	SENT_423	[p27l931t3356r969b3406],
9	,	,	O	,	_	0	SENT_423	[p27l931t3356r969b3406],
10	et	FW	O	et	nn	11	SENT_423	[p27l999t3361r1043b3396],
11	al.	FW	O	al.	appos	2	SENT_423	[p27l13t3424r68b3468],
12	.	.	O	.	_	0	SENT_423	[p27l13t3424r68b3468],

1	Randomized	VBN	O	randomize	csubj	16	SENT_424	[p27l97t3424r411b3471],
2	phase	NN	O	phase	nn	4	SENT_424	[p27l436t3424r578b3480],
3	III	CD	NUMBER	iii	num	4	SENT_424	[p27l604t3428r661b3468],
4	trial	NN	O	trial	dobj	1	SENT_424	[p27l688t3424r789b3468],
5	of	IN	O	of	_	0	SENT_424	[p27l816t3424r873b3468],
6	pemetrexed	JJ	O	pemetrexed	prep_of	4	SENT_424	[p27l888t3439r1039b3480, p27l13t3494r163b3538],
7	versus	CC	O	versus	prep	6	SENT_424	[p27l190t3509r342b3539],
8	docetaxel	NN	O	docetaxel	dep	7	SENT_424	[p27l372t3494r603b3539],
9	in	IN	O	in	_	0	SENT_424	[p27l631t3495r678b3538],
10	patients	NNS	O	patient	prep_in	1	SENT_424	[p27l706t3495r901b3550],
11	with	IN	O	with	_	0	SENT_424	[p27l929t3494r1040b3539],
12	non-small-cell	JJ	O	non-small-cell	amod	14	SENT_424	[p27l13t3565r367b3609],
13	lung	NN	O	lung	nn	14	SENT_424	[p27l419t3565r529b3622],
14	cancer	NN	O	cancer	prep_with	10	SENT_424	[p27l581t3579r741b3609],
15	previously	RB	DATE	previously	advmod	1	SENT_424	[p27l792t3565r1042b3621],
16	treated	VBN	O	treat	_	0	SENT_424	[p27l13t3636r183b3680],
17	with	IN	O	with	_	0	SENT_424	[p27l207t3636r317b3681],
18	chemotherapy	NN	O	chemotherapy	prep_with	16	SENT_424	[p27l344t3636r699b3692],
19	.	.	O	.	_	0	SENT_424	[p27l344t3636r699b3692],

1	J	NNP	O	J	nn	3	SENT_425	[p27l724t3640r744b3687],
2	Clin	NNP	O	Clin	nn	3	SENT_425	[p27l769t3636r870b3680],
3	Oncol	NNP	O	Oncol	_	0	SENT_425	[p27l896t3636r1040b3681],
4	2004	CD	DATE	2004	num	3	SENT_425	[p27l13t3712r427b3761],
5	;	:	O	;	_	0	SENT_425	[p27l13t3712r427b3761],
6	22:1589	CD	NUMBER	22:1589	number	7	SENT_425	[p27l13t3712r427b3761],
7	-97	CD	NUMBER	-97	dep	3	SENT_425	[p27l13t3712r427b3761],
8	.	.	O	.	_	0	SENT_425	[p27l13t3712r427b3761],

1	41	CD	NUMBER	41	_	0	SENT_426	[p27l1114t21r1180b59],
2	.	.	O	.	_	0	SENT_426	[p27l1114t21r1180b59],

1	Wacker	NNP	PERSON	Wacker	nn	2	SENT_427	[p27l1209t15r1390b60],
2	B	NNP	PERSON	B	_	0	SENT_427	[p27l1403t19r1449b69],
3	,	,	O	,	_	0	SENT_427	[p27l1403t19r1449b69],
4	Nagrani	NNP	PERSON	Nagrani	nn	5	SENT_427	[p27l1467t16r1667b72],
5	T	NN	PERSON	t	appos	2	SENT_427	[p27l1680t19r1724b69],
6	,	,	O	,	_	0	SENT_427	[p27l1680t19r1724b69],
7	Weinberg	NNP	PERSON	Weinberg	nn	8	SENT_427	[p27l1741t15r1979b72],
8	J	NNP	PERSON	J	appos	5	SENT_427	[p27l1987t19r2019b69],
9	,	,	O	,	_	0	SENT_427	[p27l1987t19r2019b69],
10	Witt	NNP	PERSON	Witt	nn	11	SENT_427	[p27l2036t16r2145b59],
11	K	NNP	O	K	appos	5	SENT_427	[p27l1115t90r1164b140],
12	,	,	O	,	_	0	SENT_427	[p27l1115t90r1164b140],
13	Clark	NNP	PERSON	Clark	nn	14	SENT_427	[p27l1195t86r1328b131],
14	G	NNP	PERSON	G	appos	5	SENT_427	[p27l1354t90r1406b140],
15	,	,	O	,	_	0	SENT_427	[p27l1354t90r1406b140],
16	Cagnoni	NNP	PERSON	Cagnoni	nn	17	SENT_427	[p27l1438t87r1644b143],
17	PJ	NNP	PERSON	PJ	appos	5	SENT_427	[p27l1671t90r1728b137],
18	.	.	O	.	_	0	SENT_427	[p27l1671t90r1728b137],

1	Correlation	NN	O	correlation	_	0	SENT_428	[p27l1760t86r2039b131],
2	between	IN	O	between	_	0	SENT_428	[p27l2067t86r2141b130, p27l1115t167r1262b203],
3	development	NN	O	development	prep_between	1	SENT_428	[p27l1288t158r1607b214],
4	of	IN	O	of	_	0	SENT_428	[p27l1630t158r1687b202],
5	rash	NN	O	rash	prep_of	1	SENT_428	[p27l1702t158r1807b202],
6	and	CC	O	and	_	0	SENT_428	[p27l1833t158r1923b202],
7	efficacy	NN	O	efficacy	prep_of	1	SENT_428	[p27l1949t158r2145b214],
8	in	IN	O	in	_	0	SENT_428	[p27l1115t229r1162b272],
9	patients	NNS	O	patient	prep_in	1	SENT_428	[p27l1195t229r1394b284],
10	treated	VBN	O	treat	partmod	1	SENT_428	[p27l1429t228r1603b272],
11	with	IN	O	with	_	0	SENT_428	[p27l1634t228r1747b273],
12	the	DT	O	the	det	20	SENT_428	[p27l1781t228r1857b272],
13	epidermal	JJ	O	epidermal	amod	20	SENT_428	[p27l1892t228r2142b284],
14	growth	NN	O	growth	nn	20	SENT_428	[p27l1115t299r1296b356],
15	factor	NN	O	factor	nn	20	SENT_428	[p27l1329t299r1475b344],
16	receptor	NN	O	receptor	nn	20	SENT_428	[p27l1507t309r1714b355],
17	tyrosine	NN	O	tyrosine	nn	20	SENT_428	[p27l1746t300r1947b355],
18	kinase	NN	O	kinase	nn	20	SENT_428	[p27l1981t299r2142b344],
19	inhibitor	NN	O	inhibitor	nn	20	SENT_428	[p27l1115t370r1333b415],
20	erlotinib	NN	O	erlotinib	prep_with	10	SENT_428	[p27l1355t370r1565b415],
21	in	IN	O	in	_	0	SENT_428	[p27l1590t371r1637b414],
22	two	CD	NUMBER	two	num	24	SENT_428	[p27l1661t379r1751b415],
23	large	JJ	O	large	amod	24	SENT_428	[p27l1775t370r1896b427],
24	phase	NN	O	phase	prep_in	20	SENT_428	[p27l1920t370r2061b426],
25	III	CD	NUMBER	iii	num	26	SENT_428	[p27l2085t374r2143b414],
26	studies	NNS	O	study	dep	24	SENT_428	[p27l1116t442r1301b487],
27	.	.	O	.	_	0	SENT_428	[p27l1116t442r1301b487],

1	Clin	NNP	O	Clin	nn	3	SENT_429	[p27l1322t442r1423b486],
2	Cancer	NNP	O	Cancer	nn	3	SENT_429	[p27l1441t446r1610b486],
3	Res	NNP	O	Res	_	0	SENT_429	[p27l1626t446r1711b489],
4	2007	CD	DATE	2007	num	3	SENT_429	[p27l1730t446r2139b495],
5	;	:	O	;	_	0	SENT_429	[p27l1730t446r2139b495],
6	13:3913	CD	NUMBER	13:3913	number	7	SENT_429	[p27l1730t446r2139b495],
7	-21	CD	NUMBER	-21	dep	3	SENT_429	[p27l1730t446r2139b495],
8	.	.	O	.	_	0	SENT_429	[p27l1730t446r2139b495],

1	42	CD	NUMBER	42	_	0	SENT_430	[p27l1114t518r1182b556],
2	.	.	O	.	_	0	SENT_430	[p27l1114t518r1182b556],

1	Clark	NNP	PERSON	Clark	nn	2	SENT_431	[p27l1211t512r1344b557],
2	GM	NNP	PERSON	GM	_	0	SENT_431	[p27l1365t516r1467b566],
3	,	,	O	,	_	0	SENT_431	[p27l1365t516r1467b566],
4	Perez	NNP	PERSON	Perez	appos	2	SENT_431	[p27l1494t512r1768b557],
5	.	.	O	.	_	0	SENT_431	[p27l1494t512r1768b557],

1	—	NN	O	—	_	0	SENT_432	[p27l1494t512r1768b557],
2	.	.	O	.	_	0	SENT_432	[p27l1494t512r1768b557],

1	Soler	NNP	PERSON	Soler	nn	2	SENT_433	[p27l1494t512r1768b557],
2	R	NNP	PERSON	R	nsubj	15	SENT_433	[p27l1790t516r1838b566],
3	,	,	O	,	_	0	SENT_433	[p27l1790t516r1838b566],
4	Siu	NNP	PERSON	Siu	nn	5	SENT_433	[p27l1867t513r1938b557],
5	L	NNP	PERSON	L	appos	2	SENT_433	[p27l1961t516r2004b566],
6	,	,	O	,	_	0	SENT_433	[p27l1961t516r2004b566],
7	Gordon	NNP	PERSON	Gordon	nn	8	SENT_433	[p27l2031t516r2141b557, p27l1115t584r1206b628],
8	A	NNP	PERSON	A	appos	2	SENT_433	[p27l1234t588r1284b638],
9	,	,	O	,	_	0	SENT_433	[p27l1234t588r1284b638],
10	Santabarbara	NNP	PERSON	Santabarbara	nn	13	SENT_433	[p27l1318t584r1642b628],
11	P.	NNP	PERSON	P.	nn	13	SENT_433	[p27l1670t588r1708b628],
12	Rash	NNP	PERSON	Rash	nn	13	SENT_433	[p27l1740t584r1861b631],
13	severity	NN	O	severity	appos	2	SENT_433	[p27l1891t585r2077b640],
14	is	VBZ	O	be	cop	15	SENT_433	[p27l2104t585r2141b628],
15	predictive	JJ	O	predictive	_	0	SENT_433	[p27l1114t654r1354b710],
16	of	IN	O	of	_	0	SENT_433	[p27l1374t654r1431b698],
17	increased	VBN	O	increase	amod	18	SENT_433	[p27l1440t654r1673b699],
18	survival	NN	O	survival	prep_of	15	SENT_433	[p27l1694t654r1883b699],
19	with	IN	O	with	_	0	SENT_433	[p27l1900t654r2010b699],
20	erlotinib	NN	O	erlotinib	nn	21	SENT_433	[p27l2030t654r2141b698, p27l1115t725r1230b769],
21	HCl	NN	O	hcl	prep_with	18	SENT_433	[p27l1252t725r1358b770],
22	.	.	O	.	_	0	SENT_433	[p27l1252t725r1358b770],

1	Proc	NNP	O	Proc	nn	5	SENT_434	[p27l1382t729r1491b769],
2	Am	NNP	O	Am	nn	5	SENT_434	[p27l1510t729r1596b769],
3	Soc	NNP	O	Soc	nn	5	SENT_434	[p27l1619t729r1702b770],
4	Clin	NNP	O	Clin	nn	5	SENT_434	[p27l1723t725r1823b770],
5	Oncol	NNP	O	Oncol	_	0	SENT_434	[p27l1845t725r1989b769],
6	2003	CD	DATE	2003	num	5	SENT_434	[p27l2011t729r2140b779],
7	;	:	O	;	_	0	SENT_434	[p27l2011t729r2140b779],
8	22:196	CD	NUMBER	22:196	dep	5	SENT_434	[p27l1115t801r1290b841],
9	.	.	O	.	_	0	SENT_434	[p27l1115t801r1290b841],

1	43	CD	NUMBER	43	_	0	SENT_435	[p27l1114t873r1180b911],
2	.	.	O	.	_	0	SENT_435	[p27l1114t873r1180b911],

1	Riely	NNP	PERSON	Riely	nn	3	SENT_436	[p27l1210t867r1332b923],
2	G	NNP	O	G	nn	3	SENT_436	[p27l1351t871r1419b921],
3	]	NNS	O	]	_	0	SENT_436	[p27l1351t871r1419b921],
4	,	,	O	,	_	0	SENT_436	[p27l1351t871r1419b921],
5	Politi	NNP	PERSON	Politi	nn	6	SENT_436	[p27l1443t867r1571b912],
6	KA	NN	O	ka	appos	3	SENT_436	[p27l1592t871r1681b921],
7	,	,	O	,	_	0	SENT_436	[p27l1592t871r1681b921],
8	Miller	NNP	ORGANIZATION	Miller	nn	9	SENT_436	[p27l1704t867r1852b911],
9	VA	NNP	ORGANIZATION	VA	appos	3	SENT_436	[p27l1870t871r1949b921],
10	,	,	O	,	_	0	SENT_436	[p27l1870t871r1949b921],
11	Pao	NNP	O	Pao	nn	13	SENT_436	[p27l1973t871r2058b911],
12	W.	NNP	O	W.	nn	13	SENT_436	[p27l2078t871r2139b911],
13	Update	NNP	O	Update	appos	3	SENT_436	[p27l1115t938r1288b994],
14	on	IN	O	on	_	0	SENT_436	[p27l1304t952r1364b983],
15	epidermal	JJ	O	epidermal	amod	19	SENT_436	[p27l1380t938r1626b994],
16	growth	NN	O	growth	nn	19	SENT_436	[p27l1641t938r1820b995],
17	factor	NN	O	factor	nn	19	SENT_436	[p27l1835t938r1978b983],
18	receptor	NN	O	receptor	nn	19	SENT_436	[p27l1992t953r2141b994, p27l1115t1019r1185b1054],
19	mutations	NNS	O	mutation	prep_on	13	SENT_436	[p27l1204t1010r1451b1054],
20	in	IN	O	in	_	0	SENT_436	[p27l1472t1010r1519b1053],
21	non-small	JJ	O	non-small	amod	24	SENT_436	[p27l1539t1009r1787b1053],
22	cell	NN	O	cell	nn	24	SENT_436	[p27l1808t1009r1891b1053],
23	lung	NN	O	lung	nn	24	SENT_436	[p27l1910t1009r2020b1066],
24	cancer	NN	O	cancer	prep_in	19	SENT_436	[p27l2039t1023r2141b1053, p27l1116t1096r1198b1125],
25	.	.	O	.	_	0	SENT_436	[p27l2039t1023r2141b1053, p27l1116t1096r1198b1125],

1	Clin	NNP	O	Clin	nn	3	SENT_437	[p27l1220t1081r1321b1125],
2	Cancer	NNP	O	Cancer	nn	3	SENT_437	[p27l1340t1085r1510b1125],
3	Res	NNP	O	Res	_	0	SENT_437	[p27l1527t1085r1612b1128],
4	2006	CD	DATE	2006	num	3	SENT_437	[p27l1632t1085r2047b1134],
5	;	:	O	;	_	0	SENT_437	[p27l1632t1085r2047b1134],
6	12:7232	CD	NUMBER	12:7232	number	7	SENT_437	[p27l1632t1085r2047b1134],
7	—	CD	NUMBER	—	dep	3	SENT_437	[p27l1632t1085r2047b1134],
8	41	CD	NUMBER	41	dep	7	SENT_437	[p27l1632t1085r2047b1134],
9	.	.	O	.	_	0	SENT_437	[p27l1632t1085r2047b1134],

1	44	CD	NUMBER	44	_	0	SENT_438	[p27l1114t1158r1183b1196],
2	.	.	O	.	_	0	SENT_438	[p27l1114t1158r1183b1196],

1	Jackman	NNP	PERSON	Jackman	nn	2	SENT_439	[p27l1205t1152r1421b1203],
2	DM	NN	O	dm	_	0	SENT_439	[p27l1444t1156r1544b1206],
3	,	,	O	,	_	0	SENT_439	[p27l1444t1156r1544b1206],
4	Yeap	NNP	PERSON	Yeap	nn	5	SENT_439	[p27l1570t1156r1682b1208],
5	BY	NNP	O	BY	appos	2	SENT_439	[p27l1706t1156r1778b1206],
6	,	,	O	,	_	0	SENT_439	[p27l1706t1156r1778b1206],
7	Sequist	NNP	O	Sequist	nn	8	SENT_439	[p27l1808t1153r1985b1208],
8	LV	NNP	O	LV	appos	2	SENT_439	[p27l2006t1156r2073b1206],
9	,	,	O	,	_	0	SENT_439	[p27l2006t1156r2073b1206],
10	et	FW	O	et	nn	11	SENT_439	[p27l2101t1161r2145b1196],
11	al.	FW	O	al.	appos	2	SENT_439	[p27l1115t1222r1170b1266],
12	.	.	O	.	_	0	SENT_439	[p27l1115t1222r1170b1266],

1	Exon	NN	O	exon	nsubjpass	11	SENT_440	[p27l1195t1226r1315b1267],
2	19	CD	NUMBER	19	num	4	SENT_440	[p27l1339t1226r1393b1267],
3	deletion	NN	O	deletion	nn	4	SENT_440	[p27l1416t1222r1613b1266],
4	mutations	NNS	O	mutation	dep	1	SENT_440	[p27l1635t1223r1882b1267],
5	of	IN	O	of	_	0	SENT_440	[p27l1905t1222r1962b1267],
6	epidermal	JJ	O	epidermal	amod	9	SENT_440	[p27l1974t1222r2141b1278, p27l1115t1293r1207b1337],
7	growth	NN	O	growth	nn	9	SENT_440	[p27l1224t1293r1403b1350],
8	factor	NN	O	factor	nn	9	SENT_440	[p27l1421t1293r1563b1337],
9	receptor	NN	O	receptor	prep_of	1	SENT_440	[p27l1580t1302r1782b1349],
10	are	VBP	O	be	auxpass	11	SENT_440	[p27l1798t1308r1871b1337],
11	associated	VBN	O	associate	_	0	SENT_440	[p27l1889t1293r2142b1337],
12	with	IN	O	with	_	0	SENT_440	[p27l1113t1364r1223b1409],
13	prolonged	JJ	O	prolonged	amod	14	SENT_440	[p27l1243t1364r1492b1421],
14	survival	NN	O	survival	prep_with	11	SENT_440	[p27l1514t1364r1703b1409],
15	in	IN	O	in	_	0	SENT_440	[p27l1723t1365r1770b1408],
16	non-small	JJ	O	non-small	amod	20	SENT_440	[p27l1791t1364r2039b1409],
17	cell	NN	O	cell	nn	20	SENT_440	[p27l2059t1364r2142b1408],
18	lung	NN	O	lung	nn	20	SENT_440	[p27l1114t1435r1224b1492],
19	cancer	NN	O	cancer	nn	20	SENT_440	[p27l1258t1449r1417b1479],
20	patients	NNS	O	patient	prep_in	11	SENT_440	[p27l1450t1436r1645b1491],
21	treated	VBN	O	treat	partmod	20	SENT_440	[p27l1681t1435r1851b1479],
22	with	IN	O	with	_	0	SENT_440	[p27l1884t1435r1994b1480],
23	gefitinib	NN	O	gefitinib	prep_with	21	SENT_440	[p27l2029t1435r2141b1492, p27l1115t1506r1230b1551],
24	or	CC	O	or	_	0	SENT_440	[p27l1256t1520r1306b1551],
25	erlotinib	NN	O	erlotinib	prep_with	21	SENT_440	[p27l1329t1506r1552b1550],
26	.	.	O	.	_	0	SENT_440	[p27l1329t1506r1552b1550],

1	Clin	NNP	O	Clin	nn	3	SENT_441	[p27l1580t1506r1680b1551],
2	Cancer	NNP	O	Cancer	nn	3	SENT_441	[p27l1705t1510r1874b1551],
3	Res	NNP	O	Res	_	0	SENT_441	[p27l1897t1510r1982b1553],
4	2006	CD	DATE	2006	num	3	SENT_441	[p27l2008t1510r2140b1560],
5	;	:	O	;	_	0	SENT_441	[p27l2008t1510r2140b1560],
6	12:3908	CD	NUMBER	12:3908	number	7	SENT_441	[p27l1117t1582r1393b1623],
7	-14	CD	NUMBER	-14	dep	3	SENT_441	[p27l1117t1582r1393b1623],
8	.	.	O	.	_	0	SENT_441	[p27l1117t1582r1393b1623],

1	45	CD	NUMBER	45	_	0	SENT_442	[p27l1114t1654r1180b1692],
2	.	.	O	.	_	0	SENT_442	[p27l1114t1654r1180b1692],

1	Kobayashi	NNP	LOCATION	Kobayashi	nn	2	SENT_443	[p27l1211t1648r1461b1704],
2	S	NNP	LOCATION	S	_	0	SENT_443	[p27l1487t1652r1525b1702],
3	,	,	O	,	_	0	SENT_443	[p27l1487t1652r1525b1702],
4	Boggon	NNP	PERSON	Boggon	nn	6	SENT_443	[p27l1552t1652r1741b1705],
5	T	NN	O	t	nn	6	SENT_443	[p27l1764t1652r1828b1702],
6	]	NN	O	]	appos	2	SENT_443	[p27l1764t1652r1828b1702],
7	,	,	O	,	_	0	SENT_443	[p27l1764t1652r1828b1702],
8	Dayaram	NN	ORGANIZATION	dayaram	nn	9	SENT_443	[p27l1855t1652r2073b1704],
9	T	NN	ORGANIZATION	t	appos	2	SENT_443	[p27l2096t1652r2139b1702],
10	,	,	O	,	_	0	SENT_443	[p27l2096t1652r2139b1702],
11	et	FW	O	et	nn	12	SENT_443	[p27l1115t1730r1159b1764],
12	al.	FW	O	al.	appos	2	SENT_443	[p27l1187t1720r1243b1764],
13	.	.	O	.	_	0	SENT_443	[p27l1187t1720r1243b1764],

1	EGFR	NN	ORGANIZATION	egfr	nn	2	SENT_444	[p27l1276t1724r1421b1767],
2	mutation	NN	O	mutation	_	0	SENT_444	[p27l1446t1721r1669b1765],
3	and	CC	O	and	_	0	SENT_444	[p27l1700t1720r1789b1764],
4	resistance	NN	O	resistance	conj_and	2	SENT_444	[p27l1820t1721r2064b1764],
5	of	IN	O	of	_	0	SENT_444	[p27l2096t1720r2152b1764],
6	non	JJ	O	non	amod	10	SENT_444	[p27l1115t1790r1489b1834],
7	—	JJ	O	—	amod	10	SENT_444	[p27l1115t1790r1489b1834],
8	small-cell	NN	O	small-cell	nn	10	SENT_444	[p27l1115t1790r1489b1834],
9	lung	NN	O	lung	nn	10	SENT_444	[p27l1513t1790r1625b1847],
10	cancer	NN	O	cancer	prep_of	2	SENT_444	[p27l1649t1804r1812b1834],
11	to	TO	O	to	_	0	SENT_444	[p27l1836t1800r1882b1835],
12	gefitinib	NN	O	gefitinib	prep_to	2	SENT_444	[p27l1908t1790r2139b1847],
13	.	.	O	.	_	0	SENT_444	[p27l1908t1790r2139b1847],

1	N	NN	O	n	nn	3	SENT_445	[p27l1114t1865r1156b1906],
2	Engll	NNP	O	Engll	nn	3	SENT_445	[p27l1174t1861r1319b1918],
3	Med	NNP	O	Med	_	0	SENT_445	[p27l1335t1861r1440b1905],
4	2005	CD	DATE	2005	num	3	SENT_445	[p27l1460t1865r1872b1915],
5	;	:	O	;	_	0	SENT_445	[p27l1460t1865r1872b1915],
6	352:786	CD	NUMBER	352:786	number	7	SENT_445	[p27l1460t1865r1872b1915],
7	-92	CD	NUMBER	-92	dep	3	SENT_445	[p27l1460t1865r1872b1915],
8	.	.	O	.	_	0	SENT_445	[p27l1460t1865r1872b1915],

1	46	CD	NUMBER	46	_	0	SENT_446	[p27l1114t1938r1182b1977],
2	.	.	O	.	_	0	SENT_446	[p27l1114t1938r1182b1977],

1	Pao	NNP	O	Pao	nn	2	SENT_447	[p27l1210t1937r1295b1977],
2	W	NNP	O	W	_	0	SENT_447	[p27l1315t1937r1375b1987],
3	,	,	O	,	_	0	SENT_447	[p27l1315t1937r1375b1987],
4	Miller	NNP	ORGANIZATION	Miller	nn	5	SENT_447	[p27l1397t1933r1546b1977],
5	VA	NNP	ORGANIZATION	VA	appos	2	SENT_447	[p27l1562t1937r1641b1987],
6	,	,	O	,	_	0	SENT_447	[p27l1562t1937r1641b1987],
7	Politi	NNP	PERSON	Politi	nn	8	SENT_447	[p27l1664t1933r1793b1977],
8	KA	NN	O	ka	appos	2	SENT_447	[p27l1812t1937r1901b1987],
9	,	,	O	,	_	0	SENT_447	[p27l1812t1937r1901b1987],
10	et	FW	O	et	nn	11	SENT_447	[p27l1925t1943r1968b1977],
11	al.	FW	O	al.	appos	2	SENT_447	[p27l1985t1933r2041b1977],
12	.	.	O	.	_	0	SENT_447	[p27l1985t1933r2041b1977],

1	Acquired	VBN	O	acquire	csubjpass	11	SENT_448	[p27l2062t1937r2141b1977, p27l1116t2003r1273b2059],
2	resistance	NN	O	resistance	dobj	1	SENT_448	[p27l1303t2004r1547b2047],
3	of	IN	O	of	_	0	SENT_448	[p27l1579t2003r1635b2047],
4	lung	NN	O	lung	nn	5	SENT_448	[p27l1654t2003r1764b2060],
5	adenocarcinomas	NNS	O	adenocarcinoma	prep_of	2	SENT_448	[p27l1793t2003r2141b2047, p27l1115t2089r1213b2118],
6	to	TO	O	to	_	0	SENT_448	[p27l1234t2084r1280b2119],
7	gefitinib	NN	O	gefitinib	prep_to	1	SENT_448	[p27l1300t2074r1512b2131],
8	or	CC	O	or	_	0	SENT_448	[p27l1533t2088r1583b2118],
9	erlotinib	NN	O	erlotinib	prep_to	1	SENT_448	[p27l1601t2074r1811b2119],
10	is	VBZ	O	be	auxpass	11	SENT_448	[p27l1831t2075r1868b2118],
11	associated	VBN	O	associate	_	0	SENT_448	[p27l1888t2074r2142b2118],
12	with	IN	O	with	_	0	SENT_448	[p27l1113t2146r1223b2191],
13	a	DT	DURATION	a	det	15	SENT_448	[p27l1248t2161r1273b2190],
14	second	JJ	DURATION	second	amod	15	SENT_448	[p27l1299t2146r1467b2190],
15	mutation	NN	O	mutation	prep_with	11	SENT_448	[p27l1493t2147r1716b2191],
16	in	IN	O	in	_	0	SENT_448	[p27l1741t2147r1788b2190],
17	the	DT	O	the	det	20	SENT_448	[p27l1814t2146r1889b2190],
18	EGFR	NN	ORGANIZATION	egfr	nn	20	SENT_448	[p27l1914t2150r2059b2193],
19	kinase	NN	O	kinase	nn	20	SENT_448	[p27l2078t2146r2141b2191, p27l1115t2232r1224b2261],
20	domain	NN	O	domain	prep_in	15	SENT_448	[p27l1244t2217r1444b2261],
21	.	.	O	.	_	0	SENT_448	[p27l1244t2217r1444b2261],

1	PLoS	NNP	O	PLoS	nn	2	SENT_449	[p27l1466t2221r1583b2261],
2	Med	NNP	O	Med	_	0	SENT_449	[p27l1602t2217r1708b2261],
3	2005	CD	DATE	2005	num	2	SENT_449	[p27l1727t2221r2066b2270],
4	;	:	O	;	_	0	SENT_449	[p27l1727t2221r2066b2270],
5	2	CD	NUMBER	2	number	6	SENT_449	[p27l1727t2221r2066b2270],
6	(	CD	NUMBER	(	dep	2	SENT_449	[p27l1727t2221r2066b2270],
7	3	CD	NUMBER	3	num	8	SENT_449	[p27l1727t2221r2066b2270],
8	)	NN	O	)	dep	6	SENT_449	[p27l1727t2221r2066b2270],
9	:	:	O	:	_	0	SENT_449	[p27l1727t2221r2066b2270],
10	e73	NN	O	e73	dep	6	SENT_449	[p27l1727t2221r2066b2270],
11	.	.	O	.	_	0	SENT_449	[p27l1727t2221r2066b2270],

1	47	CD	NUMBER	47	_	0	SENT_450	[p27l1114t2293r1176b2331],
2	.	.	O	.	_	0	SENT_450	[p27l1114t2293r1176b2331],

1	Balak	NNP	O	Balak	nn	2	SENT_451	[p27l1210t2287r1350b2332],
2	MN	NN	O	mn	_	0	SENT_451	[p27l1378t2291r1481b2341],
3	,	,	O	,	_	0	SENT_451	[p27l1378t2291r1481b2341],
4	Gong	NNP	PERSON	Gong	nn	9	SENT_451	[p27l1516t2291r1652b2344],
5	Y	NN	PERSON	y	nn	9	SENT_451	[p27l1680t2291r1721b2341],
6	,	,	O	,	_	0	SENT_451	[p27l1680t2291r1721b2341],
7	Riely	NNP	PERSON	Riely	dep	9	SENT_451	[p27l1755t2287r1877b2343],
8	G	NNP	O	G	nn	9	SENT_451	[p27l1907t2291r1975b2341],
9	]	NNS	O	]	appos	2	SENT_451	[p27l1907t2291r1975b2341],
10	,	,	O	,	_	0	SENT_451	[p27l1907t2291r1975b2341],
11	et	FW	O	et	nn	12	SENT_451	[p27l2011t2297r2054b2331],
12	al.	FW	O	al.	appos	9	SENT_451	[p27l2084t2287r2139b2331],
13	.	.	O	.	_	0	SENT_451	[p27l2084t2287r2139b2331],

1	Novel	JJ	O	novel	amod	2	SENT_452	[p27l1114t2359r1252b2404],
2	D761Y	NN	O	d761y	_	0	SENT_452	[p27l1298t2363r1451b2403],
3	and	CC	O	and	_	0	SENT_452	[p27l1495t2359r1585b2403],
4	common	JJ	O	common	amod	7	SENT_452	[p27l1632t2373r1848b2403],
5	secondary	JJ	O	secondary	amod	7	SENT_452	[p27l1896t2359r2145b2415],
6	T790M	NN	O	t790m	nn	7	SENT_452	[p27l1113t2433r1279b2473],
7	mutations	NNS	O	mutation	conj_and	2	SENT_452	[p27l1297t2430r1535b2474],
8	in	IN	O	in	_	0	SENT_452	[p27l1552t2430r1598b2473],
9	epidermal	JJ	O	epidermal	amod	14	SENT_452	[p27l1615t2429r1852b2485],
10	growth	NN	O	growth	nn	14	SENT_452	[p27l1868t2429r2040b2486],
11	factor	NN	O	factor	nn	14	SENT_452	[p27l2057t2429r2141b2473, p27l1115t2509r1182b2545],
12	receptor-mutant	JJ	O	receptor-mutant	amod	14	SENT_452	[p27l1202t2509r1585b2556],
13	lung	NN	O	lung	nn	14	SENT_452	[p27l1603t2500r1709b2557],
14	adenocarcinomas	NNS	O	adenocarcinoma	prep_in	2	SENT_452	[p27l1728t2500r2141b2545],
15	with	IN	O	with	_	0	SENT_452	[p27l1113t2571r1223b2616],
16	acquired	VBN	O	acquire	amod	17	SENT_452	[p27l1242t2571r1453b2627],
17	resistance	NN	O	resistance	prep_with	14	SENT_452	[p27l1471t2572r1716b2615],
18	to	TO	O	to	_	0	SENT_452	[p27l1735t2581r1781b2616],
19	kinase	NN	O	kinase	nn	20	SENT_452	[p27l1801t2571r1959b2616],
20	inhibitors	NNS	O	inhibitor	prep_to	17	SENT_452	[p27l1978t2571r2141b2615, p27l1115t2652r1222b2687],
21	.	.	O	.	_	0	SENT_452	[p27l1978t2571r2141b2615, p27l1115t2652r1222b2687],

1	Clin	NNP	O	Clin	nn	3	SENT_453	[p27l1244t2643r1345b2687],
2	Cancer	NNP	O	Cancer	nn	3	SENT_453	[p27l1364t2647r1534b2687],
3	Res	NNP	O	Res	_	0	SENT_453	[p27l1551t2647r1636b2690],
4	2006	CD	DATE	2006	num	3	SENT_453	[p27l1656t2647r2106b2696],
5	;	:	O	;	_	0	SENT_453	[p27l1656t2647r2106b2696],
6	12:6494	CD	NUMBER	12:6494	number	7	SENT_453	[p27l1656t2647r2106b2696],
7	-501	CD	NUMBER	-501	dep	3	SENT_453	[p27l1656t2647r2106b2696],
8	.	.	O	.	_	0	SENT_453	[p27l1656t2647r2106b2696],

1	48	CD	NUMBER	48	_	0	SENT_454	[p27l1114t2718r1183b2758],
2	.	.	O	.	_	0	SENT_454	[p27l1114t2718r1183b2758],

1	Bean	NNP	O	Bean	nn	2	SENT_455	[p27l1210t2717r1331b2757],
2	J	NNP	O	J	_	0	SENT_455	[p27l1343t2717r1375b2767],
3	,	,	O	,	_	0	SENT_455	[p27l1343t2717r1375b2767],
4	Brennan	NNP	PERSON	Brennan	nn	5	SENT_455	[p27l1395t2717r1603b2757],
5	C	NNP	O	C	appos	2	SENT_455	[p27l1621t2717r1667b2767],
6	,	,	O	,	_	0	SENT_455	[p27l1621t2717r1667b2767],
7	Shih	NNP	O	Shih	nn	8	SENT_455	[p27l1690t2713r1798b2757],
8	JY	NN	O	jy	appos	2	SENT_455	[p27l1810t2717r1874b2767],
9	,	,	O	,	_	0	SENT_455	[p27l1810t2717r1874b2767],
10	et	FW	O	et	nn	11	SENT_455	[p27l1895t2723r1938b2757],
11	al.	FW	O	al.	appos	2	SENT_455	[p27l1953t2713r2008b2757],
12	.	.	O	.	_	0	SENT_455	[p27l1953t2713r2008b2757],

1	MET	NN	O	met	nn	2	SENT_456	[p27l2027t2717r2144b2757],
2	amplification	NN	O	amplification	nsubj	3	SENT_456	[p27l1115t2784r1448b2840],
3	occurs	VBZ	O	occur	conj_or	3	SENT_456	[p27l1495t2798r1654b2829],
4	with	IN	O	with	_	0	SENT_456	[p27l1700t2784r1811b2829],
5	or	CC	O	or	_	0	SENT_456	[p27l1859t2798r1909b2828],
6	without	IN	O	without	_	0	SENT_456	[p27l1952t2784r2145b2829],
7	T790M	NN	O	t790m	nn	8	SENT_456	[p27l1113t2859r1284b2900],
8	mutations	NNS	O	mutation	prep_with	3	SENT_456	[p27l1313t2856r1560b2900],
9	in	IN	O	in	_	0	SENT_456	[p27l1590t2856r1637b2899],
10	EGFR	NN	ORGANIZATION	egfr	nn	13	SENT_456	[p27l1664t2859r1809b2902],
11	mutant	JJ	O	mutant	amod	13	SENT_456	[p27l1831t2864r2009b2900],
12	lung	NN	O	lung	nn	13	SENT_456	[p27l2034t2855r2144b2912],
13	tumors	NNS	O	tumor	prep_in	8	SENT_456	[p27l1115t2935r1290b2971],
14	with	IN	O	with	_	0	SENT_456	[p27l1314t2926r1425b2971],
15	acquired	VBN	O	acquire	amod	16	SENT_456	[p27l1450t2926r1661b2982],
16	resistance	NN	O	resistance	prep_with	3	SENT_456	[p27l1686t2927r1931b2970],
17	to	TO	O	to	_	0	SENT_456	[p27l1957t2935r2003b2971],
18	gefitinib	NN	O	gefitinib	prep_to	16	SENT_456	[p27l2029t2926r2141b2983, p27l1115t2998r1232b3042],
19	or	CC	O	or	_	0	SENT_456	[p27l1271t3012r1322b3042],
20	erlotinib	NN	O	erlotinib	conj_or	18	SENT_456	[p27l1358t2998r1587b3042],
21	.	.	O	.	_	0	SENT_456	[p27l1358t2998r1587b3042],

1	Proc	NNP	O	Proc	nn	4	SENT_457	[p27l1627t3002r1736b3042],
2	Natl	NNP	O	Natl	nn	4	SENT_457	[p27l1772t2998r1878b3043],
3	Acad	NNP	O	Acad	nn	4	SENT_457	[p27l1913t2998r2035b3042],
4	Sci	NNP	O	Sci	_	0	SENT_457	[p27l2073t2999r2142b3042],

1	U	NNP	O	U	nn	3	SENT_458	[p27l1115t3073r1153b3113],
2	S	NNP	O	S	nn	3	SENT_458	[p27l1174t3073r1198b3113],
3	A	NNP	O	A	_	0	SENT_458	[p27l1218t3073r1254b3113],
4	2007	CD	DATE	2007	num	3	SENT_458	[p27l1272t3073r1702b3122],
5	;	:	O	;	_	0	SENT_458	[p27l1272t3073r1702b3122],
6	104:20932	CD	NUMBER	104:20932	number	7	SENT_458	[p27l1272t3073r1702b3122],
7	-7	CD	NUMBER	-7	dep	3	SENT_458	[p27l1272t3073r1702b3122],
8	.	.	O	.	_	0	SENT_458	[p27l1272t3073r1702b3122],

1	49	CD	NUMBER	49	_	0	SENT_459	[p27l1114t3144r1180b3183],
2	.	.	O	.	_	0	SENT_459	[p27l1114t3144r1180b3183],

1	Engelman	NNP	PERSON	Engelman	nn	2	SENT_460	[p27l1210t3139r1458b3196],
2	JA	NNP	O	JA	_	0	SENT_460	[p27l1473t3143r1543b3193],
3	,	,	O	,	_	0	SENT_460	[p27l1473t3143r1543b3193],
4	Zejnullahu	NNP	PERSON	Zejnullahu	nn	5	SENT_460	[p27l1566t3139r1828b3195],
5	K	NNP	PERSON	K	appos	2	SENT_460	[p27l1849t3143r1897b3193],
6	,	,	O	,	_	0	SENT_460	[p27l1849t3143r1897b3193],
7	Mitsudomi	NNP	ORGANIZATION	Mitsudomi	nn	8	SENT_460	[p27l1920t3139r2141b3184, p27l1115t3212r1179b3255],
8	T	NN	ORGANIZATION	t	appos	2	SENT_460	[p27l1206t3215r1249b3265],
9	,	,	O	,	_	0	SENT_460	[p27l1206t3215r1249b3265],
10	et	FW	O	et	nn	11	SENT_460	[p27l1282t3220r1325b3255],
11	al.	FW	O	al.	appos	2	SENT_460	[p27l1351t3211r1407b3255],
12	.	.	O	.	_	0	SENT_460	[p27l1351t3211r1407b3255],

1	MET	NN	O	met	nn	2	SENT_461	[p27l1437t3215r1554b3255],
2	amplification	NN	O	amplification	nsubj	3	SENT_461	[p27l1581t3211r1914b3267],
3	leads	VBZ	O	lead	_	0	SENT_461	[p27l1942t3211r2065b3255],
4	to	TO	O	to	_	0	SENT_461	[p27l2095t3220r2142b3255],
5	gefitinib	JJ	O	gefitinib	amod	6	SENT_461	[p27l1115t3281r1327b3338],
6	resistance	NN	O	resistance	prep_to	3	SENT_461	[p27l1344t3282r1589b3325],
7	in	IN	O	in	_	0	SENT_461	[p27l1605t3282r1652b3325],
8	lung	NN	O	lung	nn	9	SENT_461	[p27l1668t3281r1778b3338],
9	cancer	NN	O	cancer	prep_in	6	SENT_461	[p27l1793t3295r1953b3325],
10	by	IN	O	by	_	0	SENT_461	[p27l1968t3281r2023b3337],
11	activating	VBG	O	activate	prepc_by	3	SENT_461	[p27l2037t3282r2141b3325, p27l1113t3353r1266b3409],
12	ERBB3	NN	O	erbb3	nn	13	SENT_461	[p27l1277t3356r1442b3399],
13	signaling	NN	O	signaling	dobj	11	SENT_461	[p27l1459t3352r1700b3409],
14	.	.	O	.	_	0	SENT_461	[p27l1459t3352r1700b3409],

1	Science	NNP	O	Science	_	0	SENT_462	[p27l1719t3353r1897b3396],
2	2007	CD	DATE	2007	num	1	SENT_462	[p27l1911t3356r2140b3405],
3	;	:	O	;	_	0	SENT_462	[p27l1911t3356r2140b3405],
4	316	CD	NUMBER	316	num	6	SENT_462	[p27l1911t3356r2140b3405],
5	:	:	O	:	_	0	SENT_462	[p27l1911t3356r2140b3405],
6	1039-43	CD	NUMBER	1039-43	dep	1	SENT_462	[p27l1117t3428r1320b3469],
7	.	.	O	.	_	0	SENT_462	[p27l1117t3428r1320b3469],

1	50	CD	NUMBER	50	_	0	SENT_463	[p27l1116t3499r1181b3538],
2	.	.	O	.	_	0	SENT_463	[p27l1116t3499r1181b3538],

1	Riely	NNP	PERSON	Riely	nn	2	SENT_464	[p27l1210t3494r1332b3550],
2	G	NNP	O	G	_	0	SENT_464	[p27l1368t3498r1436b3545],
3	]	NN	O	]	dep	2	SENT_464	[p27l1368t3498r1436b3545],
4	.	.	O	.	_	0	SENT_464	[p27l1368t3498r1436b3545],

1	Second-generation	JJ	O	second-generation	amod	8	SENT_465	[p27l1479t3494r1935b3551],
2	epidermal	JJ	O	epidermal	amod	8	SENT_465	[p27l1974t3494r2141b3550, p27l1115t3565r1208b3609],
3	growth	NN	O	growth	nn	8	SENT_465	[p27l1235t3565r1416b3622],
4	factor	NN	O	factor	nn	8	SENT_465	[p27l1444t3565r1590b3610],
5	receptor	NN	O	receptor	nn	8	SENT_465	[p27l1615t3574r1822b3621],
6	tyrosine	NN	O	tyrosine	nn	8	SENT_465	[p27l1848t3566r2050b3621],
7	kinase	NN	O	kinase	nn	8	SENT_465	[p27l2077t3565r2141b3610, p27l1115t3651r1226b3680],
8	inhibitors	NNS	O	inhibitor	_	0	SENT_465	[p27l1261t3636r1507b3681],
9	in	IN	O	in	_	0	SENT_465	[p27l1542t3637r1590b3680],
10	non-small	JJ	O	non-small	amod	13	SENT_465	[p27l1625t3636r1878b3680],
11	cell	NN	O	cell	nn	13	SENT_465	[p27l1913t3636r1998b3680],
12	lung	NN	O	lung	nn	13	SENT_465	[p27l2032t3636r2144b3693],
13	cancer	NN	O	cancer	prep_in	8	SENT_465	[p27l1115t3722r1286b3752],
14	.	.	O	.	_	0	SENT_465	[p27l1115t3722r1286b3752],

1	J	NNP	O	J	nn	3	SENT_466	[p27l1303t3712r1323b3759],
2	Thorac	NNP	O	Thorac	nn	3	SENT_466	[p27l1339t3708r1510b3752],
3	Oncol	NNP	O	Oncol	_	0	SENT_466	[p27l1529t3708r1673b3752],
4	2008	CD	DATE	2008	num	3	SENT_466	[p27l1692t3712r2047b3761],
5	;	:	O	;	_	0	SENT_466	[p27l1692t3712r2047b3761],
6	3	CD	NUMBER	3	dep	3	SENT_466	[p27l1692t3712r2047b3761],
7	:	:	O	:	_	0	SENT_466	[p27l1692t3712r2047b3761],
8	S146-9	NN	O	s146-9	dep	6	SENT_466	[p27l1692t3712r2047b3761],
9	.	.	O	.	_	0	SENT_466	[p27l1692t3712r2047b3761],

1	51	CD	NUMBER	51	_	0	SENT_467	[p28l96t311r129b331],
2	.	.	O	.	_	0	SENT_467	[p28l96t311r129b331],

1	Miller	NNP	ORGANIZATION	Miller	nn	2	SENT_468	[p28l145t308r222b331],
2	VA	NNP	ORGANIZATION	VA	_	0	SENT_468	[p28l231t310r272b336],
3	,	,	O	,	_	0	SENT_468	[p28l231t310r272b336],
4	O’Connor	NNP	O	O’Connor	nn	5	SENT_468	[p28l284t310r409b331],
5	P	NN	O	p	appos	2	SENT_468	[p28l418t310r437b336],
6	,	,	O	,	_	0	SENT_468	[p28l418t310r437b336],
7	Soh	NN	O	soh	nn	8	SENT_468	[p28l450t308r496b331],
8	C	NN	O	c	appos	2	SENT_468	[p28l506t310r531b336],
9	,	,	O	,	_	0	SENT_468	[p28l506t310r531b336],
10	et	FW	O	et	nn	11	SENT_468	[p28l542t313r565b331],
11	al.	FW	O	al.	appos	2	SENT_468	[p28l574t308r603b331],
12	.	.	O	.	_	0	SENT_468	[p28l574t308r603b331],

1	A	DT	O	a	_	0	SENT_469	[p28l613t310r633b331],
2	randomized	VBN	O	randomize	dep	1	SENT_469	[p28l96t345r257b373],
3	,	,	O	,	_	0	SENT_469	[p28l96t345r257b373],
4	double-blind	JJ	O	double-blind	amod	10	SENT_469	[p28l277t345r447b373],
5	,	,	O	,	_	0	SENT_469	[p28l277t345r447b373],
6	placebocontrolled	JJ	O	placebocontrolled	amod	10	SENT_469	[p28l466t345r631b374, p28l96t381r187b410],
7	,	,	O	,	_	0	SENT_469	[p28l466t345r631b374, p28l96t381r187b410],
8	phase	NN	O	phase	dep	10	SENT_469	[p28l200t382r274b411],
9	IIIb	NN	O	iiib	nn	10	SENT_469	[p28l285t381r331b405],
10	trial	NN	O	trial	dobj	2	SENT_469	[p28l343t381r396b405],
11	(	CD	NUMBER	(	num	12	SENT_469	[p28l410t383r512b409],
12	ATLAS	NN	O	atla	amod	10	SENT_469	[p28l410t383r512b409],
13	)	CD	NUMBER	)	dep	12	SENT_469	[p28l410t383r512b409],
14	comparing	VBG	O	compare	dep	13	SENT_469	[p28l526t389r631b411, p28l95t419r137b448],
15	bevacizumab	NN	O	bevacizumab	nn	16	SENT_469	[p28l147t418r313b442],
16	therapy	NN	O	therapy	dobj	14	SENT_469	[p28l325t418r420b448],
17	with	IN	O	with	prep	14	SENT_469	[p28l429t418r486b442],
18	or	CC	O	or	_	0	SENT_469	[p28l497t426r524b441],
19	without	IN	O	without	_	0	SENT_469	[p28l533t418r633b442],
20	erlotinib	NN	O	erlotinib	prep_without	30	SENT_469	[p28l96t455r208b478],
21	after	IN	O	after	_	0	SENT_469	[p28l219t455r280b478],
22	completion	NN	O	completion	prep_after	30	SENT_469	[p28l290t455r436b484],
23	of	IN	O	of	_	0	SENT_469	[p28l447t455r477b478],
24	chemotherapy	NN	O	chemotherapy	prep_of	22	SENT_469	[p28l482t455r631b478, p28l95t500r139b522],
25	with	IN	O	with	_	0	SENT_469	[p28l148t492r206b516],
26	bevacizumab	NN	O	bevacizumab	prep_with	24	SENT_469	[p28l217t492r384b516],
27	for	IN	O	for	_	0	SENT_469	[p28l395t492r432b515],
28	first-line	JJ	O	first-line	amod	29	SENT_469	[p28l442t492r553b515],
29	treatment	NN	O	treatment	prep_for	26	SENT_469	[p28l565t497r631b515, p28l96t534r162b552],
30	of	IN	O	of	advmod	2	SENT_469	[p28l176t529r206b552],
31	locally	RB	O	locally	advmod	32	SENT_469	[p28l216t529r302b559],
32	advanced	VBN	O	advance	dep	1	SENT_469	[p28l316t529r443b557],
33	,	,	O	,	_	0	SENT_469	[p28l316t529r443b557],
34	recurrent	JJ	O	recurrent	amod	41	SENT_469	[p28l461t534r589b557],
35	,	,	O	,	_	0	SENT_469	[p28l461t534r589b557],
36	or	CC	O	or	_	0	SENT_469	[p28l606t536r633b552],
37	metastatic	JJ	O	metastatic	amod	41	SENT_469	[p28l96t566r231b589],
38	non-small	JJ	O	non-small	amod	41	SENT_469	[p28l250t566r382b589],
39	cell	NN	O	cell	nn	41	SENT_469	[p28l401t566r445b589],
40	lung	NN	O	lung	nn	41	SENT_469	[p28l463t566r521b596],
41	cancer	NN	O	cancer	dobj	1	SENT_469	[p28l539t573r630b589],
42	.	.	O	.	_	0	SENT_469	[p28l539t573r630b589],

1	J	NNP	O	J	nn	3	SENT_470	[p28l93t605r104b630],
2	Clin	NNP	O	Clin	nn	3	SENT_470	[p28l114t603r166b626],
3	Oncol	NNP	O	Oncol	_	0	SENT_470	[p28l176t603r251b626],
4	2009	CD	DATE	2009	num	3	SENT_470	[p28l261t605r366b631],
5	;	:	O	;	_	0	SENT_470	[p28l261t605r366b631],
6	27	CD	NUMBER	27	dep	3	SENT_470	[p28l261t605r366b631],
7	.	.	O	.	_	0	SENT_470	[p28l261t605r366b631],

1	abstract	JJ	O	abstract	_	0	SENT_471	[p28l377t603r486b626],
2	.	.	O	.	_	0	SENT_471	[p28l377t603r486b626],

1	52	CD	NUMBER	52	_	0	SENT_472	[p28l96t643r131b663],
2	.	.	O	.	_	0	SENT_472	[p28l96t643r131b663],

1	Hainsworth	NNP	PERSON	Hainsworth	nn	2	SENT_473	[p28l145t640r299b664],
2	J	NNP	PERSON	J	_	0	SENT_473	[p28l311t642r328b668],
3	,	,	O	,	_	0	SENT_473	[p28l311t642r328b668],
4	Herbst	NNP	O	Herbst	nn	5	SENT_473	[p28l344t640r431b663],
5	RA	NN	O	ra	appos	2	SENT_473	[p28l444t642r489b665],
6	.	.	O	.	_	0	SENT_473	[p28l444t642r489b665],

1	Phase	NN	O	phase	_	0	SENT_474	[p28l506t641r578b663],
2	III	CD	NUMBER	iii	num	1	SENT_474	[p28l593t642r630b668],
3	,	,	O	,	_	0	SENT_474	[p28l593t642r630b668],
4	multicenter	NN	O	multicenter	appos	1	SENT_474	[p28l96t677r249b705],
5	,	,	O	,	_	0	SENT_474	[p28l96t677r249b705],
6	placebo-controlled	JJ	O	placebo-controlled	appos	1	SENT_474	[p28l269t677r516b707],
7	,	,	O	,	_	0	SENT_474	[p28l269t677r516b707],
8	doubleblind	NN	O	doubleblind	appos	6	SENT_474	[p28l536t677r631b701, p28l96t714r169b743],
9	,	,	O	,	_	0	SENT_474	[p28l536t677r631b701, p28l96t714r169b743],
10	randomized	VBN	O	randomize	partmod	6	SENT_474	[p28l183t714r337b738],
11	clinical	JJ	O	clinical	amod	12	SENT_474	[p28l349t714r443b738],
12	trial	NN	O	trial	dobj	10	SENT_474	[p28l455t714r508b738],
13	to	TO	O	to	_	0	SENT_474	[p28l520t719r544b738],
14	evaluN	NN	O	evalun	prep_to	10	SENT_474	[p28l557t714r631b738, p28l951t55r964b70],

1	ENGLJ	NNP	O	ENGLJ	nn	2	SENT_475	[p28l979t55r1057b77],
2	MED	NNP	O	MED	_	0	SENT_475	[p28l1072t55r1124b70],
3	364	CD	NUMBER	364	num	2	SENT_475	[p28l1134t49r1216b77],
4	;	:	O	;	_	0	SENT_475	[p28l1134t49r1216b77],
5	1o	CD	NUMBER	1o	dep	2	SENT_475	[p28l1134t49r1216b77],

1	NEjM	NNP	O	NEjM	nn	4	SENT_476	[p28l1251t55r1375b77],
2	,	,	O	,	_	0	SENT_476	[p28l1251t55r1375b77],
3	ORG	NNP	O	ORG	appos	4	SENT_476	[p28l1251t55r1375b77],
4	MARCH	NNP	DATE	MARCH	_	0	SENT_476	[p28l1412t55r1497b70],
5	"	``	O	"	punct	6	SENT_476	[p28l1510t55r1543b75],
6	Io	NNP	O	Io	dep	4	SENT_476	[p28l1510t55r1543b75],
7	,	,	O	,	_	0	SENT_476	[p28l1510t55r1543b75],
8	2011	CD	DATE	2011	appos	6	SENT_476	[p28l1555t55r1606b71],

1	The	DT	O	the	det	4	SENT_477	[p28l936t88r987b112],
2	New	NNP	O	New	nn	4	SENT_477	[p28l996t89r1058b112],
3	England	NNP	O	England	nn	4	SENT_477	[p28l1067t88r1178b119],
4	Journal	NNP	O	Journal	_	0	SENT_477	[p28l1187t88r1284b112],
5	of	IN	O	of	_	0	SENT_477	[p28l1294t88r1323b112],
6	Medicine	NNP	O	Medicine	prep_of	4	SENT_477	[p28l1330t88r1455b112],

1	Downloaded	VBN	O	download	_	0	SENT_478	[p28l378t129r548b152],
2	from	IN	O	from	_	0	SENT_478	[p28l557t129r622b152],
3	nejm.org	NN	O	nejm.org	prep_from	1	SENT_478	[p28l630t129r749b159],
4	at	IN	O	at	_	0	SENT_478	[p28l759t133r782b152],
5	UW-Madison	NN	O	uw-madison	prep_at	1	SENT_478	[p28l790t129r973b152],
6	on	IN	O	on	_	0	SENT_478	[p28l982t136r1015b152],
7	January	NNP	DATE	January	prep_on	1	SENT_478	[p28l1023t129r1126b159],
8	5	CD	DATE	5	num	7	SENT_478	[p28l1136t129r1159b156],
9	,	,	DATE	,	_	0	SENT_478	[p28l1136t129r1159b156],
10	2014	CD	DATE	2014	num	7	SENT_478	[p28l1169t129r1242b152],
11	.	.	O	.	_	0	SENT_478	[p28l1169t129r1242b152],

1	For	IN	O	for	_	0	SENT_479	[p28l1252t129r1299b152],
2	personal	JJ	O	personal	amod	3	SENT_479	[p28l1307t129r1419b159],
3	use	NN	O	use	pobj	1	SENT_479	[p28l1428t136r1472b152],
4	only	RB	O	only	advmod	3	SENT_479	[p28l1481t129r1546b159],
5	.	.	O	.	_	0	SENT_479	[p28l1481t129r1546b159],

1	No	DT	O	no	det	3	SENT_480	[p28l1557t129r1596b152],
2	other	JJ	O	other	amod	3	SENT_480	[p28l1606t129r1674b152],
3	uses	NNS	O	use	_	0	SENT_480	[p28l1683t136r1739b152],
4	without	IN	O	without	_	0	SENT_480	[p28l1749t129r1850b152],
5	permission	NN	O	permission	prep_without	3	SENT_480	[p28l1858t129r2011b159],
6	.	.	O	.	_	0	SENT_480	[p28l1858t129r2011b159],

1	Copyright	NN	O	copyright	_	0	SENT_481	[p28l729t170r863b201],
2	©	CD	NUMBER	©	num	6	SENT_481	[p28l872t170r896b194],
3	2011	CD	DATE	2011	num	6	SENT_481	[p28l906t170r968b194],
4	Massachusetts	NNP	ORGANIZATION	Massachusetts	nn	6	SENT_481	[p28l980t170r1171b194],
5	Medical	NNP	ORGANIZATION	Medical	nn	6	SENT_481	[p28l1181t170r1289b194],
6	Society	NNP	ORGANIZATION	Society	dep	1	SENT_481	[p28l1300t170r1405b201],
7	.	.	O	.	_	0	SENT_481	[p28l1300t170r1405b201],

1	All	DT	O	all	det	2	SENT_482	[p28l1416t170r1457b194],
2	rights	NNS	O	rights	nsubj	3	SENT_482	[p28l1466t170r1541b201],
3	reserved	VBN	O	reserve	_	0	SENT_482	[p28l1551t170r1669b194],
4	.	.	O	.	_	0	SENT_482	[p28l1551t170r1669b194],

1	CLINICAL	JJ	O	clinical	amod	2	SENT_483	[p28l726t214r885b233],
2	THERAPEUTICS	NNS	O	therapeutics	_	0	SENT_483	[p28l896t214r1149b233],

1	ate	VBD	O	eat	_	0	SENT_484	[p28l671t313r707b331],
2	the	DT	O	the	det	3	SENT_484	[p28l716t308r756b331],
3	efficacy	NN	O	efficacy	dobj	1	SENT_484	[p28l766t308r866b338],
4	of	IN	O	of	_	0	SENT_484	[p28l874t308r904b331],
5	bevacizumab	NN	O	bevacizumab	prep_of	3	SENT_484	[p28l908t308r1074b332],
6	in	IN	O	in	_	0	SENT_484	[p28l1084t308r1109b331],
7	combination	NN	O	combination	prep_in	5	SENT_484	[p28l1119t308r1206b331, p28l671t345r753b368],
8	with	IN	O	with	_	0	SENT_484	[p28l777t345r835b368],
9	erlotinib	NN	O	erlotinib	prep_with	7	SENT_484	[p28l862t345r971b368],
10	compared	VBN	O	compare	_	0	SENT_484	[p28l998t345r1124b374],
11	with	IN	O	with	prepc_compared_with	9	SENT_484	[p28l1149t345r1207b368],
12	erlotinib	NN	O	erlotinib	pobj	9	SENT_484	[p28l671t382r780b405],
13	alone	RB	O	alone	advmod	1	SENT_484	[p28l792t382r860b405],
14	for	IN	O	for	_	0	SENT_484	[p28l871t381r908b405],
15	treatment	NN	O	treatment	prep_for	1	SENT_484	[p28l918t386r1044b405],
16	of	IN	O	of	_	0	SENT_484	[p28l1054t381r1083b405],
17	advanced	JJ	O	advanced	amod	21	SENT_484	[p28l1089t381r1207b405],
18	non-small	JJ	O	non-small	amod	21	SENT_484	[p28l671t418r800b441],
19	cell	NN	O	cell	nn	21	SENT_484	[p28l810t418r854b441],
20	lung	NN	O	lung	nn	21	SENT_484	[p28l863t418r920b448],
21	cancer	NN	O	cancer	prep_of	15	SENT_484	[p28l929t426r1012b441],
22	after	IN	O	after	_	0	SENT_484	[p28l1021t418r1081b441],
23	failure	NN	O	failure	prep_after	1	SENT_484	[p28l1090t418r1172b442],
24	of	IN	O	of	_	0	SENT_484	[p28l1182t418r1212b441],
25	standard	JJ	O	standard	amod	27	SENT_484	[p28l671t455r784b478],
26	first-line	JJ	O	first-line	amod	27	SENT_484	[p28l795t455r906b478],
27	chemotherapy	NN	O	chemotherapy	prep_of	23	SENT_484	[p28l918t455r1099b484],
28	(	CD	NUMBER	(	num	30	SENT_484	[p28l1111t457r1205b482],
29	BETA	NN	O	beta	nn	30	SENT_484	[p28l1111t457r1205b482],
30	)	NN	O	)	dep	27	SENT_484	[p28l1111t457r1205b482],
31	.	.	O	.	_	0	SENT_484	[p28l1111t457r1205b482],

1	Presented	VBN	O	present	_	0	SENT_485	[p28l670t492r795b515],
2	at	IN	O	at	_	0	SENT_485	[p28l803t497r826b515],
3	the	DT	O	the	det	5	SENT_485	[p28l833t492r873b515],
4	Multidisciplinary	NNP	O	Multidisciplinary	nn	5	SENT_485	[p28l880t492r1103b522],
5	Symposium	NNP	O	Symposium	prep_at	1	SENT_485	[p28l1111t494r1206b522, p28l671t529r733b553],
6	in	IN	O	in	_	0	SENT_485	[p28l743t529r768b552],
7	Thoracic	NNP	O	Thoracic	nn	8	SENT_485	[p28l777t529r888b552],
8	Oncology	NNP	O	Oncology	prep_in	5	SENT_485	[p28l898t529r1025b559],
9	,	,	O	,	_	0	SENT_485	[p28l898t529r1025b559],
10	Chicago	NNP	LOCATION	Chicago	appos	8	SENT_485	[p28l1037t529r1147b559],
11	,	,	O	,	_	0	SENT_485	[p28l1037t529r1147b559],
12	November	NNP	DATE	November	tmod	1	SENT_485	[p28l1159t531r1206b552, p28l669t566r763b590],
13	2008	CD	DATE	2008	num	12	SENT_485	[p28l773t568r841b589],
14	.	.	O	.	_	0	SENT_485	[p28l773t568r841b589],

1	53	CD	NUMBER	53	_	0	SENT_486	[p28l671t606r705b626],
2	.	.	O	.	_	0	SENT_486	[p28l671t606r705b626],

1	Ready	JJ	O	ready	amod	2	SENT_487	[p28l720t603r799b633],
2	N	NN	O	n	_	0	SENT_487	[p28l814t605r842b631],
3	,	,	O	,	_	0	SENT_487	[p28l814t605r842b631],
4	Janne	NNP	PERSON	Janne	nn	5	SENT_487	[p28l858t605r933b630],
5	PA	NN	PERSON	pa	appos	2	SENT_487	[p28l950t605r990b631],
6	,	,	O	,	_	0	SENT_487	[p28l950t605r990b631],
7	Bogar	NNP	PERSON	Bogar	nn	8	SENT_487	[p28l1009t605r1086b633],
8	J	NNP	PERSON	J	appos	2	SENT_487	[p28l1100t605r1117b631],
9	,	,	O	,	_	0	SENT_487	[p28l1100t605r1117b631],
10	et	FW	O	et	nn	11	SENT_487	[p28l1136t608r1160b626],
11	al.	FW	O	al.	appos	2	SENT_487	[p28l1175t603r1205b626],
12	.	.	O	.	_	0	SENT_487	[p28l1175t603r1205b626],

1	Chemoradiotherapy	JJ	PERSON	chemoradiotherapy	_	0	SENT_488	[p28l671t640r924b670],
2	and	CC	O	and	_	0	SENT_488	[p28l932t640r978b663],
3	gefitinib	NN	O	gefitinib	conj_and	1	SENT_488	[p28l987t640r1098b670],
4	in	IN	O	in	dep	1	SENT_488	[p28l1107t641r1132b663],
5	stage	NN	O	stage	nn	10	SENT_488	[p28l1141t645r1207b670],
6	III	CD	NUMBER	iii	num	10	SENT_488	[p28l670t679r700b700],
7	non-small	JJ	O	non-small	amod	10	SENT_488	[p28l709t677r836b700],
8	cell	NN	O	cell	nn	10	SENT_488	[p28l846t677r889b700],
9	lung	NN	O	lung	nn	10	SENT_488	[p28l898t677r955b707],
10	cancer	NN	O	cancer	pobj	4	SENT_488	[p28l964t685r1046b700],
11	with	IN	O	with	dep	1	SENT_488	[p28l1053t677r1110b700],
12	epidermal	JJ	O	epidermal	amod	15	SENT_488	[p28l1121t677r1206b707, p28l671t714r718b738],
13	growth	NN	O	growth	nn	15	SENT_488	[p28l727t714r818b744],
14	factor	NN	O	factor	nn	15	SENT_488	[p28l827t714r900b738],
15	receptor	NN	O	receptor	pobj	11	SENT_488	[p28l908t719r1012b744],
16	and	CC	O	and	_	0	SENT_488	[p28l1020t714r1066b738],
17	KRAS	NN	ORGANIZATION	kra	nn	19	SENT_488	[p28l1074t716r1147b739],
18	mutation	NN	O	mutation	nn	19	SENT_488	[p28l1157t722r1206b738, p28l1246t308r1319b331],
19	analysis	NN	O	analysis	conj_and	15	SENT_488	[p28l1327t308r1433b338],
20	:	:	O	:	_	0	SENT_488	[p28l1327t308r1433b338],
21	cancer	NN	O	cancer	dep	27	SENT_488	[p28l1443t316r1524b331],
22	and	CC	O	and	_	0	SENT_488	[p28l1531t308r1577b331],
23	leukemia	NN	O	leukemia	nn	24	SENT_488	[p28l1585t308r1700b332],
24	group	NN	O	group	dep	27	SENT_488	[p28l1708t315r1781b338],
25	B	NN	O	b	dep	27	SENT_488	[p28l1245t347r1262b368],
26	(	CD	NUMBER	(	num	25	SENT_488	[p28l1271t347r1371b371],
27	CALEB	NNP	ORGANIZATION	CALEB	dep	35	SENT_488	[p28l1271t347r1371b371],
28	)	CD	NUMBER	)	num	27	SENT_488	[p28l1271t347r1371b371],
29	30106	CD	NUMBER	30106	dep	27	SENT_488	[p28l1381t347r1460b373],
30	,	,	O	,	_	0	SENT_488	[p28l1381t347r1460b373],
31	a	DT	O	a	det	33	SENT_488	[p28l1469t353r1482b368],
32	CALGB-stratified	JJ	O	calgb-stratified	amod	33	SENT_488	[p28l1489t345r1703b368],
33	phase	NN	O	phase	appos	29	SENT_488	[p28l1710t345r1782b374],
34	II	CD	NUMBER	ii	num	35	SENT_488	[p28l1245t384r1265b405],
35	trial	NN	O	trial	dep	1	SENT_488	[p28l1275t382r1335b405],
36	.	.	O	.	_	0	SENT_488	[p28l1275t382r1335b405],

1	J	NNP	O	J	nn	3	SENT_489	[p28l1343t384r1354b408],
2	Thorac	NNP	O	Thorac	nn	3	SENT_489	[p28l1362t381r1451b405],
3	Oncol	NNP	O	Oncol	_	0	SENT_489	[p28l1461t382r1537b405],
4	2010	CD	DATE	2010	num	3	SENT_489	[p28l1546t383r1746b410],
5	;	:	O	;	_	0	SENT_489	[p28l1546t383r1746b410],
6	5:1382	CD	NUMBER	5:1382	number	7	SENT_489	[p28l1546t383r1746b410],
7	—	CD	NUMBER	—	dep	3	SENT_489	[p28l1546t383r1746b410],
8	90	CD	NUMBER	90	dep	7	SENT_489	[p28l1546t383r1746b410],
9	.	.	O	.	_	0	SENT_489	[p28l1546t383r1746b410],

1	54	CD	NUMBER	54	_	0	SENT_490	[p28l1246t421r1281b441],
2	.	.	O	.	_	0	SENT_490	[p28l1246t421r1281b441],

1	Choong	NNP	ORGANIZATION	Choong	nn	2	SENT_491	[p28l1296t418r1398b448],
2	NW	NNP	ORGANIZATION	NW	_	0	SENT_491	[p28l1411t420r1467b446],
3	,	,	O	,	_	0	SENT_491	[p28l1411t420r1467b446],
4	Mauer	NNP	ORGANIZATION	Mauer	nn	5	SENT_491	[p28l1483t420r1565b442],
5	AM	NNP	ORGANIZATION	AM	appos	2	SENT_491	[p28l1578t421r1631b446],
6	,	,	O	,	_	0	SENT_491	[p28l1578t421r1631b446],
7	Harah	NNP	O	Harah	nn	8	SENT_491	[p28l1648t419r1729b441],
8	DJ	NNP	O	DJ	appos	2	SENT_491	[p28l1744t420r1780b446],
9	,	,	O	,	_	0	SENT_491	[p28l1744t420r1780b446],
10	et	FW	O	et	nn	11	SENT_491	[p28l1246t460r1269b478],
11	al.	FW	O	al.	appos	2	SENT_491	[p28l1278t455r1308b478],
12	.	.	O	.	_	0	SENT_491	[p28l1278t455r1308b478],

1	Phase	NN	O	phase	_	0	SENT_492	[p28l1319t455r1392b478],
2	I	CD	NUMBER	i	num	3	SENT_492	[p28l1402t457r1411b478],
3	trial	NN	O	trial	dep	1	SENT_492	[p28l1421t455r1474b478],
4	of	IN	O	of	_	0	SENT_492	[p28l1484t455r1514b478],
5	erlotinib-based	JJ	O	erlotinib-based	amod	7	SENT_492	[p28l1518t455r1713b478],
6	multimodality	NN	O	multimodality	nn	7	SENT_492	[p28l1723t455r1781b478, p28l1246t492r1380b522],
7	therapy	NN	O	therapy	prep_of	3	SENT_492	[p28l1387t492r1483b522],
8	for	IN	O	for	_	0	SENT_492	[p28l1490t492r1527b515],
9	inoperable	JJ	O	inoperable	amod	10	SENT_492	[p28l1534t492r1669b522],
10	stage	NN	O	stage	prep_for	7	SENT_492	[p28l1678t497r1744b522],
11	III	CD	NUMBER	iii	num	13	SENT_492	[p28l1752t494r1782b515],
12	non-small	JJ	O	non-small	amod	13	SENT_492	[p28l1246t529r1373b552],
13	cell	NN	O	cell	dep	1	SENT_492	[p28l1382t529r1424b552],
14	lung	NN	O	lung	nn	15	SENT_492	[p28l1433t529r1490b559],
15	cancer	NN	O	cancer	dep	13	SENT_492	[p28l1498t537r1585b552],
16	.	.	O	.	_	0	SENT_492	[p28l1498t537r1585b552],

1	J	NNP	O	J	nn	3	SENT_493	[p28l1593t531r1604b556],
2	Thorac	NNP	O	Thorac	nn	3	SENT_493	[p28l1611t529r1699b552],
3	Oncol	NNP	O	Oncol	_	0	SENT_493	[p28l1708t529r1782b552],
4	2008	CD	DATE	2008	num	3	SENT_493	[p28l1246t568r1445b594],
5	;	:	O	;	_	0	SENT_493	[p28l1246t568r1445b594],
6	3:1003	CD	DATE	3:1003	number	7	SENT_493	[p28l1246t568r1445b594],
7	-11	CD	DATE	-11	dep	3	SENT_493	[p28l1246t568r1445b594],
8	.	.	O	.	_	0	SENT_493	[p28l1246t568r1445b594],

1	55	CD	NUMBER	55	_	0	SENT_494	[p28l1246t606r1279b626],
2	.	.	O	.	_	0	SENT_494	[p28l1246t606r1279b626],

1	The	DT	O	the	det	5	SENT_495	[p28l1295t603r1342b626],
2	National	NNP	O	National	nn	5	SENT_495	[p28l1357t603r1468b626],
3	Comprehensive	NNP	O	Comprehensive	nn	5	SENT_495	[p28l1483t603r1679b633],
4	Cancer	NNP	O	Cancer	nn	5	SENT_495	[p28l1694t605r1782b626],
5	Network	NNP	O	Network	_	0	SENT_495	[p28l1245t640r1357b664],
6	home	NN	O	home	nn	7	SENT_495	[p28l1370t640r1440b663],
7	page	NN	O	page	dep	5	SENT_495	[p28l1455t648r1521b670],
8	.	.	O	.	_	0	SENT_495	[p28l1455t648r1521b670],

1	(	NN	O	(	_	0	SENT_496	[p28l1538t640r1782b670],
2	http://www.NCCN	NN	O	http://www.nccn	dep	1	SENT_496	[p28l1538t640r1782b670],
3	.	.	O	.	_	0	SENT_496	[p28l1247t679r1311b707],

1	org	NN	O	org	_	0	SENT_497	[p28l1247t679r1311b707],
2	.	.	O	.	_	0	SENT_497	[p28l1247t679r1311b707],
3	)	SYM	O	)	dep	1	SENT_497	[p28l1247t679r1311b707],

1	Copyright	NN	O	copyright	_	0	SENT_498	[p28l1246t720r1340b746],
2	©	CD	NUMBER	©	num	6	SENT_498	[p28l1349t722r1370b744],
3	2011	CD	DATE	2011	num	6	SENT_498	[p28l1380t722r1427b740],
4	Massachusetts	NNP	ORGANIZATION	Massachusetts	nn	6	SENT_498	[p28l1438t720r1578b740],
5	Medical	NNP	ORGANIZATION	Medical	nn	6	SENT_498	[p28l1587t720r1664b740],
6	Society	NNP	ORGANIZATION	Society	dep	1	SENT_498	[p28l1672t721r1744b746],
7	.	.	O	.	_	0	SENT_498	[p28l1672t721r1744b746],

1	N	NN	O	n	nn	3	SENT_499	[p28l610t831r623b846],
2	ENGLJ	NN	O	englj	nn	3	SENT_499	[p28l638t831r716b853],
3	MED	NN	O	med	_	0	SENT_499	[p28l731t831r782b846],
4	364	CD	NUMBER	364	dep	3	SENT_499	[p28l793t825r875b853],
5	;	:	O	;	_	0	SENT_499	[p28l793t825r875b853],
6	1o	CD	NUMBER	1o	num	8	SENT_499	[p28l793t825r875b853],
7	NEJM.ORG	NN	O	nejm.org	nn	8	SENT_499	[p28l909t831r1033b853],
8	MARCH	NN	DATE	march	dep	4	SENT_499	[p28l1070t831r1155b846],
9	10	CD	DATE	10	dep	8	SENT_499	[p28l1168t831r1202b851],
10	,	,	DATE	,	_	0	SENT_499	[p28l1168t831r1202b851],
11	2011	CD	DATE	2011	appos	9	SENT_499	[p28l1213t831r1265b847],

1	Downloaded	VBN	O	download	_	0	SENT_500	[p28l195t929r365b952],
2	from	IN	O	from	_	0	SENT_500	[p28l374t929r439b952],
3	nejm.org	NN	O	nejm.org	prep_from	1	SENT_500	[p28l447t929r566b959],
4	at	IN	O	at	_	0	SENT_500	[p28l576t933r599b952],
5	UW-Madison	NN	O	uw-madison	prep_at	1	SENT_500	[p28l607t929r790b952],
6	on	IN	O	on	_	0	SENT_500	[p28l799t936r832b952],
7	January	NNP	DATE	January	prep_on	1	SENT_500	[p28l840t929r943b959],
8	5	CD	DATE	5	num	7	SENT_500	[p28l953t929r976b956],
9	,	,	DATE	,	_	0	SENT_500	[p28l953t929r976b956],
10	2014	CD	DATE	2014	num	7	SENT_500	[p28l986t929r1058b952],
11	.	.	O	.	_	0	SENT_500	[p28l986t929r1058b952],

1	For	IN	O	for	_	0	SENT_501	[p28l1069t929r1116b952],
2	personal	JJ	O	personal	amod	3	SENT_501	[p28l1124t929r1236b959],
3	use	NN	O	use	pobj	1	SENT_501	[p28l1245t936r1289b952],
4	only	RB	O	only	advmod	3	SENT_501	[p28l1298t929r1363b959],
5	.	.	O	.	_	0	SENT_501	[p28l1298t929r1363b959],

1	No	DT	O	no	det	3	SENT_502	[p28l1374t929r1413b952],
2	other	JJ	O	other	amod	3	SENT_502	[p28l1423t929r1491b952],
3	uses	NNS	O	use	_	0	SENT_502	[p28l1500t936r1556b952],
4	without	IN	O	without	_	0	SENT_502	[p28l1566t929r1667b952],
5	permission	NN	O	permission	prep_without	3	SENT_502	[p28l1675t929r1828b959],
6	.	.	O	.	_	0	SENT_502	[p28l1675t929r1828b959],

1	The	DT	O	the	det	4	SENT_503	[p28l753t888r804b912],
2	New	NNP	O	New	nn	4	SENT_503	[p28l813t889r875b912],
3	England	NNP	O	England	nn	4	SENT_503	[p28l884t888r995b919],
4	Journal	NNP	O	Journal	_	0	SENT_503	[p28l1004t888r1101b912],
5	of	IN	O	of	_	0	SENT_503	[p28l1111t888r1140b912],
6	Medicine	NNP	O	Medicine	prep_of	4	SENT_503	[p28l1147t888r1272b912],

1	Copyright	NN	O	copyright	_	0	SENT_504	[p28l546t970r680b1001],
2	©	CD	NUMBER	©	num	6	SENT_504	[p28l689t970r713b994],
3	2011	CD	DATE	2011	num	6	SENT_504	[p28l723t970r785b994],
4	Massachusetts	NNP	ORGANIZATION	Massachusetts	nn	6	SENT_504	[p28l797t970r988b994],
5	Medical	NNP	ORGANIZATION	Medical	nn	6	SENT_504	[p28l998t970r1106b994],
6	Society	NNP	ORGANIZATION	Society	dep	1	SENT_504	[p28l1117t970r1222b1001],
7	.	.	O	.	_	0	SENT_504	[p28l1117t970r1222b1001],

1	All	DT	O	all	det	2	SENT_505	[p28l1233t970r1274b994],
2	rights	NNS	O	rights	nsubj	3	SENT_505	[p28l1283t970r1358b1001],
3	reserved	VBN	O	reserve	_	0	SENT_505	[p28l1368t970r1486b994],
4	.	.	O	.	_	0	SENT_505	[p28l1368t970r1486b994],

